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A B S T R A C T
Background
Chlorpromazine is an aliphatic phenothiazine, which is one of the widely-used typical antipsychotic drugs. Chlorpromazine is reliable
for its efﬁcacy and one of the most tested ﬁrst generation antipsychotic drugs. It has been used as a ‘gold standard’ to compare the
efﬁcacy of older and newer antipsychotic drugs. Expensive new generation drugs are heavily marketed worldwide as a better treatment
for schizophrenia, but this may not be the case and an unnecessary drain on very limited resources.
Objectives
To compare the effects of chlorpromazine with atypical or second generation antipsychotic drugs, for the treatment of people with
schizophrenia.
Search methods
We searched the Cochrane Schizophrenia Group’s Trials Register up to 23 September 2013.
Selection criteria
We included randomised controlled trials (RCTs) that compared chlorpromazine with any other atypical antipsychotic drugs for treating
people with schizophrenia. Adults (as deﬁned in each trial) diagnosed with schizophrenia, including schizophreniform, schizoaffective
and delusional disorders were included in this review.
Data collection and analysis
At least two review authors independently screened the articles identiﬁed in the literature search against the inclusion criteria and
extracted data from included trials. For homogeneous dichotomous data, we calculated the risk ratio (RR) and the 95% conﬁdence
intervals (CIs). For continuous data, we determined the mean difference (MD) values and 95% CIs. We assessed the risk of bias in
included studies and rated the quality of the evidence using the GRADE approach.
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Main results
This review includes 71 studies comparing chlorpromazine to olanzapine, risperidone or quetiapine. None of the included trials reported
any data on economic costs.
1. Chlorpromazine versus olanzapine
In the short term, there appeared to be a signiﬁcantly greater clinical response (as deﬁned in each study) in people receiving olanzapine
(3 RCTs, N = 204; RR 2.34, 95% CI 1.37 to 3.99, low quality evidence). There was no difference between drugs for relapse (1 RCT,
N = 70; RR 1.5, 95% CI 0.46 to 4.86, very low quality evidence), nor in average endpoint score using the Brief Psychiatric Rating
Scale (BPRS) for mental state (4 RCTs, N = 245; MD 3.21, 95% CI −0.62 to 7.05,very low quality evidence). There were signiﬁcantly
more extrapyramidal symptoms experienced amongst people receiving chlorpromazine (2 RCTs, N = 298; RR 34.47, 95% CI 4.79 to
248.30,very low quality evidence). Quality of life ratings using the general quality of life interview (GQOLI) - physical health subscale
were more favourable with people receiving olanzapine (1 RCT, N = 61; MD −10.10, 95% CI −13.93 to −6.27, very low quality
evidence). There was no difference between groups for people leaving the studies early (3 RCTs, N = 139; RR 1.69, 95% CI 0.45 to
6.40, very low quality evidence).
2. Chlorpromazine versus risperidone
In the short term, there appeared to be no difference in clinical response (as deﬁned in each study) between chlorpromazine or risperidone
(7 RCTs, N = 475; RR 0.84, 95% CI 0.53 to 1.34, low quality of evidence), nor in average endpoint score using the BPRS for mental
state 4 RCTs, N = 247; MD 0.90, 95% CI −3.49 to 5.28, very low quality evidence), or any observed extrapyramidal adverse effects (3
RCTs, N = 235; RR 1.7, 95% CI 0.85 to 3.40,very low quality evidence). Quality of life ratings using the QOL scale were signiﬁcantly
more favourable with people receiving risperidone (1 RCT, N = 100; MD−14.2, 95% CI−20.50 to−7.90, very low quality evidence).
There was no difference between groups for people leaving the studies early (one RCT, N = 41; RR 0.21, 95% CI 0.01 to 4.11, very
low quality evidence).
3. Chlorpromazine versus quetiapine
In the short term, there appeared to be no difference in clinical response (as deﬁned in each study) between chlorpromazine or quetiapine
(28 RCTs, N = 3241; RR 0.93, 95% CI 0.81 to 1.06, moderate quality evidence) nor in average endpoint score using the BPRS for
mental state (6 RCTs, N = 548; MD−0.18, 95%CI−1.23 to 0.88, very low quality evidence). Quality of life ratings using the GQOL1-
74 scale were signiﬁcantly more favourable with people receiving quetiapine (1 RCT, N = 59; MD−6.49, 95% CI −11.30 to −1.68,
very low quality evidence). Signiﬁcantly more people receiving chlorpromazine experienced extrapyramidal adverse effects (8 RCTs, N
= 644; RR 8.03, 95% CI 4.78 to 13.51, low quality of evidence). There was no difference between groups for people leaving the studies
early in the short term (12 RCTs, N = 1223; RR 1.04, 95% CI 0.77 to 1.41,moderate quality evidence).
Authors’ conclusions
Most included trials included inpatients from hospitals in China. Therefore the results of this Cochrane review are more applicable to
the Chinese population. Mostincluded trials were short term studies, therefore we cannot comment on the medium and long term use
of chlorpromazine compared to atypical antipsychotics. Low qualityy evidence suggests chlorpromazine causes more extrapyramidal
adverse effects. However, all studiesused varying dose ranges, and higher doses would be expected to be associated with more adverse
events.
P L A I N L A N G U A G E S U M M A R Y
Chlorpromazine compared with newer atypical antipsychotics
People with schizophrenia often hear voices or see things (hallucinations) and have strange beliefs (delusions). The main treatment
for people with these symptoms of schizophrenia is antipsychotic drugs. Chlorpromazine was one of the ﬁrst drugs discovered to be
effective for treating people with schizophrenia. It remains one of the most commonly used and inexpensive treatments. However, being
an older drug (typical or ﬁrst generation) it also has serious side effects, including blurred vision, a dry mouth, tremors or uncontrollable
shaking, depression, muscle stiffness and restlessness.
In this Cochrane review we examined the effects of chlorpromazine for treating people with schizophrenia compared with newer
antipsychotic drugs.
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We searched the literature for randomised controlled trials up to 23 September 2013, and included 71 trials. The included studies
compared chlorpromazine with three newer antipsychotics: risperidone, quetiapine or olanzapine. Most included trials were short term
studies and undertaken in China. Based on low quality evidence, we found that chlorpromazine is not much different to risperidone or
quetiapine but is associated with more side effects. More favourable results were found for olanzapine with those receiving olanzapine
experiencing fewer side effects and greater improvements in global state and quality of life than those receiving chlorpromazine, but
again this is based on low quality evidence. Larger, longer, better conducted and reported trials should focus on important outcomes
such as quality of life, levels of satisfaction with treatment or care, relapse, costs and hospital discharge or admission. Also, more
international studies are needed. Outpatient treatment was under-represented in the included studies, and future research should also
include work with this group of people.
Due to the limitations of evidence in this Cochrane review, it is difﬁcult to draw ﬁrm conclusions. Chlorpormazine is available widely,
is comparable with the newer antipsychotics and is relatively cheap so despite its propensity to cause side effects, is likely to remain one
of the benchmark antipsychotics.
The plain language summary has been written by a consumer. BenGray: Senior Peer Researcher,McPin Foundation. http://mcpin.org/.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Chlorpromazine versus olanzapine for schizophrenia
Patient or population: people with schizophrenia
Settings: inpat ient and outpat ient
Intervention: chlorpromazine
Comparison: olanzapine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Olanzapine Chlorpromazine
No significant clinical
response: short term
(up to 6 months)
Follow-up: 6 to 12
weeks
Low1 RR 2.34
(1.37 to 3.99)
204
(3 studies)
⊕⊕©©
low2,3
-
700 per 1000 1000 per 1000
(959 to 1000)
High1
190 per 1000 445 per 1000
(260 to 758)
Relapse: long term
(over 12 months)
Follow-up: mean 2
years
Study population RR 1.5
(0.46 to 4.86)
70
(1 study)
⊕©©©
very low3,4
-
114 per 1000 171 per 1000
(53 to 555)
M oderate
114 per 1000 171 per 1000
(52 to 554)
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M ental state: short
term (up to 6 months)
BRPS average endpoint
score (high = poor)
Follow-up: 6 to 12
weeks
The mean mental state:
short term (up to 6
months) in the interven-
t ion groups was
3.21 higher
(0.62 lower to 7.05
higher)
245
(4 studies)
⊕©©©
very low2,3,5,6,7
-
Adverse effects: any
observed extrapyrami-
dal symptoms - short
term (up to 6 months)
Follow-up: mean 8
weeks
Low RR 34.47
(4.79 to 248.3)
298
(2 studies)
⊕©©©
very low2,3,8
-
10 per 1000 345 per 1000
(48 to 1000)
M oderate
100 per 1000 1000 per 1000
(479 to 1000)
High
250 per 1000 1000 per 1000
(1000 to 1000)
Quality of life: short
term (up to 6 months)
GQOLI-physical health
subscale score (high =
good)
Follow-up: mean 8
weeks
The mean quality of lif e:
short term (up to 6
months) in the interven-
t ion groups was
10.10 lower
(13.93 to 6.27 lower)
61
(1 study)
⊕©©©
very low2,3,7,9,10
-
Leaving the study early
due to any reason:
short term (up to 6
months)
Follow-up: mean 6
weeks
Study population11 RR 1.69
(0.45 to 6.4)
139
(3 studies)
⊕©©©
very low3,12,13
-
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159 per 1000 268 per 1000
(71 to 1000)
M oderate11
229 per 1000 387 per 1000
(103 to 1000)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Control risk: the control risks are representat ive of the control group risks of the study populat ion.
2Risk of bias: rated serious - most included studies had unclear risk of bias in terms of allocat ion and blinding, hence select ion
and detect ion bias are likely to be present. Two studies also had high risk of report ing bias.
3Publicat ion bias: strongly suspected - we ident if ied only small t rial(s) f rom China for this outcome. Publicat ion bias is highly
suspected.
4Imprecision: serious - only one small t rial with unclear risk of select ion and detect ion bias contributed data to this outcome.
The result was imprecise with few event and a wide CI.
5Inconsistency: serious - unexplained heterogeneity present, suggest ing dif ferent magnitude of ef fect.
6Indirectness: serious - binary outcome assessing mental state is unavailable. We, therefore, employed BPRS score as an
alternat ive indicator.
7Imprecision: serious - a relat ively wide CI around the point of est imate of ef fect. Sample size is smaller than the opt imal
information size.
8Imprecision: serious - although signif icant dif f erence was observed between groups, the CI was wide (95% CI 4.97 to 248.3).
9Indirectness: serious - binary outcome for quality of lif e is unavailable. We, thus, used outcome f rom QOL- physical health
subscale as an alternat ive indicator.
10Imprecision: serious - although signif icant dif f erence was observed between group, the total sample size is smaller than the
opt imal information size.
11Control risk: the control risks in the study populat ion are very close to the moderate risk observed here. Thus we adopted it
to represent the control risk.
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12Risk of bias: serious - most included studies that contributed data to this outcome had high risk of bias with the select ion,
detect ion and report ing of the result .
13Imprecision: serious - est imate of ef fect was not signif icant and the total sample size is smaller than the desired opt imal
information size.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Schizophrenia is a severe form of mental health disorder. It has a
high lifetime prevalence rate, affecting (4 per 1000 people (Saha
2005), but low incident rate because of the chronic nature of
the illness. The median incident rate of schizophrenia is 15.2 per
100,000 people (McGrath 2008).
The International Classiﬁcation ofDiseases (ICD) classiﬁes the ill-
ness into categories F20 to F29 as ‘schizophrenia, schizotypal and
delusional disorder’ (ICD-10 1992), particularly ‘schizophrenia’
in F20. The ICD-10 states that “schizophrenic disorders are char-
acterized in general by fundamental and characteristic distortions
of thinking and perception, and affects that are inappropriate or
blunted”. The Diagnostic and Statistical Manual of the Ameri-
can Psychiatric Association has also used the term ‘schizophrenia’
(DSM-IV-TR 2000).
The prognosis of schizophrenia is quite variable, and in the
past psychiatrists were not very optimistic about its treatment
(Kraeplin 1919). However, recent studies show that the outcome
of schizophrenia treatment is better than previously thought. The
use of phenothiazines may have contributed to this as well as other
factors, such as improving community services (Bland 1978).
Description of the intervention
Psychiatrists have prescribed typical antipsychotic drugs since the
1950s, when the ﬁrst antipsychotic medication, chlorpromazine,
was synthesized. Chlorpromazine was ﬁrst used as an antihis-
taminic agent to treat allergies. Later, surgeons used it as a pre-
surgical medication to sedate people before surgical procedures
(Laborit 1951). In 1952, Paul Charpentier, from Laboratories
Rhône-Poulenc inFrance, andDelay andDeniker’s teamdescribed
the antipsychotic properties of chlorpromazine (Delay 1952).
Chlorpromazine is considered a pivotal discovery in the ﬁeld of
psychosis treatment, with other antipsychotics often measured in
’chlorpromazine equivalents’ (Turner 2007; Yorston 2000).
There are now many antipsychotic drugs available. They are
broadly divided into two groups: ‘typical antipsychotic drugs’ and
‘atypical antipsychotic drugs’. Typical antipsychotic drugs are also
known as ‘ﬁrst generation’, ‘conventional’ or ‘classical’ antipsy-
chotic drugs, e.g. chlorpromazine and haloperidol. Atypical an-
tipsychotic drugs are also known as ‘second generation’ or ‘newer
antipsychotic drugs’, e.g. clozapine, risperidone, quetiapine and
olanzapine. Typical antipsychotic drugs have a good reputation
regarding their efﬁcacy in treating the ’positive’ symptoms of
schizophrenia (e.g. delusions andhallucinations) (Mathews 2007).
They are also well known for their adverse effects, such as move-
ment disorders (extrapyramidal symptoms (EPS) or extrapyrami-
dal side effects (EPSE)), sedation, metabolic syndromes and some-
times potentially fatal conditions, such as neuroleptic malignant
syndrome (Arana 2000). The second generation antipsychotic
drugs arrived on the market, claiming notable differences. They
had a reputed low side-effect proﬁle and, according to pharmaceu-
tical companies, higher efﬁcacy (Janssen 1988). However, research
funded independently of pharmaceutical companies has suggested
that there may be little difference between the older and newer
drugs (Adams 2014). This has subsequently fuelled debate as to
whether new atypical antipsychotics are more effective than older
established ﬁrst-generation antipsychotics, and whether question-
ing the efﬁcacy of the two classiﬁcations of drugs creates an im-
proper generalisation of antipsychotics that donot formahomoge-
nous class (Leucht 2009). Against this backdrop, chlorpromazine
remains a benchmark drug in the treatment of schizophrenia. Al-
though imperfect, it is relatively inexpensive and remains one of
the most common drugs used for treating people with schizophre-
nia worldwide (Adams 2005).
How the intervention might work
Chlorpromazine is an aliphatic phenothiazine, which is one of the
widely-used typical antipsychotic drugs. Chlorpromazine is reli-
able for its efﬁcacy and one of the most tested ﬁrst generation an-
tipsychotic drugs. It has been used as a ‘gold standard’ to compare
the efﬁcacy of older and newer antipsychotic drugs. It blocks alpha
1, 5HT2A, D2 and D1 receptors in the brain, and thus it works
as an antipsychotic. It also has effect on muscarinic, serotonin
and H1 receptors. By blocking D2 receptor it can also cause ex-
trapyramidal side effects. Other adverse effects include dry mouth,
blurred vision, restlessness, sedation, neuroleptic malignant syn-
drome (DSM-IV 1994) etc. On the other hand, atypical antipsy-
chotic drugs by deﬁnition may cause decreased or no extrapyra-
midal side effects (Kinon 1996). Different atypical antipsychotic
drugs act in different ways; for example, clozapine blocks D2 and
5HT2 receptors (Meltzer 1989). Both clozapine and quetiapine
blocksmore 5HT2 receptors thanD2 receptors. olanzapine blocks
5HT2A, 5HT6, D1, D2, D3 and muscarinic receptors (Zhang
1999).
Why it is important to do this review
This is one of a family of related Cochrane reviews on this impor-
tant compound (Table 1).
Chlorpromazine is one of two oral antipsychotic drugs on the
World Health Organization’s Essential Drug list (WHO 2011).
It is globally accessible and has been known for its effective-
ness in schizophrenia treatment since the 1950s (Adams 2014),
and it is also the most commonly used and inexpensive treat-
ment for schizophrenia (Odejide 1982). Expensive new generation
drugs are heavily marketed worldwide as a better treatment for
schizophrenia. However, this may not be the case and may be an
unnecessary drain on very limited resources (Adams 2006). Also,
8Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
comparisons with new generation drugs, which are coming off-
patent and are therefore more accessible, are important to assist
informed and independent choice of treatment for people with
schizophrenia.
O B J E C T I V E S
To compare the effects of chlorpromazine with atypical or sec-
ond generation antipsychotic drugs, for treatment of people with
schizophrenia (seeDifferences between protocol and review).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all relevant randomised controlled trials (RCTs). If
a trial was described as double-blind but implied randomisation,
we included such trials in a sensitivity analysis (see Sensitivity
analysis). If their inclusion did not result in a substantive differ-
ence, we kept these trials in the analyses. If their inclusion resulted
in statistically signiﬁcant differences, we did not add the data from
these lower quality studies to the results of the better trials, but pre-
sented such data within a subcategory. We excluded quasi-RCTs
(e.g. allocating by alternate days of the week). Where people were
given additional treatments within the chlorpromazine and atypi-
cal antipsychotic groups, we only includeddata if the adjunct treat-
ment was evenly distributed between groups and only the chlor-
promazine and atypical antipsychotic groups were randomised.
Types of participants
Adults (as deﬁned in each trial) diagnosed with schizophrenia, in-
cluding schizophreniform, schizoaffective and delusional disorders
(any means of diagnosis, including operational criteria (DSM-IV
1994; ICD-10 1992) or clinical opinion).
We are interested in making sure that information is as rele-
vant to the current care of people with schizophrenia as possible
so if the information was reported we clearly highlighted in the
Characteristics of included studies and Description of studies, the
current clinical state (acute, early post - acute, partial remission,
remission) as well as the stage (prodromal, ﬁrst episode, early ill-
ness, persistent) and as to whether the studies primarily focused
on people with particular problems (for example, negative symp-
toms, treatment-resistant illnesses).
Types of interventions
1. Chlorpromazine
Any dose and any route of administration.
2. Any atypical antipsychotic
Atypical antipsychotic drugs including: amisulpride, aripipra-
zole, asenapine (Smith 2010), clozapine, clothiapine or clotiap-
ine (Toren 1995), iloperidone (Caccia 2010), lurasidone (Risbood
2012), mosapramine (Takahashi 1999), olanzapine, paliperidone,
perospirone (Bian 2008), quetiapine, remoxipride (Nadal 2001),
risperidone, sertindole (Cincotta 2010), sulpiride (Rzewuska
1988), ziprasidone and zotepine (list non-exhaustive).
Any dose and any route of administration.
Types of outcome measures
If possible, we divided outcomes into short term (up to six
months), medium term (seven to 12 months) and long term (over
one year).
Primary outcomes
1. Clinical response
Clinically signiﬁcant improvement as deﬁned by each included
trial.
2. Relapse
As deﬁned by each trial.
Secondary outcomes
1. Death: natural death or suicide
2. Global state
2.1 Any change in global state.
2.2 Deterioration.
2.3 Need for additional antipsychotic drugs.
2.4 Need for additional benzodiazepines.
2.5 Poor compliance.
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3. Mental state
3.1 General symptoms
3.1.1 Any change in general symptoms.
3.1.2 Average endpoint general symptom score.
3.1.3 Average change in general symptom score.
3.2 Speciﬁc symptoms (positive and negative symptoms of
schizophrenia, depression and mania/hypomania)
3.2.1 Any change of speciﬁc symptoms.
3.2.2 Average endpoint speciﬁc symptom score.
3.2.3 Average change speciﬁc symptom score.
4. Service involvement
4.1 Duration of hospital stay.
4.2 Re-hospitalisation.
4.3 Engagement with community services.
4.4 Engagement with inpatient/outpatient services.
5. Functioning
5.1 General functioning
5.1.1 Any change in general functioning.
5.1.2 Average endpoint score in general functioning.
5.1.3 Average change score in general functioning.
5.2 Social functioning
5.1.1 Any change in social functioning.
5.1.2 Average endpoint score in social functioning.
5.1.3 Average change score in social functioning
5.3 Employment status
5.1.1 Any change in employment status.
5.1.2 Average endpoint score in employment functioning.
5.1.3 Average change score in employment functioning.
6. Behaviour
6.1 General behaviour.
6.2 Any improvement in behaviour, as deﬁned in each trial.
6.3 Speciﬁc behaviour (e.g. agitation, aggression, violent inci-
dents).
6.4 Average endpoint in behaviour scores.
6.5 Average change in behaviour scores.
7. Adverse effects
7.1 Anticholinergic.
7.2 Cardiovascular.
7.3 Central nervous system.
7.4 Gastrointestinal.
7.5 Endocrine (e.g. amenorrhoea, galactorrhoea, hyperlipidaemia,
hyperglycaemia, hyperinsulinemia).
7.6 Haematology (e.g. haemogram, leukopenia, agranulocytosis/
neutropenia).
7.7 Hepatitic (e.g. abnormal transaminase, abnormal liver func-
tion).
7.8 Metabolic.
7.9 Movement disorders.
7.10 Various other.
8. Satisfaction
8.1 Patient satisfaction.
8.2 Carer satisfaction.
8.3 Professional satisfaction (managers/doctors/nurses).
9. Economic outcomes
9.1 Direct costs, as deﬁned in each study.
9.2 Indirect costs, as deﬁned in each study.
9.3 Cost-effectiveness, as deﬁned in each study.
10. Quality of life
10.1 Average endpoint score in quality of life.
10.2 Average change score in quality of life.
10.3 Any improvement in quality of life.
11. Leaving the study early
’Summary of findings’ tables
Weused theGRADEapproach to interpret ﬁndings (Schünemann
2008) and used GRADE proﬁler (GRADEPRO) to import data
fromRevMan5 (Teview Manager) to create ’Summary of ﬁndings’
tables. These tables provide outcome - speciﬁc information con-
cerning the overall quality of evidence from each included study
in the comparison, the magnitude of effect of the interventions
examined, and the sum of available data on all outcomes we rated
as important to patient care and decision making. We aimed to
select the following main outcomes for inclusion in the ’Summary
of ﬁndings’ tables:
• Clinical response: clinically signiﬁcant improvement (as
deﬁned by each of the studies) by medium term.
• Relapse (as deﬁned by each of the studies) by medium term.
• Mental state: average endpoint score (Brief Psychiatric
Rating Scale (BPRS)) by medium term.
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• Adverse effects: extrapyramidal side effects: reported by the
number participants by medium term.
• Quality of life: improvement as deﬁned by each of the study
by medium term.
• Participants leaving the study early by medium term.
• Economic outcomes: cost effectiveness (as deﬁned in each
study) by long term.
Search methods for identification of studies
Electronic searches
1. Cochrane Schizophrenia Group Trials Register
We searched the Cochrane Schizophrenia Group’s Trials Register
up to 23 September 2013 using the phrase:
[((*chlorpromazine* AND (*amisulprid* or *aripiprazol* or
*clozapin* or *olanzapin* or *quetiapin* or *risperidon* or *sertin-
dol* or *ziprasidon* or *zotepin*or *sulpiride* or *remoxipride*
or *paliperidone* or *perospirone* or asenapine or clothiapine or
clotiapine or iloperidone or lurasidone or mosapramine or ((Atyp-
ical or (Second NEXT generation)) and antipsychotic*))) in ti-
tle, abstract or index terms of REFERENCE or interventions of
STUDY)]
The Cochrane Schizophrenia Group’s Trials Register is compiled
by systematic searches of major databases, handsearches and con-
ference proceedings (see Group Module).
The seatch strategy was changed after protocol publication and
we added new search terms to the strategy. The search strategy in
protocol step is in Appendix 1.
Searching other resources
1. Reference searching
We inspected references of all included trials for further relevant
studies published in any language.
2. Personal contact
If necessary we contacted the ﬁrst author, relevant pharmaceuti-
cal companies, and drug approval agencies of trials for additional
information.
Data collection and analysis
Selection of studies
Two review authors (BL and SZ) independently inspected cita-
tions from the searches and identiﬁed relevant abstracts. JX inde-
pendently re-inspected a random 20% sample to ensure reliabil-
ity. Where disputes arose, the full report was acquired for more
detailed scrutiny. BL obtained and inspected full reports of the
abstracts meeting the review criteria and JX re-inspected a random
20% of these reports in order to ensure reliable selection. Where
it was not possible to resolve disagreement by discussion, we at-
tempted to contact the authors of the study for clariﬁcation.
Data extraction and management
1. Extraction
Two review authors (BL and SZ) extracted data from all included
trials. To ensure reliability of data extraction, JX independently
extracted data from a random sample of these studies, comprising
10% of the total. We discussed and documented any disagree-
ments. Another review author (SS) helped to clarify any remain-
ing issues and we documented these ﬁnal decisions. If possible,
we extracted data presented only in graphs and ﬁgures, but only
included this data if two review authors independently had the
same result. If necessary, we attempted to contact the trial authors
through an open-ended request in order to obtain missing infor-
mation or for clariﬁcation whenever necessary.
2. Management
2.1 Forms
We extracted data onto standard, pre-designed simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
• The psychometric properties of the measuring instrument
had been described in a peer-reviewed journal (Marshall 2000);
and
• The measuring instrument had not been written or
modiﬁed by one of the trialists for that particular trial.
Ideally, the measuring instrument should either be i. a self-report
or ii. completed by an independent rater or relative (not the ther-
apist). We realise that this is not often reported clearly. We noted
in the ’Description of studies’ if this was the case or not.
2.3 Endpoint versus change data
There are advantages to both endpoint and change data. Change
data can remove a component of between person variability from
the analysis. However, calculation of change requires two assess-
ments (baseline and endpoint), which can be difﬁcult in unsta-
ble and difﬁcult to measure conditions, such as schizophrenia.
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We decided to primarily use endpoint data, and only use change
data if the former were unavailable. We combined endpoint and
change data in the analysis as we preferred to use MD rather than
standardised mean difference (SMD) values throughout (Higgins
2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data we applied the following standards to
all data before inclusion:
For change data:
We entered change data, as when continuous data are presented
on a scale that includes a possibility of negative values (such as
change data), it is difﬁcult to tell whether data are skewed or not.
We presented and entered change data into statistical analyses.
For endpoint data:
a) When a scale started from the ﬁnite number 0, we subtracted
the lowest possible value from the mean, and divided this by the
SD. If this value was < 1, it strongly suggested a skew, and we
excluded the study. If this ratiowas higher than1but below2, there
was suggestion of skew. We entered the study and tested whether
its inclusion or exclusion would change the results substantially.
Finally, if the ratio was > 2, we included the study because skew
was less likely (Altman 1996; Higgins 2011).
b) If a scale started from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS), which can have values from
30 to 210) (Kay 1986), we modiﬁed the calculation described
above to take into account the scale starting point. In such cases
skew was present if 2 SD > (S - Smin), where S is the mean score
and Smin is the minimum score.
(Please note, irrespective of the above rules, we entered endpoint
data from studies of at least 200 participants in the analysis because
skewed data pose less of a problem in large studies).
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (e.g. mean days per month). However, we did not identify
such data.
2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures to
dichotomous data. This can be done by identifying cut-off points
on rating scales and dividing participants accordingly into ’clini-
cally improved’ or ’not clinically improved’. It is generally assumed
that if there is a 50% reduction in a scale derived score, such as
the BPRS (Overall 1962) or the PANSS (Kay 1986), this could be
considered a clinically signiﬁcant response (Leucht 2005a; Leucht
2005b).
2.7 Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicates a favourable outcome
for chlorpromazine. Where keeping to this made it impossible to
avoid outcome titles with clumsy double-negatives (e.g. ’not un-
improved’) we reported data where the left of the line indicates an
unfavourable outcome. We have noted this in the relevant graphs.
Assessment of risk of bias in included studies
Two review authors (BL and SZ) independently assessed the risk
of bias of included trials by using criteria described in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
This set of criteria is based on evidence of association between
overestimate of effect and high risk of bias of the article, such as se-
quence generation, allocation concealment, blinding, incomplete
outcome data and selective reporting.
If the two review authors disagreed, we made the ﬁnal rating by
consensus, with the involvement of another review author from
the team. Where inadequate details of randomisation and other
characteristics of trials were provided, we contacted trial authors
for further information. We reported non-concurrence in quality
assessment, but if disputes arose as to which category a trial was
to be allocated, again, we resolved this by discussion.
We described the results of the ’Risk of bias’ assessments in both
the review text and in the ’Summary of ﬁndings’ tables.
Measures of treatment effect
1. Binary data−
For binary outcomes we calculated a standard estimation of the
risk ratio (RR) and its 95% conﬁdence interval (CI). It has been
shown that RR is more intuitive (Boissel 1999) than odds ratios
(ORs) and that ORs tend to be interpreted as RRs by clinicians
(Deeks 2000). The number needed to treat for an additional bene-
ﬁcial outcome (NNTB)/number needed to treat for an additional
harmful outcome (NNTH) statistic with its CIs is intuitively at-
tractive to clinicians but is problematic both in its accurate cal-
culation in meta analyses and interpretation (Hutton 2009). For
binary data presented in the ’Summary of ﬁndings’ table(s), where
possible, we calculated illustrative comparative risks.
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2. Continuous data
For continuous outcomes, we estimated the MD between groups.
We preferred not to calculate effect size measures (SMD). How-
ever, if scales of considerable similarity were used, we assumed
there was a small difference in measurement, calculated effect size
and transformed the effect back to the units of one or more of the
speciﬁc instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, study authors often fail to
account for intra-class correlation in clustered studies, leading to
a ’unit of analysis’ error (Divine 1992) whereby P values are spu-
riously low, CIs unduly narrow and statistical signiﬁcance overes-
timated. This causes type I errors (Bland 1997; Gulliford 1999).
We did not identify any cluster-randomised studies. However, if
we identify such studies in future updates of this Cochrane review
where clustering is not accounted for in primary studies, we will
present data in a table, with an asterisk (*) to indicate the presence
of a probable unit of analysis error. In updates of this review we
will try to contact ﬁrst authors of such studies to obtain intra-
class correlation coefﬁcients (ICCs) for their clustered data and to
adjust for this by using accepted methods (Gulliford 1999).
Where clustering was incorporated into the analysis of primary
studies, we presented these data as if from a non-cluster ran-
domised study, but adjusted for the clustering effect.
We received statistical advice that binary data presented in a report
should be divided by a ’design effect’. This is calculated using the
mean number of participants per cluster (m) and the ICC [Design
effect = 1 + (m − 1)*ICC] (Donner 2002). If the ICC was not
reported, we assumed it was 0.1 (Ukoumunne 1999).
Where cluster studies had been appropriately analysed taking into
account ICCs and relevant data documented in the report, syn-
thesis with other studies was possible using the generic inverse
variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the ﬁrst phase is carried over to the
second phase. As a consequence on entry to the second phase,
the participants can differ systematically from their initial state
despite a wash-out phase. For the same reason cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
planned to only use data from the ﬁrst phase of cross-over studies.
However, we did not identify any cross-over trials for inclusion in
this review.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if rele-
vant, we presented the additional treatment arms in comparisons.
If data were binary, we simply added these and combined within
the two-by-two table. If data were continuous, we had planned
to combine data following the formula in Section 7.7.3.8 (Com-
bining groups) of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011a). Where the additional treatment
arms were irrelevant, we did not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we would not reproduce
these data or use them within analyses. If more than 50% of those
in one arm of a study were lost but the total loss was less than 50%,
we addressed this within the ’Summary of ﬁndings’ table(s) by
downgrading the quality of the evidence. We also downgraded the
quality of the evidence within the ’Summary of ﬁndings’ table(s)
where loss was 25% to 50% in total.
2. Binary
In the case where attrition for a binary outcome was between
0% and 50% and where these data were not clearly described,
we presented these data on a ’once-randomised-always-analyse’
basis (an intention-to-treat (ITT) analysis). We assumed all those
leaving the study early to have the same rates of negative outcome
as those who completed, with the exception of the outcome of
death and adverse effects. For these outcomes, we used the rate
of those who stayed in the study in that particular arm of the
trial for those who did not. We undertook a sensitivity analysis
to test how prone the primary outcomes were to change when
’completer’ data only were compared to the ITT analysis using the
above assumptions.
3. Continuous
3.1 Attrition
In cases where attrition for a continuous outcome was between 0%
and 50% and completer-only data was reported, we reproduced
these.
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3.2 Standard deviations
If SD values were not reported, we ﬁrst tried to obtain the miss-
ing values from the trial authors. If unavailable, where there were
missing measures of variance for continuous data, but an exact
standard error (SE) and CIs available for group means, and either
’P’ value or ’t’ value available for differences in mean, we calculated
them according to theCochraneHandbook for Systematic Reviews of
Interventions (Higgins 2011): when only the standard error (SE) is
reported, SDs are calculated by the formula SD = SE * square root
(n). Chapters 7.7.3 and 16.1.3 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011a; Higgins 2011b)
present detailed formulae for estimating SDs from P values, t or
F values, CIs, ranges or other statistics. If these formula did not
apply, we calculated the SDs according to a validated imputation
method, which is based on the SDs of the other included studies
(Furukawa 2006). Although some of these imputation strategies
can introduce error, the alternative would be to exclude a given
study’s outcome and thus to lose information. We did not impute
any continuous data in this review.
3.3 Last observation carried forward
We anticipated that in some studies would employ the method of
last observation carried forward (LOCF) within the study report.
As with all methods of imputation to deal with missing data,
LOCF introduces uncertainty about the reliability of the results
(Leucht 2007). Therefore, where LOCFdatawere used in the trial,
if less than 50% of the data had been assumed, we reproduced
these data and indicated that they were the product of LOCF
assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying people or situations which we had
not predicted would arise and discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlying methods which we had
not predicted would arise, and discussed.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I² statistic
We investigated heterogeneity between studies by considering the
I² statistic alongside the Chi² test P value. The I² statistic provides
an estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed I² statistic
value depends on: i. magnitude and direction of effects; and ii.
strength of evidence for heterogeneity (e.g. P value from the Chi²
test, or a CI for I² statistic). We interpreted an I² statistic estimate
≥ around 50% accompanied by a statistically signiﬁcant Chi² test
as evidence of substantial levels of heterogeneity (Section 9.5.2 -
Deeks 2011). When we found substantial levels of heterogeneity
in the primary outcome, we explored reasons for heterogeneity
(Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research ﬁndings
is inﬂuenced by the nature and direction of results. These are de-
scribed in Section 10.1 (Sterne 2011).We tried to locate protocols
of included RCTs. If the protocol was available, we compared out-
comes in the protocol and in the published report. If the proto-
col was unavailable, we compared outcomes listed in the methods
section of the trial report with actually reported results.
2. Funnel plot
Reporting biases arise when the dissemination of research ﬁndings
is inﬂuenced by the nature and direction of results (Egger 1997).
These are again described in Section 10 of theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We are aware
that funnel plots may be useful in investigating reporting biases
but are of limited power to detect small-study effects. We did
not use funnel plots for outcomes where there were 10 or fewer
studies, or where all studies were of similar sizes. In other cases,
where funnel plots are possible, we sought statistical advice in their
interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of ﬁxed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
signiﬁcant heterogeneity. However, there is a disadvantage to the
random-effects model. It puts added weight onto small studies
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which often are the most biased ones. Depending on the direction
of effect, these studies can either inﬂate or deﬂate the effect size.
We used the random-effects model for all analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
We did not anticipate any subgroup analyses.
1.2 Clinical state, stage or problem
We proposed to provide an overview of the effects of chlor-
promazine versus atypical antipsychotic drugs for people with
schizophrenia in general in this Cochrane review. In addition, we
tried to report data on subgroups of people in the same clinical
state, stage and with similar problems.
2. Investigation of heterogeneity
We reported if inconsistency in trial results was high. First, we
investigated whether data had been entered correctly. Second, if
data were correct, we visually inspected the graph and successively
removed outlying studies to see if homogeneity was restored. For
this Cochrane review, we decided that should this occur with data
contributing to the summary ﬁnding of no more than around
10% of the total weighting, we presented these data. If not, we
did not pool these data and discussed any issues. We know of no
supporting research for this 10% cut-off but are investigating use
of prediction intervals as an alternative to this unsatisfactory state.
If we observed obvious unanticipated clinical or methodological
heterogeneity, we simply stated hypotheses regarding these for fu-
ture reviews or versions of this Cochrane review. We did not an-
ticipate undertaking analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. For the primary
outcomes, we included these studies. If there was no substantive
difference whenwe added the implied randomised studies to those
with better description of randomisation, then we used relevant
data from these studies.
2. Assumptions for lost binary data
Where assumptions have to be made regarding people lost to fol-
low-up (see Dealing with missing data), we compared the ﬁndings
of the primary outcomes when we used our assumption compared
with completer data only. If there was a substantial difference, we
reported results and discussed them but continued to employ our
assumption.
Where assumptions had to be made regarding missing SDs data
(see Dealing with missing data), we compared the ﬁndings on
primary outcomes when we used our assumption compared with
completer data only. We performed a sensitivity analysis testing
how prone results were to change when ’completer’ data only were
compared to the imputed data using the above assumption. If
there was a substantial difference, we reported results and discussed
them but continued to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that we judged to be at
’high’ risk of bias across one or more of the domains of randomi-
sation (implied as randomised with no further detail available),
allocation concealment, blinding and outcome reporting for the
meta-analysis of the primary outcome. If the exclusion of trials at
’high’ risk of bias did not substantially alter the direction of effect
or the precision of the effect estimates, thenwe included data from
these trials in the analysis.
4. Imputed values
We had also planned to undertake a sensitivity analysis to assess
the effects of including data from trials where we used imputed
values for ICC in calculating the design effect in cluster-RCTs.
However, we did not impute any values in this Cochrane review.
5. Fixed-effect and random-effects
We synthesised all data using a random-effects model. However,
we also synthesised data for the primary outcome using a ﬁxed-
effect model to evaluate whether this altered the signiﬁcance of
the results.
R E S U L T S
Description of studies
Results of the search
We identiﬁed 444 references following our literature search, of
which we excluded 298 after screening by title/abstract. For this
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Cochrane reviewwith the three comparisons of olanzapine, risperi-
done and quetiapine, we obtained and scrutinised 146 full-text
articles. Of these, 42 articles did not meet the inclusion criteria
(see Characteristics of excluded studies) and were excluded. We
included 71 trials (Figure 1). In the same literature search, we
identiﬁed 33 more studies comparing chlorpromazine to atyp-
ical antipsychotics, including aripiprazole, clotiapine, clozapine,
iloperidone, remoxipride, sulpiride, ziprasidone and zotepine. We
will include all of these comparisons in a future update of this
Cochrane review.
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Figure 1. Study flow diagram.
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Included studies
1. Chlorpromazine versus olanzapine
For this comparison, we included 12 studies (total N = 919; chlor-
promazine N = 432 and olanzapine N = 487).
1. Trial length
Most included studies were eight weeks in duration (vs OLZ -
Chang 2003; vs OLZ - Chen 2006; vs OLZ - He 2003; vs OLZ -
Luo 2007; vs OLZ - Wang 2002; vs OLZ - Wang 2008; vs OLZ -
Zhao 2006), with three studies at six weeks in duration (HGCQ
(Turkey) 2000; HGDV (Morocco) 1999; vs OLZ - Loza 1999
(HGDT)). The ﬁnal two studies were 12 weeks (vs OLZ - Wu
2008) and two years (vs OLZ - An 2006) in duration. Therefore
most included studies provided data for our short term outcome,
with only one study providing any data for the long term.
2. Design
All included studies were parallel arm RCTs. Four out of the
12 studies provided information as to randomisation methods,
which included methods such as computer-generated randomisa-
tion and random number tables (HGCQ (Turkey) 2000; HGDV
(Morocco) 1999; vs OLZ - Chang 2003; vs OLZ - Luo 2007).
3. Participants
All included participants had a diagnosis of schizophrenia; diag-
nostic criteria used included DSM-IV (HGCQ (Turkey) 2000;
HGDV (Morocco) 1999; vs OLZ - Loza 1999 (HGDT)) and
CCMD (vs OLZ - An 2006; vs OLZ - Wang 2008; vs OLZ - Wu
2008; vs OLZ - Zhao 2006). Diagnostic criteria were unclear in
the remaining studies, with participants described either as having
’schizophrenia’ (vs OLZ - Chang 2003; vs OLZ - Chen 2006; vs
OLZ - He 2003) or ’ﬁrst-episode schizophrenia (vs OLZ - Luo
2007; vs OLZ - Wang 2002).
4. Setting
Nine of the included studies were undertaken in China, and in-
cluded both inpatient and outpatient settings. Other studies were
completed in Turkey (HGCQ (Turkey) 2000), Morocco (HGDV
(Morocco) 1999) and Egypt (vs OLZ - Loza 1999 (HGDT)).
5. Study size
Study sizes ranged from 30 (HGCQ (Turkey) 2000) to 100 par-
ticipants (vs OLZ - Wu 2008); and the mean sample size was 77
participants.
6. Interventions
6.1 Chlorpromazine
Chlorpromazine doses ranged from 25 to 600 mg/day (vs OLZ
- Wang 2002) to 200 to 800 mg/day (HGCQ (Turkey) 2000;
HGDV (Morocco) 1999; vs OLZ - Chen 2006; vs OLZ - Loza
1999 (HGDT)).Doses tended to be fairy consistent between stud-
ies.
6.2 Olanzapine
Olanzapine doses between studies were largely uniform, with a
range in 10 of the included studies of 5 mg/day to 20 mg/day, and
in vs OLZ - Luo 2007 the range was 5 mg/day to 25 mg/day, with
vs OLZ - Wang 2008 using a range of 5 mg/day to 15 mg/day.
7. Outcomes
7.1 General remarks
The included studies for this comparison provided generally well-
reported outcomes, including clinical response, global state out-
comes, relapse rates and adverse events. Death was not reported
in any of the included studies for any reason.
7.2 Acceptability and efﬁcacy
Each included study provided data regarding mental and global
state outcomes (widely accepted rating scales, including the BPRS,
PANSS and CGI). However, some of these data were skewed and
were presented in an additional table.
7.3 Adverse events
Adverse events, including extrapyramidal averse effects, anti-
cholinergic effect, cardiovascular effects, gastrointestinal effects
and ’others’ were generally well-reported in the included studies.
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7.4 Outcome scales
7.4.1 Global state
i) Clinical Global Impression (CGI)
This is a rating instrument that enables clinicians to quantify sever-
ity of illness and overall clinical improvement during therapy (Guy
1976). A 7-point scoring system is usually used, with low scores
indicating decreased severity or greater recovery, or both.
7.4.2 Mental state
i) Brief Psychiatric Rating Scale (BPRS)
This scale is used to assess the severity of abnormal mental states
(Overall 1962). The original scale has 16 items, but a revised 18-
item scale is commonly used. Each item is deﬁned on a seven-point
scale varying from ’not present’ to ’extremely severe’, scoring from
zero to six or one to seven. Scores can range from 0 to 108 or 18 to
126, respectively.High scores indicatemore severe symptoms. The
BPRS-positive cluster comprises four items, which are conceptual
disorganisation, suspiciousness, hallucinatory behaviour and un-
usual thought content. The BPRS-negative cluster comprises only
three items, which are emotional withdrawal, motor retardation
and blunted affect.
ii) Hamilton Anxiety Scale (HAMA)
HAMA is a rating scale developed to quantify the severity of anx-
iety symptomatology and consists of 14 items, each deﬁned by a
series of symptoms (Maier 1988). Each item is rated on a 5-point
scale, ranging from zero (not present) to four (severe).
iii) Montgomery-Åsberg Depression Rating Scale (MADRS)
The MADRS is a 10- item clinician-administered diagnostic
questionnaire used to measure the severity of depressive episodes
(Montgomery 1979). There are 10 items (including apparent sad-
ness, reported sadness, inner tension, reduced sleep, reduced ap-
petite, concentration difﬁculties, lassitude, inability to feel, pes-
simistic thoughts and suicidal thoughts), each rated zero (absent)
to six (severe). Overall scores range from zero to 60.
iv) Nurses’ Observation Scale for Inpatient Evaluation (NOSIE)
This scale assesses the behaviour of patients on an inpatient unit (
Honigfeld 1965). The scale has 30 items, each rated from zero (not
present) to four (markedly present), and includes such behaviours
as ’gets angry or annoyed easily’, ’cries’ or ’is impatient’.
iv) Positive and Negative Syndrome Scale (PANSS)
The PANSS was originated as a method for evaluating positive,
negative and other symptom dimensions in schizophrenia (Kay
1987). The scale has 30 items, and each item can be rated on a 7-
point scoring system varying from one (absent) to seven (extreme).
This scale can be divided into three subscales for measuring the
severity of general psychopathology, positive symptoms (PANSS-
P) and negative symptoms (PANSS-N). A low score indicates low
levels of symptoms.
v) Scale for Assessment of Positive Symptoms (SAPS)
This scale measures the positive symptoms of schizophrenia and
is split into four items including hallucinations, delusions, bizarre
behaviour and positive formal thought disorder, each rated on a
scale of zero (absent) to ﬁve (severe) (Andreasen 1984).
7.4.3 Functioning
i) Wisconsin Card Sorting Test (WCST-IQ/MQ)
The WCST is a neuropsychological test in which participants
are expected to organise a set of speciﬁcally-designed cards, with-
out instruction (Monchi 2001). The test is a measure of execu-
tive functioning, assessing primarily strategic planning, organized
searching, utilizing environmental feedback to shift cognitive sets,
directing behavior toward achieving a goal, and modulating im-
pulsive responding.
7.4.4 Adverse events
i) Extrapyramidal Symptom Rating Scale (ESRS)
The ESRS is a physical examination with 12 items that include
both subjective and objective assessments (Chouinard 1980).
iii) Leeds Sleep Evaluation Questionnaire (LSEQ)
The LSEQ is a 10-item, self-rating measurement designed to as-
sess changes in sleep quality over the course of psychopharmaco-
logical treatment (Parrott 1980). Four domains are rated, includ-
ing ’ease of initiating sleep’, ’quality of sleep’, ’ease of waking’ and
’behaviour following wakefulness’.
7.4.5 Quality of life
i) Gothenburg Quality of Life Instrument (GQOLI/ GQOL1 - 74)
This scale assesses overall sleep quality; participants respondon a7-
point Linkert-type scale with one (excellent) and seven (very poor)
(Sullivan 1993). Participants also rate other aspects of quality of
life, including a self-evaluation of their economic situation, social
and friendship situation and home/family situation.
ii) Quality of life scale (QoL)
The QoL scale is a 16-item instrument that measures six concep-
tual domains of quality of life: material and physical well-being,
relationships with other people, social, community and civic ac-
tivities, personal development and fulﬁlment, recreation and in-
dependence (Flanagan 1982). Scores range from 16 to 112, with
a higher score indicating a better outcome.
7.5 Missing outcomes
Studies did not provide vast amounts of data, nor even measured
in many instances, outcomes including service involvement, func-
tioning, behaviour, satisfaction with treatment, or economic out-
comes.
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2. Chlorpromazine versus risperidone
For this comparison, we included 14 studies, with a total of 991
participants (chlorpromazine N = 474; risperidone N = 517).
1. Trial length
Duration of included studies ranged from three weeks (vs RPD -
Liu 2005) to ﬁve months (vs RPD - Chang 1998). The average
length of studies was around eight weeks, therefore all included
studies provided only short term data.
2. Design
All included studies were parallel-arm RCTs. No included study
adequately described randomisation methods.
3. Participants
All participants were diagnosed with schizophrenia according to
Chinese Classiﬁcation of Mental Disorders (CCMD) criteria (
Chen 2002).
4. Setting
All included studies were undertaken in China with inpatient and
outpatient settings both represented.
5. Study size
Sample sizes between studies ranged from 32 (vs RPD - Liu 2000)
to 107 participants (vs RPD - Luo 2001), with a mean sample size
of 70 participants.
6. Interventions
6.1 Chlorpromazine
All studies used different dosage ranges, and included 25 to 450
mg/day (vs RPD - Wang 2005); 100 to 450 mg/day (vs RPD -
Lin 2005); 300/400 to 600 mg/day (vs RPD - Wu 2002; vs RPD
- Wu 2004); and 100 to 700 mg/day (vs RPD - Luo 2001). Not
all studies reported mean doses, with only vs RPD - Cui 2001 and
vs RPD - Feng 2003 using a mean dose of 426 mg/day and 355
mg/day respectively.
6.2 Risperidone
Risperidone doses also varied between studies, with the highest
range of 1 mg/day to 9 mg/day used in vs RPD - Ma 2004; most
included studies used a range of risperidone up to 6 mg/day (vs
RPD - Chang 1998; vs RPD - He 1999; vs RPD - Wang 2005;
vs RPD - Wu 2002; vs RPD - Wu 2004; vs RPD - Zheng 2001).
Again, only two studies described the mean doses used in the
studies (vs RPD - Cui 2001; vs RPD - Feng 2003) of 4.19 mg/
day and 3.62 mg/day respectively.
7. Outcomes
7.1 General remarks
The included studies for this comparison provided generally well-
reported outcomes, including clinical response, global state out-
comes and adverse events. Death was not reported in any of the
included studies for any reason.
7.2 Acceptability and efﬁcacy
Data regarding mental and global state outcomes were measured
using widely accepted rating scales, including the BPRS, PANSS
and CGI. However some of these data were skewed and were
presented in an additional table.
7.3 Adverse events
Adverse events, including extrapyramidal averse effects, anti-
cholinergic effect, cardiovascular effects, gastrointestinal effects
and ’others’ were generally well reported in the included studies.
7.4 Outcome scales presenting useable data
7.4.1 Global state
i) Clinical Global Impression (CGI)
This is a rating instrument that enables clinicians to quantify sever-
ity of illness and overall clinical improvement during therapy (Guy
1976). A 7-point scoring system is usually used with low scores
indicating decreased severity or greater recovery, or both.
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7.4.2 Mental state
i) Brief Psychiatric Rating Scale (BPRS)
This scale is used to assess the severity of abnormal mental states
(Overall 1962). The original scale has 16 items, but a revised 18-
item scale is commonly used. Each item is deﬁned on a 7-point
scale varying from ’not present’ to ’extremely severe’, scoring from
zero to six or one to seven. Scores can range from zero to 108 or 18
to 126, respectively. High scores indicate more severe symptoms.
The BPRS-positive cluster comprises four items, which are con-
ceptual disorganisation, suspiciousness, hallucinatory behaviour
and unusual thought content. The BPRS-negative cluster com-
prises only three items, which are emotional withdrawal, motor
retardation and blunted affect.
ii) Positive and Negative Syndrome Scale (PANSS)
The PANSS was originated as a method for evaluating positive,
negative and other symptom dimensions in schizophrenia (Kay
1987). The scale has 30 items, and each item can be rated on a 7-
point scoring system varying from one (absent) to seven (extreme).
This scale can be divided into three subscales for measuring the
severity of general psychopathology, positive symptoms (PANSS-
P) and negative symptoms (PANSS-N). A low score indicates low
levels of symptoms.
iii) Scale for Assessment of Negative Symptoms (SANS)
The SANS measures the incidence and severity of negative symp-
toms using a 25-item scale, using a six-point scoring system, of
zero ( = better) to ﬁve ( = worse), where a higher score equals a
more severe experience of negative symptoms (Andreasen 1982).
iv) Scale for Assessment of Positive Symptoms (SAPS)
This scale measures the positive symptoms of schizophrenia and
is split into four items including hallucinations, delusions, bizarre
behaviour and positive formal thought disorder, each rated on a
scale of zero (absent) to ﬁve (severe) (Andreasen 1984).
7.4.3 Functioning
i) Wisconsin Card Sorting Test (WCST-IQ/MQ)
The WCST is a neuropsychological test in which participants
are expected to organise a set of speciﬁcally-designed cards, with-
out instruction (Monchi 2001). The test is a measure of execu-
tive functioning, assessing primarily strategic planning, organized
searching, utilizing environmental feedback to shift cognitive sets,
directing behavior toward achieving a goal, and modulating im-
pulsive responding.
7.4.4 Adverse events
i) Treatment-Emergent Signs and Symptoms (TESS)
The ICH E3 1995 guideline has stated that ’treatment-emergent
signs and symptoms’ (TESS) are to be deﬁned as “events not seen
at baseline and events that worsened even if present at baseline”.
It can be difﬁcult to document this accurately taking into account
variables in time, dosage, adverse events and severity. Generally,
TESS scores for particular adverse events are categorised as ’mild’,
’moderate’ or ’severe’, with an appropriate action taken (e.g. none,
discontinued, dose changed’, hospitalisation and additional med-
ication given). It is not often that studies publish continuous data
from these measurements, with the more common presentation
of dichotomised TESS ratings.
7.4.5 Quality of life
i) Quality of life scale (QoL)
The QoL scale is a 16-item instrument that measures six concep-
tual domains of quality of life: material and physical well-being;
relationships with other people; social, community and civic ac-
tivities; personal development and fulﬁlment; recreation and in-
dependence (Flanagan 1982). Scores range from 16 to 112, with
a higher score indicating a better outcome.
7.5 Missing outcomes
Studies did not report any data for relapse rates, service use, be-
haviour, satisfaction with care or treatment, or economic out-
comes.
3. Chlorpromazine versus quetiapine
For this comparison, we included 45 studies with a total of 4388
participants (chlorpromazine N = 2183; quetiapine N = 2205).
1. Trial length
Thirty-seven of the 45 studies were under eight weeks in length.
The shortest study was 42 days in length (vs QTP - Peng 2006).
The longest study was six months long (vs QTP - Li 2003) and
was the only study to provide data at the medium term. All other
outcomes were reported at short term (< six months).
2. Design
All included studies were parallel-arm RCTs. No included study
adequately described randomisation methods.
3. Participants
All participants had a diagnosis of schizophrenia, with diagnosis
using the Chinese Classiﬁcation of Mental Disorders (CCMD)
employed in 42 included studies. Two studies used DSM criteria
to diagnose schizophrenia (vs QTP - Hu 2003; vs QTP - Peuskens
1997), and one study used a combination of CCMD and ICD-
10 criteria (vs QTP - Zhou 2004).
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4. Setting
All included studies were undertaken in China with both inpatient
and outpatient settings represented.
5. Study size
Sample sizes between studies ranged from 30 (vs QTP - Kong
2003) to 237 participants (vs QTP - Zhang 2003).
6. Interventions
6.1 Chlorpromazine
The most common dose range between groups was between 300
to 600 mg/day. Only one study stated dosages used were ’less than
1000 mg/day’ (vs QTP - Guo 2008), with other maximum doses
stated as 750 mg/day (vs QTP - Peuskens 1997).
6.2 Quetiapine
Quetiapine doses were mostly between 300 and 700 mg/day. One
study did not state the dosages used in either group (vs QTP -
Zhou 2003).
7. Outcomes
7.1 General remarks
The included studies for this comparison generally provided well-
reported outcomes, including clinical response, global state out-
comes and adverse events. Death was not reported in any of the
included studies for any reason. Most outcomes were reported us-
ing measurement scales, although we ensured they had been peer-
reviewed as the lack of dichotomous outcomes makes valuable in-
terpretation of these results difﬁcult.
7.2 Acceptability and efﬁcacy
Data regarding mental and global state outcomes were reported
using widely accepted rating scales, including the BPRS, PANSS
and CGI. However some of these data were skewed and were
presented in an additional table.
7.3 Adverse events
Adverse events, including extrapyramidal averse effects, anti-
cholinergic effect, cardiovascular effects, gastrointestinal effects
and ’others’ were generally well reported in the included studies.
7.4 Outcome scales
7.4.1 Global state
i) Clinical Global Impression (CGI)
This is a rating instrument that enables clinicians to quantify sever-
ity of illness and overall clinical improvement during therapy (Guy
1976). A 7-point scoring system is usually used with low scores
indicating decreased severity or greater recovery, or both.
7.4.2 Mental state
i) Brief Psychiatric Rating Scale (BPRS)
This scale is used to assess the severity of abnormal mental states
(Overall 1962). The original scale has 16 items, but a revised 18-
item scale is commonly used. Each item is deﬁned on a 7-point
scale varying from ’not present’ to ’extremely severe’, scoring from
zero to six or one to seven. Scores can range from zero to 108 or 18
to 126, respectively. High scores indicate more severe symptoms.
The BPRS-positive cluster comprises four items, which are con-
ceptual disorganisation, suspiciousness, hallucinatory behaviour
and unusual thought content. The BPRS-negative cluster com-
prises only three items, which are emotional withdrawal, motor
retardation and blunted affect.
ii) Hamilton Rating Scale for Depression (HAMD)
The HAMD rates severity of depression in adults including items
of mood, feelings of guilt, suicide ideation, insomnia, agitation or
retardation, anxiety, weight loss and somatic symptoms (Hamilton
1960). There are 20 items rated on a Linket-type scale, where zero
equals an absence of symptoms and a higher score indicates a worse
outcome.
iii) Positive and Negative Syndrome Scale (PANSS)
The PANSS was originated as a method for evaluating positive,
negative and other symptom dimensions in schizophrenia (Kay
1987). The scale has 30 items, and each item can be rated on a 7-
point scoring system varying from one (absent) to seven (extreme).
This scale can be divided into three subscales for measuring the
severity of general psychopathology, positive symptoms (PANSS-
P) and negative symptoms (PANSS-N). A low score indicates low
levels of symptoms.
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7.4.3 Functioning
i) Wisconsin Card Sorting Test (WCST-IQ/MQ)
The WCST is a neuropsychological test in which participants
are expected to organise a set of speciﬁcally-designed cards, with-
out instruction (Monchi 2001). The test is a measure of execu-
tive functioning, assessing primarily strategic planning, organized
searching, utilizing environmental feedback to shift cognitive sets,
directing behaviour toward achieving a goal and modulating im-
pulsive responding.
ii) Wechsler Memory Scale-revised (WMS-RC)
TheWMS-RC is a neuropsychological test that is used to measure
a person’s memory functions (WMS-IV 2009). The scale consists
of seven subtests: spatial addition, symbol span, design memory,
general cognitive screener, logical memory, verbal paired associates
and visual reproduction. A high score indicates a better outcome.
7.4.4 Adverse events
i) Treatment-Emergent Signs and Symptoms (TESS)
The ICH E3 1995 guideline has stated that ’treatment-emergent
signs and symptoms’ (TESS) are to be deﬁned as “events not seen
at baseline and events that worsened even if present at baseline”.
It can be difﬁcult to document this accurately taking into account
variables in time, dosage, adverse events and severity. Generally,
TESS scores for particular adverse events are categorised as ’mild’,
’moderate’ or ’severe’, with an appropriate action taken (e.g. none,
discontinued, dose changed’ hospitalisation, and additional med-
ication given). It is not often that studies publish continuous data
from these measurements, with the more common presentation
of dichotomised TESS ratings.
7.4.5 Quality of life
i) Gothenburg Quality of Life Instrument (GQOLI/ GQOL1-74)
This scale assesses overall sleep quality; participants respond on a
7-point Linkert-type scale ranging from one(’excellent’) and seven
(’very poor’) (Sullivan 1993). Participants also rate other aspects
of quality of life, including a self-evaluation of their economic sit-
uation, social and friendship situation and home/family situation.
7.5 Missing outcomes
Excluded studies
We excluded 42 studies; for details please consult the
Characteristics of excluded studies section,
Risk of bias in included studies
For a graphical overview, please see Figure 2 and Figure 3.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
Allocation
1. Chlorpromazine versus olanzapine
Only four included studies provided adequate information regard-
ing randomisation, which included methods such as a computer-
generated randomisation and random number tables (HGCQ
(Turkey) 2000; HGDV (Morocco) 1999; vs OLZ - Chang 2003;
vs OLZ - Luo 2007). We judged each of these studies as at ’low’
risk of bias. The remaining studies in this comparison were rated
as at ’unclear’ risk of bias, as ’randomisation’ or ’random allocated’
was stated, however no description was provided. However, three
studies were rated as a ’high’ risk of bias due to the lack of allocation
concealment (HGCQ (Turkey) 2000; HGDV (Morocco) 1999;
vs OLZ - Loza 1999 (HGDT)); each study stated that “the [study
drug] bottles were labelled ’Olanzapine’ or ’Chlorpromazine’ in
addition to the study number”. We rated all other studies as ’un-
clear’ for allocation bias.
2. Chlorpromazine versus risperidone
None of the included studies provided details as to randomisation
methods and therefore we rated each as at ’unclear’ risk of bias,
since ’randomisation’ or ’random allocated’ was stated but no de-
scription was provided.
3. Chlorpromazine versus quetiapine
Only eight of the 45 included studies provided adequate data as to
randomisation methods; ﬁve studies used a random number table
(vsQTP -Chen2001; vsQTP -Guo 2008; vsQTP - Peng 2006; vs
QTP -Wang 2005; vsQTP -Zhou 2003), two studies randomised
by tossing a coin (vs QTP - Guo 2003a; vs QTP - Zhang 2002)
and one study randomised through computer-generated random
numbers (vs QTP - Zhang 2003). We rated these studies at ’low’
risk of bias, with the remaining studies rated at ’unclear’ risk.
Blinding
1. Chlorpromazine versus olanzapine
We rated four studies at ’high’ risk of bias for blinding and de-
tection bias (HGCQ (Turkey) 2000; HGDV (Morocco) 1999; vs
OLZ - Loza 1999 (HGDT); vs OLZ - Wang 2002). Each of these
were open label studies where both participant and study investi-
gator knew what was being given and received. All other studies
were rated at ’unclear’ risk of bias.
2. Chlorpromazine versus risperidone
Only two studies were rated at ’low’ risk of bias for performance
and detection bias in blinding (vs RPD - Cui 2001; vs RPD -
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Feng 2003). Double blinding was used via, identical study drugs,
dispensed by an independent pharmacist. All other studies were
rated as at ’unclear’ risk of bias.
3. Chlorpromazine versus quetiapine
We rated only one study as at ’low’ risk of bias, since it speciﬁed
assessor blinding (vs QTP - Peng 2006). All other studies were
rated at ’unclear’ risk of bias.
Incomplete outcome data
1. Chlorpromazine versus olanzapine
All studies apart from one were rated at ’low’ risk of attrition bias
either because all participants were stated to have complete the
study, or those that left the study early were included in the ﬁnal
analysis. We rated only one study as a ’high’ risk of bias because 13
and 11 people dropped out of the olanzapine and chlorpromazine
groups respectively (vs OLZ - Wang 2008). These people were
excluded from the ﬁnal analysis and reasons for dropout were not
given.
2. Chlorpromazine versus risperidone
We rated all but two studies as at ’low’ risk of attrition bias either
because all participants were stated to have completed the study,
or those that left the study early were included in the ﬁnal analysis.
We rated two studies as at ’unclear’ risk (vs RPD - Feng 2003; vs
RPD -Wang 2005) as there were dropouts, however it was unclear
whether these were included in the ﬁnal analysis.
3. Chlorpromazine versus quetiapine
Thirty-seven included studies were rated as at ’low’ risk of attrition
bias either because all participants were stated to have complete the
study, or those that left the study early were included in the ﬁnal
analysis. We rated eight studies as at ’high’ risk of attrition bias (vs
QTP - Cao 2005; vs QTP - Cheng 2003; vs QTP - Guo 2003b;
vs QTP - Ji 2004; vs QTP - Li 2003; vs QTP - NCT00882518;
vs QTP - Wang 2005; vs QTP - Yang 2007) either because it was
unclear if these were included in the ﬁnal analysis, or dropouts
were excluded from the analysis.
Selective reporting
1. Chlorpromazine versus olanzapine
We rated ﬁve studies at ’high’ risk of bias for selective reporting
(HGCQ (Turkey) 2000; vs OLZ - Chang 2003; vs OLZ - Chen
2006; vs OLZ - Loza 1999 (HGDT); vs OLZ - Wang 2002) due
to pre-speciﬁed outcomes in each study not being fully reported,
or partially reported.One study was rated as at ’unclear’ risk of bias
(vs OLZ - Wu 2008) as it was not explicit whether all outcomes
were reported. We rated all remaining studies as at ’low’ risk of
bias.
2. Chlorpromazine versus risperidone
We rated two studies as at ’high’ risk of bias for selective reporting
due to pre-speciﬁed outcomes in each study not being fully re-
ported or partially reported (vs RPD - Lin 2005; vs RPD - Zheng
2001). Two studies were rated as at ’unclear’ risk of bias as it was
not explicit whether all outcomes were reported (vs RPD - Feng
2003; vs RPD - Liu 2000). We rated all other studies as at ’low’
risk of bias.
3. Chlorpromazine versus quetiapine
Twelve studies were rated as at ’high’ risk of bias for selective re-
porting due to pre-speciﬁed outcomes in each study not being fully
reported, or partially reported (vs QTP - Ai 2007; vs QTP - Chen
2007; vs QTP - Chen 2008; vs QTP - Deng 2004; vs QTP - Guo
2007; vs QTP - Jiang 2006; vs QTP - Jiang 2008; vs QTP - Jin
2007; vs QTP - Nai 2007; vs QTP - Wan 2002; vs QTP - Zhang
2003; vs QTP - Zou 2006). We rated one study as at ’unclear’ risk
of bias as it was not explicit whether all outcomes were reported
(vs QTP - Liu 2003). We rated all other studies as at ’low’ risk of
bias. See Figure 4.
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Figure 4. Funnel plot of comparison: 3 Chlorpromazine vs Quetiapine, outcome: 3.1 Clinical response: no
significant clinical response.
Other potential sources of bias
1. Chlorpromazine versus olanzapine
All studies were rated at ’low’ risk of other potential sources of
bias, since we did not detect any obvious bias.
2. Chlorpromazine versus risperidone
We rated all studies at ’low’ risk of other potential sources of bias,
since we did not detect any obvious bias.
3. Chlorpromazine versus quetiapine
We rated two studies at ’high’ risk of bias as they were both
funded by the pharmaceutical company AstraZeneca, the man-
ufacturers of quetiapine (vs QTP - Peuskens 1997; vs QTP -
NCT00882518). All remaining studies were rated at ’low’ risk of
other potential sources of bias, since we did not detect any obvious
bias.
Effects of interventions
See: Summary of findings for the main
comparison CHLORPROMAZINE versus OLANZAPINE for
schizophrenia; Summary of findings 2 CHLORPROMAZINE
versus RISPERIDONE for schizophrenia; Summary of
findings 3 CHLORPROMAZINE versus QUETIAPINE for
schizophrenia
Comparison 1: CHLORPROMAZINE versus
OLANZAPINE
1.1 Clinical response: 1. No significant clinical response
1.1.1 short term - up to 6 months
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In this subgroup we found three relevant trials (N = 204). There
was a statistically signiﬁcant difference (P = 0.002) in favour of
olanzapine (RR 2.34, 95% CI 1.37 to 3.99; Analysis 1.1).
1.1.2 long term - over 12 months
We only found one relevant trial in this subgroup (N = 70) (vs
OLZ - An 2006). There was no signiﬁcant difference between
chlorpromazine and olanzapine (RR 1.83, 95% CI 0.76 to 4.41;
Analysis 1.1).
1.1.3 total
Overall there was a statistically signiﬁcant difference in favour of
olanzapine in both short and long term (4 RCTs, N = 274; RR
2.19, 95% CI 1.39 to 3.45; P = 0.0008; Analysis 1.1)
1.2 Clinical response: 2. Average endpoint score of CGI (high
= poor) - short term (up to 6 months)
In this subgroup we included three trials (N = 110). There was
a statistically signiﬁcant difference in favour of olanzapine (MD
0.93, 95%CI0.36 to 1.51; P =0.002; Analysis 1.2). This subgroup
had moderate levels of heterogeneity (Chi² test = 3.9; df = 2; P =
0.142; I² statistic = 49%).
1.3 Clinical response: 3. Relapse - long term (over 12
months)
In this subgroup we only found one relevant trial (N = 70) (vs
OLZ - An 2006). There was no signiﬁcant difference between
chlorpromazine and olanzapine (RR 1.5, 95% CI 0.46 to 4.86;
Analysis 1.3).
1.4 Mental state: 1. Average endpoint score of various scales
(high = poor) - short term (up to 6 months)
1.4.1 BPRS total
In this subgroupwe found four relevant trials (N =245). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(MD 3.21, 95% CI −0.62 to 7.05; Analysis 1.4). This subgroup
had important levels of heterogeneity (Chi² test = 23.38; df = 3;
P = 0.0; I² statistic = 87%).
1.4.2 BPRS activation subscale
In this subgroup we found two relevant trials (N = 299). There was
a statistically signiﬁcant difference in favour of olanzapine (MD
0.47, 95% CI 0.27 to 0.67; P < 0.00001; Analysis 1.4).
1.4.3 BPRS anxiety-depression subscale
In this subgroup we only included one trial (N = 213) (vs OLZ
- Wang 2008). There was a statistically signiﬁcant difference in
favour of olanzapine (MD 1.57, 95% CI 1.36 to 1.78; P <
0.00001; Analysis 1.4).
1.4.4 BPRS hostile-suspiciousness subscale
In this subgroup we found two relevant trials (N = 299). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(MD−0.31, 95%CI−1.98 to 1.35; Analysis 1.4). This subgroup
had important levels of heterogeneity (Chi² test = 16.24; df = 1;
P = 0.0; I² statistic = 94%).
1.4.5 BPRS thinking disorder subscale
We found two relevant trials in this subgroup (N=299). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(MD−0.8, 95% CI−2.66 to 1.06; Analysis 1.4). This subgroup
had important levels of heterogeneity (Chi² test = 16.59; df = 1;
P = 0.0; I² statistic = 94%).
1.4.6 BPRS withdraw-retardation subscale
In this subgroup we found two relevant trials (N = 299). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(MD−0.49 95%CI−2.25 to 1.26; Analysis 1.4). This subgroup
had important levels of heterogeneity (Chi² test = 53.34; df = 1;
P = 0.0; I² statistic = 98%).
1.4.7 NOSIE total
We only included one trial in this subgroup (N = 213) (vs OLZ
- Wang 2008). There was a statistically signiﬁcant difference in
favour of chlorpromazine (MD −18.36, 95% CI −22.39 to
−14.33; P < 0.00001; Analysis 1.4).
1.4.8 PANSS total
In this subgroup we included six trials (N = 351). There was
a statistically signiﬁcant difference in favour of olanzapine (MD
10.46, 95% CI 4.49 to 16.43; P = 0.006; Analysis 1.4). This
subgroup had important levels of heterogeneity (Chi² test = 15.31;
df = 5; P = 0.009; I² statistic = 67%).
1.4.9 PANSS general pathology subscale
In this subgroup we only found one relevant trial (N = 100) (vs
OLZ - Wu 2008). There was no signiﬁcant difference between
chlorpromazine and olanzapine (MD 1.31, 95% CI −0.32 to
2.94; Analysis 1.4).
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1.4.10 PANSS negative symptom subscale
In this subgroup we found two relevant trials (N = 141). There was
a statistically signiﬁcant difference in favour of olanzapine (MD
2.38, 95% CI 0.31 to 4.45; P = 0.02; Analysis 1.4).
1.4.11 PANSS positive symptom subscale
We found two relevant trials in this subgroup (N=161). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(MD 0.91, 95% CI −0.30 to 2.11; Analysis 1.4).
1.4.12 SAPS total
In this subgroup we only found one relevant trial (n = 86) (vs
OLZ - Chen 2006). There was no signiﬁcant difference between
chlorpromazine and olanzapine (MD −2.1, 95% CI −4.53 to
0.33; Analysis 1.4).
1.5 Mental state: 3. Average endpoint score (BPRS, high =
poor) - medium term (7 - 12 months)
In this subgroup we only found one relevant trial (N = 60) (vs
OLZ - Wang 2002). There was a statistically signiﬁcant difference
in favour of olanzapine (MD 8.60, 95% CI 5.94 to 11.26; P <
0.00001; Analysis 1.5).
1.6 Mental state: 2. Average endpoint score of various scales
(high = poor) - skewed data
Data using the various mental state scales, including the BPRS,
PANSS,MADRS andHAMA, were skewed and are best inspected
by viewing (Analysis 1.6).
1.7 Service involvement: 1. Re-hospitalisation
1.7.1 long term (over 12 months)
We found only one trial in this subgroup (N = 70) (vs OLZ -
An 2006). There was no signiﬁcant difference between chlorpro-
mazine and olanzapine (RR 1.50, 95% CI 0.46 to 4.86; Analysis
1.7).
1.8 Functioning: 1. Executive function - average endpoint
score (WCST, high = poor)
1.8.1 short term (up to 6 months)
In this subgroup we only found one relevant trial (N = 53) (vs
OLZ - An 2006). There was a statistically signiﬁcant difference
in favour of olanzapine (MD 10.96, 95% CI 1.01 to 20.91; P =
0.03; Analysis 1.8).
1.9 Adverse effects: 1. Anticholinergic - short term (up to 6
months)
1.9.1 blurred vision
In this subgroup we found three relevant trials (N = 241). There
was no signiﬁcant difference between chlorpromazine and olan-
zapine (RR 2.59, 95% CI 0.66 to 10.22; Analysis 1.9). This sub-
group had moderate levels of heterogeneity (Chi² test = 3.4; df =
2; P = 0.183; I² statistic = 41%).
1.9.2 dry mouth
In this subgroup we found ﬁve relevant trials (N = 536). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(RR 1.13, 95% CI 0.29 to 4.45; Analysis 1.9). This subgroup had
important levels of heterogeneity (Chi² test = 18.59; df = 4; P =
0.001; I² statistic = 78%).
1.9.3 excessive sweating
We included two relevant trials in this subgroup (N = 180). There
was no signiﬁcant difference between chlorpromazine and olanza-
pine (RR 3.00, 95% CI 0.62 to 14.46; Analysis 1.9).
1.9.4 hypersalivation
In this subgroup we found two relevant trials (N = 166). There
was a statistically signiﬁcant difference in favour of olanzapine (RR
10.99, 95% CI 4.14 to 29.17; P < 0.00001; Analysis 1.9).
1.9.5 stuffy nose
In this subgroup we only found one relevant trial (N = 80) (vs
OLZ - He 2003). There was a statistically signiﬁcant difference in
favour of olanzapine (RR 3.00, 95% CI 1.06 to 8.52; P = 0.04;
Analysis 1.9).
1.10 Adverse effects: 2. Cardiovascular - short term (up to 6
months)
1.10.1 abnormal ECG
In this subgroup we found two relevant trials (N = 180). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(RR 3.60, 95% CI 0.60 to 21.55; Analysis 1.10).
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1.10.2 apathism - short term (up to six months)
In this subgroup we included only one relevant trial (N = 100) (vs
OLZ -Wu 2008). There was a statistically signiﬁcant difference in
favour of olanzapine (RR 5.00, 95% CI 1.15 to 21.67; P = 0.03;
Analysis 1.10).
1.10.3 blood pressure (drop)
We included two trials in this subgroup (N = 180). There was
a statistically signiﬁcant difference in favour of olanzapine (RR
8.82, 95% CI 1.13 to 68.52 Analysis 1.10.
1.10.4 orthostatic hypotension
In this subgroup we found ﬁve relevant trials (N = 561). There was
a statistically signiﬁcant difference in favour of olanzapine (RR
9.78, 95% CI 2.68 to 35.71; P = 0.006; Analysis 1.10).
1.10.5 palpitation
In this subgroup we only found one relevant trial (N = 237) (vs
OLZ - Wang 2008). There was a statistically signiﬁcant difference
in favour of olanzapine (RR 40.66, 95% CI 2.49 to 664.56; P =
0.009; Analysis 1.10).
1.10.6 tachycardia
In this subgroup we found three relevant trials (N = 241). There
was a statistically signiﬁcant difference in favour of olanzapine (RR
3.53, 95% CI 1.66 to 7.48; P = 0.001; Analysis 1.10).
1.11 Adverse effects: 3. Central nervous system - short term
(up to 6 months)
1.11.1 dizziness
We included two trials in this subgroup (N = 180). There was
a statistically signiﬁcant difference in favour of olanzapine (RR
3.85, 95% CI 1.11 to 13.32; P = 0.03; Analysis 1.11).
1.11.2 drowsiness
In this subgroup we found ﬁve relevant trials (N = 536). There was
a statistically signiﬁcant difference in favour of olanzapine (RR
2.46, 95% CI 1.66 to 3.64; P < 0.00001; Analysis 1.11).
1.11.3 fatigue
In this subgroup we found two relevant trials (N = 161). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(RR 1.00, 95% CI 0.13 to 7.66; Analysis 1.11). This subgroup
had moderate levels of heterogeneity (Chi² test = 1.79; df = 1; P
= 0.181; I² statistic = 44%).
1.12 Adverse effects: 4. Gastrointestinal - short term (up to
6 months)
1.12.1 appetite loss
In this subgroup we found two relevant trials (N = 180). There
was a statistically signiﬁcant difference in favour of olanzapine (RR
11.01, 95% CI 2.82 to 42.94; P = 0.0006; Analysis 1.12). This
subgroup had moderate levels of heterogeneity (Chi² test = 1.78;
df = 1; P = 0.182; I² statistic = 44%).
1.12.2 constipation
In this subgroup we found six relevant trials (N = 622). There was
a statistically signiﬁcant difference in favour of olanzapine (RR
4.29, 95% CI 2.61 to 7.05; P < 0.00001; Analysis 1.12).
1.12.3 diarrhoea
We found only one trial in this subgroup (N = 80) (vs OLZ -
He 2003). There was no signiﬁcant difference between chlorpro-
mazine andolanzapine (RR5.00, 95%CI 0.25 to 100.97; Analysis
1.12).
1.12.4 dysphagia
We found only one relevant trial in this subgroup (N = 100) (vs
OLZ - Wu 2008). There was no signiﬁcant difference between
chlorpromazine and olanzapine (RR 3.00, 95% CI 0.13 to 71.92;
Analysis 1.12).
1.12.5 nausea/vomiting
We included two relevant trials in this subgroup (N = 180). There
was no signiﬁcant difference between chlorpromazine and olanza-
pine (RR 1.49, 95% CI 0.43 to 5.20; Analysis 1.12).
1.13 Adverse effects: 5. Haematology - - short term (up to 6
months)
1.13.1 abnormal haemogram
In this subgroup we found two relevant trials (N = 180). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(RR 4.00, 95% CI 0.87 to 18.31; Analysis 1.13).
1.13.2 leukopenia
In this subgroup we only found one relevant trial (N = 86) (vs
OLZ - Chen 2006). There was no signiﬁcant difference between
chlorpromazine andolanzapine (RR6.69, 95%CI 0.36 to 125.71;
Analysis 1.13).
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1.14 Adverse effects: 6. Hepatitic - short term (up to 6
months)
1.14.1 abnormal liver function
In this subgroup we only found one relevant trial (N = 100) (vs
OLZ - Wu 2008). There was no signiﬁcant difference between
chlorpromazine andolanzapine (RR5.00, 95%CI 0.25 to 101.58;
Analysis 1.14).
1.14.2 abnormal transaminase
In this subgroup we found two relevant trials (N = 147). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(RR 0.88, 95% CI 0.01 to 150.45; Analysis 1.14). This subgroup
had important levels of heterogeneity (Chi² test = 6.56; df = 1; P
= 0.01; I² statistic = 85%).
1.15 Adverse effects: 7a Metabolic - weight gain - short term
(up to 6 months)
In this subgroup we found ﬁve relevant trials (N = 536). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(RR 0.70, 95% CI 0.25 to 1.96; Analysis 1.15 ). This subgroup
had important levels of heterogeneity (Chi² test = 12.17; df = 4;
P = 0.016; I² statistic = 67%).
1.16 Adverse effects: 7b. Metabolic - weight gain -
continuous measures
1.16.1 short term (up to to 6 months)
In this subgroupwe found four relevant trials (N =160). There was
a statistically signiﬁcant difference in favour of chlorpromazine
(MD −5.11, 95% CI −9.15 to −1.07; P = 0.01; Analysis 1.16).
1.16.1 medium term (7 to 12 months)
We included only one trial in this subgroup (N = 50) (vs OLZ
- Luo 2007). There was no signiﬁcant difference between chlor-
promazine and olanzapine (MD 0.59, 95% CI −11.87 to 13.05;
Analysis 1.16).
1.17 Adverse effects: 7c. Metabolic - other - continuous
measures
1.17.1 cholesterol (TC) - short term (up to 6 months)
In this subgroup we included one relevant trial (N = 50) (vs
OLZ - Luo 2007). There was no signiﬁcant difference between
chlorpromazine and olanzapine (MD −0.40, 95% CI −1.02 to
0.22; Analysis 1.17).
1.17.2 high-density lipoprotein (HDL) - short term (up to 6
months)
We only found one trial in this subgroup (N = 50) (vs OLZ -
Luo 2007). There was no signiﬁcant difference between chlor-
promazine and olanzapine (MD 0.05, 95% CI −0.12 to 0.22;
Analysis 1.17).
1.17.3 low-density lipoprotein (LDL) - short term (up to 6
months)
We found only one relevant trial in this subgroup (N = 50) (vs
OLZ - Luo 2007). There was no signiﬁcant difference between
chlorpromazine and olanzapine (MD −0.01, 95% CI −0.31 to
0.29; Analysis 1.17).
1.17.4 low-density lipoprotein (LDL) - medium term (7 to
12 months)
In this subgroup we only found one relevant trial (N = 50) (vs
OLZ - Luo 2007). There was no signiﬁcant difference between
chlorpromazine and olanzapine (MD 0.06, 95% CI −0.41 to
0.53; Analysis 1.16).
1.18 Adverse effects: 7d. Metabolic - other - average
endpoint scores - skewed data
Data for endpoint scores in cholesterol, high-density lipoprotein
and triglyceride are skewed and are best inspected by viewing
Analysis 1.18.
1.19 Adverse effects: 8a. Movement disorders -
extrapyramidal symptoms - short term (up to 6 months)
1.19.1 akathisia
In this subgroup we found three relevant trials (N = 417). There
was no signiﬁcant difference between chlorpromazine and olanza-
pine (RR 1.86, 95% CI 0.29 to 11.84; Analysis 1.19). This sub-
group had important levels of heterogeneity (Chi² test = 5.51; df
= 2; P = 0.064; I² statistic = 64%).
1.19.2 any EPS symptoms
In this subgroup we found two relevant trials (N = 298). There
was a statistically signiﬁcant difference in favour of olanzapine (RR
34.47, 95% CI 4.79 to 248.3; P = 0.0004; Analysis 1.19).
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1.19.3 muscle stiffness
In this subgroup we found two relevant trials (N = 180). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(RR 6.13, 95% CI 0.73 to 51.45; Analysis 1.19).
1.19.4 tremor
In this subgroup we found two relevant trials (N = 180). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(RR 6.78, 95% CI 0.84 to 54.57; Analysis 1.19).
1.20 Adverse effects: 8b. Movement disorders -
extrapyramidal symptoms - average endpoint score (ESRS,
high = poor)
1.20.1 short term (up to 6 months)
We included two relevant trials in this subgroup (N = 80). There
was a statistically signiﬁcant difference in favour of olanzapine
(MD 0.9, 95% CI 0.14 to 1.66; P = 0.02; Analysis 1.20)
1.21 Adverse effects: 9a. Various other - sleep - average
endpoint score (LSEQ, high = better) - short term (up to 6
months)
1.21.1 awaking from sleep
We found only one relevant trial in this subgroup (N = 30)
(HGCQ (Turkey) 2000). There was no signiﬁcant difference
between chlorpromazine and olanzapine (MD −5.30, 95% CI
−21.91 to 11.31; Analysis 1.21).
1.21.2 getting to sleep score
In this subgroupwe only foundone relevant trial (N=30) (HGCQ
(Turkey) 2000). Therewas no signiﬁcant difference between chlor-
promazine andolanzapine (MD−0.60, 95%CI−19.88 to 18.68;
Analysis 1.21).
1.21.3 quality of sleep
In this subgroupwe only foundone relevant trial (N=30) (HGCQ
(Turkey) 2000). Therewas no signiﬁcant difference between chlor-
promazine andolanzapine (MD−15.00, 95%CI−33.07 to 3.07;
Analysis 1.21).
1.22 Adverse effects: 9b. Various other - sleep - average
length of sleep (hour/day)
1.22.1 short term (up to 6 months)
We found one trial in this subgroup (N = 50) (vs OLZ - Luo
2007). There was a statistically signiﬁcant difference in favour of
olanzapine (MD3.63, 95%CI 2.08 to 5.18; P < 0.00001; Analysis
1.22).
1.22.2 medium term (7 to 12 months)
In this subgroup we only found one relevant trial (N = 50) (vs
OLZ - Luo 2007). There was a statistically signiﬁcant difference
in favour of olanzapine (MD 4.41, 95% CI 2.82 to 6.00; P <
0.00001; Analysis 1.22).
1.23 Adverse effects: 9c. Various other - sleep - average
score - behaviour following waking - skewed data
Data for this study are skewed and are best inspected by viewing
Analysis 1.23.
1.24 Adverse effects: 9d. Various other - rash
1.24.1 short term (up to 6 months)
We included one relevant trial in this subgroup (N = 30) (HGCQ
(Turkey) 2000). Therewas no signiﬁcant difference between chlor-
promazine and olanzapine (RR 2.00, 95% CI 0.14 to 28.76;
Analysis 1.24).
1.25 Quality of life: 1a. Average endpoint scores (various
scales, high = better) - short term (up to 6 months)
1.25.1 GQOLI - living condition
In this subgroup we only found one relevant trial (N = 61) (vs
OLZ - Zhao 2006). There was no signiﬁcant difference between
chlorpromazine and olanzapine (MD −1.00, 95% CI −4.21 to
2.21; Analysis 1.25).
1.25.2 GQOLI - physical health
In this subgroup we only found one relevant trial (N = 61) (vs
OLZ - Zhao 2006). There was a statistically signiﬁcant difference
in favour of olanzapine (MD−10.10, 95% CI−13.93 to−6.27;
P < 0.00001; Analysis 1.25).
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1.25.3 GQOLI - psychological health
In this subgroup we only found one relevant trial (N = 61) (vs
OLZ - Zhao 2006). There was a statistically signiﬁcant difference
in favour of olanzapine (MD−22.60, 95%CI−25.94 to−19.26;
P < 0.00001; Analysis 1.25).
1.25.4 GQOLI - social function
In this subgroup we only found one relevant trial (N = 61) (vs
OLZ - Zhao 2006). There was a statistically signiﬁcant difference
in favour of olanzapine (MD−18.20, 95%CI−20.51 to−15.89;
P < 0.00001; Analysis 1.25).
1.26 Quality of life: 1b. Average endpoint score (QoL, high =
better) - skewed data
Data for this outcome are skewed, and are best inspected by view-
ing Analysis 1.25.
1.27 Leaving the study early - short term (up to 6 months)
1.27.1 due to any reason
In this subgroup we found three relevant trials (N = 139). There
was no signiﬁcant difference between chlorpromazine and olan-
zapine (RR 1.69, 95% CI 0.45 to 6.40; Analysis 1.27). This sub-
group had moderate levels of heterogeneity (Chi² test = 3.64; df
= 2; P = 0.162; I² statistic = 45%).
1.27.2 due to lack of efficacy
In this subgroup we found two relevant trials (N = 71). There was
no signiﬁcant difference between chlorpromazine and olanzapine
(RR 0.47, 95% CI 0.08 to 2.66; Analysis 1.27).
Comparison 2: CHLORPROMAZINE versus
RISPERIDONE
2.1 Clinical response: 1. No significant clinical response
2.1.1 short term (up to 6 months)
In this subgroup we found seven relevant trials (N = 475). There
was no signiﬁcant difference between chlorpromazine and risperi-
done (RR 0.84, 95% CI 0.53 to 1.34; Analysis 2.1).
2.2 Global state: 1. Average endpoint score (CGI-CI, high =
poor) - skewed data
Data for this outcome are skewed and are best inspected by viewing
Analysis 2.2.
2.3 Global state: 2. Need of additional benzhexol
2.3.1 short term (up to 6 months)
We included two trials in this subgroup (N = 137). There was
no signiﬁcant difference between chlorpromazine and risperidone
(RR 1.20, 95% CI 0.26 to 5.53; Analysis 2.3). This subgroup had
important levels of heterogeneity (Chi² test = 2.36; df = 1; P =
0.124; I² statistic = 58%).
2.4 Mental state: 1a. Average endpoint score (various scales,
high = poor) short term (up to 6 months)
2.4.1 BPRS total
In this subgroupwe found four relevant trials (N =247). There was
no signiﬁcant difference between chlorpromazine and risperidone
(MD 0.90, 95% CI −3.49 to 5.28; Analysis 2.4). This subgroup
had important levels of heterogeneity (Chi² test = 14.61; df = 3;
P = 0.002; I² statistic = 79%).
2.4.2 BPRS activation subscale
In this subgroup we found two relevant trials (N = 130). There was
no signiﬁcant difference between chlorpromazine and risperidone
(MD 0.41, 95% CI −0.81 to 1.63; Analysis 2.4). This subgroup
had important levels of heterogeneity (Chi² test = 4.41; df = 1; P
= 0.036; I² statistic = 77%).
2.4.3 BPRS anxiety-depression subscale
In this subgroup we found two relevant trials (N = 130). There was
no signiﬁcant difference between chlorpromazine and risperidone
(MD 0.09, 95% CI −1.56 to 1.73; Analysis 2.4). This subgroup
had important levels of heterogeneity (Chi² test = 11.14; df = 1;
P = 0.001; I² statistic = 91%).
2.4.4 BPRS hostile-suspiciousness subscale
We found two relevant trials in this subgroup (N=130). There was
no signiﬁcant difference between chlorpromazine and risperidone
groups (MD 0.89, 95% CI −1.41 to 3.18; Analysis 2.4). This
subgroup had important levels of heterogeneity (Chi² test = 12.36;
df = 1; P = 0.0; I² statistic = 92%).
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2.4.5 NORS total
In this subgroup we only found one relevant trial (N = 39) (vs
RPD - He 1999). There was no signiﬁcant difference between
chlorpromazine and risperidone (MD 1.80, 95% CI −2.53 to
6.13; Analysis 2.4).
2.4.6 PANSS total
In this subgroup we found ﬁve relevant trials (N = 397). There was
no signiﬁcant difference between chlorpromazine and risperidone
(MD−1.95, 95%CI−5.58 to 1.69; Analysis 2.4). This subgroup
had important levels of heterogeneity (Chi² test = 8.7; df = 4; P =
0.069; I² statistic = 54%).
2.4.7 PANSS positive symptom subscale
In this subgroupwe found four relevant trials (N =337). There was
no signiﬁcant difference between chlorpromazine and risperidone
(MD 0.03, 95% CI −1.67 to 1.74; Analysis 2.4). This subgroup
had important levels of heterogeneity (Chi² test = 11.12; df = 3;
P = 0.011; I² statistic = 73%).
2.4.8 PANSS negative symptom subscale
We found three relevant trials in this subgroup (N = 230). There
was no signiﬁcant difference between chlorpromazine and risperi-
done (MD 3.16, 95% CI −1.57 to 7.89; Analysis 2.4). This sub-
group had important levels of heterogeneity (Chi² test = 40.11; df
= 2; P = 0.0; I² statistic = 95%).
2.4.9 PANSS general pathology subscale
In this subgroup we found three relevant trials (N = 267). There
was no signiﬁcant difference between chlorpromazine and risperi-
done (MD −0.85, 95% CI −2.15 to 0.46; Analysis 2.4).
2.4.10 SANS total
In this subgroup we found two relevant trials (N = 71). There was
no signiﬁcant difference between chlorpromazine and risperidone
(MD10.89, 95%CI−4.49 to 26.27; Analysis 2.4). This subgroup
had important levels of heterogeneity (Chi² test = 13.51; df = 1;
P = 0.0; I² statistic = 93%).
2.5 Mental state: 1b. Average endpoint score (various scales,
high = poor) - skewed data
Data for this outcome are skewed and are best inspected by viewing
Analysis 2.5.
2.6 Mental state: 2. Average change score - decreased rate
(various scales, high = poor) - short term (up to 6 months)
2.6.1 PANSS total
In this subgroup we only found one relevant trial (N = 57) (vs
RPD - Wang 2002). There was no signiﬁcant difference between
chlorpromazine and risperidone (MD −0.11, 95% CI −0.23 to
0.01; Analysis 2.6).
2.6.2 PANSS negative subscale
In this subgroup we only found one relevant trial (N = 57) (vs
RPD - Wang 2002). There was no signiﬁcant difference between
chlorpromazine and risperidone (MD −0.21, 95% CI −0.44 to
0.02; Analysis 2.6).
2.6.3 PANSS positive subscale
We only found one relevant trial in this subgroup (N = 57) (vs
RPD - Wang 2002). There was no signiﬁcant difference between
chlorpromazine and risperidone (MD −0.07, 95% CI −0.36 to
0.22; Analysis 2.6).
2.7 Functioning: average endpoint score (WCST subscales,
high = good) - short term (up to 6 months)
2.7.1 WCST-IQ
In this subgroup we only found one relevant trial (N = 100) (vs
RPD -Wang 2005). There was a statistically signiﬁcant difference
in favour of risperidone (MD−11.30, 95%CI−18.34 to−4.26;
P = 0.002; Analysis 2.7).
2.7.2 WCST-MQ
We only found one relevant trial in this subgroup (N = 100) (vs
RPD -Wang 2005). There was a statistically signiﬁcant difference
in favour of risperidone (MD−19.6, 95% CI−28.83 to−10.37;
P < 0.0001; Analysis 2.7).
2.8 Adverse effects: 1. Anticholinergic - short term (up to 6
months)
2.8.1 blurred vision
In this subgroup we found ﬁve relevant trials (N = 387). There was
a statistically signiﬁcant difference in favour of risperidone (RR
2.44, 95% CI 1.32 to 4.50; P = 0.004; Analysis 2.8).
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2.8.2 dry mouth
There were nine relevant trials in this subgroup (N = 852). There
was no signiﬁcant difference between chlorpromazine and risperi-
done (RR 2.00, 95% CI 0.88 to 4.51; Analysis 2.8). This sub-
group had important levels of heterogeneity (Chi² test = 28.49; df
= 8; P = 0.0; I² statistic = 72%).
2.8.3 excessive sweating
In this subgroup we found two relevant trials (N = 180). There was
no signiﬁcant difference between chlorpromazine and risperidone
(RR 3.00, 95% CI 0.62 to 14.46; Analysis 2.8).
2.8.4 hypersalivation
In this subgroup we found ﬁve relevant trials (N = 373). There was
a statistically signiﬁcant difference in favour of risperidone (RR
8.67, 95% CI 3.80 to 19.8; P < 0.00001; Analysis 2.8).
2.8.5 stuffy nose
In this subgroup we only found one relevant trial (N = 80) (vs
OLZ - He 2003). There was a statistically signiﬁcant difference in
favour of risperidone (RR 3.00, 95% CI 1.06 to 8.52; P = 0.04;
Analysis 2.8).
2.9 Adverse effects: 2a. Cardiovascular - short term (up to 6
months)
2.9.1 abnormal ECG
In this subgroup we found three relevant trials (N = 229). There
was no signiﬁcant difference between chlorpromazine and risperi-
done (RR 2.41, 95% CI 0.96 to 6.06; Analysis 2.9).
2.9.2 apathism
In this subgroup we only found one relevant trial (N = 100) (vs
RPD - Wu 2004). There was a statistically signiﬁcant difference
in favour of risperidone (RR 6.25, 95% CI 2.35 to 16.65; P =
0.0002; Analysis 2.9).
2.9.3 bood pressure drop
In this subgroup we found three relevant trials (N = 250). There
was a statistically signiﬁcant difference in favour of risperidone
(RR 8.25, 95% CI 2.61 to 26.12; P = 0.0003; Analysis 2.9).
2.9.4 bradycardia
In this subgroup we only found one relevant trial (N = 100) (vs
RPD - Wu 2004). There was no signiﬁcant difference between
chlorpromazine and risperidone (RR 0.50, 95% CI 0.05 to 5.34;
Analysis 2.9).
2.9.5 orthostatic hypotension
In this subgroup we found ﬁve relevant trials (N = 546). There was
a statistically signiﬁcant difference in favour of risperidone (RR
5.74, 95% CI 2.28 to 14.44; P = 0.0002; Analysis 2.9).
2.9.6 palpitation
We only found one relevant trial in this subgroup (N = 237) (vs
OLZ - Wang 2008). There was a statistically signiﬁcant difference
in favour of risperidone (RR 40.66, 95% CI 2.49 to 664.56; P =
0.009; Analysis 2.9).
2.9.7 sinus tachycardia
In this subgroup we only found one relevant trial (N = 51) (vs
RPD - Zheng 2001). There was no signiﬁcant difference between
chlorpromazine and risperidone (RR 3.12, 95% CI 0.35 to 28.03;
Analysis 2.9).
2.9.8 tachycardia
In this subgroup we found seven relevant trials (N = 557). There
was a statistically signiﬁcant difference in favour of risperidone
(RR 2.64, 95% CI 1.64 to 4.26; P ≤ 0.0001; Analysis 2.9).
2.10 Adverse effects: 2b. Cardiovascular - continuous
measures - short term (up to 6 months)
2.10.1 cardiac rate (upright position)
In this subgroup we only found one relevant trial (N = 100) (vs
RPD - Liu 2005). There was no signiﬁcant difference between
chlorpromazine and risperidone (MD 3.90, 95% CI −1.57 to
9.37; Analysis 2.10).
2.10.2 cardiac rate (horizontal position)
In this subgroup we only found one relevant trial (N = 100) (vs
RPD - Liu 2005). There was a statistically signiﬁcant difference
in favour of risperidone (MD 7.42, 95% CI 3.47 to 11.37; P =
0.0002; Analysis 2.10).
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2.10.3 contractive blood pressure (upright position)
In this subgroup we only found one relevant trial (N = 100) (vs
RPD - Liu 2005). There was no signiﬁcant difference between
chlorpromazine and risperidone (MD −1.06, 95% CI −2.20 to
0.08; Analysis 2.10).
2.10.4 ontractive blood pressure (horizontal position)
In this subgroup we only found one relevant trial (N = 100) (vs
RPD - Liu 2005). There was a statistically signiﬁcant difference
in favour of risperidone (MD 1.38, 95% CI 0.61 to 2.15; P =
0.0005; Analysis 2.10).
2.10.5 diastolic blood pressure (upright position)
In this subgroup we only found one relevant trial (N = 100) (vs
RPD - Liu 2005). There was no signiﬁcant difference between
chlorpromazine and risperidone (MD −0.53, 95% CI −1.29 to
0.23; Analysis 2.10).
2.10.6 diastolic blood pressure (horizontal position)
We only found one relevant trial in this subgroup (N = 100) (vs
RPD - Liu 2005). There was no signiﬁcant difference between
chlorpromazine and risperidone (MD 0.39, 95% CI −0.18 to
0.96; Analysis 2.10).
2.11 Adverse effects: 3. Central nervous system - short term
(up to 6 months)
2.11.1 agitation
In this subgroup we only found one relevant trial (N = 65) (vs
RPD - Feng 2003). There was no signiﬁcant difference between
chlorpromazine and risperidone (RR 0.32, 95% CI 0.01 to 7.66;
Analysis 2.11).
2.11.2 dizziness
We found four relevant trials in this subgroup (N = 299). There
was a statistically signiﬁcant difference between chlorpromazine
and risperidone (RR 2.37, 95% CI 1.38 to 4.07; Analysis 2.11).
2.11.3 drowsiness
In this subgroup we found four relevant trials (N = 307). There
was a statistically signiﬁcant difference in favour of risperidone
(RR 3.62, 95% CI 1.56 to 8.39; P = 0.003; Analysis 2.11). This
subgroup had moderate levels of heterogeneity (Chi² test = 5.14;
df = 3; P = 0.162; I² statistic = 42%).
2.11.4 fatigue
We only found one relevant trial in this subgroup (N = 100) (vs
RPD - Wu 2004). There was a statistically signiﬁcant difference
in favour of risperidone (RR 2.69, 95% CI 1.77 to 4.09; P <
0.00001; Analysis 2.11).
2.11.4 insomnia
In this subgroup we found ﬁve relevant trials (N = 342). There was
a statistically signiﬁcant difference in favour of chlorpromazine
(RR 0.33, 95% CI 0.12 to 0.91; P = 0.03; Analysis 2.11).
2.11.5 reduced activity
We only found one relevant trial in this subgroup (N = 78) (vs
RPD - Ma 2004). There was no signiﬁcant difference between
chlorpromazine and risperidone (RR 2.00, 95% CI 0.19 to 21.16;
Analysis 2.11).
2.12 Adverse effects: 4. Gastrointestinal- short term (up to 6
months)
2.12.1 constipation
In this subgroup we found nine relevant trials (N = 868). There
was a statistically signiﬁcant difference in favour of risperidone
(RR 3.00, 95% CI 2.05 to 4.39; P < 0.00001; Analysis 2.12).
2.12.2 diarrhoea
In this subgroupwe only found one relevant trial (N =80) (vs OLZ
- He 2003). There was no signiﬁcant difference between chlor-
promazine and risperidone (RR 5.00, 95% CI 0.25 to 100.97;
Analysis 2.12).
2.12.3 dysphagia
In this subgroup we only found one relevant trial (N = 100) (vs
RPD -Wu 2004). There was a statistically signiﬁcant difference (P
= 0.04) in favour of risperidone (RR 3.67, 95% CI 1.09 to 12.36;
Analysis 2.12).
2.12.4 loss of appetite
In this subgroup we found two relevant trials (N = 180). There
was a statistically signiﬁcant difference in favour of risperidone
(RR 11.01, 95% CI 2.82 to 42.94; P = 0.0006; Analysis 2.12).
This subgroup had moderate levels of heterogeneity (Chi² test =
1.78; df = 1; P = 0.182; I² statistic = 44%).
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2.12.5 nausea/vomiting
We found four relevant trials in this subgroup (N=350). Therewas
no signiﬁcant difference between chlorpromazine and risperidone
(RR 0.85, 95% CI 0.37 to 1.91; Analysis 2.12).
2.13 Adverse effects: 5. Haematology - short term (up to 6
months)
2.13.1 Abnormal haemogram
In this subgroup we found two relevant trials (N = 180). There was
no signiﬁcant difference between chlorpromazine and risperidone
(RR 4.00, 95% CI 0.87 to 18.31; Analysis 2.13).
2.13.2 leukopenia
Weonly foundone relevant trial in this subgroup (N=86) (vs OLZ
- Chen 2006). There was no signiﬁcant difference between chlor-
promazine and risperidone (RR 6.69, 95% CI 0.36 to 125.71;
Analysis 2.13).
2.14 Adverse effects: 6. Hepatitic - short term (up to 6
months)
2.14.1 abnormal liver function - short term (up to six
months)
In this subgroupwe only found one relevant trial (N = 78) (vs RPD
- Ma 2004). There was no signiﬁcant difference between chlor-
promazine and risperidone (RR 5.00, 95% CI 0.25 to 100.89;
Analysis 2.14).
2.14.2 abnormal transaminase - short term (up to six
months)
We found three relevant trials in this subgroup (N = 229). There
was no signiﬁcant difference between chlorpromazine and risperi-
done (RR 0.88, 95% CI 0.07 to 11.58; Analysis 2.14). This sub-
group had important levels of heterogeneity (Chi² test = 6.3; df =
2; P = 0.043; I² statistic = 68%).
2.15 Adverse effects: 7. Metabolic - weight gain
2.15.1 short term (up to six months)
In this subgroupwe found four relevant trials (N =302). There was
no signiﬁcant difference between chlorpromazine and risperidone
(RR 1.36, 95% CI 0.52 to 3.59; Analysis 2.15). This subgroup
had important levels of heterogeneity (Chi² test = 6.75; df = 3; P
= 0.08; I² statistic = 56%).
2.16 Adverse effects: 8. Movement disorders - short term
(up to 6 months)
2.16.1 akathisia
In this subgroup we found six relevant trials (N = 435). There was
a statistically signiﬁcant difference in favour of risperidone (RR
2.37, 95% CI 1.46 to 3.85; P = 0.0005; Analysis 2.16).
2.16.2 any EPS symptoms
In this subgroup we found three relevant trials (N = 235). There
was no signiﬁcant difference between chlorpromazine and risperi-
done (RR 1.70, 95% CI 0.85 to 3.40; Analysis 2.16). This sub-
group had important levels of heterogeneity (Chi² test = 4.33; df
= 2; P = 0.115; I² statistic = 54%).
2.16.3 dystonia
In this subgroup we found three relevant trials (N = 228). There
was no signiﬁcant difference between chlorpromazine and risperi-
done (RR 1.61, 95% CI 0.97 to 2.66; Analysis 2.16).
2.16.4 muscle stiffness
In this subgroup we found ﬁve relevant trials (N = 335). There was
no signiﬁcant difference between chlorpromazine and risperidone
(RR 2.96, 95% CI 0.92 to 9.49; Analysis 2.16). This subgroup
had important levels of heterogeneity (Chi² test = 8.82; df = 4; P
= 0.066; I² statistic = 55%).
2.16.5 torsion movements
Weonly foundone relevant trial in this subgroup (N=78) (vs RPD
- Ma 2004). There was no signiﬁcant difference between chlor-
promazine and risperidone (RR 9.00, 95% CI 0.50 to 161.73;
Analysis 2.16).
2.16.6 tremor
In this subgroup we found six relevant trials (N = 435). There was
a statistically signiﬁcant difference in favour of risperidone (RR
2.15, 95% CI 1.47 to 3.14, P < 0.0001; Analysis 2.16).
2.17 Adverse effects: 9. Average endpoint score (TESS) -
skewed data
Data for this outcome are skewed and are best inspected by viewing
Analysis 2.17.
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2.18 Adverse effects: 10. Various - short term (up to 6
months)
2.18.1 concentration (poor)
In this subgroup we only found one relevant trial (N = 100) (vs
RPD -Wu 2004). There was a statistically signiﬁcant difference in
favour of risperidone (RR 1.95, 95% CI 1.35 to 2.82; P = 0.0003;
Analysis 2.18).
2.18.2 memory deterioration
In this subgroup we only found one relevant trial (N = 100) (vs
RPD -Wu 2004). There was a statistically signiﬁcant difference in
favour of risperidone (RR 1.95, 95% CI 1.35 to 2.82; P = 0.0004;
Analysis 2.18).
2.18.3 sexual dysfunction
In this subgroup we only found one relevant trial (N = 100) (vs
RPD -Wu 2004). There was a statistically signiﬁcant difference in
favour of risperidone (RR 2.55, 95% CI 1.43 to 4.53; P = 0.002;
Analysis 2.18).
2.18.4 unspecified
In this subgroup we only found one relevant trial (N = 100) (vs
RPD - Wang 2005). There was no signiﬁcant difference between
chlorpromazine and risperidone (RR 1.38, 95% CI 0.97 to 1.95;
Analysis 2.18).
2.19 Quality of life: 1. Average endpoint scale score (QOL,
high = good)
2.19.1 short term (up to 6 months)
In this subgroup we only found one relevant trial (N = 100) (vs
RPD -Wu 2004). There was a statistically signiﬁcant difference in
favour of risperidone (MD −14.20, 95% CI −20.50 to −7.90;
P < 0.00001; Analysis 2.19).
2.20 Leaving the study early - short term (up to 6 months)
2.20.1 due to adverse events
In this subgroup we only found one relevant trial (N = 41) (vs
RPD - He 1999). There was no signiﬁcant difference between
chlorpromazine and risperidone (RR 0.21, 95% CI 0.01 to 4.11;
Analysis 2.20).
Comparison 3: CHLORPROMAZINE versus
QUETIAPINE
3.1 Clinical response: No significant clinical response
3.1.1 short term (up to six months)
In this subgroup we found 28 relevant trials (N = 3241). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(RR 0.93, 95% CI 0.81 to 1.06; Analysis 3.1).
3.2 Global state: 1. Need of additional
benzodiazepines/benzhexol
3.2.1 short term (up to 6 months)
In this subgroup we found two relevant trials (N = 290). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
1.39, 95% CI 1.1 to 1.75; Analysis 3.2).
3.3 Global state: 2a. Average endpoint scores (various scales,
high = poor) - short term (up to 6 months)
3.3.1 CGI-SI
In this subgroup we found two relevant trials (N = 177). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(MD 0.01, 95% CI −0.82 to 0.84; Analysis 3.3. This subgroup
had important levels of heterogeneity (Chi² test = 5.67; df = 1; P
= 0.017; I² statistic = 82%).
3.3.2 CGI-GI
In this subgroup we found three relevant trials (N = 229). There
was no signiﬁcant difference between chlorpromazine and queti-
apine (MD −0.11, 95% CI −0.33 to 0.11; Analysis 3.3).
3.4 Global state: 2b. Average endpoint score (CGI-SI, high =
poor) - skewed data
Data for this outcome are skewed and are best inspected by viewing
Analysis 3.4.
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3.5 Global state: 3. Average change scores (CGI-SI, high =
poor)
3.5.1 short term (up to six months)
We only found one relevant trial in this subgroup (N = 384) (vs
QTP - NCT00882518). There was a statistically signiﬁcant dif-
ference in favour of chlorpromazine (MD−0.30, 95% CI−0.32
to −0.28; P < 0.00001; Analysis 3.5).
3.6 Mental state: 1a. Average endpoint scores (various scale,
high = poor) - short term (up to 6 months)
3.6.1 BPRS total
In this subgroup we found six relevant trials (N = 548). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(MD −0.18, 95% CI −1.23 to 0.88; Analysis 3.6).
3.6.2 BPRS anxiety-depression subscale
In this subgroup we only found one relevant trial (N = 60) (vs
QTP - Yang 2007). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD −0.27, 95% CI −1.16 to
0.62; Analysis 3.6).
3.6.3 BPRS activation subscale
In this subgroup we only found one relevant trial (N = 60) (vs
QTP - Yang 2007). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD 0.22, 95% CI −0.26 to
0.70; Analysis 3.6).
3.6.4 BPRS hostile-suspiciousness subscale
In this subgroup we only found one relevant trial (N = 60) (vs
QTP - Yang 2007). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD −0.09, 95% CI −1.15 to
0.97; Analysis 3.6).
3.6.5 BPRS thinking disorder subscale
We only found one relevant trial in this subgroup (N = 60) (vs
QTP - Yang 2007). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD −0.15, 95% CI −1.39 to
1.09; Analysis 3.6).
3.6.6 BPRS withdraw-retardation subscale
In this subgroup we only found one relevant trial (N = 60) (vs
QTP - Yang 2007). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD −0.10, 95% CI −0.76 to
0.56; Analysis 3.6).
3.6.7 PANSS total
In this subgroup we found 25 relevant trials (N = 2049). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(MD−0.05, 95% CI−2.3 to 2.19; Analysis 3.6). This subgroup
had important levels of heterogeneity (Chi² test = 102.88; df = 24;
P = 0.0; I² statistic = 77%).
3.6.8 PANSS positive symptom
In this subgroup we found 13 relevant trials (N = 1102). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(MD 0.39, 95% CI −0.11 to 0.88; Analysis 3.6).
3.6.9 PANSS negative symptoms
In this subgroup we found 17 relevant trials (N = 1361). There was
a statistically signiﬁcant difference in favour of quetiapine (MD
1.05, 95%CI 0.13 to 1.98; P = 0.03; Analysis 3.6). This subgroup
had important levels of heterogeneity (Chi² test = 54.37; df = 16;
P = 0.0; I² statistic = 71%).
3.6.10 PANSS general pathology
In this subgroup we found 18 relevant trials (N = 1530). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(MD−1.11, 95%CI−3.06 to 0.84; Analysis 3.6). This subgroup
had important levels of heterogeneity (Chi² test = 160.66; df = 17;
P = 0.0; I² statistic = 89%).
3.6.11 HAMD total
In this subgroup we only found one relevant trial (N = 63) (vs
QTP - Li 2010). There was a statistically signiﬁcant difference
in favour of quetiapine (MD 7.40, 95% CI 5.13 to 9.67; P <
0.00001; Analysis 3.6).
3.7 Mental state: 1b. Average endpoint scores (various
scales, high = poor) - medium term (6 to 12 months)
3.7.1 PANSS total
In this subgroup we only found one relevant trial (N = 41) (vs
QTP - Li 2003). There was a statistically signiﬁcant difference in
favour of quetiapine (MD 4.90, 95% CI 1.74 to 8.06; P = 0.002;
Analysis 3.7).
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3.7.2 PANSS general pathology
We only found one relevant trial in this subgroup (N = 41) (
vs QTP - Li 2003). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD −0.20, 95% CI −4.34 to
3.94; Analysis 3.7).
3.7.3 PANSS negative symptoms
In this subgroup we only found one relevant trial (N = 77) (vs
QTP - Li 2003). There was a statistically signiﬁcant difference in
favour of quetiapine (MD 2.70, 95% CI 0.44 to 4.96; P = 0.02;
Analysis 3.7).
3.8 Mental state: 1c. Average endpoint scores (various
scales, high = poor) - skewed data
Data for this outcome are skewed and are best inspected be viewing
Analysis 3.8.
3.9 Mental state: Average change score (various scales, high
= poor) - short term (up to 6 months)
3.9.1 PANSS total
In this subgroup we found two relevant trials (N = 426). There was
a statistically signiﬁcant difference in favour of chlorpromazine
(MD −2.50, 95% CI −2.82 to −2.19; P < 0.00001; Analysis
3.9).
3.9.2 PANSS positive symptoms
In this subgroup we only found one relevant trial (N = 384) (
vs QTP - NCT00882518). There was a statistically signiﬁcant
difference in favour of quetiapine (MD 1.20, 95% CI 1.10 to
1.30, Analysis 3.9).
3.9.3 PANSS negative symptom
In this subgroup we only found one relevant trial (N = 384) (
vs QTP - NCT00882518). There was a statistically signiﬁcant
difference) in favour of quetiapine (MD 0.80, 95% CI 0.70 to
0.90; P < 0.00001; Analysis 3.9).
3.9.4 PANSS general pathology
In this subgroup we only found one relevant trial (N = 384) (
vs QTP - NCT00882518). There was a statistically signiﬁcant
differenc in favour of quetiapine (MD 1.00, 95%CI 0.85 to 1.15;
P < 0.00001; Analysis 3.9).
3.10 Mental state: 1e. Average score decreased rate of
BPRS/PANSS (%) - short term (up to 6 months)
3.10.1 BPRS
In this subgroup we only found one relevant trial (N = 197) (vs
QTP - Cai 2006). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD −0.80, 95% CI −4.86 to
3.26; Analysis 3.10).
3.10.2 PANSS
In this subgroup we found six relevant trials (N = 782). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(MD −1.96, 95% CI −7.20 to 3.28; Analysis 3.10). This sub-
group had important levels of heterogeneity (Chi² test = 18.14; df
= 5; P = 0.003; I² statistic = 72%).
3.11 Functioning: 1. Average endpoint score (various scales,
high = better) - short term (up to 6 months)
3.11.1 WCST-IQ
In this subgroup we only found one relevant trial (N = 120) (vs
QTP - Nai 2007). There was a statistically signiﬁcant difference
in favour of quetiapine (MD−11.30, 95% CI−17.62 to−4.98;
P = 0.0005; Analysis 3.11).
3.11.2 WCST-MQ
In this subgroup we only found one relevant trial (N = 120) (vs
QTP - Nai 2007). There was a statistically signiﬁcant difference
in favour of quetiapine (MD−19.6, 95% CI−27.37 to−11.83;
P < 0.00001; Analysis 3.11).
3.12 Cognitive function: 1. Average endpoint scores (various
scales, high = better) short term (up to 6 months)
3.12.1 WCST
In this subgroup we found two relevant trials (N = 123). There was
a statistically signiﬁcant difference in favour of quetiapine (MD
8.92, 95% CI 0.40 to 17.43; P = 0.04; Analysis 3.12).
3.12.2 WMS-RC
In this subgroup we only found one relevant trial (N = 71) (vs
QTP - Sun 2006). There was a statistically signiﬁcant difference
in favour of chlorpromazine (MD −9.34, 95% CI −17.53 to
−1.15; P = 0.03; Analysis 3.12).
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3.13 Adverse effects: 1. Anticholinergic - short term (up to 6
months)
3.13.1 blurred vision
In this subgroup we found 18 relevant trials (N = 1780). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
5.00, 95% CI 3.46 to 7.22; P < 0.00001; Analysis 3.13).
3.13.2 dry mouth
In this subgroup we found 18 relevant trials (N = 1682). There
was a statistically signiﬁcant difference (P < 0.0001) in favour of
quetiapine (RR 2.34, 95% CI 1.54 to 3.54; Analysis 3.13). This
subgroup had moderate levels of heterogeneity (Chi² test = 32.99;
df = 17; P = 0.011; I² statistic = 48%).
3.13.2 excessive sweating
In this subgroup we found three relevant trials (N = 162). There
was no signiﬁcant difference between chlorpromazine and queti-
apine (RR 3.91, 95% CI 0.84 to 18.19; Analysis 3.13).
3.13.3 hypersalivation
We found 11 relevant trials in this subgroup (N = 1135). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
3.85, 95% CI 2.36 to 6.28; P < 0.0001; Analysis 3.13).
3.13.4 stuffy nose
In this subgroup we found eight relevant trials (N = 972). There
was no signiﬁcant difference between chlorpromazine and queti-
apine (RR 0.69, 95% CI 0.45 to 1.06; Analysis 3.13).
3.14 Adverse effects: 2. Cardiovascular - short term (up to 6
months)
3.14.1 abnormal ECG
In this subgroup we found seven relevant trials (N = 708). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
1.82, 95% CI 1.11 to 2.98; P = 0.02; Analysis 3.14).
3.14.2 blood pressure drop
In this subgroup we found eight relevant trials (N = 690). There
was no signiﬁcant difference between chlorpromazine and queti-
apine (RR 0.97, 95% CI 0.53 to 1.79; Analysis 3.14). This sub-
group had moderate levels of heterogeneity (Chi² test = 13.18; df
= 7; P = 0.068; I² statistic = 47%).
3.14.3 orthostatic hypotension
In this subgroup we found seven relevant trials (N = 605). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
2.64, 95% CI 1.14 to 6.12; P = 0.02; Analysis 3.14).
3.14.4 tachycardia
In this subgroup we found 17 relevant trials (N = 1752). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
1.70, 95% CI 1.33 to 2.18; P < 0.0001; Analysis 3.14).
3.15 Adverse effects: 3. Central nervous system - short term
(up to 6 months)
3.15.1 dizziness
In this subgroup we found 12 relevant trials (N = 1206). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(RR 1.40, 95% CI 0.83 to 2.35; Analysis 3.15). This subgroup
had moderate levels of heterogeneity (Chi² test = 16.88; df = 11;
P = 0.111; I² statistic = 35%).
3.15.2 drowsiness
In this subgroup we found 17 relevant trials (N = 1677). There
was a statistically signiﬁcant difference in favour of quetiapine
(RR 2.28, 95% CI 1.51 to 3.45; P < 0.0001; Analysis 3.15). This
subgroup had moderate levels of heterogeneity (Chi² test = 31.15;
df = 16; P = 0.013; I² statistic = 49%).
3.15.3 headache
In this subgroup we found three relevant trials (N = 192). There
was no signiﬁcant difference between chlorpromazine and queti-
apine (RR 0.74, 95% CI 0.13 to 4.18; Analysis 3.15).
3.15.4 insomnia
In this subgroupwe foundnine relevant trials (N=867). Therewas
no signiﬁcant difference between chlorpromazine and quetiapine
(RR 0.92, 95% CI 0.55 to 1.54; Analysis 3.15).
3.15.5 reduced activity
In this subgroup we found eight relevant trials (N = 788). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
7.80, 95% CI 3.05 to 19.92; P < 0.0001; Analysis 3.15).
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3.15.6 sedation
In this subgroup we only found one relevant trial (N = 40) (vs
QTP - He 2003). There was no signiﬁcant difference between
chlorpromazine and quetiapine (RR 0.33, 95% CI 0.01 to 7.72;
Analysis 3.15).
3.16 Adverse effects: 4. Gastrointestinal - short term (up to
6 months)
3.16.1 constipation
In this subgroup we found 22 relevant trials (N = 2048). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
2.55, 95% CI 2.04 to 3.20; P < 0.00001; Analysis 3.16).
3.16.2 diarrhoea
In this subgroup we only found one relevant trial (N = 62) (vs
QTP - Chen 2007). There was no signiﬁcant difference between
chlorpromazine and quetiapine (RR5.32, 95%CI 0.27 to 106.54;
Analysis 3.16).
3.16.3 loss of appetite
In this subgroup we found ﬁve relevant trials (N = 472). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(RR 2.52, 95% CI 0.82 to 7.72; Analysis 3.16). This subgroup
had moderate levels of heterogeneity (Chi² test = 7.06; df = 4; P
= 0.133; I² statistic = 43%).
3.16.4 nausea/vomiting
In this subgroupwe foundnine relevant trials (N=819). Therewas
no signiﬁcant difference between chlorpromazine and quetiapine
(RR 1.23, 95% CI 0.58 to 2.63; Analysis 3.16).
3.17 Adverse effects: 5a. Endocrine - various - short term
(up to 6 months)
3.17.2 gynaecomastia, galactorrhoea
In this subgroup we only found one relevant trial (N = 83) (vs
QTP - Guo 2008). There was no signiﬁcant difference between
chlorpromazine and quetiapine (RR5.37, 95%CI 0.27 to 108.47;
Analysis 3.17).
3.17.2 hyperprolactinemia
In this subgroup we found two relevant trials (N = 277). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
5.69, 95% CI 2.74 to 11.79; P < 0.00001; Analysis 3.17).
3.17.3 menstrual irregularities
In this subgroup we only found one relevant trial (N = 52) (vs
QTP - Guo 2007). There was no signiﬁcant difference between
chlorpromazine and quetiapine (RR 5.00, 95% CI 0.25 to 99.34;
Analysis 3.17).
3.18 Adverse effects: 5b. Endocrine - average endpoint -
short term (up to 6 months)
3.1.18 prolactin level (ng/mL)
In this subgroup we only found one relevant trial (n = 30) (vs
QTP - Kong 2003). There was a statistically signiﬁcant difference
in favour of quetiapine (MD 24.62, 95% CI 17.76 to 31.48; P <
0.00001; Analysis 3.18).
3.19 Adverse effect: 5c. Endocrine - skewed data - short
term (up to 6 months)
3.19.1 average prolactin level (ng/mL)
Data for this outcome are skewed and are best inspected by viewing
Analysis 3.19.
3.20 Adverse effects: 6a. Haematology - short term (up to 6
months)
3.20.1 elevated ALT
In this subgroup we found eight relevant trials (N = 775). There
was no signiﬁcant difference between chlorpromazine and queti-
apine (RR 1.62, 95% CI 0.92 to 2.87; Analysis 3.20).
3.20.2 decreased white blood cell count
In this subgroupwe found four relevant trials (N =427). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(RR 1.02, 95% CI 0.43 to 2.42; Analysis 3.20).
3.20.3 increased white blood cell count
We only found one relevant trial in this subgroup (N = 79) (vs
QTP - Zhou 2004). There was no signiﬁcant difference between
chlorpromazine and quetiapine (RR 2.05, 95% CI 0.40 to 10.56;
Analysis 3.20).
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3.21 Adverse effects: 6b. Haematology - average endpoint -
short term (up to 6 months)
3.21.1 blood glucose
In this subgroup we only found one relevant trial (N = 130) (vs
QTP - Guo 2006). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD 0.10, 95% CI −0.18 to
0.38; Analysis 3.21).
3.21.2 blood TG
In this subgroup we only found one relevant trial (N = 130) (vs
QTP - Guo 2006). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD 0.00, 95% CI −0.28 to
0.28; Analysis 3.21).
3.21.3 blood TC
We only found one relevant trial (N = 130) in this subgroup (vs
QTP - Guo 2006). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD 0.20, 95% CI −0.11 to
0.51; Analysis 3.21).
3.22 Adverse effects: 7. Hepatitic - short term (up to 6
months)
3.22.1 abnormal liver function
In this subgroup we found ﬁve relevant trials (N = 561). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
2.10, 95% CI 1.32 to 3.33; P = 0.002; Analysis 3.22).
3.23 Adverse effects: 8. Movement disorders - short term
(up to 6 months)
3.23.1 agitation
We found ﬁve relevant trials in this subgroup (N = 313). There was
a statistically signiﬁcant difference in favour of chlorpromazine
(RR 0.36, 95% CI 0.14 to 0.95; P = 0.04; Analysis 3.23).
3.23.2 akathisia
In this subgroup we found 17 relevant trials (N = 1757). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
3.73, 95% CI 2.55 to 5.47; P < 0.00001; Analysis 3.23).
3.23.3 any EPS symptoms
In this subgroup we found eight relevant trials (N = 644). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
8.03, 95% CI 4.78 to 13.51; P < 0.00001; Analysis 3.23).
3.23.4 dystonia
In this subgroup we only found one relevant trial (N = 201) (
vs QTP - Peuskens 1997). There was no signiﬁcant difference
between chlorpromazine and quetiapine (RR 0.33, 95% CI 0.01
to 8.01; Analysis 3.23).
3.23.5 myotonia
In this subgroup we found 12 relevant trials (N = 1257). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
4.59, 95% CI 3.18 to 6.64; P < 0.00001; Analysis 3.23).
3.23.6 need additional medication for EPS symptoms
We only found one relevant trial in this subgroup (N = 202)
(vs QTP - Peuskens 1997). There was no signiﬁcant difference
between chlorpromazine and quetiapine (RR 1.50, 95% CI 0.71
to 3.18; Analysis 3.23).
3.23.7 torsion movement
In this subgroup we found nine relevant trials (N = 1063). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
5.81, 95% CI 2.76 to 12.23; P < 0.00001; Analysis 3.23).
3.23.8 tremor
In this subgroup we found 13 relevant trials (N = 1343). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
2.90, 95% CI 1.89 to 4.45; P < 0.00001; Analysis 3.23).
3.24 Adverse effects: 9a. Metabolic - weight gain
3.24.1 short term (up to six months)
In this subgroup we found 15 relevant trials (N = 1259). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
1.67, 95% CI 1.17 to 2.39; P = 0.005; Analysis 3.24).
3.25 Adverse effects: 9b. Metabolic - continuous - short term
(up to 6 months)
3.25.1 average BMI
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In this subgroup we only found one relevant trial (N = 105) (vs
QTP - Wang 2005). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD 0.50, 95% CI −0.67 to
1.67; Analysis 3.25).
3.25.2 average weight (KG)
In this subgroup we only found one relevant trial (N = 130) (vs
QTP - Guo 2006). There was no signiﬁcant difference between
chlorpromazine and quetiapine (MD −1.00, 95% CI −4.68 to
2.68; Analysis 3.25).
3.26 Adverse effects: 10. Various other - short term (up to 6
months)
3.26.1 unspecified adverse effects
In this subgroup we found four relevant trials (N = 560). There
was a statistically signiﬁcant difference (P = 0.004) in favour of
quetiapine (RR 1.73, 95% CI 1.20 to 2.51; Analysis 3.26). This
subgroup had important levels of heterogeneity (Chi² test = 10.42;
df = 3; P = 0.015; I² statistic = 71%).
3.27 Adverse effects: 11. Average endpoint score (TESS,
high = poor) - skewed data
Data for this outcome are skewed and are best inspected by viewing
Analysis 3.27.
3.28 Quality of life: 1. General - average endpoint score
(GQOL1 - 74, high = better)
3.28.1 short term (up to 6 months)
In this subgroup we only found one relevant trial (N = 59) (vs
QTP - Ji 2004). There was a statistically signiﬁcant difference in
favour of quetiapine (MD −6.49, 95% CI −11.3 to −1.68; P =
0.008; Analysis 3.28).
3.29 Leaving the study early: 1a. Short term (up to six
months)
3.29.1 due to adverse effect
In this subgroup we found ten relevant trials (N = 1680). There
was a statistically signiﬁcant difference in favour of quetiapine (RR
1.43, 95% CI 1.04 to 1.98; P = 0.03; Analysis 3.29).
3.29.2 due to inefficacy
In this subgroup we found three relevant trials (N = 695). There
was no signiﬁcant difference between chlorpromazine and queti-
apine (RR 1.42, 95% CI 0.68 to 2.96; Analysis 3.29).
3.29.3 due to any other reason
We found 12 relevant trials in this subgroup (N=1223). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(RR 1.04, 95% CI 0.77 to 1.41; Analysis 3.29).
3.29.4 due to lost to follow-up
In this subgroup we found two relevant trials (N = 400). There was
no signiﬁcant difference between chlorpromazine and quetiapine
(RR 0.56, 95% CI 0.23 to 1.37; Analysis 3.29).
3.30 Leaving the study early: 1b. Medium term (seven to 12
months)
For this outcome we only found one relevant trial (N = 103)
(vs QTP - Li 2003). There was no signiﬁcant difference between
chlorpromazine and quetiapine (RR 1.19, 95% CI 0.61 to 2.32;
Analysis 3.30).
4. Sensitivity analysis
1. Implication of randomisation
1.1 Chlorpromazine versus olanzapine - clinical response: no
significant clinical response
After removing studies that did not adequately explain randomi-
sation methods, there was no substantial difference in the estimate
of the effect, with results statistically signiﬁcant in favour of olan-
zapine (1 RCT, N = 58; RR 2.49, 95% CI 1.10 to 5.64).
1.2 Chlorpromazine versus risperidone - clinical response: no
significant clinical response
After removing studies that did not adequately explain randomi-
sation methods, there were no data left in the short term outcome
to compare, since all included studies did not provide explanation.
1.3 Chlorpromazine versus quetiapine - clinical response: no
significant clinical response
After removing studies that did not adequately explain randomi-
sation methods, there was no substantial difference in the estimate
of the effect.
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2. Assumptions for lost binary data
We did not assume any binary data from the included studies.
3. Risk of bias
3.1 Chlorpromazine versus olanzapine - clinical response: no
significant clinical response
After we removed studies that were rated as ’high’ across one or
more of the ’Risk of bias’ domains, there were no data left in the
short-term outcome to compare, since all included studies were
rated as ’high’ (vs OLZ - Chang 2003; vs OLZ - Chen 2006; vs
OLZ - Wang 2002). However, there was no difference in long-
term outcome.
3.2 Chlorpromazine versus risperidone - clinical response: no
significant clinical response
After we removed studies that we had rated as ’high’ across one
or more of the ’Risk of bias’ domains, there was no substantial
difference in the estimate of the effect.
3.3 Chlorpromazine versus quetiapine - clinical response: no
significant clinical response
After removing studies that rated as ’high’ across one or more of
the ’Risk of bias’ domains, there was no substantial difference in
the estimate of the effect.
4. Imputed values
We had also planned to undertake a sensitivity analysis to assess
the effects of including data from trials where we used imputed
values for ICC in calculating the design effect in cluster-RCTs.
However, we did not impute any values in this Cochrane review.
5. Fixed-effect and random-effects
5.1 Chlorpromazine versus olanzapine - clinical response: no
significant clinical response
There was no difference in the estimate of effect if a ﬁxed-effect
model was used in place of the random-effects model.
5.2 Chlorpromazine versus risperidone - clinical response: no
significant clinical response
There was no difference in the estimate of effect if a ﬁxed-effect
model was used in place of the random-effects model.
5.3 Chlorpromazine versus quetiapine - clinical response: no
significant clinical response
There was no difference in the estimate of effect if a ﬁxed-effect
model was used in place of the random-effects model.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Chlorpromazine versus risperidone for schizophrenia
Patient or population: people with schizophrenia
Settings: inpat ient and outpat ient
Intervention: chlorpromazine
Comparison: risperidone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Risperidone Chlorpromazine
No significant clinical
response - short term
(up to 6 months)
Follow-up: median 8 to
12 weeks
Low1 RR 0.84
(0.53 to 1.34)
475
(7 studies)
⊕⊕©©
low2,3
-
60 per 1000 50 per 1000
(32 to 80)
M oderate1
114 per 1000 96 per 1000
(60 to 153)
High1
240 per 1000 202 per 1000
(127 to 322)
M ental state: short
term (up to 6 months)
BPRS endpoint scale
score (high = poor)
Follow-up: 6 to 12
weeks
The mean mental state:
short term (up to 6
months) in the interven-
t ion groups was
0.9 higher
(3.49 lower to 5.28
higher)
247
(4 studies)
⊕©©©
very low2,4,5,6,7
-
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Adverse effects: any
observed extrapyrami-
dal symptoms - short
term (up to 6 months)
Follow-up: 8 to 12
weeks
Low1 RR 1.7
(0.85 to 3.4)
235
(3 studies)
⊕©©©
very low2,6,7
-
130 per 1000 221 per 1000
(111 to 442)
High1
240 per 1000 408 per 1000
(204 to 816)
Quality of life: short
term (up to 6 months)
QOL endpoint scale
score (high = good)
Follow-up: mean 12
weeks
The mean quality of lif e:
short term (up to 6
months) in the interven-
t ion groups was
14.2 lower
(20.5 to 7.9 lower)
100
(1 study)
⊕©©©
very low7,8,9,10
-
Leaving the study early
due to adverse effects
- short term (up to 6
months)
Follow-up: mean 8
weeks
Study population RR 0.21
(0.01 to 4.11)
41
(1 study)
⊕©©©
very low7,10
-
95 per 1000 20 per 1000
(1 to 391)
M oderate
95 per 1000 20 per 1000
(1 to 390)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Control risk: the control risks are representat ive of those observed in the study populat ion.
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2Risk of bias: serious - most of the included studies had unclear risk of bias in terms of allocat ion and blinding, hence
select ion and detect ion bias are likely to be present. Some of the studies also had high risk of report ing bias.
3Publicat ion bias: strongly suspected - only Chinese studies with relat ively small sample size were ident if ied. Publicat ion bias
is highly likely.
4Inconsistency: serious - unexplained heterogeneity present, suggest ing dif ferent magnitude of ef fect.
5Indirectness: serious - binary outcome assessing mental state is unavailable. We, therefore, employed BPRS score as an
alternat ive indicator.
6Imprecision: serious - although the CI around the est imate of ef fect relat ively t ight, the result was not signif icant and sample
size was smaller than the opt imal information size.
7Publicat ion bias: strongly suspected - only one study with unclear risk of select ion and detect ion bias available for this
outcome.
8Indirectness: serious - binary outcome for quality of lif e was not available. Therefore, we adopted QOL score as an indicator.
9Imprecision: serious - est imate of ef fect was signif icant with t ight CI, but the study sample size is smaller than the opt imal
information size.
10Imprecision: serious - est imate of ef fect was not signif icant and with relat ively wide CI. Sample size was smaller than the
opt imal information size.
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Chlorpromazine versus quetiapine for schizophrenia
Patient or population: people with schizophrenia
Settings: inpat ient and outpat ient
Intervention: chlorpromazine
Comparison: quet iapine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Quetiapine Chlorpromazine
No significant clinical
response: short term
(up to 6 months)
Follow-up: 4 to 16
weeks
Low1 RR 0.93
(0.81 to 1.06)
3241
(28 studies)
⊕⊕⊕©
moderate2
-
70 per 1000 65 per 1000
(57 to 74)
M oderate1
128 per 1000 119 per 1000
(104 to 136)
High1
360 per 1000 335 per 1000
(292 to 382)
M ental state: short
term (up to 6 months)
BPRS endpoint scale
score (high = poor)
Follow-up: 6 to 12
weeks
The mean mental state:
short term (up to 6
months) in the interven-
t ion groups was
0.18 lower
(1.23 lower to 0.88
higher)
548
(6 studies)
⊕©©©
very low2,3,4,5
-
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Quality of life: short
term (up to 6 months)
GQOL1-74 end-
point scale score (high
= good)
Follow-up: mean 12
weeks
The mean quality of lif e:
short term (up to 6
months) in the interven-
t ion groups was
6.49 lower
(11.3 to 1.68 lower)
59
(1 study)
⊕©©©
very low6,7,8,9
-
Adverse effects: any
observed extrapyrami-
dal symptoms - short
term (up to 6 months)
Follow-up: 6 to 8 weeks
Study population RR 8.03
(4.78 to 13.51)
644
(8 studies)
⊕⊕©©
low2,5
-
36 per 1000 293 per 1000
(174 to 493)
M oderate
0 per 1000 0 per 1000
(0 to 0)
High
80 per 1000 642 per 1000
(382 to 1000)
Leaving the study early
due to any reason short
term (up to 6 months)
Follow-up: 6 to 16
weeks
M oderate1 RR 1.04
(0.77 to 1.41)
1223
(12 studies)
⊕⊕⊕©
moderate2
-
93 per 1000 97 per 1000
(72 to 131)
High1
280 per 1000 291 per 1000
(216 to 395)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Control risk: are representat ive of those observed in the study populat ion.
2Risk of bias: serious - most of the included studies had unclear risk of bias in terms of allocat ion and blinding, hence
select ion and detect ion bias are likely to be present. Some of the studies also had high risk of report ing bias.
3Indirectness: serious - binary outcome on mental state is not available. Thus we employed BPRS rat ing as an indicator.
4Imprecision: serious - although the est imate of ef fect was not signif icant, the CI was relat ively t ight around the point of
est imate. The sample size is also relat ively large and exceed the calculated opt imal information size.
5Publicat ion bias: strongly suspected - only Chinese trials with small sample size were ident if ied for this outcome.
6Risk of bias: serious - the only study contributed data to this outcome had unclear risk of select ion and detect ion bias. It also
had attrit ion data that we excluded f rom the f inal analysis.
7Indirectness: serious - there was no binary measurement available on quality of lif e. Therefore, we used GQOLI-74 as an
alternat ive indicator.
8Imprecision: serious - sample size was smaller than the opt imal information size.
9Publicat ion bias: strongly suspected - we only ident if ied a Chinese trial with a small sample size with posit ive f indings for
this outcome.
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D I S C U S S I O N
Summary of main results
1. Chlorpromazine versus olanzapine
1.1 Clinical response
Data from included studies indicate that olanzapine is more effec-
tive than chlorpromazine when it comes to ’clinical response’ out-
comes, at least in the short term, since long-term data are equivo-
cal. Notably, each study providing data deﬁned ’clinical response’
differently; one study classiﬁed response as a decrease in BPRS
score, while another measured the number of people who became
stabilised on their studymedication.The remaining studies did not
explain how clinical response was measured. However, regarding
average endpoint scores using the CGI, scores were signiﬁcantly
lower in the olanzapine groups. Disappointingly, only one small
study (N = 70) provided data for relapse, which demonstrated no
signiﬁcant difference between groups; a result that will need to be
conﬁrmed by future large, high-quality RCTs.
1.2 Mental state
These outcomes were difﬁcult to interpret, with most included
studies using a different scale of measurement to rate mental state
in participants. Clearly there was no signiﬁcant difference between
the two compounds regarding total mean BPRS scores. However
there was a signiﬁcant level of heterogeneity in the studies. The
source of this heterogeneity was vs OLZ - Chen 2006 and removal
of this study demonstrated a statistically signiﬁcant difference be-
tween groups, in favour of olanzapine. The reasons for this hetero-
geneity have not been conﬁrmed, since all studies shared a similar
setting and used differing dose ranges of chlorpromazine (either
25 to 600 mg/day or 200 to 800 mg/day) and its olanzapine com-
parator. These ﬁndings need clarifying in future studies, as only a
small sample provided data (N = 245). Changes in PANSS score
were signiﬁcant, with a greater decrease seen in people receiving
olanzapine (N = 351).
1.3 Service involvement
Unfortunately, data for service usage/involvement was seriously
lacking; the only study that provided data for re-hospitalisation
rates (N = 70) demonstrated an equivocal result between groups.
1.4 Functioning
Data from one study (N = 53) suggest that olanzapine is signiﬁ-
cantly better at improving functioning, using the WCST. A nat-
uralistic study has suggested that people who received atypicals
showed a better cognitive pattern in terms of WCST performance
than those on typical antipsychotics (Rossi 2006). However, al-
though this is a test that is generally accepted in schizophrenia re-
search, it has not been widely used in the included studies, making
it difﬁcult to conﬁrm this result.
1.5 Adverse effects
Extrapyramidal adverse effects were largely equivocal; only data
for ’any observed EPS’ event were signiﬁcant, with more events
in people receiving chlorpromazine; however, this ﬁnding is based
on only two studies (N = 298). There is a strong dataset indicat-
ing that chlorpromazine causes signiﬁcantly greater instances of
drowsiness and constipation. Other signiﬁcant ﬁndings, particu-
larly associated with cardiovascular outcomes (palpitation, tachy-
cardia and blood pressure decrease) are only based on the ﬁndings
of two small RCTs.
1.6 Quality of life
Two different rating scales were used in the two studies that pro-
vided data, neither of which weremeta-analysed, with skewed data
only available using the QoL scale. GQOLI scores show that rat-
ings on speciﬁc areas of quality of life (including physical health,
psychological health and social functioning) were signiﬁcantly bet-
ter in people receiving olanzapine. Again, this is a result that will
need to be conﬁrmedwith future studies reporting data using these
validated scales.
1.7 Leaving the study early
There was no difference between groups for people leaving the
studies early for any reason.
2. Chlorpromazine versus risperidone
2.1 Clinical response
Data from the seven included RCTs (N = 475) indicate there is
no signiﬁcant difference between compounds in ’clinical response’
(as deﬁned in the different studies). Other global state outcomes
are equivocal, with skewed data only available using the CGI, and
data equivocal for amounts of participants requiring additional
antiparkinsonian medication.
2.2 Mental state
Most included studies measured mental state outcomes using one
of the widely-accepted rating scales (BPRS, PANSS or SANS),
with data for each subscale demonstrating no signiﬁcant difference
between groups.
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2.3 Functioning
Data show signiﬁcantly better scores for improvement in function-
ing using the WCST when receiving risperidone. Again, as only
one small study reported data for two subscales of the WCST, it
is impossible to make a generalisation with this result.
2.4 Adverse effects
Extrapyramidal adverse effects were largely equivocal; however,
akathisia was signiﬁcantly more prominent in people receiving
chlorpromazine (31% versus 13%), as was tremor (32% versus
14%). vs RPD - Wang 2002 was the source of heterogeneity in
the two aforementioned signiﬁcant ﬁndings, and this was the only
study to use a ﬁxed dose of chlorpromazine (400 mg/day) and
two further treatment arms of risperidone (4 mg/day or 6 mg/
day). Chlorpromazine was also associated signiﬁcantly with more
events of constipation (N = 868), loss of appetite (N = 180),
tachycardia (N = 557), hypersalivation (N = 373), blurred vision
(N = 387), drop of blood pressure (N = 250) and orthostatic
hypotension (N = 546), drowsiness (N = 307) and dizziness (N
= 299). However, signiﬁcantly more people receiving risperidone
experienced insomnia (N = 342).
2.5 Quality of life
With only one study providing data using the QoL scale demon-
strating signiﬁcantly greater improvement in people receiving
risperidone (N = 100), it is difﬁcult to generalise this ﬁnding to a
real-world setting.
2.6 Leaving the study early
There was no difference between groups for people leaving the
studies early for any reason with roughly equal numbers of partic-
ipants leaving their groups.
3. Chlorpromazine versus quetiapine
3.1 Clinical response
Data from the 28 included RCTs (N = 3241) indicate there is no
signiﬁcant difference in ’clinical response’ (as deﬁned in the differ-
ent studies) between compounds; however, signiﬁcantlymore peo-
ple receiving chlorpromazine required additional benzodiazepines
or antiparkinsonian drugs. Furthermore, global state outcomes us-
ing the CGI are largely equivocal, making it difﬁcult to weigh up
any further beneﬁts of either drug taking into account the fact that
there was no difference in clinical response.
3.2 Mental state
Mental state outcomes using either the BPRS or PANSS were
largely equivocal again, with no signiﬁcant difference between
groups. There were some results that suggested quetiapine was
signiﬁcantly more effective at reducing negative symptoms (using
PANSS). However, there was a signiﬁcant degree of heterogeneity
in these results.
3.3 Functioning
Data showed signiﬁcantly better scores for improvement in func-
tioning using the WCST when receiving quetiapine. Again, with
only one small study reporting data for two subscales of theWCST,
it is impossible to make a generalisation with this result.
3.4 Adverse effects
Extrapryamidal symptoms were signiﬁcantly more prominent in
people receiving chlorpromazine, particularly with akathisia (N
= 1757), ’any’ EPS symptom (N = 644), myotonia (N = 1257),
torsion movement (N = 1063) and tremor (N = 1343). However,
levels of agitation tended to be higher in people receiving que-
tiapine. Other speciﬁc adverse effects, including drowsiness, re-
duced activity, weight gain, constipation, orthostatic hypotension,
tachycardia, hypersalivation, blurred vision and dry mouth, were
signiﬁcantly greater in people receiving chlorpromazine.
3.5 Quality of life
GQOLI scores show that ratings on QoL were signiﬁcantly better
in people receiving quetiapine. Again, this needs to be conﬁrmed
with future studies reporting data using this validated scale.
3.6 Leaving the study early
More people left their study early due to adverse effects if they
were receiving chlorpromazine; a ﬁnding that reﬂects the expected
tolerability of this drug based on the adverse events recorded above.
Leaving the studies early for other reasons were not signiﬁcantly
different between groups in the short or medium term.
Overall completeness and applicability of
evidence
None of the included studies providedmeasured outcomes for eco-
nomic consideration, nor behaviour or satisfaction with treatment
or care. These outcomes are important for managers and policy
makers’ consideration, as well as for carers. Cearly data for ’satis-
faction of treatment or care’ would provide a basis for evidence
of patient acceptability of either compound. No study reported
the outcome of death. Reported outcomes were largely clinician
oriented, and outcomes including service involvement was under-
reported, and future studies would need to address this patient
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important, policy important outcome. The majority of included
studies provided data at the short term only (less than six months),
making it impossible to assess any medium or long-term effect
either compound has on patients. Several studies were excluded
because they did not provide any useable data.
Most included studies included inpatients fromhospitals inChina.
Therefore the results of this Cochrane review are more applicable
to the Chinese population and are not particularly suitable to
apply to community-treated patients. The dose range employed
in most studies was as high as 1000 mg/day, which is far beyond
the maximum BNF recommended dosage (BNF 2014). As most
studies provided a range as opposed to a mean dosage, it is not
possible to generalise these ﬁndings to other populations.
Quality of the evidence
Unfortunately, the overall quality of the evidence was poor (see
Figure 2; Figure 3 for a graphical overview and summary). No
included studies provided details as to randomisation methods
and selective reporting was relatively prominent in most included
studies. Furthermore, as most studies were undertaken in China
(concerns have previously been raised about the quality of report-
ing in Chinese studies; Anon 2010; Wu 2006), this data requires
interpreting with caution as biases may have inﬂated the estimate
of effect in statistically signiﬁcant outcomes. We identiﬁed dupli-
cated data in two studies (vs OLZ -Wu 2008; vs RPD -Wu 2004)
where these two studies compared chlorpromazine to olanzapine
and risperidone, respectively. vs OLZ - Wu 2008 measured qual-
ity of life using the SF-36 scale, and vs RPD - Wu 2004 mea-
sured QoL using the GQOLI scale; however the data for these are
identical in both studies. The mean scores, SDs and sample size
in each group were identical; and we therefore strongly suspect
reporting biases, but need to clarify this with the trial authors. In
the meantime, we have included the QoL data from vs RPD -Wu
2004, and cross-checked all other data between studies and found
no further duplication.
Potential biases in the review process
Chlorpromazine is an old antipsychotic drug that has been ex-
tensively compared with other compounds. There exists the pos-
sibility that there are unpublished, unidentiﬁed studies that we
have not included in this review. We strictly adhered to our proto-
col regarding data extraction and data management. However, we
have presented comparisons with chlorpromazine with the spe-
ciﬁc name of the comparator drug, instead of the planned, generic
’chlorpromazine versus atypical antipsychotics’. We have only in-
cluded data for three of the drug comparisons and plan in future
updated of this Cochrane review to include all other comparator
atypical antipsychotics. We also note that due to the size of the
2012 search results, the search date for this review is out-of-date.
We intend to re-run a search this year and republish as soon as
possible.
Agreements and disagreements with other
studies or reviews
ThisCochrane review clariﬁes the evidence relating to the effects of
chlorpromazine versus three comparator atypical antipsychotics,
namely olanzapine, risperidone and quetiapine. It provides the ev-
idence base for the disputed adverse effect proﬁle, which has been
claimed to be more severe in the older, atypical antipsychotics as
compared to the newer compounds. However, 96% of the studies
from which this data have been derived were undertaken in Chi-
nese hospitals making it difﬁcult to generalise the ﬁnding.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Based on weak evidence, chlorpromazine is not much different to
risperidone or quetiapine and slightly less effective than olanzap-
ine for levels of clinical response. Chlorpromazine was associated
with more extrapyramidal adverse effects, particularly akathisia
and tremor compared to risperidone and quetiapine. Risperidone
has a lower adverse event proﬁle than any of the other atypical
comparators.Generally, chlorpromazinewas associatedwithmore,
and varied adverse effects. There is a lack of evidence relating to
patient-oriented outcomes, including satisfaction with treatment
or care and well-reported QoL outcomes.
2. For clinicians
It is surprising how few studies outside of China have investigated
the effects of chlorpromazine versus other atypical antipsychotics
on people with schizophrenia. Most data relate only to short-term
studies; therefore it is impossible to comment on the medium and
long-termuse of chlorpromazine in the research setting. Chlorpro-
mazine was generally associated with more adverse events. How-
ever all studies made use of varying dose ranges; and the use of
higher doses would be expected to be associated with greater ad-
verse events. As included studies did not provide mean doses, we
could not perform a sensitivity analysis to assess such differences
in the results.
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3. For managers or policy makers
Included studies reported no data relating to service utilisation,
functioning in the community or cost features. Chlorpromazine is
a cheap drug compared to new ’atypical’ antipsychotics. Therefore,
investing somemoney in research on this drug could be cost saving
in the long run.
Implications for research
1. General
Future studies in this area need to be well reported, long term (>
one year) and adhere to the Consolidated Standards of Report-
ing Trials (CONSORT) statement (CONSORT; Moher 2001).
This states that all research needs to be clearly and transparently
reported, and be accompanied by a ﬂow diagram to simply display
the study progress and process.
2. Specific
The trials that met the inclusion criteria of this Cochrane review
were all undertaken in China, predominantly in an inpatient sur-
rounding, and focused only on short-term outcomes (average of
eight weeks). Further research should be international in scope
and fairly representative of other healthcare systems. Outpatient
treatment was under-represented in the included studies, and fu-
ture research should work with this population. More participant
focused outcomes (e.g. functioning in social, occupational, fam-
ily life, satisfaction with care, etc.) and economic considerations
could be addressed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
HGCQ (Turkey) 2000
Methods Allocation: randomised, blocks, computer-generated, 2:1 for each investigator, concealed
from investigators.
Blindness: double, medication kits issued.
Duration: 6 weeks.
Design: parallel 2 centres, Turkey.
Setting: inpatients and outpatients.
Participants Diagnosis: schizophrenia (DSM-IV).
Length of illness: informed consent obtained.
N = 30.
Age: range 18 to 47 years, mean 32.8 years.
Sex: male = 17, female = 13.
Inclusion criteria: CGI severity at least 4.
Excluded: pregnant, seriously unstable illness, includinghepatic, renal, gastroenterologic,
respiratory, cardiovascular, endocrinologic, neurologic or hematologic disease, glaucoma,
uncontrolled thyroid disease, myasthenia gravis, urinary retention, seizures, leucopenia
Interventions 1. Chlorpromazine: dose range 200 to 800 mg/day. N = 10.
2. Olanzapine: dose range 5 to 20 mg/day. N = 20.
Outcomes Leaving the study early.
Mental state: BPRS, PANSS.
Global state: CGI.
Adverse events: ESRS, COSTART list, weight change.
Quality of life: VPS, LSEQ.
Unable to use:
Adverse events: UKU, weight change (no data).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation.
Allocation concealment (selection bias) High risk No concealment of allocation. Quote:
“the bottles were labelled ’Olanzapine’ or
’Chlorpromazine’ in addition to the study
number”
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HGCQ (Turkey) 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding, which may introduce detec-
tion bias, especially, for those subjective
outcomes involving rating scales
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was included in the ﬁnal analysis.
Selective reporting (reporting bias) High risk UKU adverse effect rating scale data and
weight change data were not reported
Other bias Low risk None obvious.
HGDV (Morocco) 1999
Methods Allocation: randomised, computer-generated, blocks for each investigator, 2:1, olanza-
pine to chlorpromazine.
Blindness: open-label, medication kits issued.
Duration: 6 weeks (preceded by washout phase; extension for responders).
Design: single centre Morocco.
Participants Diagnosis: schizophrenia (DSM-IV).
Length of illness: previously hospitalised (mean ~ 1.5 times), informed consent obtained.
N = 40.
Age: 18 to 47.
Sex: 6 male, 33 female.
Setting: inpatients and outpatients.
Inclusion criteria: initial CGI severity score of 4.
Excluded: pregnant, seriously unstable illness, includinghepatic, renal, gastroenterologic,
respiratory, cardiovascular, endocrinologic, neurologic or hematologic disease; glaucoma,
uncontrolled thyroid disease, myasthenia gravis, urinary retention, seizures, leucopenia
Interventions 1. Olanzapine: dose range 5 to 20 mg/day. N = 27.
2. Chlorpromazine: dose range 200 to 800 mg/day. N = 13.
Outcomes Leaving study early.
Mental state: BPRS, PANSS, MADRS, HAMA.
Global state: CGI.
Adverse events: ESRS, COSTART list, weight gain.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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HGDV (Morocco) 1999 (Continued)
Random sequence generation (selection
bias)
Low risk Computer generated randomisation.
Allocation concealment (selection bias) High risk No concealment of allocation. Quote:
“the bottles were labelled ’Olanzapine’ or
’Chlorpromazine’ in addition to the study
number”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding. Quote: “This is an open label
study...personnel at the study site, patients
and personnel at Lilly were not blinded as
to the treatment being administered.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding, which may introduce detec-
tion bias, especially, for those subjective
outcomes involving rating scales
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two participants left chlorpromazine
group early, but were included in the ﬁnal
analysis
Selective reporting (reporting bias) Low risk It appears that all measured outcomes were
reported.
Other bias Low risk None obvious.
vs OLZ - An 2006
Methods Allocation: randomised, no further information.
Blinding: not stated.
Duration: 2 years.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 70.
Age: mean ~ 27 years, SD ~ 6 years.
Sex: male and female.
Length of illness: mean ~ 32 months, SD ~ 13 months.
Inclusion criteria: PANSS ≥ 60, length of illness less than 5 years, without organic dis-
eases, without history of drug or alcohol dependence, clear of any antipsychotic medi-
cation for at least 1 month prior to hospital admission, able to complete cognitive test
and consent to participation to the study
Interventions 1. Olanzapine: dose range 10.3 ± 4.2 mg/d. N = 35.
2. Chlorpromazine: dose range 240 ± 53 mg/d. N = 35.
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Outcomes Clinical response: number of people stabilised on current medication
Relapse.
Service involvement: re-hospitalisation.
Functioning: executive functioning as measured by WCST.
Leaving the study early.
Unable to use:
Functioning: executive functioningWCSTsubscale score. The subscales are not validated
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, but no detail provided.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Eight and 16 people dropped out of olan-
zapine and chlorpromazine group respec-
tively. The drop out is unlikely to have had
any impact on the outcomes measured, ex-
cept forWCST (executive functioning) test
Selective reporting (reporting bias) Low risk All measured outcomes were reported.
Other bias Low risk None obvious.
vs OLZ - Chang 2003
Methods Allocation: randomised with random number table.
Blindness: not reported.
Duration: 8 weeks.
Design: parallel group.
Setting: hospital and community, China.
Participants Diagnosis: schizophrenia.
N = 62.
Age: 18 to 53 years.
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Sex: male and female.
Length of illness: 4 to 5 years.
Inclusion criteria: not reported.
Interventions 1. Olanzapine: 5 to 20 mg/day. N = 32.
2. Chlorpromazine: 25 to 600 mg/day. N = 30.
Outcomes Clinical response: no clinically signiﬁcant improvement*.
Mental state: BPRS.
Adverse effects.
Notes *BPRS scale score decreased rate ≤ 29%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised with random number table.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) High risk TESS was measured, but not reported.
Other bias Low risk None obvious.
vs OLZ - Chen 2006
Methods Allocation: randomised, no further detail.
Blindness: not reported.
Duration: 8 weeks.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia.
N = 86.
Age: 20 to 55 years.
Sex: male and female.
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Length of illness: 3 months to 5 years; median 2 years.
Inclusion criteria: BPRS ≥ 30, SAPS ≥ 28, SANS ≤ 12.
Exclusion criteria: severe physical impairment, history of drug or alcohol abuse, pregnant
or lactating women
Interventions 1. Chlorpromazine: 200 to 800 mg/day. N = 44.
2. Olanzapine: 5 to 20 mg/day. N = 42.
Outcomes Clinical response: no clinically signiﬁcant improvement*.
Mental state: BPRS and SAPS endpoint scale score.
Adverse effects.
Unable to use:
Mental state: BPRS anxiety - depression subscale data, as it was skewed
Notes *Unclear how this was assessed.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further description.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) High risk TESS was measured, but not reported.
Other bias Low risk None obvious.
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Methods Allocation: randomised, no further detail.
Blindness: not reported.
Duration: 8 weeks.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia.
N = 80.
Age: 20 to 55 years.
Sex: male and female.
Length of illness: olanzapine group = 1.5 ± 3.2 years; chlorpromazine group = 2.2 ± 3.0
years.
Inclusion criteria: PANSS ≥ 60
Exclusion criteria: severe liver, renal, heart, haematological diseases; peoplewith glaucoma
or history of drug or alcohol abuse, pregnant or lactating women
Interventions 1. Chlorpromazine: 100 to 600 mg/day. N = 40.
2. Olanzapine: 5 to 30 mg/day. N = 42.
Outcomes Mental state: PANSS endpoint scale score, subscale scores.
Adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further description.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Low risk All measured outcomes were reported.
Other bias Low risk None obvious.
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Methods Allocation: randomised, computer-generated, blocks for each investigator, 2:1, olanza-
pine to chlorpromazine, concealed from investigators.
Blindness: open label.
Duration: 6 weeks (preceded by washout phase of 2 to 9 days; extension for responders)
.
Setting: inpatients and outpatients, multi-centre: two sites, Egypt
Participants Diagnosis: schizophrenia (DSM-IV).
N = 41.
Age: range 17 to 47 years, mean 32.3.
Sex: male 33, female 8.
Inclusion criteria: initial score of at least four on the CGI severity scale.
Excluded: pregnant, seriously unstable illness, includinghepatic, renal, gastroenterologic,
respiratory, cardiovascular, endocrinologic, neurologic or hematologic disease; glaucoma,
uncontrolled thyroid disease, myasthenia gravis, urinary retention, seizures, leucopenia
Interventions 1. Olanzapine: dose range 5 to 20 mg/day. N = 27.
2. Chlorpromazine: dose range 200 to 800 mg/day. N = 14.
Outcomes Leaving study early.
Mental state: BPRS, PANSS.
Global state: CGI-S.
Quality of Life Scale: QoL.
Adverse events: ESRS, COSTART list, weight change.
Unable to use:
Adverse events: UKU (no data).
Hospital status: (no data).
Laboratory tests & physiological measures: (no data).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It’s unclear if appropriate tools/methods
were used to facility the random allocation.
Quote: “qualiﬁed patients were assigned by
random allocation at Visit 2 to one of the
two treatment groups. Randomisation was
performed at 2:1 ratio.”
Allocation concealment (selection bias) High risk No concealment of allocation. Quote:
“Medication was dispensed to the patients
by the study site...the bottles were labelled
’Olanzapine’ or ’Chlorpromazine’ in addi-
tion to the study number”
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk This is an open label study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk LOCF was used to account for any missing
values in the ﬁnal analysis
Selective reporting (reporting bias) High risk Laboratory tests, physiological measures
and hospital status, as well as UKUSide Ef-
fect Rating Scale scores were not reported
Other bias Low risk None obvious.
vs OLZ - Luo 2007
Methods Allocation: randomised, using computer generated random numbers.
Blindness: not reported.
Duration: 8 weeks trial period, plus 52 weeks follow-up.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: ﬁrst episode schizophrenia.
N = 50.
Age: 18 to 60 years.
Sex: male and female.
Length of illness: unclear, but stated as ﬁrst episode schizophrenia.
Inclusion criteria: CCMD-3 diagnosed schizophrenia, not receiving any other antipsy-
chotic medications in combination
Exclusion criteria: simple obesity, hypertension, hypothyroidism, severe heart, liver or
renal disease
Interventions 1. Chlorpromazine: 50 to 400 mg/day. N = 20.
2. Olanzapine: 5 to 25 mg/day. N = 30.
Outcomes Cholesterol analysis: TC, TG, LDL, HDL.
Adverse effects: weight, sleep time.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomised with computer generated ran-
dom numbers.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not stated, but most of the outcomes re-
ported are objective lab test results, which
is unlikely to introduce bias to the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Low risk All measured outcomes are reported.
Other bias Low risk None obvious.
vs OLZ - Wang 2002
Methods Allocation: randomised, using computer generated random numbers.
Blindness: not reported.
Duration: 8 weeks trial period, plus 52 weeks follow-up.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: ﬁrst episode schizophrenia.
N = 60.
Age: 18 to 60 years.
Sex: male and female.
Length of illness: unclear, but stated as ﬁrst episode schizophrenia.
Inclusion criteria: CCMD-3 diagnosed schizophrenia, BPRS > 30
Exclusion criteria: severe organic disease, heart, liver or renal disease, substance misuse
induced mental disorders
Interventions 1. Chlorpromazine: 25 to 600 mg/day. N = 28.
2. Olanzapine: 5 to 20 mg/day. N = 32.
Outcomes Clinical response: no signiﬁcant clinical response*.
Mental state: BPRS
Adverse effects.
Unable to use:
Mental state: ’BPRS reducing score’, as it’s unclear what the trial author meant by this.
We are uncertain as to how the score is calculated or what it means
Notes *Paper did not report on how they measured signiﬁcant clinical response
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label. Quote: “test and control drugs
were administrated openly.” p2665
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated, but most of the outcomes re-
ported are objective laboratory test results,
which is unlikely to introduce bias to the
study
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) High risk TESS is measured, but not reported.
Other bias Low risk None obvious.
vs OLZ - Wang 2008
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 1 week washout period, plus 8 weeks trial.
Design: parallel group.
Setting: inpatients and community patients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 237.
Age: mean age ~ 27 years, SD ~ 10 years.
Sex: male and female.
Length of illness: mean ~ 4 years, SD ~ 5 years.
Inclusion criteria: CCMD-3 diagnosed schizophrenia, BPRS > 36, obtained informed
consent, lab test results within normal range
Exclusion criteria: severe organic disease, heart, liver or renal disease and any other severe
mental disorders
Interventions 1. Chlorpromazine: 200 to 700 mg/day. N = 119.
2. Olanzapine: 5 to 15 mg/day. N = 118.
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Outcomes Mental state: BPRS subscale and endpoint scale score*. NOSIE endpoint scale score*
Adverse effects.
Leaving the study early.
Unable to use:
Mental state: unvalidated NOSIE subscale scores.
Notes *The published BPRS and NOSIE endpoint scale score were implied as ’mean ± SD’,
but we suspect they are ’mean ± SE’ for the SDs are extremely tight around the mean.
Therefore, we converted these reported SE to SD following SD = SEM X sq rt (N)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk Thirteen and 11 people dropped out of
Olazapine and chlorpromazine group re-
spectively. These people were excluded
from ﬁnal analysis. Reason for drop out
were not given
Selective reporting (reporting bias) Low risk None obvious. All measured outcomes ap-
pear to be reported.
Other bias Low risk None obvious.
vs OLZ - Wu 2008
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: twelve weeks trial.
Design: parallel group.
Setting: inpatients, China.
77Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
vs OLZ - Wu 2008 (Continued)
Participants Diagnosis: schizophrenia (CCMD-3).
N = 100.
Age: 18 to 60 years.
Sex: male and female.
Length of illness: mean ~ 4 years, SD ~ 5 years.
Inclusion criteria: CCMD-3 diagnosed schizophrenia, PANSS > 60, obtained informed
consent
Exclusion criteria: severe organic disease, drug or alcohol dependence
Interventions 1. Chlorpromazine: 50 to 600 mg/day. N = 50.
2. Olanzapine: 5 to 20 mg/day. N = 50.
Outcomes Mental state: PANSS subscale and endpoint scale score. NOSIE endpoint scale score
Adverse effects.
Leaving the study early.
Unable to use:
Mental state: invalidated SF-36 subscale scores.
Quality of life: SF-36 total scale score*.
Notes *Data derived from this scale overlapped with the QOL data reported in another study
published by the same author. Therefore, we decided to report the QOL data that was
published earlier (published in 2004) than this paper
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Unclear risk None obvious. All measured outcomes ap-
pear to be reported.
Other bias Low risk None obvious.
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Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 8 weeks trial.
Design: parallel group.
Setting: inpatients and community patients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 61.
Age: mean ~ 30 years, SD ~ 9.6 years.
Sex: male and female.
Length of illness: mean ~ 1.5 years, SD ~ 3 years.
Inclusion criteria: CCMD-3 diagnosed schizophrenia, PANSS > 60, obtained informed
consent
Exclusion criteria: severe organic disease, drug or alcohol dependence, pregnant or lac-
tating women, learning disability
Interventions 1. Chlorpromazine: 50 to 600 mg/day. N = 29.
2. Olanzapine: 5 to 20 mg/day. N = 32.
Outcomes Mental state: PANSS subscale and endpoint scale score.
Quality of life: QGOLI score.
Adverse effects.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Low risk None obvious. All measured outcomes ap-
pear to be reported.
Other bias Low risk None obvious.
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Methods Allocation: randomised, no further detail.
Blinding: not reported.
Duration: 12 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 85.
Sex: male = 44, female = 41.
Age: mean ~ 30 years, SD ~ 11 years.
Length of illness: mean ~ 5.8 years, SD ~ 3.3 years.
Inclusion criteria: schizophrenia (CCMD-3).
Exclusion criteria: severe physical illness.
Interventions 1. Chlorpromazine: 400 to 550 mg/day. N = 42.
2. Quetiapine: 400 to 750 mg/day. N = 43.
Outcomes Clinical response: no clinical improvement*.
Mental state: BPRS.
Adverse effects.
Notes * BPRS decreased rate < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) High risk TESS measured, but not reported fully.
Other bias Low risk None obvious.
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vs QTP - An 2005
Methods Allocation: randomised, no further information.
Blindness: not stated.
Duration: 8 weeks.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 60.
Age: 23.7 ± 5.4 years.
Sex*: male = 45, female = 12.
Length of illness: 0.8 ± 0.6 years.
Inclusion criteria: ﬁrst episode schizophrenia (CCMD-2-R), did not receive systematic
treatment prior to admission, PANSS≥ 60, length of illness less than 2 years, laboratory
tests normal
Exclusion criteria: patients with physical or organic diseases
Interventions 1. Chlorpromazine: titrated over a 1 week period to a treatment dosage of 200 to
400 mg/d, a further 7 weeks ﬁxed dosage. N = 30.
2. Quetiapine: titrated over one week period to a treatment dosage of 300 to 500
mg/d, followed by a further 7 weeks ﬁxed dosage. N = 30.
Outcomes Mental state: PANSS positive, negative, general pathology and total score
Function: general function as measured by WAIS - RC endpoint subscale score, WMS
endpoint subscale score
Uable to use
unvalidated WMS subscale score.
Notes *We contacted the trial author for clariﬁcation of the number of male and female par-
ticipants but didn’t receive any reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients completed the trial.
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Selective reporting (reporting bias) Low risk All measured outcomes were well reported.
Other bias Low risk None obvious.
vs QTP - Cai 2006
Methods Allocation: randomised.
Blindness: not stated.
Duration: 1 week wash out, plus 8 weeks trial.
Design: parallel.
Setting: inpatients from 8 hospitals, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 197.
Age: mean ~ 31.1 years, SD ~ 10.1 years.
Sex: male = 109, female = 88.
Length of illness: mean ~ 5.6 years.
Inclusion criteria: BRPS score ≥ 36.
Exclusion criteria: patients with severe physical diseases, organic disease or pregnant
women
Interventions 1. Chlorpromazine: chlorpromazine was titrated to a treatment dosage (decided by
the doctor). N = 96, no further details were provided.
2. Quetiapine: quetiapine was titrated from 100 mg/d to a treatment dosage (decided
by the doctor) which is usually < 800 mg/d. N = 101, no further detail were provided.
No ECT or any other antipsychotic medication were combined during the treatment,
but benzodiazepine or other medications for adverse effects were allowed
Outcomes Mental state: decreased rate of BPRS score.
Leave the study early**.
Adverse effect.
Unable to use.
Clinical response: no clinical improvement*.
Notes *The total N of this outcome exceeded the total number of people randomised, therefore,
we are unable to determine the true proportion of cases without clinical improvement
**We adopted 96 and 101 as the number of participants in the chlorpromazine and
quetiapine groups respectively, rather than using 100 and 109 as reported in the paper,
as the total of the latter exceeds the number of people randomised
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details were re-
ported.
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Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Twelve cases left the study early with no
reason reported, but ITT analysis was con-
ducted
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk None obvious.
vs QTP - Cai 2007
Methods Allocation: randomised, no further detail were reported.
Blindness: not reported.
Duration: 1 week washout period, plus 8 week trial.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 94.
Age: Quetiapine group, range: 18 to 68 years, average: 37.6 ± 15.3 years; chlorpromazine
group, range: 19 to 65 years, average: 34 ± 10.5 years
Sex: Quetiapine group, male 35, female 13; chlorpromazine group, male 32, female 14.
Length of illness: quetiapine group, range: 2 months to 15 years, average: 3.3 ± 3.5 years;
chlorpromazine group, range: 3 months to 16 years, average: 3.6 ± 4.3 years
Inclusion criteria: PANSS score ≥ 60.
Exclusion criteria: patients with organic mental disorder, alcohol abuse or other drugs
abuse, with learning disability, pregnant or breastfeeding women. Patients on slow release
depot antipsychotic
Interventions 1. Chlorpromazine: chlorpromazine was titrated from a dosage of 100 mg/d to a
maximum dosage of 700 mg/d, frequency. N = 46.
2. Quetiapine: Quetiapine was titrated from a dosage of 100 mg/d to a treatment
dosage which should be less than 700 mg/d. N = 48.
Outcomes Clinical response:no clinical improvement*, decreased rate of PANSS score
Mental state: PANSS endpoint scale score decreased rate, positive subscale score decreased
rate, negative subscale score decreased rate
Adverse effect: TESS.
Unable to use:
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Mental state: PANSS subscale scores on cognitive function, agitation and depression.
These subscales are not validated
Notes *Decreased rate of PANSS score: < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail were re-
ported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All the patients completed the study.
Selective reporting (reporting bias) Low risk All the outcomes were well reported.
Other bias Low risk None obvious.
vs QTP - Cao 2005
Methods Allocation: randomised, no further detail.
Blinding: open label.
Duration: 16 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 50.
Age: 25 to 40 years.
Sex: male.
Length of illness: not stated.
Exclusion: having other mental health problems, other physical illness, drug/alcohol
dependent, abnormal lab test results, problematic marital relationships
Interventions 1. Chlorpromazine: dosage not stated. N = 25.
2. Quetiapine: dosage not stated. N = 25.
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Outcomes Leaving the study early.
Unable to use:
Adverse effects - continuous data was reported, but the scale used was unclear.
Sexual arousal, and other sexual related outcomes thatweremeasuredusing an invalidated
scale
Notes Only male participants were included in the study; therefore, gender bias is likely
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop outs were excluded from analysis.
Selective reporting (reporting bias) Low risk All measured outcomes reported.
Other bias Low risk None obvious.
vs QTP - Chen 2001
Methods Allocation: randomised by using random number table.
Blinding: double blind, no further detail.
Duration: 1 week washout period, plus 8 weeks intervention.
Setting: inpatients, multi-centre, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 221.
Sex: male = 113 and female = 108.
Age: mean ~ 35 years, SD ~ 11 years.
Length of illness: not stated.
Inclusion criteria: CCMD-3 diagnosed schizophrenia, BPRS ≥ 36.
Exclusion criteria: severe heart, renal, liver illness, nerve system illness, hypertension,
blood disease, pregnant/lactating women, received ECT within 2 weeks prior to current
study, suicidal patients, participated in other clinical trials within 1 month prior to
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current study
Interventions 1. Quetiapine: 200 to 800 mg/day. N = 114.
2. Chlorpromazine: 200 to 800 mg/day. N = 107.
Outcomes Clinical response: no clinical improvement*, decreased rate of PANSS score
Global state: poor compliance, leave the study early.
Mental state: BPRS, PANSS.
Adverse events.
Notes *Decreased rate of PANSS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using random number table.
Allocation concealment (selection bias) Low risk Pharmacist produced identical pills, only
they know which pill contains experimen-
tal drug
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT was used.
Selective reporting (reporting bias) Low risk Outcomes reported as measured.
Other bias Low risk None obvious.
vs QTP - Chen 2007
Methods Allocation: randomised, no further detail.
Blinding: not reported.
Duration: 3 months.
Setting: inpatients and outpatients, Xuzhou, Jiangsu province, China
Participants Diagnosis: schizophrenia (CCMD-3).
N = 62.
Sex: male = 33 and female = 29.
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vs QTP - Chen 2007 (Continued)
Age: mean ~ 20.1 years, SD ~ 2.1 years.
Length of illness: average, mean 1.6 years, SD 0.8 years.
Inclusion criteria: length of illness between 6 months to 7 years.
Exclusion criteria: severe physical illness, drug/alcohol dependent, pregnant/lactating
women
Interventions 1. Chlorpromazine: 360.3 ± 82.5 mg/day. N = 30.
2. Quetiapine: 300.7 ± 00.3 mg/day. N = 32.
Outcomes Mental state: PANSS, BPRS.
Adverse events.
Unable to use:
GQOLI-74. Only subscale scores were reported. The subscales were not validated
Notes *Decreased rate of PANSS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) High risk Clinical response wasmeasured, but not re-
ported.
Other bias Low risk None obvious.
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vs QTP - Chen 2008
Methods Allocation: randomised, no further detail.
Blindness: no further detail.
Duration: 3 days wash out period, plus 8 weeks trial.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 60.
Age: 18 to 50 years.
Sex: male = 33, female = 27.
Length of illness: mean ~ 21.25 months, SD ~ 13.90 months;
Inclusion criteria: PANSS score ≥ 60.
Exclusion criteria: severe physical diseases or other mental diseases, pregnant or breast-
feeding women, allergic to medication
Interventions 1. Chlorpromazine: titrated over a 1 week period from 100 mg/d to 400 to 600 mg/
d. N = 30.
2. Quetiapine: titrated over a 1 week period from 50 mg/d to 300 to 500 mg/d. N =
30.
During 8 weeks treatment period, benzodiazepine or anticholinergics agents were used
when necessary
Outcomes Clinical response: no clinical improvement*
Mental health: PANSS scale score; PANSS negative.
Notes *Decreased rate of PANSS score: < 25%
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients completed the trial.
Selective reporting (reporting bias) High risk TESS were not fully reported.
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vs QTP - Chen 2008 (Continued)
Other bias Low risk None obvious.
vs QTP - Cheng 2003
Methods Allocation: Randomised, no further detail.
Blindness: not reported.
Duration: 8 weeks.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 89.
Age: average, 33.1 ± 10.3 years; chlorpromazine group:34.8 ± 10.5 years.
Sex: quetiapine group: male 20, female 24; chlorpromazine group: male 22, female 23.
Length of illness: quetiapine group: 6.4 ± 5.8 years; chlorpromazine group: 6.4 ± 5.7
years
Inclusion criteria: PANSS score ≥ 60.
Exclusion criteria: physical impairment.
Interventions Chlorpromazine: titrated over a 1 week period from 50 mg/d to 200 mg/d, average
dosage in the end of the 4th week post treatment was 400 ± 150 mg/d and 250 ± 100
mg/d at the end of 8th week. N = 45
Quetiapine: titrated over a 1 week period from 50 mg/d to 200 mg/d, average dosage in
the end of the 4th week post treatment was 450 ± 250 mg/d and 260 ± 110 mg/d at the
end of 8th week. N = 44
Outcomes Global state: CGI*, need of additional non-antipsychotic drugs
Mental state: PANSS*
Adverse effect: TESS.
Leaving the study early.
Uable to use:
Clinical response, the total number of patients in each group doesn’t match the number
reported at baseline. We contacted the trial author, but did not receive any response
Notes *Numbers of participants in these two studies were not clearly stated in the paper. We
assumed that each arm had the same number of participants as when randomised
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
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vs QTP - Cheng 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Three cases left study early in the quetiap-
ine group because of advanced condition;
2 cases left the study early in the chlor-
promazine group because of adverse effects.
Unclear if these were included in the ﬁnal
analysis
Selective reporting (reporting bias) Low risk All the outcomes were well reported.
Other bias Low risk None obvious.
vs QTP - Deng 2004
Methods Allocation: Randomised, no further detail.
Blindness: double blind, the medication was put into capsules.
Duration: 3 to 7 days of wash out period, plus 12 weeks trial.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2)
N = 90.
Age: Quetiapine group, range: 18 to 70 years, average: 37.6 ± 15.5 years; chlorpromazine
group, range: 20 to 65 years, average: 34.2 ± 10.6 years
Sex: quetiapine group: male 20, female 25; chlorpromazine group: male 26, female 19
Length of illness: quetiapine group, 3.3 ± 3.6 years; chlorpromazine group, 3.5 ± 4.2
years
Inclusion criteria:
1. Schizophrenia, CCMD-2.
2. BPRS score ≥ 35.
Exclusion criteria: severe physical diseases, extremely agitated or restless
Interventions Chlorpromazine: dosage started from 50 mg/d and increased to 100 mg/d on the 3rd
day of treatment, then 150 mg/d on the 5th day. Maintenance dosage: 200 to 800 mg/
d. N = 45
Quetiapine: dosage started from 50 mg/d increased to 100 mg/d on the third day of
treatment, then 150 mg/d on the ﬁfth day. Maintenance dosage 200 to 800 mg/d. N =
45
Benzodiazepine or benzhexol were used when necessary. Without combination with
other antipsychotic drugs
90Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
vs QTP - Deng 2004 (Continued)
Outcomes Clinical response: no clinical improvement*.
Effects on physiology: blood test result, liver function.
Notes *Decreased rate of BPRS score: < 30%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed the trial.
Selective reporting (reporting bias) High risk Clinical response, BPRS, SANS, SAPS and
TESS were not reported
Other bias Low risk None obvious.
vs QTP - Guo 2003a
Methods Allocation: randomised (by tossing a coin).
Blinding: not reported.
Duration: 8 weeks.
Setting: outpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 148.
Sex: male (N = 74) and female (N = 74).
Age: 18 to 55 years.
Length of illness: range, 3 months to 1 year, mean 0.1 year, SD 0.5 year
Inclusion: PANSS≥ 60, length of illness < 1 year, not receiving long-acting antipsychotic
drugs.
Exclusion: severe physical illness, drug/alcohol dependent.
Interventions 1. Chlorpromazine: 600 ± 50 mg/day. N = 73.
2. Quetiapine: 450 ± 25 mg/day. N = 75.
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vs QTP - Guo 2003a (Continued)
Outcomes Clinical response: no clinical improvement*, decreased rate of PANSS score
Mental state: PANSS (total, positive and negative score).
Adverse events.
Effects on physiology: laboratory ﬁndings. liver function.
Notes *Decreased rate of PANSS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by tossing a coin.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) Low risk All the outcomes were well reported.
Other bias Low risk None obvious.
vs QTP - Guo 2003b
Methods Allocation: randomised, no further detail.
Blinding: single blind, assessor blind.
Duration: 3 months.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 71.
Sex*: male 28 and female 31.
Age: 17 to 58 years, mean ~ 26.22 years, SD ~ 6.73 years.
Length of illness: mean 5.72 months, SD 3.97 months.
Inclusion: PANSS > 60, length of illness < 2 years.
Exclusion: severe physical illness, pregnant or breast feeding women
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vs QTP - Guo 2003b (Continued)
Interventions 1. Quetiapine: titration period :1 to 2 weeks, average dosage: 300.72 ± 101.25 mg/
d. N = 35.
2. Chlorpromazine: titration period :1 to 2 weeks, average dosage: 360.28 ± 82.45
mg/d. N = 35.
Antan was used when EPS appears, no other antipsychotic drugs were used during
treatment
Outcomes Mental state: PANSS (total, positive and negative score).
Leave the study early.
Adverse events.
Effects on physiology: laboratory ﬁndings. liver function.
Unable to use:
WHO-QOL-100, no scale scores reported and the subscales were not validated
Notes *The total number of male and female participants does not match to the total number
randomised
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk Five patients left the study early in the que-
tiapine group, 6 patients left the study early
in the chlorpromazine group, without any
reason reported. No ITT analysis was ap-
plied
Selective reporting (reporting bias) Low risk All the outcomes were well reported
Other bias Low risk None obvious.
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vs QTP - Guo 2005
Methods Allocation: randomised, no further detail reported.
Blindness: not stated.
Duration: 3 days wash out period, plus 8 weeks trial.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 80.
Age: 16 to 57 years, mean ~ 28.3 years, SD ~ 10.2 years.
Sex: male = 42, female = 38.
Length of illness: 2 months to 10 years; mean ~ 6.5 years, SD ~ 5.9 years
Inclusion criteria: PANSS ≥ 60.
Exclusion criteria: severe physical impairment or other mental disorders, pregnant or
breastfeeding women, allergic to medication
Interventions 1. Chlorpromazine: titrated over a 1 week period from 100 mg/d to a treatment
dosage of 400 to 600 mg/d. N = 40.
2. Quetiapine: titrated over a 1 week period from 50 mg/d to a treatment dosage of
300 to 500 mg/d. N = 40.
Antan was used for EPS; alprazolam was used for insomnia or anxiety; β-blokers was
used for tachycardia
Liver function, ECG and blood test were measured at baseline, 2 , 4 and 8 weeks post-
treatment
Outcomes Clinical response: no clinical improvement*.
Globle state: need for non-antipsychotic drugs.
Mental state: PANSS scale score, positive score, negative score, general pathological score
Adverse effects: TESS.
Notes *Decreased rate of PANSS score < 20%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details reported.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All the patients completed the trial.
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vs QTP - Guo 2005 (Continued)
Selective reporting (reporting bias) Low risk All measured outcomes were reported.
Other bias Low risk None obvious.
vs QTP - Guo 2006
Methods Allocation: randomised, no further details.
Blindness: not stated.
Duration: 8 weeks.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 130.
Age: mean ~ 33 years, SD ~ 11 years.
Sex: male = 57, female = 73.
Length of illness: not stated.
Inclusion criteria: FBG < 6.7 mmol/L, without use of antipsychotic, antidepressant or
any other medication having an inﬂuence on the metabolites of blood glucose or blood
lipid
Exclusion criteria: disturbance of carbohydrate or lipid metabolics, severe physical im-
pairments
Interventions 1. Chlorpromazine: chlorpromazine titrated over a 2-week period from 50 mg/d to
200 to 800 mg/d. N = 65.
2. Quetiapine: quetiapine titrated over a 2-week period from 50 mg/d to 200 to 800
mg/d. N = 65.
Without combination of antipsychotic, antidepressant, or any other medication having
a inﬂuence on the metabolites of blood glucose or blood lipid
Outcomes Adverse effects: weight gain/loss.
Effects on physiology: blood glucose, cholesterol.
Notes This trial was funded by the National Science and Technology Research Fund
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
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vs QTP - Guo 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients completed this
trial.
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk None obvious.
vs QTP - Guo 2007
Methods Allocation: randomised, no further detail.
Blinding: not reported.
Duration: 8 weeks.
Setting: inpatients and outpatients, Kangning hospital, Guangzhou city, China
Participants Diagnosis: schizophrenia (CCMD-3).
N = 52.
Age: 18 to 40 years, mean ~ 26.8 years, SD ~ 4.2 years.
Sex: male = 23, female = 29.
Length of illness: 0.5 to 2 years, mean ~ 1.1 years, SD ~ 0.6 years
Inclusion: PANSS ≥ 60, CGI-SI ≥ 4.
Exclusion: organic brain diseases, severe physical illness, drug/alcohol dependent, preg-
nant/lactating women
Interventions 1. Chlorpromazine: 300 to 500 mg/day. N = 26.
2. Quetiapine: 600 to 800 mg/day. N = 26.
Antan or propranolol were used when necessary.
Outcomes Global state: CGI-S, CGI-I.
Mental state: PANSS.
Function: global function WCST.
Adverse events.
Unable to use:
WCST subcale score, as it is not validated.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
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vs QTP - Guo 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) High risk TESS was measured, but not reported.
Other bias Low risk None obvious.
vs QTP - Guo 2008
Methods Allocation: randomised, using random number table.
Blindness: double-blind, patients and assessor were blinded.
Duration: 16 weeks.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 86.
Age: mean ~ 30 years, SD ~ 10 years.
Sex: male = 39, female = 44.
Length of illness: less than 1 year: 57 cases; more than 1 year: 26 cases
Inclusion criteria: PANSS ≥ 60.
Exclusion criteria: organic diseases or severe cardiac, liver, kidney diseases, patients re-
ceiving 2 or more antipsychotic drugs, patients taking antipsychotic drugs 1 week before
randomisation
Interventions 1. Chlorpromazine: < 1000 mg. N = 40.
2. Quetiapine: initial dosage is 100 mg/d, titrated to a treatment dosage (exact
dosage not reported), N = 46.
Outcomes Clinical response: no clinical improvement*
Mental state: PANSS.
Quality of life: WHO-QOL-100 endpoint scale score.
Adverse effect: TESS.
Effects of physiology: laboratory ﬁndings,blood count, cholesterol, glucose, liver function
Leave the study early.
Unable to use:
WHO-QOL-100 subscale score. The subscales were not validated
Notes *Decreased rate of PANSS score < 50%.
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vs QTP - Guo 2008 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by using random number ta-
ble.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk A total of 3 patients in the quetiapine group
left the study early: 1 case left due lack of
efﬁcacy, 2 cases due to adverse effects. ITT
was employed in the ﬁnal result analysis
Selective reporting (reporting bias) Low risk All the outcomes were reported.
Other bias Low risk None obvious.
vs QTP - He 2003
Methods Allocation: randomised, no further details.
Blinding: open label.
Duration: six weeks.
Setting: Jiangsu City, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 40.
Sex: male 24, female 16.
Age: 18 to 50 years, mean ~ 32.4 years, SD ~ 8.1 years.
Length of illness: one month to 10 years, mean 4.3 years, SD 3.4 years
Inclusion criteria: PANSS ≥ 60.
Exclusion criteria: severe physical illness, alcohol/drug abuse, pregnant/lactating women
Interventions 1. Chlorpromazine: 468 ± 39 mg/day. N = 20.
2. Quetiapine: 433 ± 19 mg/day. N = 20.
Outcomes Clinical improvement: no clinical improvement*.
Mental state: PANSS endpoint scale score, positive, negative, general pathology score
Adverse effects.
98Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
vs QTP - He 2003 (Continued)
Notes *Decreased rate of PANSS score < 40%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) Low risk All the outcomes were well reported.
Other bias Low risk None obvious.
vs QTP - Hu 2003
Methods Allocation: randomised, no further detail.
Blinding: not reported.
Duration: 4 weeks.
Setting: inpatients, Mental health centre, Sichuan, China.
Participants Diagnosis: schizophrenia (DSM-IV), ﬁrst onset, inpatients.
N = 41.
Sex: male
Age: mean ~ 26.94 years, SD ~ 8.82 years.
Length of illness: not reported.
Exclusion: severe physical illness, lactating/pregnant women
Interventions 1. Chlorpromazine: 350 ± 67.8 mg/d. N = 19.
2. Quetiapine: 410 ± 108.77 mg/d. N = 22.
Outcomes Mental state: PANSS (positive, negative, general psychopathology subscale)
Adverse effects: TESS, RSESE.
Unable to use: GAF score - some data missing.
Notes
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vs QTP - Hu 2003 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) Low risk Evidence of selective reporting was no
found.
Other bias Low risk None obvious.
vs QTP - Ji 2004
Methods Allocation: randomised, no further detail.
Blinding: not reported.
Duration: 3 months.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 66.
Age: 18 to 45 years, mean ~ 25.6 years, SD ~ 7 years.
Sex: male = 33 and female = 26.
Length of illness: mean ~ 1.6 years, SD ~ 0.5 years.
Inclusion: PANSS ≥ 60.
Exclusion: patients with severe physical illnesses, drug or alcohol dependency, pregnant
or lactating women
Interventions 1. Chlorpromazine: average dosage, 507 ± 27.8 mg/d. N = 33.
2. Quetiapine: average dosage,501.2 ± 31.2 mg/d. N = 33.
Outcomes Global state: poor compliance, leave the study early.
Mental state: PANSS total, negative, positive, general psychopathology score.
Quality of life: GQOLI - 74 endpoint scale score.
Adverse effects.
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vs QTP - Ji 2004 (Continued)
Uable to use:
Quality of life:GQOLI - 74 subscale score. These subscales were not validated
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk Four patients in the chlorpromazine group
left the study early, 3 patients in the que-
tiapine group left the study early, all due
to adverse effects. Dropouts were excluded
from analysis
Selective reporting (reporting bias) Low risk Evidence of selective reporting was not
found.
Other bias Low risk None obvious.
vs QTP - Jiang 2006
Methods Allocation: randomised, no further details.
Blinding: not reported.
Duration: 8 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 191.
Age: mean ~ 34 years, SD ~ 9.7 years.
Sex: not reported.
Length of illness: duration ill mean 58 months, SD 68 months
Inclusion: PANSS ≥ 60, or a score of at least 3 on two or more of the PANSS items
’delusion’, ’hallucination’, ’Incoherence’, ’suspiciousness’, ’persecution’.
Exclusion: severe physical illness, drug/alcohol dependent, received experimental drugs
within 4 weeks prior to the trial
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vs QTP - Jiang 2006 (Continued)
Interventions 1. Chlorpromazine: 100 to 600 mg/d. N = 97.
2. Quetiapine: 100 to 800 mg/d. N = 94.
Outcomes Clinical response: no clinical improvement*.
Adverse events: TESS.
Effects on physiology: laboratory ﬁndings.
Leave the study early.
Unable to use:
PANSS score, this data is not reported.
Notes *No clinical improvement: decreased rate of PANSS score < 30%
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Twenty-one cases in the quetiapine group
left the study early, 5 cases because of agi-
tation, 10 because of abnormal liver func-
tion, 1 because of orthostatic hypotension,
5 cases lost to follow-up.Twenty cases in the
chlorpromazine group left the study early:
17 cases because of adverse effects and 3
were lost to follow-up. The drop-out cases
were also reported
Selective reporting (reporting bias) High risk PANSS measured, but not reported.
Other bias Low risk None obvious.
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vs QTP - Jiang 2008
Methods Allocation: randomised, no further detail.
Blinding: not stated.
Duration: 6 weeks.
Setting: inpatient, China.
Participants Diagnosis: schizophrenia (CCMD-3).
Sex: male = 36, female = 24.
Age: 18 to 60 years, mean ~ 33.54 years, SD ~ 5.26 years
N = 60.
Length of illness: mean ~ 8.24 years, SD ~ 3.15 years.
Inclusion criteria: PANSS ≥ 60, patients who weren’t receiving any antipsychotic drugs
before randomisation, or with a suspension of antipsychotic drugs at least 1 week before
randomisation.
Exclusion criteria: severe physical illness, organic brain disease, drug abuse, pregnant/
lactating women, allergic to the medication
Interventions 1. Chlorpromazine: 300 to 800 mg/d. N = 30.
2. Quetiapine: 300 to 800 mg/d. N = 30.
Antan or benzodiazepine were used when necessary, no other antipsychotic medication
were used during treatment course
Outcomes Clinical improvement: no clinical improvement*.
Mental state: PANSS and BPRS endpoint total score.
Measured at baseline, 2, 4 and 6 weeks post treatment.
Adverse events: TESS.
Notes *Decreased rate of PANSS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed the trial.
Selective reporting (reporting bias) High risk TESS were not fully reported.
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vs QTP - Jiang 2008 (Continued)
Other bias Low risk None obvious.
vs QTP - Jin 2007
Methods Allocation: randomised, no further details.
Blinding: not reported.
Duration: 4 weeks.
Setting: outpatients and inpatients, Hebei province, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 60.
Sex: male = 33 and female = 27.
Age: 18 to 60 years.
Length of illness: 1 to 24 months.
Exclusion: severe physical illness, drug abuse, pregnant/lactatingwomen, allergic to either
of the intervention drugs
Interventions 1. Chlorpromazine: 200 to 600 mg/day. N = 30.
2. Quetiapine: 200 to 800 mg/day. N = 30.
Outcomes Clinical response: no clinical improvement*, decreased rate of PANSS score
Adverse effects.
Notes *Decreased rate of PANSS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) High risk TESS measured, but not reported.
Other bias Low risk None obvious.
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vs QTP - Kong 2003
Methods Allocation: randomised, no further details.
Blinding: not reported.
Duration: 6 weeks.
Setting: outpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 30.
Sex: male 8, female 22.
Age: mean 26 to 38 years.
Length of illness: 0.5 to 5 years.
Inclusion: patients did not take antipsychotic drugs 1 week before randomisation, with-
out cardiac, liver, kidney or endocrine diseases.
Exclusion: lactating/pregnant women.
Interventions 1. Chlorpromazine: 200 to 400 mg/d. N = 15.
2. Quetiapine: 300 to 500 mg/d. N = 15.
Outcomes Effects on physiology: laboratory ﬁndings.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed the trial.
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk None obvious.
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vs QTP - Li 2003
Methods Allocation: randomised, no further details.
Blinding: not reported.
Duration: 6 months.
Setting: inpatients and outpatients, mental health centre, Shandong, China
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 103.
Sex: male 36, female 31.
Age: 18 to 56 years, mean ~ 31.3 years, SD ~ 9.5 years.
Length of illness: mean ~ 1.3 years, SD ~ 2.0 years.
Inclusion: schizophrenia, CCMD-3; PANSS ≥ 60.
Exclusion: severe physical illness, drug/alcohol dependent, pregnant/lactating women
Interventions 1. Chlorpromazine: 503 ± 134 mg/day. N = 51.
2. Quetiapine: 482 ± 124 mg/day. N = 52.
Outcomes Mental state: PANSS scores.
Adverse effects: TESS scores.
Unable to use:
Quality of life: WHO-QOL-100 subscale scores. The subscales were not validated
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Twelve cases left the study early in quetiap-
ine group; 14 patients left the study early
in chlorpromazine group. The reasons for
dropout were either lack of efﬁcacy or ad-
verse effects. ITT was not used
Selective reporting (reporting bias) Low risk We did not ﬁnd any evidence of selective
reporting.
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vs QTP - Li 2003 (Continued)
Other bias Low risk None obvious.
vs QTP - Li 2010
Methods Allocation: randomised, no further detail.
Blinding: not reported.
Duration: 6 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 64.
Sex: male = 37 and female = 27.
Age: mean ~ 27.9 years, SD ~ 7.22 years.
Length of illness: mean 32 months, SD 22 months.
Inclusion: schizophrenia, CCMD-3.
Exclusion: not reported.
Interventions 1. Chlorpromazine: 550 ± 12.5 mg/day. N = 32.
2. Quetiapine: 500 ± 17.5 mg/day. N = 32.
Outcomes Leave the study early.
Mental state: HAMD scores.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One case in the chlorpromazine group left
the study early. Reason not stated, neither
was it included in the ﬁnal analysis
Selective reporting (reporting bias) Low risk All the outcomes were well reported.
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vs QTP - Li 2010 (Continued)
Other bias Low risk None obvious.
vs QTP - Liu 2003
Methods Allocation: randomised, no further detail.
Blinding: not reported.
Duration: 6 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 83.
Sex: male = 45 and female = 38.
Age: mean ~ 64.3 years, SD ~ 2.8 years.
Length of illness: mean ~ 3.98 months, SD ~ 2.57 months.
Inclusion: primary schizophrenia, CCMD-2-R; age ≥ 60 years, PANSS ≥ 60.
Exclusion: not reported.
Interventions 1. Quetiapine: titrated upwards from initial dosage of 50 mg/d to 200 to 350 mg/
day. N = 44.
2. Chlorpromazine: titrated upwards from initial dosage of 50 mg/d to 200 to 350
mg/day. N = 39.
Outcomes Clinical response: no clinical improvement*.
Mental state: PANSS scores.
Adverse effects: TESS scores.
Effects on physiology: laboratory ﬁndings, blood test and liver function
Notes *Decreased rate of PANSS score < 40%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed the trial.
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vs QTP - Liu 2003 (Continued)
Selective reporting (reporting bias) Unclear risk TESS were not well reported.
Other bias Low risk None obvious.
vs QTP - Mei 2007
Methods Allocation: randomised, no further details.
Blinding: not reported.
Duration: 3 days wash out period, plus 8 weeks trial.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 96.
Sex: male = 43, female = 53.
Age: 17 to 60 years, mean ~ 29.4 years, SD ~ 11.5 years.
Length of illness: 3 months to 12 years, median = 6.1 years.
Inclusion: PANSS≥ 60, patients did not take antipsychotic drugs within 1 week before
admission. patients did not accept long-acting antipsychotic drugs within one month
before admission.
Exclusion: severe physical illness, organic brain diseases, drug/alcohol dependent, preg-
nant or breastfeeding women
Interventions 1. Chlorpromazine: 425 ± 106 mg/day. N = 49.
2. Quetiapine: 600 ± 50 mg/day. N = 47.
No other antipsychotic drugs were used during treatment, but some medications was
used for EPS
Outcomes Clinical response: no clinical improvement*.
Mental state: PANSS.
Adverse events.
Effects of physiology: Laboratory ﬁndings.(blood glucose, serum prolactin)
Notes *PANSS decreased rate < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
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vs QTP - Mei 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk None obvious.
vs QTP - Nai 2007
Methods Allocation: randomised, no further details.
Blinding: not reported.
Duration: 3 days wash out period, plus 8 weeks trial.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 120.
Sex: male = 63, female = 57.
Age: 18 to 45 years, mean ~ 28 years, SD ~ 7.9 years.
Length of illness: 1 month to 24 months.
Inclusion: primary schizophrenia, without taking any antipsychotic drugs, PANSS ≥
60, did not take antipsychotic drugs within 1 week before admission, did not accept
long-acting antipsychotic drugs within one month before admission.
Exclusion: severe physical illness, pregnant or breastfeeding women
Interventions 1. Chlorpromazine: 100 to 450 mg/day. N = 60.
2. Quetiapine: 300 to 750 mg/day. N = 60.
No other antipsychotic drugs will be used during treatment course, but Antan or ben-
zodiazepine were used when necessary
Outcomes Function: global function, WCST-IQ, WCST-MQ scores.
Unable to use:
WCST subscale scores were not validated.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not stated.
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vs QTP - Nai 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed the trial.
Selective reporting (reporting bias) High risk PANSS were not well reported.
Other bias Low risk None obvious.
vs QTP - NCT00882518
Methods Allocation: randomised, no further detail reported.
Blindness: double-blind, patients, caregiver and investigator were blinded.
Duration: 6 weeks.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia.
N = 388.
Age: mean ~ 32.5 years, SD ~ 10.52 years.
Sex: male = 202, female = 182.
Length of illness: not reported.
Inclusion criteria: patients gave written informed consent.
Exclusion criteria: AIDs or hepatitis, History of epilepsy, hospitalised for schizophrenic
disorder 1 month prior to entering into study
Interventions 1. Chlorpromazine: The initial dose was 50 to 100 mg/d then increased to a
treatment dosage varying between 300 to 600 mg/d. N = 192.
2. Quetiapine: the initial dose was 300 mg/d then increased to a treatment dosage
varying between 400 to 800 mg/d. N = 196.
Outcomes Clinical response: no clinical improvement*.
Global state: CGI, CGI severity of illness score, poor compliance, leave the study early**
Mental state: PANSS scale score, positive score, negative score, general pathological score.
PANSS aggression score, depression clusters score
Adverse effects.
Unable to use:
PANSS aggression score, depression clusters score. The subscale is not validated
Notes *Decreased rate of PANSS score < 30%.
**Patients who left the study early were categorised by the following reasons: “withdrawal
by subject” , “severe non - compliance to protocol” , “incorrect enrolment” , “central lab
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vs QTP - NCT00882518 (Continued)
closure for national day” as “any reason” in our meta analysis. We added the number of
these patients and imputed the total number into our meta analysis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details were re-
ported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Thirty-eight patients in the quetiapine
group and 44 patients in the chlorpro-
mazine group left the study early and no
ITT analysis were applied. Among them,
9 patients in the quetiapine group and 18
patients in the chlorpromazine group left
because of adverse effects. Twelve patients
in the quetiapine group and 9 patients in
the chlorpromazine group left due to lack
of efﬁcacy
Selective reporting (reporting bias) Low risk All the outcomes were well reported.
Other bias High risk The study was sponsored by AstraZenenca-
-the producer of quetiapine fumarate ex-
tended-release (SEROQUEL-XR)
vs QTP - Peng 2006
Methods Allocation: randomised using random number table.
Blinding: double-blind, patients, investigator and assessor were blinded.
Duration: 42 days.
Setting: inpatients, West China Hospital, Sichuan, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 40.
Age: mean ~ 30.6 years, SD ~ 11.26 years.
Sex: male and female
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vs QTP - Peng 2006 (Continued)
Length of illness: mean ~ 28.5 years, SD ~ 6.45years
Exclusion: not stated.
Interventions 1. Chlorpromazine: 473.61 ± 107.26 mg/day. N = 20.
2. Quetiapine: 555.56 ± 137.74 mg/day. N = 20.
Outcomes Globle state: poor compliance, leaving the study early.
Unable to use:
PANSS, BPRS, TESS, RSESE scores - no SD reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using random number table.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double blind, but untested.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether people dropped out are
included in the analysis
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk None obvious.
vs QTP - Peuskens 1997
Methods Allocation: randomised, no further detail.
Blinding: double blind, investigator-blinded, no further details.
Duration: six weeks.
Design: parallel, multicentre.
Setting: Belgium, UK, Spain, France, South Africa.
Participants Diagnosis: schizophrenia, schizophreniform disorder (DSM-III-R).
N = 201.
Sex: male = 129, female = 72.
Age: 18 to 65 years.
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vs QTP - Peuskens 1997 (Continued)
Length of illness: BPRS >= 27, at least 3 on 2 or more of the BPRS positive symptom
items ’conceptual disorganisation’, ’suspiciousness’, hallucinatory behaviour’ and ’un-
usual thought content’; CGI-S >= 4
Inclusion:
1. Acute exacerbation of chronic schizophrenia, or schizophreniform disorder
(DSM-IV).
2. A total score of at least 27 on the 18 items of BPRS.
3. A score of at least 3 on 2 or more of the BPRS positive symptom items’
conceptual. disorganisation’ , ’suspiciousness’ , ’hallucinatory behaviour ’ , and ’
unusual thought content’.
4. A score of at least four on the CGI severity of illness item.
Exclusion:
1. Medical condition or laboratory abnormality that might confound the trial results
or put the patient at risk.
2. Receiving long-acting depot medication.
3. Participated in another investigational drug trial during the 4 weeks prior to
randomisation.
4. Signiﬁcant alcohol or other drug abuse within the previous 12 months.
Interventions 1. Chlorpromazine: mean 384 mg/day; maximum 750 mg/day. N = 100.
2. Quetiapine: mean 407 mg/day; maximum 750 mg/day (but not > 500 mg/day
for more than 14 days). N = 101.
Outcomes Clinical response: no clinical improvement*.
Global state: Need of additional antipsychotic drugs.
Leave the study early.
Adverse effects: extrapyramidal side effects (AIMS, BAS, SAS), haematology, liver func-
tion test, thyroid function tests, ECGs, need for medication to reduce EPS
Uable to use:
CGI (no SD), PANSS (no raw data), BPRS (no SD).
Notes *No clinical improvement: decreased rate of BPRS score ≤ 50%
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
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vs QTP - Peuskens 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data for leaving study early were available.
ITT method was not used but overall dis-
continuation rate was low (2.5%)
Selective reporting (reporting bias) Low risk Evidence of selective reporting was not
found.
Other bias High risk Sponsored by manufacturer of quetiapine
AstraZenenca.
vs QTP - Sun 2006
Methods Allocation: randomised, no further details.
Blinding: not reported.
Duration: 8 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 71.
Sex: male = 46 and female = 25.
Age: mean ~ 26.3 years, SD ~ 5.9 years.
Length of illness: mean ~ 1.2 years, SD ~ 0.6 years.
Inclusion: ﬁrst episode schizophrenia and no history of taking antipsychotic drugs,
PANSS ≥ 60.
Exclusion: severe physical disease, pregnant or breastfeeding women, allergic to the
related medication
Interventions 1. Chlorpromazine: mean ~ 485 mg/d, SD ~ 132 mg/d. N = 36.
2. Quetiapine: mean ~ 530 mg/d, SD ~ 128 mg/d. N = 35.
No combination with other antipsychotic drugs.Benzodiazepine, anticholinergic medi-
cation or propranolol was used for adverse effects
Outcomes Mental state: PANSS total score, positive score, negative score, general pathological score
Function: Global function-WCST endpoint total score, WMS-RC endpoint total score
Unable to use:
WCST, WMS-RS subscale score. The subscale is not validated.
NCT total and subscale score. The NCT scale is not validated
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details provided.
Allocation concealment (selection bias) Unclear risk Not reported.
115Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
vs QTP - Sun 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed this trial.
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk None obvious.
vs QTP - Tian 2006
Methods Allocation: randomised, no further details reported.
Blinding: not reported.
Duration: 8 weeks.
Setting: inpatients and outpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
Paticipant: N = 92.
Sex: male = 35 and female = 57.
Age: 18 to 61 years, mean ~ 27.8 years, SD ~ 8.4 years.
Length of illness: mean ~ 6.2 years, SD ~ 4.2 years.
Inclusion: schizophrenia.
Exclusion: severe physical illness, drug/alcohol dependent, pregnant/lactating women,
aggressive and suicidal patients
Interventions 1. Chlorpromazine: 420 ± 67.2 mg/day. N = 46.
2. Quetiapine: 421 ± 18 mg/day. N = 46.
Outcomes Clinical response: no clinical improvement*.
Mental state: PANSS score,positive score, negative score and general pathological score
Adverse effects.
Notes *Decreased rate of PANSS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details provided.
Allocation concealment (selection bias) Unclear risk Not stated.
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vs QTP - Tian 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) Low risk We did not ﬁnd any evidence of selective
reporting.
Other bias Low risk None obvious.
vs QTP - Wan 2002
Methods Allocation: randomised, no further information.
Blinding: double-blind.
Duration: 6 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 60.
Sex: not reported.
Age: 18 to 60 years.
Length of illness: not reported.
Inclusion: ﬁrst episode schizophrenia, PANSS ≥ 60.
Exclusion: organic diseases, severe physical illness, alcohol or drug abuse, pregnant or
breastfeeding women
Interventions 1. Chlorpromazine: 300 to 750 mg/d. N = 30.
2. Quetiapine: 300 to 750 mg/d. N = 30.
No other antipsychotic drugs were used during treatment course, but Antan or benzo-
diazepine were used when necessary
Outcomes Clinical response: no clinical improvement*.
Mental state: PANSS scores (total, positive, negative and general pathological)
Adverse effect: TESS.
Notes *No clinical improvement: decreased rate of PANSS score ≤ 29% or symptoms deteri-
oration
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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vs QTP - Wan 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed the trial.
Selective reporting (reporting bias) High risk SAS were not reported.
Other bias Low risk None obvious.
vs QTP - Wan 2008
Methods Allocation: randomised, no further information.
Blinding: not reported.
Duration: 6 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 60.
Sex: male = 32, female = 28.
Age: 18 to 60 years, mean ~ 33.54 years, SD ~ 5.26 years.
Length of illness: mean ~ 8.24 years, SD ~ 3.15 years.
Inclusion: PANSS ≥ 60, have no history of taking antipsychotic drugs or suspended
antipsychotic drugs for 1 week before randomisation.
Exclusion: organic brain diseases, severe physical illness, alcohol or drug abuse, pregnant
or breastfeeding women
Interventions 1. Chlorpromazine: 300 to 800 mg/d. N = 30.
2. Quetiapine: 300 to 800 mg/d. N = 30.
No other antipsychotic drugs were used during treatment course, but Antan or benzo-
diazepine were used when necessary
Outcomes Clinical response: no clinical improvement*.
Mental state: PANSS total score,BPRS total score.
Adverse effect: TESS
Notes *Decreased rate of PANSS score ≤ 29% or symptoms deterioration
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vs QTP - Wan 2008 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information pro-
vided.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All the patients completed the trial.
Selective reporting (reporting bias) Low risk All the outcomes were well reported.
Other bias Low risk None obvious.
vs QTP - Wang 2004
Methods Allocation: randomised, no further details provided.
Blinding: no details.
Duration: 6 weeks.
Setting: inpatients, Guangzhou Mental Health Hospital, China
Participants Diagnosis: schizophrenia (CCMD-3).
N = 96.
Sex: male and female.
Age: 19 to 58 years.
Length of illness: 2 months to 14 years.
Exclusion criteria: pregnant/lactating women, drug/alcohol dependent patients, severe
physical illness, took quetiapine or chlorpromazine within 4 weeks prior to the study,
suicidal, allergic to any of the intervention drugs, participated in other clinical trials
within 30 days prior to the current study
Interventions 1. Chlorpromazine: 300 to 750 mg/day. N = 48.
2. Quetiapine: 300 to 750 mg/day. N = 48.
Outcomes Leaving the study early.
Mental state: PANSS (total, positive, negative,general psychopathology subscale)
Global state: CGI endpoint total improvement score, illness severity score, no clinical
improvement*
119Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
vs QTP - Wang 2004 (Continued)
Adverse effects.
Notes *PANSS decreased rate < 30%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details provided.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT was used.
Selective reporting (reporting bias) Low risk We did not ﬁnd any evidence of selective
reporting.
Other bias Low risk None obvious.
vs QTP - Wang 2005
Methods Allocation: randomised, randomised by the random number.
Blinding: open label.
Duration: 3 days washout period, plus 8 weeks trial.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 112.
Age: mean 33.3 years, SD 11.7 years.
Sex: not stated.
Length of illness: mean ~ 65.1 days, SD ~ 8.4 days.
Inclusion: PANSS score ≥ 60, score of at least 4 on 2 or more of the PANSS items
’delusion’, ’hallucination behavior’ , ’Incoherence’ , ’suspiciousness’, ’persecution’.
Exclusion: drug/alcohol dependent patients, severe physical illness, accept quetiapine or
chlorpromazine within 4 weeks prior to the study and have no response to both of them
Interventions 1. Chlorpromazine: 100 to 600 mg/day. N = 57.
2. Quetiapine: 400 to 750 mg/day. N = 48.
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vs QTP - Wang 2005 (Continued)
Outcomes Clinical response:no clinical improvement*.
Mental state: PANSS scores (total, positive, negative and general pathological)
Adverse effect:TESS, weight gain/loss.
Effects on physiology: laboratory ﬁndings, blood glucose and PRL
Unable to use:
Leaving the study early: 7 cases left the study early because of poor compliance, use other
medication, withdrew informed consent. We were unable to use this data, as it is not
reported by groups and we were unable to separate them
Notes *decreased rate of PANSS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation, randomised by the ran-
dom number.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk Seven patients left the study early because
of poor compliance, or lost to follow-up.
Theywere not included in the ﬁnal analysis
Twenty-three patients left the study but
were included in the adverse effects analy-
sis: 12 cases from the chlorpromazine group
and 11 cases from the quetiapine group
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk None obvious.
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vs QTP - Yang 2007
Methods Allocation: randomised, no further detail.
Blindness: not reported.
Duration: 8 weeks.
Design: parallel.
Setting: outpatients and inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 63.
Age: mean ~ 33.1 years, SD ~ 9.69 years
Sex: male = 35, female = 28.
Length of illness: mean ~ 4.90 months, SD ~ 3.60 months.
Inclusion criteria: BPRS score > 35, did not take any antipsychotic drugs within 2 weeks
before randomisation
Exclusion criteria: severe physical impairment or organic brain diseases, alcohol or drug
abuse, pregnant or breastfeeding women
Interventions 1. Chlorpromazine: titrated over a 2 week period from 50 mg/d to 300 to 600 mg/d,
average dosage, mean ~ 474.19 mg/d, SD ~ 99.89 mg/d. N = 32.
2. Quetiapine: titrated over a two week period from 50 mg/d to 300 to 750 mg/d,
average dosage, mean ~ 595.16 mg/d, SD ~ 126.72 mg/d. N = 31.
Outcomes Clinical response: no clinical improvement*.
Leave the study early.
Mental state: BPRS
Adverse effect: TESS
Notes *Decreased rate of BPRS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details provided.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk One patient in the quetiapine group and 2
patients in the chlorpromazine group left
the study early. No reason given and no
ITT analysis was applied
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vs QTP - Yang 2007 (Continued)
Selective reporting (reporting bias) Low risk All the patients completed the trial.
Other bias Low risk None obvious.
vs QTP - Zhang 2002
Methods Allocation: randomised (by tossing a coin).
Blinding: double-blind, investigator was blinded.
Duration: 8 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 117.
Sex: male 89 and female 28.
Age: average, mean 23.89 years, SD 5.63 years.
Length of illness: mean 3.87 years, SD 1.03 years.
Exclusion criteria: length of illness > 5 years, with severe physical or neurological illness,
pregnant or lactating women
Interventions 1. Chlorpromazine: 300 mg to 550 mg/day. N = 57.
2. Quetiapine: 300 mg to 550 mg/day. N = 60.
Outcomes Clinical response: no clinical improvement*.
Mental state: PANSS positive, negative, general psychopathology and endpoint score.
Adverse event: TESS endpoint score.
Notes *Decreased rate of PANSS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by tossing a coin.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed the trial.
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vs QTP - Zhang 2002 (Continued)
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk None obvious.
vs QTP - Zhang 2003
Methods Allocation: randomised using computer generated random number.
Blinding: double-blinded, no further details provided.
Duration: 1 week wash out period, plus 6 weeks of intervention, followed by 1 week of
reduced dose of medication to help patients to withdraw from the interventions.
Setting: inpatients, multicentre, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 237.
Sex: male = 121 and female = 99.
Age: mean ~ 32.27 years, SD ~ 11.33 years.
Length of illness: mean ~ 7.0 years, SD ~ 7.3 years.
Inclusion: BPRS score ≥ 36.
Exclusion:
1. Patients with neurological, heart, liver, renal or other severe physical illnesses.
2. Pregnant or lactating women.
3. Alcohol or drug dependent patients.
4. Patients who received quetiapine or chlorpromazine 4 weeks prior to the study.
5. Patients with allergy of quetiapine and chlorpromazine.
6. Patients who participated in other clinical drug trials within the last 30 days of
this study.
Interventions 1. Chlorpromazine: ﬁrst week 75 mg to 300 mg/day, second week onwards 300 mg
to 750 mg/day. N = 118.
2. Quetiapine: ﬁrst week 75 mg to 300 mg/day, second week onwards 300 mg to
750 mg/day. N = 119.
Outcomes Clinical response:no clinical improvement*, decreased rate of PANSS score
Globel state: poor compliance, leave the study early.
Mental state, PANSS endpoint score.
Adverse effect: weight gain/loss, ECG, Tachycaridia.
Effects on physiology: pulse, blood pressure, laboratory ﬁndings
Notes *Decreased rate of PANSS score < 30%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using computer-generated
random number.
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vs QTP - Zhang 2003 (Continued)
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Twenty-eight patients left the study early
with reasons reported in the study. ITTwas
used
Selective reporting (reporting bias) High risk CGI and adverse events weremeasured, but
data were not reported
Other bias Low risk None obvious.
vs QTP - Zhang 2006
Methods Allocation: randomised, no further details reported.
Blindness: single blinded, assessor was blinded.
Duration: 2 weeks wash out period, plus 8 weeks trial.
Design: parallel.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 61.
Age: 18 to 59 years.
Sex: not reported.
Length of illness: < 2 years.
Inclusion criteria: length of illness < 2 years, PANSS ≥ 60.
Exclusion criteria: patients with severe physical impairment or abnormal laboratory
ﬁndings, pregnant or breastfeeding women, allergic to quetiapine or chlorpromazine,
patients with long-acting antipsychotic drugs treatment at present
Interventions 1. Chlorpromazine: mean ~ 404.55 mg/d, SD ~ 66.42 mg/d. N = 33.
2. Quetiapine: mean ~ 484.10 mg/d, SD ~ 143.54 mg/d. N = 28.
Outcomes Clinical response: no clinical improvement*, decreased rate of PANSS score
Mental state: PANSS scale score, positive score, negative score, general pathological score
Adverse effects: TESS.
Notes *Decreased rate of PANSS score < 30%.
Risk of bias Risk of bias
125Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
vs QTP - Zhang 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details were re-
ported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed the trial.
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk None obvious.
vs QTP - Zhang 2008
Methods Allocation: randomised, no further details were reported.
Blinding: not reported.
Duration: 8 weeks.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
Paticipan: N = 60.
Sex: male 45 and female 15.
Age: mean 35.6 years, SD 9.7 years.
Length of illness:4 to 17 years.
Inclusion: PANSS score ≥ 60.
Exclusion: patients with severe physical illnesses, pregnant or lactating women, alcohol
or drug dependent patients, patients with allergy to quetiapine and chlorpromazine
Interventions 1. Chlorpromazine: titration period: 2 weeks, from 75 mg/d to a treatment dosage
of 350 to 550 mg/d. N = 30.
2. Quetiapine: titration period: two weeks, from 100 mg/d to a treatment dosage of
400 to 800 mg/d. N = 30.
Outcomes Clinical response:no clinical improvement*.
Mental state, PANSS endpoint total score.
Adverse effects: TESS.
Notes *Decreased rate of PANSS score < 25%.
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vs QTP - Zhang 2008 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details were re-
ported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All included patients completed the trial.
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk None obvious.
vs QTP - Zhou 2003
Methods Allocation: randomised, using a random number table.
Blinding: assessors were blinded, unclear if the patients were.
Duration: 6 weeks.
Setting: inpatients, Mental health centre, Sichuan, China.
Participants Diagnosis: schizophrenia (CCMD-3), inpatients.
N = 40.
Sex: male and female.
Age: mean ~ 28, SD ~ 10 years.
Length of illness: mean ~ 25 years, SD ~ 6 years.
Exclusion: not described.
Interventions 1. Chlorpromazine: dosage not stated. N = 20.
2. Quetiapine: dosage not stated. N = 20.
Outcomes Leave the study early.
Unable to use: WCST subscale scores, as they are not validated
Notes
Risk of bias Risk of bias
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vs QTP - Zhou 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using a randomnumber table.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One case of early discharge due to family
emergency, 3 other patients withdrew for
their family members were unsatisﬁed with
the efﬁcacy. The above drop out reasons are
unlikely to have an impact on the outcome
reported in this study
Selective reporting (reporting bias) Low risk Evidence of selective reporting was not
found.
Other bias Low risk None obvious.
vs QTP - Zhou 2004
Methods Allocation: randomised, no further details provided.
Blinding: not reported.
Duration: 12 weeks.
Setting: inpatients, Jinan psychiatric hospital, Shandong province, China
Participants Diagnosis: schizophrenia (ICD-10, CCMD-3).
N = 83.
Age: 17 to 51 years old.
Sex: male and female.
Length of illness: 4 months to 21 years.
Inclusion: without receiving antipsychotic drugs, PANSS ≥ 60; patients without severe
physical diseases and organic brain diseases, learning disability, allergic to quetiapine or
chlorpormazine, abnormal laboratory ﬁndings;
Exclusion: pregnant or breast feeding women.
Interventions 1. Chlorpromazine: 200 to 600 mg/d. N = 41.
2. Quetiapine: 300 to 400 mg/d. N = 42.
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vs QTP - Zhou 2004 (Continued)
Outcomes Clinical response: no clinical improvement*
Leave the study early.
Mental state: PANSS positive, negative, general psychopathology, total score
Adverse events: TESS score.
Unable to use
GQOLI subscale score. These subscales were not validated.
Notes *PANSS decreased rate < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details provided.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Four patients left the study early because of
discharge or ﬁnancial problems. They were
not included in the efﬁcacy and adverse ef-
fect analysis, but this should have minimal
inﬂuence in the accuracy of results
Selective reporting (reporting bias) Low risk Evidence of selective reporting was unclear.
Other bias Low risk None obvious.
vs QTP - Zou 2006
Methods Allocation: randomised, no further details provided.
Blinding: not reported.
Duration: 8 weeks.
Setting: Community and hospital, Zhejiang, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 86.
Age: 17 to 56 years.
Sex: male and female.
Length of illness: < 10 years.
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vs QTP - Zou 2006 (Continued)
Exclusion: severe physical illness, drug/alcohol dependent, pregnant/lactating women,
allergic to experimental drugs
Interventions 1. Quetiapine: 483.1 ± 25.5 mg/day. N = 43.
2. Chlorpromazine: 450.2 ± 30.2 mg/day. N = 43.
Outcomes Clinical response: no clinical improvement*.
Mental state: PANSS scores.
Adverse events.
Notes *Decreased rate of PANSS score < 25%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details provided.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) High risk TESS scores measured, but not reported.
Other bias Low risk None obvious.
vs RPD - Chang 1998
Methods Allocation: randomised, no further information.
Blinding: not stated.
Duration: 21 weeks.
Design: parallel.
Setting: China.
Participants Diagnosis: schizophrenia (CCMD).
N = 58.
Age: mean ~ 35 years, SD ~ 7 years.
Sex: male and female.
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vs RPD - Chang 1998 (Continued)
Length of illness: mean ~ 12 years, SD ~ 7 years.
Inclusion criteria: without organic diseases.
Interventions 1. Chlorpromazine: dose range 0.6g/d, N = 20.
2. Risperidone: dose range 1 to 6mg/d, N = 38.
Outcomes Clinical response: no signiﬁcant clinical response.
Adverse effects.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, but no detail provided.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Unclear risk Unclear what the study intended to mea-
sure, as we were unable to obtain its proto-
col
Other bias Low risk None obvious.
vs RPD - Cui 2001
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 1 week wash out period, plus 6 weeks trial.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 60.
Age: 18 to 57 years.
Sex: male and female.
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vs RPD - Cui 2001 (Continued)
Length of illness: in risperidone group mean ~ 69 months, SD ~ 82 months; in chlor-
promazine group mean ~ 59 months, SD ~ 77 months.
Inclusion criteria: BPRS > 35, without antipsychotic medication one week prior to trial,
blood test normal, ECG and EEG normal
Exclusion criteria: nervous system and endocrine systemdisease, heart, liver, renal disease,
pregnant and lactating women
Interventions 1. Chlorpromazine: 426.67 ± 81.38 mg/day. N = 30.
2. Risperidone: 4.19 ± 0.68 mg/day. N = 30.
Outcomes Clinical response: no signiﬁcant clinical response*.
Mental state: BPRS.
Adverse effects.
Notes *BPRS score decreased rate <30% is regarded as no signiﬁcant clinical response
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind (clinician and patients are
blinded).Quote “risperidone and chlorpro-
mazine were placed into capsules of equal
size and same colour, dispensed by pharma-
cist. Neither patients or clinician are aware
of the content of the capsule.” p206
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Low risk it appears that all measured outcomes were
reported.
Other bias Low risk None obvious.
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vs RPD - Feng 2003
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: three months.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 65.
Age: mean ~ 26 years, SD ~ 8 years.
Sex: male and female.
Length of illness: in chlorpromazine group mean ~ 5.82 months, SD ~ 3.97 months; in
risperidone group mean ~ 6.02 months, SD ~ 4.38 months.
Inclusion criteria: PANSS > 60, without systematic antipsychotic treatment, length of
illness is within two years
Exclusion criteria: severe physical impairment, heart, liver, renal disease, drug or alcohol
dependence, pregnant and lactating women
Interventions 1. Chlorpromazine: 355.79 ± 82.45 mg/day. N = 33.
2. Risperidone: 3.62 ± 1.07 mg/day. N = 32.
Outcomes Mental state: PANSS.
Adverse effects.
Quality of life: QOL-100.
Leaving the study early.
Unable to use:
Adverse effects: we were unable to report on the following adverse effects for their
data were pooled together - fatigue, drowsiness, constipation, dry mouth, tachycardia,
deteriorated memory, blurred vision
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but untested.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded.
133Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
vs RPD - Feng 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Three and 2 people dropped out of chlor-
promazine and risperidone groups respec-
tively. Trial authors did not report the rea-
son for drop out. It’s unclear if these par-
ticipants were included in the ﬁnal analysis
Selective reporting (reporting bias) Unclear risk It appears that all measured outcomes were
reported.
Other bias Low risk None obvious.
vs RPD - He 1999
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 1 week wash out period, plus 8 weeks trial.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 41.
Age: mean ~ 45 years, SD ~ 11 years.
Sex: male and female.
Length of illness: mean ~ 16 years, SD ~ 10 years.
Inclusion criteria: CCMD-2-R diagnosed schizophrenia.
Exclusion criteria: severe organic or heart, liver, renal disease
Interventions 1. Chlorpromazine: 100 to 600 mg/day. N = 20.
2. Risperidone: 2 to 6 mg/day. N = 21.
Outcomes Clinical response: no signiﬁcant clinical response*.
Mental state: BPRS, SAPS, SANS, NORS.
Adverse effects: TESS.
Leaving the study early.
Unable to use:
Mental state: unvalidated SAPS and SANS subscale scores.
Notes *BPRS score decreased rate < 50% is regarded as no signiﬁcant clinical response
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
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vs RPD - He 1999 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two people dropped out of risperidone
group due to agitation and severe nausea.
This is unlikely to have any serious impact
on other outcomes assessed
Selective reporting (reporting bias) Low risk It appears that all measured outcomes were
reported.
Other bias Low risk None obvious.
vs RPD - Lin 2005
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 8 weeks trial.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: ﬁrst episode schizophrenia (CCMD-3).
N = 70.
Age: mean ~ 32 years, SD ~ 14 years.
Sex: male and female.
Length of illness: chlorpromazine group 25.19 ± 42.54 months; risperidone group 32.
59 ± 45.80 months.
Inclusion criteria: ﬁrst episode schizophrenia, without receiving oral antipsychotic drugs
one week prior to trial, or depot antipsychotic one month prior to trial, PANSS > 60
Exclusion criteria: severe organic or heart, liver, renal disease, pregnant or lactating
women, or abnormal ECG
Interventions 1. Chlorpromazine: 100 to 450 mg/day. N = 35.
2. Risperidone: 1 to 4 mg/day. N = 35.
Outcomes Clinical response: no signiﬁcant clinical response*.
Mental state: PANSS.
Adverse effects.
Notes *Paper did not describe the criteria of ’no signiﬁcant clinical response’
Risk of bias Risk of bias
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vs RPD - Lin 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) High risk CGI was measured, but not reported.
Other bias Low risk None obvious.
vs RPD - Liu 2000
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 3 months.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: ﬁrst episode schizophrenia (CCMD-2).
N = 32.
Age: 18 to 45 years.
Sex: male and female.
Length of illness: < 5 years.
Inclusion criteria: no history of substance misuse prior to admission, without the use of
antipsychotic drugs at least two weeks prior to admission,
Exclusion criteria: severe physical impairment or central nervous system disease or trau-
matic head injury
Interventions 1. Chlorpromazine: 500 to 700 mg/day. N = 15.
2. Risperidone: 3 to 4.5 mg/day. N = 17.
Outcomes Mental state: SANS.
Unable to use:
Mental state: unvalidated SANS subscale scores.
Notes
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vs RPD - Liu 2000 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) Unclear risk Not enough information to make a judge-
ment.
Other bias Low risk None obvious.
vs RPD - Liu 2005
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 21 days.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 100.
Age: 18 to 59 years.
Sex: male only.
Length of illness: not stated.
Inclusion criteria: no severe physical impairment or primary hypotension
Exclusion criteria: severe organic or heart, liver, renal disease
Interventions 1. Chlorpromazine: 50 to 450 mg/day. N = 50.
2. Risperidone: 1 to 4 mg/day. N = 50.
Outcomes Adverse effects.
Blood pressure.
Unable to use:
Adverse effects: TESS subscale score.
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vs RPD - Liu 2005 (Continued)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) Low risk All measured outcomes are reported.
Other bias Low risk None obvious.
vs RPD - Luo 2001
Methods Allocation: randomised, no further information.
Blindness: double-blind, but untested.
Duration: 8 weeks trial.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 107.
Age: 15 to 46 years.
Sex: male and female.
Length of illness: mean ~ 3 years, SD ~ 4 years.
Inclusion criteria: not stated.
Exclusion criteria: severe organic or heart, liver, renal disease, substance misuse, epilepsy,
pregnant or lactating women
Interventions 1. Chlorpromazine: 100 to 700 mg/day. N = 52.
2. Risperidone: 1 to 7 mg/day. N = 55.
Outcomes Clinical response: no signiﬁcant clinical response*.
Mental state: PANSS
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vs RPD - Luo 2001 (Continued)
Notes *PANSS score decreased rate < 30%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double blind, but untested.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) Low risk All measured outcomes are reported.
Other bias Low risk None obvious.
vs RPD - Ma 2004
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 1 week wash out period, plus 12 weeks trial.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 78.
Age: 19 to 65 years.
Sex: male and female.
Length of illness: mean ~ 6.6 years.
Inclusion criteria: no severe physical impairment of chronic diseases, no epilepsy or
history of organic disease; blood, urine test normal, liver function normal, ECG and
EEG normal, BPRS > 35
Interventions 1. Chlorpromazine: average dose 475 mg/day. N = 39.
2. Risperidone: 1 to 9 mg/day. N = 39.
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vs RPD - Ma 2004 (Continued)
Outcomes Global state: CGI-SI (skewed data), need of additional Benzhexol
Mental state: BPRS.
Adverse effects.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data.
Selective reporting (reporting bias) Low risk All measured outcomes are reported.
Other bias Low risk None obvious.
vs RPD - Wang 2002
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 8 weeks trial.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 59.
Age: 18 to 58 years.
Sex: male and female.
Length of illness: mean ~ 100 months, SD ~ 85 months.
Inclusion criteria: without intake of antipsychotic medication one week prior to trial, or
slow release depot antipsychotic one month prior to trial, PANSS > 60
Exclusion criteria: severe organic, brain or other disease.
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Interventions 1. Chlorpromazine: 400 mg/day. N = 20.
2. Risperidone: 4 mg/day. N = 19.**
3. Risperidone: 6 mg/day. N = 20.**
Outcomes Clinical response: no signiﬁcant clinical response*.
Global state: need of additional Benzhexol.
Mental state: PANSS change score.
Adverse effects.
Unable to use.
Mental state: PANSS score at week 1. This is an eight weeks trial, but there was no
endpoint PANSS score reported at week 8, instead the author reported improved PANSS
score measured at week 1
Notes *Paper did not report on how this is measured.
**We combined the 4 mg and 6 mg risperidone group, when reporting their outcomes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One case was discharged early from risperi-
done (4 mg group), but it is unlikely to
have had any signiﬁcant impact on other
outcome assessments such as PANSS score
Selective reporting (reporting bias) Low risk All measured outcomes are reported.
Other bias Low risk None obvious.
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vs RPD - Wang 2005
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 8 weeks trial.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: ﬁrst episode schizophrenia (CCMD-3).
N = 100.
Age: 18 to 45 years.
Sex: male and female.
Length of illness: 1 to 24 months.
Inclusion criteria: not stated.
Exclusion criteria: not stated.
Interventions 1. Chlorpromazine: 25 to 450 mg/day. N = 50.
2. Risperidone: 0.5 to 6 mg/day. N = 50.
Outcomes Functioning: WCST IQ and MQ score.
Adverse effects.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No incomplete outcome data.
Selective reporting (reporting bias) Low risk All measured outcomes are reported.
Other bias Low risk None obvious.
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vs RPD - Wu 2002
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 12 weeks trial.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: chronic schizophrenia (CCMD-2-R).
N = 70.
Age: 21 to 60 years.
Sex: male and female.
Length of illness: 5 to 23 years.
Inclusion criteria: BPRS > 38.
Exclusion criteria: severe physical impairment.
Interventions 1. Chlorpromazine: 400 to 600 mg/day. N = 35.
2. Risperidone: 4 to 6 mg/day. N = 35.
Outcomes Clinical response: no signiﬁcant clinical response*.
Adverse effects.
Notes *The paper did not report on how this is determined.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Low risk All measured outcomes are reported.
Other bias Low risk None obvious.
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vs RPD - Wu 2004
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 3 months.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-3).
N = 100.
Age: 18 to 43 years.
Sex: male and female.
Length of illness: 3 months to 7.2 years.
Inclusion criteria: PANSS > 60, give informed consent to participate
Exclusion criteria: severe organic or heart, liver, renal disease, drug or alcohol dependent
Interventions 1. Chlorpromazine: 300 to 600 mg/day. N = 50.
2. Risperidone: 3 to 6 mg/day. N = 50.
Outcomes Mental state: PANSS.
Quality of life: QOL.
Adverse effects.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) Low risk All measured outcomes are reported.
Other bias Low risk None obvious.
144Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by J
vs RPD - Zheng 2001
Methods Allocation: randomised, no further information.
Blindness: not reported.
Duration: 1 week washout period, plus 8 weeks trial.
Design: parallel group.
Setting: inpatients, China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 51.
Age: mean ~ 45 years, SD ~ 11 years.
Sex: male and female.
Length of illness: mean ~ 16 years, SD ~ 10 years.
Inclusion criteria: not stated.
Exclusion criteria: severe organic or heart, liver, renal disease
Interventions 1. Chlorpromazine: 100 to 600 mg/day. N = 25.
2. Risperidone: 5 to 6 mg/day. N = 26.
Outcomes Clinical response: no signiﬁcant clinical response*.
Adverse effects.
Notes *BPRS score decreased rate < 50% is regarded as no signiﬁcant clinical response
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further information.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data.
Selective reporting (reporting bias) High risk BPRS, SAPS, SANS, NORS, TESS are all
tested, but none were reported
Other bias Low risk None obvious.
Abbreviations: AIMS = Abnormal Involuntary Movement Scale
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BAS = Barne’s Akathisa Scale
BPRS = Brief Psychiatric Rating Scale
CCMD = Chinese Classiﬁcation of Mental Disorders
CGI = Clinical Global Impression
COSTART = Coding Symbols for a Thesaurus of Adverse Reaction Terms
DSM = Diagnositc Statistics Manual
ECG = Electrocardiogram
EPS = Extrapyramidal Symptoms
ESRS = Extrapyramidal Symptom Rating Scale
FBG = fasting blood glucose
GAF = Global Assessment of Functioning
GQOL = General Quality of Life Scale
HAMA = Hamilton Rating Scale for Anxiety
HAMD = Hamilton Rating Scale for Depression
HDL = High-density lipoprotein
LDL = Low-density lipoprotein
LSEQ = Leeds Sleep Evaluation Questionnaire
MADRS = Montgomery-Åsberg Depression Rating Scale
NORS = Nurse Observation Rating Scale
NOSIE = Nurses’ Observation Scale for Inpatient Evaluation
PANSS = Positive and Negative Syndrome Scale
PRL = prolactin
QoL = Quality of Life
RSESE = Rating Scale for Extrapyramidal Side Effects
SANS = Scale for the Assessment of Negative Symptoms
SAPS = Scale for the Assessment of Positive Symptoms
SAS = Simpson-Angus Extrapyramidal Side-Effects scale
SF-36 = SF-36 Health Survey
TC = Total Cholesterol
TESS = Treatment-Emergent Signs and Symptoms
TG = triglycerides
UKU = Undersogelser side effect rating scale
VPS = Vitality Plus Scale
WAIS-RC = Wechsler Adult Intelligence Scale-Revised
WCST = Wisconsin Card Sorting Test
WHO-QOL = World Health Organisation Quality of Life scale
WMS = Wechsler Memory Scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Appelberg 2004 Allocation: randomised.
Participants: schizophrenia.
Intervention: olanzapine versus conventional neuroleptics (which may or may not include chlorpro-
mazine)
Beuzen 1998 (HGCF) Allocation: randomised.
Participants: treatment-resistant schizophrenia.
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(Continued)
Bouchard 1998 Allocation: randomised.
Participants: treatment-resistant schizophrenia.
Chen 2001 Allocation: not randomised, summary of several trials.
Conley 1998 Allocation: randomised.
Participants: treatment-resistant schizophrenia.
Czekalla 2001 Allocation: randomised.
Participants: schizophrenia.
Intervention: olanzapine versus placebo versus haloperidol versus risperidone
de Jesus Mari 2004 Allocation: randomised.
Participants: schizophrenia.
Intervention: olanzapine versus conventional treatment (including chlorpromazine, as well as other
drugs). Results cannot be separated
Edgell 1998 Allocation: randomised.
Participants: schizophrenia.
Intervention: olanzapine versus risperidone.
Feng 2001 Allocation: randomised.
Participants: treatment-resistant schizophrenia.
Hu 2005 Allocation: randomised.
Participants: treatment-resistant schizophrenia.
Huang 2000a Allocation: quasi-randomisation. Randomised according to admission order
Huang 2000b Allocation: randomised.
Participants: schizophrenia.
Intervention: risperidone versus chlorpromazine versus olanzapine
Outcome: no usable data reported.
Kostakoglu 2001 Allocation: unclear.
Participants: not stated.
Intervention: olanzapine versus chlorpromazine.
Outcome: no usable data.
Li 2007 Allocation: quasi-randomisation. Randomised according the odd and even numbers of hospital ad-
mission order
Pappas 1997 Allocation: unclear.
Participants: acute schizophrenia.
Intervention: risperidone versus haloperidol versus chlorpromazine
Outcome: no usable data reported.
Qu 2006 Allocation: quasi-randomisation, according to odd and even admission numbers
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(Continued)
Shi 2007 Allocation: randomised.
Participants: schizophrenia.
Intervention: chlorpromazine versus risperidone.
Outcome: no usable data. Paper reported on tracked eye movement only
Su 2002 Allocation: quasi-randomisation, according to hospital admission order
Tian 2005 Allocation: randomised.
Participants: schizophrenia.
Intervention: risperidone and chlorpromazine versus risperidone and benzodiazepines
vs QTP - Arvanitis 1996 Allocation: double-blind, randomised, multicentre.
Patients: schizophrenia.
Intervention: ﬁve ﬁxed dose of quetiapine versus a standard dose of haloperidol or placebo
vs QTP - AstraZeneca 2000 Allocation: randomised multicentre, double-blind, parallel-group trial
Patients: treatment-resistant schizophrenia.
vs QTP - AstraZeneca 2005 Allocation: randomised multicentre, double-blind, parallel-group trial
Patients: treatment-resistant schizophrenia.
vs QTP - Bai 2006 Allocation: not randomised. The randomisation was based on the admission sequence
vs QTP - Cai 2008 Allocation: not randomised. The randomisation was based on the admission sequence
vs QTP - Du 2004 Allocation: not randomised. The randomisation was based on the admission sequence
vs QTP - Jiang 2004 Allocation: randomised.
Participants: schizophrenia.
Intervention: chlorpromazine versus quetiapine.
Outome: no usable outcome data reported.
vs QTP - Li 2005 Allocation: not randomised. The randomisation was based on the admission sequence
vs QTP - Ma 2004 Allocation: not randomised.
vs QTP - Ning 2008 Allocation: randomised, no further information.
Participants: schizophrenia, CCMD - 3.
Intervention: chlorpromazine versus quetaipine.
The data is unable to use, as the number of each group is inconsistent in the result reporting and
method statement
vs QTP - Tang 2004 Allocation: not randomised. The randomisation was based on the admission sequence
vs QTP - Tang 2008 Allocation: not randomised. The randomisation was based on the requirement (unclear from patients
or physician) and patients ﬁnancial capacity
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(Continued)
vs QTP - Wang 2007 Allocation: not randomised. The randomisation was based on the admission sequence
vs QTP - Zhang 2007 Allocation: not randomised. The randomisation was based on the admission number
vs QTP - Zhong 2005 Allocation: double-blind, randomised, multicentre.
Participants: schizophrenia, age range of 16 to 60 years but no average data reported
Wang 1998 Allocation: randomised.
Participants: patients with schizophrenia aged between 16 and 62. The average age is approximately 24
years with a SD of 12.9 years. we consulted statistician and were unable to determine the proportion
of people under 18 involved in this trial
Wang 2004 Allocation: randomised.
Participants: treatment-resistant schizophrenia.
Wang 2006 Allocation: quasi-randomisation, according to the odd and even numbers of hospital admission order
Xiong 2004 Allocation: randomised.
Participants: children with schizophrenia (7 to 16 years).
Yu 2001 Allocation: quasi-randomisation, according to the odd and evennumbers of hospital admissionnumber
Yuan 2006 Allocation: quasi-randomisation, according to the odd and evennumbers of hospital admissionnumber
Zou 2005 Allocation: quasi-randomisation, according to the odd and evennumbers of hospital admissionnumber
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D A T A A N D A N A L Y S E S
Comparison 1. CHLORPROMAZINE versus OLANZAPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical response: 1. No
signiﬁcant clinical response
4 274 Risk Ratio (M-H, Random, 95% CI) 2.19 [1.39, 3.45]
1.1 short term - up to 6
months
3 204 Risk Ratio (M-H, Random, 95% CI) 2.34 [1.37, 3.99]
1.2 long term - over 12
months
1 70 Risk Ratio (M-H, Random, 95% CI) 1.83 [0.76, 4.41]
2 Clinical response: 2. Average
endpoint score (CGI, high =
poor) - short term (up to 6
months)
3 110 Mean Difference (IV, Random, 95% CI) 0.93 [0.36, 1.51]
3 Clinical response: 3. Relapse -
long term (over 12 months)
1 70 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.46, 4.86]
4 Mental state: 1. Average
endpoint score (various scales,
high = poor) - short term (up
to 6 months)
10 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 BPRS total 4 245 Mean Difference (IV, Random, 95% CI) 3.21 [-0.62, 7.05]
4.2 BPRS activation subscale 2 299 Mean Difference (IV, Random, 95% CI) 0.47 [0.27, 0.67]
4.3 BPRS anxiety-depression
subscale
1 213 Mean Difference (IV, Random, 95% CI) 1.57 [1.36, 1.78]
4.4 BPRS
hostile-suspiciousness subscale
2 299 Mean Difference (IV, Random, 95% CI) -0.31 [-1.98, 1.35]
4.5 BPRS thinking disorder
subscale
2 299 Mean Difference (IV, Random, 95% CI) -0.80 [-2.66, 1.06]
4.6 BPRS
withdraw-retardation subscale
2 299 Mean Difference (IV, Random, 95% CI) -0.49 [-2.25, 1.26]
4.7 NOSIE total 1 213 Mean Difference (IV, Random, 95% CI) -18.36 [-22.39, -14.
33]
4.8 PANSS total 6 351 Mean Difference (IV, Random, 95% CI) 10.46 [4.49, 16.43]
4.9 PANSS general pathology
subscale
1 100 Mean Difference (IV, Random, 95% CI) 1.31 [-0.32, 2.94]
4.10 PANSS negative
symptom subscale
2 141 Mean Difference (IV, Random, 95% CI) 2.38 [0.31, 4.45]
4.11 PANSS positive
symptom subscale
2 161 Mean Difference (IV, Random, 95% CI) 0.91 [-0.30, 2.11]
4.12 SAPS total 1 86 Mean Difference (IV, Random, 95% CI) -2.10 [-4.53, 0.33]
5 Mental state: 2. Average
endpoint score (BPRS, high =
poor) - medium term (7 to 12
months)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 BPRS total 1 60 Mean Difference (IV, Random, 95% CI) 8.60 [5.94, 11.26]
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6 Mental state: 3. Average
endpoint score (various scales,
high = poor) - skewed data
Other data No numeric data
6.1 BPRS total Other data No numeric data
6.2 HAMA (anxiety) Other data No numeric data
6.3 MADRS (depression) Other data No numeric data
6.4 PANSS negative symptom
subscale
Other data No numeric data
6.5 PANSS positive symptom
subscale
Other data No numeric data
7 Service involvement: 1.
Re-hospitalisation
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 long term (over 12
months)
1 70 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.46, 4.86]
8 Functioning: 1. Executive
function - average endpoint
score (WCST, high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 short term (up to 6
months)
1 53 Mean Difference (IV, Random, 95% CI) 10.96 [1.01, 20.91]
9 Adverse effects: 1.
Anticholinergic - short term
(up to 6 months)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 blurred vision 3 241 Risk Ratio (M-H, Random, 95% CI) 2.59 [0.66, 10.22]
9.2 dry mouth 5 536 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.29, 4.45]
9.3 excessive sweating 2 180 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.62, 14.46]
9.4 hypersalivation 2 166 Risk Ratio (M-H, Random, 95% CI) 10.99 [4.14, 29.17]
9.5 stuffy nose 1 80 Risk Ratio (M-H, Random, 95% CI) 3.0 [1.06, 8.52]
10 Adverse effects: 2.
Cardiovascular - short term (up
to 6 months)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 abnormal ECG 2 180 Risk Ratio (M-H, Random, 95% CI) 3.60 [0.60, 21.55]
10.2 apathism 1 100 Risk Ratio (M-H, Random, 95% CI) 5.0 [1.15, 21.67]
10.3 blood pressure (drop) 2 180 Risk Ratio (M-H, Random, 95% CI) 8.82 [1.13, 68.52]
10.4 orthostatic hypotension 5 561 Risk Ratio (M-H, Random, 95% CI) 9.78 [2.68, 35.71]
10.5 palpitation 1 237 Risk Ratio (M-H, Random, 95% CI) 40.66 [2.49, 664.56]
10.6 tachycardia 3 241 Risk Ratio (M-H, Random, 95% CI) 3.53 [1.66, 7.48]
11 Adverse effects: 3. Central
nervous system - short term
(up to 6 months)
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 dizziness 2 180 Risk Ratio (M-H, Random, 95% CI) 3.85 [1.11, 13.32]
11.2 drowsiness 5 536 Risk Ratio (M-H, Random, 95% CI) 2.46 [1.66, 3.64]
11.3 fatigue 2 161 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.13, 7.66]
12 Adverse effects: 4.
Gastrointestinal - short term
(up to 6 months)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 appetite loss 2 180 Risk Ratio (M-H, Random, 95% CI) 11.01 [2.82, 42.94]
12.2 constipation 6 622 Risk Ratio (M-H, Random, 95% CI) 4.29 [2.61, 7.05]
12.3 diarrhoea 1 80 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.25, 100.97]
12.4 dysphagia 1 100 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 71.92]
12.5 nausea/vomiting 2 180 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.43, 5.20]
13 Adverse effects: 5. Haematology
- short term (up to 6 months)
3 266 Risk Ratio (M-H, Random, 95% CI) 4.46 [1.16, 17.22]
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13.1 abnormal haemogram 2 180 Risk Ratio (M-H, Random, 95% CI) 4.0 [0.87, 18.31]
13.2 leukopenia 1 86 Risk Ratio (M-H, Random, 95% CI) 6.69 [0.36, 125.71]
14 Adverse effects: 6. Hepatitic -
short term (up to 6 months)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 abnormal liver function 1 100 Risk Ratio (M-H, Random, 95% CI) 5.00 [0.25, 101.58]
14.2 abnormal transaminase 2 147 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.01, 150.45]
15 Adverse effects: 7a. Metabolic -
weight gain - short term (up to
6 months)
5 536 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.25, 1.96]
16 Adverse effects: 7b. Metabolic
- weight gain - continuous
measures
4 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 short term (up to 6
months)
4 160 Mean Difference (IV, Random, 95% CI) -5.11 [-9.15, -1.07]
16.2 medium term (7 to 12
months)
1 50 Mean Difference (IV, Random, 95% CI) 0.59 [-11.87, 13.05]
17 Adverse effects: 7c. Metabolic -
other - continuous measures
1 Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 cholesterol (TC) - short
term (up to 6 months)
1 50 Mean Difference (IV, Random, 95% CI) -0.40 [-1.02, 0.22]
17.2 high-density lipoprotein
(HDL) - short term (up to 6
months)
1 50 Mean Difference (IV, Random, 95% CI) 0.05 [-0.12, 0.22]
17.3 low-density lipoprotein
(LDL) - short term (up to 6
months)
1 50 Mean Difference (IV, Random, 95% CI) -0.01 [-0.31, 0.29]
17.4 low-density lipoprotein
(LDL) - medium term (7 to 12
months)
1 50 Mean Difference (IV, Random, 95% CI) 0.06 [-0.41, 0.53]
18 Adverse effects: 7d. Metabolic -
other - average endpoint scores
- skewed data
Other data No numeric data
18.1 cholesterol (TC) -
medium term (7 to 12 months)
Other data No numeric data
18.2 high-density lipoprotein
(HDL) - short term (up to 6
months)
Other data No numeric data
18.3 triglyceride (TG) - short
term (up to 6 months)
Other data No numeric data
18.4 triglyceride (TG) -
medium term (7 to 12 months)
Other data No numeric data
19 Adverse effects: 8a. Movement
disorders - extrapyramidal
symptoms - short term (up to 6
months)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
19.1 akathisia 3 417 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.29, 11.84]
19.2 any EPS symptoms 2 298 Risk Ratio (M-H, Random, 95% CI) 34.47 [4.79, 248.30]
19.3 muscle stiffness 2 180 Risk Ratio (M-H, Random, 95% CI) 6.13 [0.73, 51.45]
19.4 tremor 2 180 Risk Ratio (M-H, Random, 95% CI) 6.78 [0.84, 54.57]
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20 Adverse effects: 8b. Movement
disorders - extrapyramidal
symptoms - average endpoint
score (ESRS, high = poor)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 short term (up to 6
months)
2 80 Mean Difference (IV, Random, 95% CI) 0.90 [0.14, 1.66]
21 Adverse effects: 9a. Various
other - sleep - average endpoint
score (LSEQ, high = better) -
short term (up to 6 months)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 awaking from sleep 1 30 Mean Difference (IV, Random, 95% CI) -5.30 [-21.91, 11.
31]
21.2 getting to sleep score 1 30 Mean Difference (IV, Random, 95% CI) -0.60 [-19.88, 18.
68]
21.3 quality of sleep 1 30 Mean Difference (IV, Random, 95% CI) -15.0 [-33.07, 3.07]
22 Adverse effects: 9b. Various
other - sleep - average length of
sleep (hour/day)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 short term (up to 6
months)
1 50 Mean Difference (IV, Random, 95% CI) 3.63 [2.08, 5.18]
22.2 medium term (7 to 12
months)
1 50 Mean Difference (IV, Random, 95% CI) 4.41 [2.82, 6.00]
23 Adverse effects: 9c. Various
other - sleep - behaviour
following waking (LSEQ) -
skewed data
Other data No numeric data
23.1 short term (up to 6
months)
Other data No numeric data
24 Adverse effects: 9b. Various
other - rash
1 30 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.14, 28.76]
24.1 short term (up to 6
months)
1 30 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.14, 28.76]
25 Quality of life: 1a. Average
endpoint scores (various scales,
high = better) - short term (up
to 6 months)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 GQOLI - living
condition
1 61 Mean Difference (IV, Random, 95% CI) -1.0 [-4.21, 2.21]
25.2 GQOLI - physical health 1 61 Mean Difference (IV, Random, 95% CI) -10.10 [-13.93, -6.
27]
25.3 GQOLI - psychological
health
1 61 Mean Difference (IV, Random, 95% CI) -22.60 [-25.94, -19.
26]
25.4 GQOLI - social function 1 61 Mean Difference (IV, Random, 95% CI) -18.20 [-20.51, -15.
89]
26 Quality of life: 1b. Average
endpoint score (QoL, high =
better) - skewed data
Other data No numeric data
26.1 short term (up to 6
months)
Other data No numeric data
27 Leaving the study early - short
term (up to 6 months)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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27.1 due to any reason 3 139 Risk Ratio (M-H, Random, 95% CI) 1.69 [0.45, 6.40]
27.2 due to lack of efﬁcacy 2 71 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.08, 2.66]
Comparison 2. CHLORPROMAZINE versus RISPERIDONE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical response: 1. No
signiﬁcant clinical response
7 475 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.53, 1.34]
1.1 short term (up to 6
months)
7 475 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.53, 1.34]
2 Global state: 1. Average endpoint
score (CGI-CI, high = poor) -
skewed data
Other data No numeric data
2.1 short term (up to 6
months)
Other data No numeric data
3 Global state: 2. Need of
additional benzhexol
2 137 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.26, 5.53]
3.1 short term (up to 6
months)
2 137 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.26, 5.53]
4 Mental state: 1a. Average
endpoint score (various scales,
high = poor) - short term (up
to 6 months)
9 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 BPRS total 4 247 Mean Difference (IV, Random, 95% CI) 0.90 [-3.49, 5.28]
4.2 BPRS activation subscale 2 130 Mean Difference (IV, Random, 95% CI) 0.41 [-0.81, 1.63]
4.3 BPRS anxiety-depression
subscale
2 130 Mean Difference (IV, Random, 95% CI) 0.09 [-1.56, 1.73]
4.4 BPRS
hostile-suspiciousness subscale
2 130 Mean Difference (IV, Random, 95% CI) 0.89 [-1.41, 3.18]
4.5 NORS total 1 39 Mean Difference (IV, Random, 95% CI) 1.80 [-2.53, 6.13]
4.6 PANSS total 5 397 Mean Difference (IV, Random, 95% CI) -1.95 [-5.58, 1.69]
4.7 PANSS positive symptom
subscale
4 337 Mean Difference (IV, Random, 95% CI) 0.03 [-1.67, 1.74]
4.8 PANSS negative symptom
subscale
3 230 Mean Difference (IV, Random, 95% CI) 3.16 [-1.57, 7.89]
4.9 PANSS general pathology
subscale
3 267 Mean Difference (IV, Random, 95% CI) -0.85 [-2.15, 0.46]
4.10 SANS total 2 71 Mean Difference (IV, Random, 95% CI) 10.89 [-4.49, 26.27]
5 Mental state: 1b. Average
endpoint score (various scales,
high = poor) - skewed data -
short term (up to 6 months)
Other data No numeric data
5.1 BPRS thinking disorder
subscale
Other data No numeric data
5.2 BPRS
withdraw-retardation subscale
Other data No numeric data
154Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5.3 PANSS general pathology
subscale
Other data No numeric data
5.4 PANSS negative symptom
subscale
Other data No numeric data
5.5 PANSS positive symptom
subscale
Other data No numeric data
5.6 SAPS total Other data No numeric data
6 Mental state: 2. Average change
score - decreased rate (various
scales, high = poor) - short term
(up to 6 months)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 PANSS total 1 57 Mean Difference (IV, Random, 95% CI) -0.11 [-0.23, 0.01]
6.2 PANSS negative subscale 1 57 Mean Difference (IV, Random, 95% CI) -0.21 [-0.44, 0.02]
6.3 PANSS positive subscale 1 57 Mean Difference (IV, Random, 95% CI) -0.07 [-0.36, 0.22]
7 Functioning: 1. Average
endpoint score (WCST
subscales, high = good) - short
term (up to 6 months)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 WCST-IQ 1 100 Mean Difference (IV, Random, 95% CI) -11.30 [-18.34, -4.
26]
7.2 WCST-MQ 1 100 Mean Difference (IV, Random, 95% CI) -19.60 [-28.83, -10.
37]
8 Adverse effects: 1.
Anticholinergic - short term
(up to 6 months)
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 blurred vision 5 387 Risk Ratio (M-H, Random, 95% CI) 2.44 [1.32, 4.50]
8.2 dry mouth 9 852 Risk Ratio (M-H, Random, 95% CI) 2.00 [0.88, 4.51]
8.3 excessive sweating 2 180 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.62, 14.46]
8.4 hypersalivation 5 373 Risk Ratio (M-H, Random, 95% CI) 8.67 [3.80, 19.80]
8.5 stuffy nose 1 80 Risk Ratio (M-H, Random, 95% CI) 3.0 [1.06, 8.52]
9 Adverse effects: 2a.
Cardiovascular - short term (up
to 6 months)
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 abnormal ECG 3 229 Risk Ratio (M-H, Random, 95% CI) 2.41 [0.96, 6.06]
9.2 apathism 1 100 Risk Ratio (M-H, Random, 95% CI) 6.25 [2.35, 16.65]
9.3 blood pressure drop 3 250 Risk Ratio (M-H, Random, 95% CI) 8.25 [2.61, 26.12]
9.4 bradycardia 1 100 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.05, 5.34]
9.5 orthostatic hypotension 5 546 Risk Ratio (M-H, Random, 95% CI) 5.74 [2.28, 14.44]
9.6 palpitation 1 237 Risk Ratio (M-H, Random, 95% CI) 40.66 [2.49, 664.56]
9.7 sinus tachycardia 1 51 Risk Ratio (M-H, Random, 95% CI) 3.12 [0.35, 28.03]
9.8 tachycardia 7 557 Risk Ratio (M-H, Random, 95% CI) 2.64 [1.64, 4.26]
10 Adverse effects: 2b.
Cardiovascular - continuous
measures - short term (up to 6
months)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 cardiac rate (upright
position)
1 100 Mean Difference (IV, Random, 95% CI) 3.90 [-1.57, 9.37]
10.2 cardiac rate (horizontal
position)
1 100 Mean Difference (IV, Random, 95% CI) 7.42 [3.47, 11.37]
10.3 contractive blood
pressure (upright position)
1 100 Mean Difference (IV, Random, 95% CI) -1.06 [-2.20, 0.08]
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10.4 contractive blood
pressure (horizontal position)
1 100 Mean Difference (IV, Random, 95% CI) 1.38 [0.61, 2.15]
10.5 diastolic blood pressure
(upright position)
1 100 Mean Difference (IV, Random, 95% CI) -0.53 [-1.29, 0.23]
10.6 diastolic blood pressure
(horizontal position)
1 100 Mean Difference (IV, Random, 95% CI) 0.39 [-0.18, 0.96]
11 Adverse effects: 3. Central
nervous system - short term
(up to 6 months)
6 1191 Odds Ratio (M-H, Random, 95% CI) 1.96 [0.92, 4.22]
11.1 agitation 1 65 Odds Ratio (M-H, Random, 95% CI) 0.31 [0.01, 7.98]
11.2 dizziness 4 299 Odds Ratio (M-H, Random, 95% CI) 3.57 [1.75, 7.30]
11.3 drowsiness 4 307 Odds Ratio (M-H, Random, 95% CI) 4.93 [1.49, 16.32]
11.4 fatigue 1 100 Odds Ratio (M-H, Random, 95% CI) 13.05 [4.82, 35.33]
11.5 insomnia 5 342 Odds Ratio (M-H, Random, 95% CI) 0.29 [0.10, 0.90]
11.6 reduced activity 1 78 Odds Ratio (M-H, Random, 95% CI) 2.05 [0.18, 23.63]
12 Adverse effects: 4.
Gastrointestinal - short term
(up to 6 months)
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 constipation 9 868 Risk Ratio (M-H, Random, 95% CI) 3.00 [2.05, 4.39]
12.2 diarrhoea 1 80 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.25, 100.97]
12.3 dysphagia 1 100 Risk Ratio (M-H, Random, 95% CI) 3.67 [1.09, 12.36]
12.4 loss of appetite 2 180 Risk Ratio (M-H, Random, 95% CI) 11.01 [2.82, 42.94]
12.5 nausea/vomiting 4 350 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.37, 1.91]
13 Adverse effects: 5. Haematology
- short term (up to 6 months)
3 266 Risk Ratio (M-H, Random, 95% CI) 4.46 [1.16, 17.22]
13.1 abnormal haemogram 2 180 Risk Ratio (M-H, Random, 95% CI) 4.0 [0.87, 18.31]
13.2 leukopenia 1 86 Risk Ratio (M-H, Random, 95% CI) 6.69 [0.36, 125.71]
14 Adverse effects: 6. Hepatitic -
short term (up to 6 months)
3 307 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.17, 10.09]
14.1 abnormal liver function 1 78 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.25, 100.89]
14.2 abnormal transaminase 3 229 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.07, 11.58]
15 Adverse effects: 7. Metabolic -
weight gain
4 302 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.52, 3.59]
15.1 short term (up to 6
months)
4 302 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.52, 3.59]
16 Adverse effects: 8. Movement
disorders - short term (up to 6
months)
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 akathisia 6 435 Risk Ratio (M-H, Random, 95% CI) 2.37 [1.46, 3.85]
16.2 any EPS symptoms 3 235 Risk Ratio (M-H, Random, 95% CI) 1.70 [0.85, 3.40]
16.3 dystonia 3 228 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.97, 2.66]
16.4 muscle stiffness 5 335 Risk Ratio (M-H, Random, 95% CI) 2.96 [0.92, 9.49]
16.5 torsion movements 1 78 Risk Ratio (M-H, Random, 95% CI) 9.00 [0.50, 161.73]
16.6 tremor 6 435 Risk Ratio (M-H, Random, 95% CI) 2.15 [1.47, 3.14]
17 Adverse events: 9. Average
endpoint score (TESS) -
skewed data
Other data No numeric data
17.1 short term (up to 6
months)
Other data No numeric data
18 Adverse effects: 10. Various
other - short term (up to 6
months)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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18.1 concentration (poor) 1 100 Risk Ratio (M-H, Random, 95% CI) 1.95 [1.35, 2.82]
18.2 memory deterioration 1 100 Risk Ratio (M-H, Random, 95% CI) 1.95 [1.35, 2.82]
18.3 sexual dysfunction 1 100 Risk Ratio (M-H, Random, 95% CI) 2.55 [1.43, 4.53]
18.4 unspeciﬁed 1 100 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.97, 1.95]
19 Quality of life: 1. Average
endpoint score (QOL, high =
good)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 short term (up to 6
months)
1 100 Mean Difference (IV, Random, 95% CI) -14.20 [-20.50, -7.
90]
20 Leaving the study early - short
term (up to 6 months)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 due to adverse events 1 41 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.01, 4.11]
Comparison 3. CHLORPROMAZINE versus QUETIAPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical response: 1. No
signiﬁcant clinical response
28 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 short term (up to 6
months)
28 3241 Risk Ratio (IV, Random, 95% CI) 0.93 [0.81, 1.06]
2 Global state: 1.
Need of additional
benzodiazepines/benzhexol
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 short term (up to 6
months)
2 290 Risk Ratio (M-H, Random, 95% CI) 1.39 [1.10, 1.75]
3 Global state: 2a. Average
endpoint scores (various scales,
high = poor) - short term (up
to 6 months)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 CGI-SI 2 177 Mean Difference (IV, Random, 95% CI) 0.01 [-0.82, 0.84]
3.2 CGI-GI 3 229 Mean Difference (IV, Random, 95% CI) -0.11 [-0.33, 0.11]
4 Global state: 2b. Average
endpoint score (CGI-SI, high =
poor) - skewed data)
Other data No numeric data
4.1 short term (up to 6
months)
Other data No numeric data
5 Global state: 3. Average change
scores (CGI-SI, high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 short term (up to 6
months)
1 384 Mean Difference (IV, Random, 95% CI) -0.30 [-0.32, -0.28]
6 Mental state: 1a. Average
endpoint scores (various scales,
high = poor) - short term (up
to 6 months)
31 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 BPRS total 6 548 Mean Difference (IV, Random, 95% CI) -0.18 [-1.23, 0.88]
6.2 BPRS anxiety-depression
subscale
1 60 Mean Difference (IV, Random, 95% CI) -0.27 [-1.16, 0.62]
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6.3 BPRS activation subscale 1 60 Mean Difference (IV, Random, 95% CI) 0.22 [-0.26, 0.70]
6.4 BPRS
hostile-suspiciousness subscale
1 60 Mean Difference (IV, Random, 95% CI) -0.09 [-1.15, 0.97]
6.5 BPRS thinking disorder
subscale
1 60 Mean Difference (IV, Random, 95% CI) -0.15 [-1.39, 1.09]
6.6 BPRS
withdraw-retardation subscale
1 60 Mean Difference (IV, Random, 95% CI) -0.10 [-0.76, 0.56]
6.7 PANSS total 25 2049 Mean Difference (IV, Random, 95% CI) -0.05 [-2.30, 2.19]
6.8 PANSS positive symptoms 13 1102 Mean Difference (IV, Random, 95% CI) 0.39 [-0.11, 0.88]
6.9 PANSS negative
symptoms
17 1361 Mean Difference (IV, Random, 95% CI) 1.05 [0.13, 1.98]
6.10 PANSS general
pathology
18 1530 Mean Difference (IV, Random, 95% CI) -1.11 [-3.06, 0.84]
6.11 HAMD total 1 63 Mean Difference (IV, Random, 95% CI) 7.4 [5.13, 9.67]
7 Mental state: 1b. Average
endpoint scores (various scales,
high = poor) - medium term (6
to 12 months)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 PANSS total 1 41 Mean Difference (IV, Random, 95% CI) 4.90 [1.74, 8.06]
7.2 PANSS general pathology 1 41 Mean Difference (IV, Random, 95% CI) -0.20 [-4.34, 3.94]
7.3 PANSS negative
symptoms
1 77 Mean Difference (IV, Random, 95% CI) 2.70 [0.44, 4.96]
8 Mental state: 1c. Average
endpoint scores (various scales,
high = poor) -skewed data
Other data No numeric data
8.1 PANSS total - short term
(up to 6 months)
Other data No numeric data
8.2 PANSS positive symptoms
- short term (up to 6 months)
Other data No numeric data
8.3 PANSS negative
symptoms - short term (up to 6
months)
Other data No numeric data
8.4 PANSS general pathology
- short term (up to 6 months
Other data No numeric data
9 Mental state: 1d. Average change
score (various scales, high =
poor) - short term (up to 6
months)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 PANSS total 2 426 Mean Difference (IV, Random, 95% CI) -2.50 [-2.82, -2.19]
9.2 PANSS positive symptoms 1 384 Mean Difference (IV, Random, 95% CI) 1.20 [1.10, 1.30]
9.3 PANSS negative
symptoms
1 384 Mean Difference (IV, Random, 95% CI) 0.80 [0.70, 0.90]
9.4 PANSS general pathology 1 384 Mean Difference (IV, Random, 95% CI) 1.0 [0.85, 1.15]
10 Mental state: 1e. Average score
decreased rate of BPRS/PANSS
(%) - short term (up to 6
months)
7 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 BPRS 1 197 Mean Difference (IV, Random, 95% CI) -0.80 [-4.86, 3.26]
10.2 PANSS 6 782 Mean Difference (IV, Random, 95% CI) -1.96 [-7.20, 3.28]
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11 Functioning: 1. Average
endpoint score (various scales,
high = better) - short term (up
to 6 months)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 WCST-IQ 1 120 Mean Difference (IV, Random, 95% CI) -11.30 [-17.62, -4.
98]
11.2 WCST-MQ 1 120 Mean Difference (IV, Random, 95% CI) -19.60 [-27.37, -11.
83]
12 Cognitive function: 1. Average
endpoint score (various scales,
high = better) - short term (up
to 6 months)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 WCST 2 123 Mean Difference (IV, Random, 95% CI) 8.92 [0.40, 17.43]
12.2 WMS-RC 1 71 Mean Difference (IV, Random, 95% CI) -9.34 [-17.53, -1.15]
13 Adverse effects: 1.
Anticholinergic - short term
(up to 6 months)
22 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 blurred vision 18 1780 Risk Ratio (M-H, Random, 95% CI) 5.00 [3.46, 7.22]
13.2 dry mouth 18 1682 Risk Ratio (M-H, Random, 95% CI) 2.34 [1.54, 3.54]
13.3 excessive sweating 3 162 Risk Ratio (M-H, Random, 95% CI) 3.91 [0.84, 18.19]
13.4 hypersalivation 11 1135 Risk Ratio (M-H, Random, 95% CI) 3.85 [2.36, 6.28]
13.5 stuffy nose 8 972 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.45, 1.06]
14 Adverse effects: 2.
Cardiovascular - short term (up
to 6 months)
22 Risk Ratio (IV, Random, 95% CI) Subtotals only
14.1 abnormal ECG 7 708 Risk Ratio (IV, Random, 95% CI) 1.82 [1.11, 2.98]
14.2 blood pressure drop 8 690 Risk Ratio (IV, Random, 95% CI) 0.97 [0.53, 1.79]
14.3 orthostatic hypotension 7 605 Risk Ratio (IV, Random, 95% CI) 2.64 [1.14, 6.12]
14.4 tachycardia 17 1752 Risk Ratio (IV, Random, 95% CI) 1.70 [1.33, 2.18]
15 Adverse effects: 3. Central
nervous system - short term
(up to 6 months)
21 Risk Ratio (IV, Random, 95% CI) Subtotals only
15.1 dizziness 12 1206 Risk Ratio (IV, Random, 95% CI) 1.40 [0.83, 2.35]
15.2 drowsiness 17 1677 Risk Ratio (IV, Random, 95% CI) 2.28 [1.51, 3.45]
15.3 headache 3 192 Risk Ratio (IV, Random, 95% CI) 0.74 [0.13, 4.18]
15.4 insomnia 9 867 Risk Ratio (IV, Random, 95% CI) 0.92 [0.55, 1.54]
15.5 reduced activity 8 788 Risk Ratio (IV, Random, 95% CI) 7.80 [3.05, 19.92]
15.6 sedation 1 40 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 7.72]
16 Adverse effects: 4.
Gastrointestinal - short term
(up to 6 months)
22 Risk Ratio (IV, Random, 95% CI) Subtotals only
16.1 constipation 22 2048 Risk Ratio (IV, Random, 95% CI) 2.55 [2.04, 3.20]
16.2 diarrhoea 1 62 Risk Ratio (IV, Random, 95% CI) 5.32 [0.27, 106.54]
16.3 loss of appetite 5 472 Risk Ratio (IV, Random, 95% CI) 2.52 [0.82, 7.72]
16.4 nausea/vomiting 9 819 Risk Ratio (IV, Random, 95% CI) 1.23 [0.58, 2.63]
17 Adverse effects: 5a. Endocrine -
various - short term (up to 6
months)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 gynaecomastia,
galactorrhoea
1 83 Risk Ratio (M-H, Random, 95% CI) 5.37 [0.27, 108.47]
17.2 hyperprolactinemia 2 277 Risk Ratio (M-H, Random, 95% CI) 5.69 [2.74, 11.79]
17.3 menstrual irregularities 1 52 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.25, 99.34]
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18 Adverse effects: 5b. Endocrine -
average endpoint - short term
(up to 6 months)
1 30 Mean Difference (IV, Random, 95% CI) 24.62 [17.76, 31.48]
18.1 prolactin level (ng/mL) 1 30 Mean Difference (IV, Random, 95% CI) 24.62 [17.76, 31.48]
19 Adverse effects: 5c. Endocrine -
skewed data - short term (up to
6 months)
Other data No numeric data
19.1 average prolactin level
(ng/mL)
Other data No numeric data
20 Adverse effects: 6a.
Haematology - short term (up
to 6 months)
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 elevated ALT 8 775 Risk Ratio (M-H, Random, 95% CI) 1.62 [0.92, 2.87]
20.2 decreased white blood
cell count
4 427 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.43, 2.42]
20.3 increased white blood
cell count
1 79 Risk Ratio (M-H, Random, 95% CI) 2.05 [0.40, 10.56]
21 Adverse effects: 6b.
Haematology - average
endpoint - short term (up to 6
months)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 blood glucose 1 130 Mean Difference (IV, Random, 95% CI) 0.10 [-0.18, 0.38]
21.2 blood TG 1 130 Mean Difference (IV, Random, 95% CI) 0.0 [-0.28, 0.28]
21.3 blood TC 1 130 Mean Difference (IV, Random, 95% CI) 0.20 [-0.11, 0.51]
22 Adverse effects: 7. Hepatitic -
short term (up to 6 months)
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
22.1 abnormal liver function 5 561 Risk Ratio (M-H, Random, 95% CI) 2.10 [1.32, 3.33]
23 Adverse effects: 8. Movement
disorders - short term (up to 6
months)
24 Risk Ratio (IV, Random, 95% CI) Subtotals only
23.1 agitation 5 313 Risk Ratio (IV, Random, 95% CI) 0.36 [0.14, 0.95]
23.2 akathisia 17 1757 Risk Ratio (IV, Random, 95% CI) 3.73 [2.55, 5.47]
23.3 any EPS symptoms 8 644 Risk Ratio (IV, Random, 95% CI) 8.03 [4.78, 13.51]
23.4 dystonia 1 201 Risk Ratio (IV, Random, 95% CI) 0.33 [0.01, 8.01]
23.5 myotonia 12 1257 Risk Ratio (IV, Random, 95% CI) 4.59 [3.18, 6.64]
23.6 need additional
medication for EPS symptoms
1 202 Risk Ratio (IV, Random, 95% CI) 1.5 [0.71, 3.18]
23.7 torsion movement 9 1063 Risk Ratio (IV, Random, 95% CI) 5.81 [2.76, 12.23]
23.8 tremor 13 1343 Risk Ratio (IV, Random, 95% CI) 2.90 [1.89, 4.45]
24 Adverse effects: 9a. Metabolic -
weight gain
15 1259 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.17, 2.39]
24.1 weight gain 15 1259 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.17, 2.39]
25 Adverse effects: 9b. Metabolic -
short term (up to 6 months)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 average BMI 1 105 Mean Difference (IV, Random, 95% CI) 0.5 [-0.67, 1.67]
25.2 average weight (KG) 1 130 Mean Difference (IV, Random, 95% CI) -1.0 [-4.68, 2.68]
26 Adverse effects: 10. Various
other - short term (up to 6
months)
4 560 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.19, 2.52]
26.1 unspeciﬁed adverse
effects
4 560 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.19, 2.52]
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27 Adverse effects: 11. Average
endpoint score (TESS, high =
poor) - skewed data
Other data No numeric data
27.1 short term (up to 6
months)
Other data No numeric data
27.2 medium term (7 to 12
months)
Other data No numeric data
28 Quality of life: 1. General
- average endpoint score
(GQOL1 - 74, high = better)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 short term (up to 6
months)
1 59 Mean Difference (IV, Random, 95% CI) -6.49 [-11.30, -1.68]
29 Leaving the study early: 1a.
Short term (up to 6 months)
19 Risk Ratio (IV, Random, 95% CI) Subtotals only
29.1 due to adverse effect 10 1680 Risk Ratio (IV, Random, 95% CI) 1.43 [1.04, 1.98]
29.2 due to inefﬁcacy 3 695 Risk Ratio (IV, Random, 95% CI) 1.42 [0.68, 2.96]
29.3 due to any other reason 12 1223 Risk Ratio (IV, Random, 95% CI) 1.04 [0.77, 1.41]
29.4 due to loss to follow-up 2 400 Risk Ratio (IV, Random, 95% CI) 0.56 [0.23, 1.37]
30 Leaving the study early: 1b.
Medium term (7 to 12 months)
1 103 Risk Ratio (IV, Random, 95% CI) 1.19 [0.61, 2.32]
Analysis 1.1. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 1 Clinical response: 1.
No significant clinical response.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 1 Clinical response: 1. No signiﬁcant clinical response
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term - up to 6 months
vs OLZ - Chang 2003 13/27 6/31 31.1 % 2.49 [ 1.10, 5.64 ]
vs OLZ - Chen 2006 4/44 3/42 10.1 % 1.27 [ 0.30, 5.35 ]
vs OLZ - Wang 2002 14/28 6/32 31.7 % 2.67 [ 1.19, 6.00 ]
Subtotal (95% CI) 99 105 72.9 % 2.34 [ 1.37, 3.99 ]
Total events: 31 (Chlorpromazine), 15 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 3.11 (P = 0.0019)
2 long term - over 12 months
vs OLZ - An 2006 11/35 6/35 27.1 % 1.83 [ 0.76, 4.41 ]
0.01 0.1 1 10 100
Chlorpromazine Olanzapine
(Continued . . . )
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(. . . Continued)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 35 35 27.1 % 1.83 [ 0.76, 4.41 ]
Total events: 11 (Chlorpromazine), 6 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Total (95% CI) 134 140 100.0 % 2.19 [ 1.39, 3.45 ]
Total events: 42 (Chlorpromazine), 21 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.36 (P = 0.00077)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.64), I2 =0.0%
0.01 0.1 1 10 100
Chlorpromazine Olanzapine
Analysis 1.2. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 2 Clinical response: 2.
Average endpoint score (CGI, high = poor) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 2 Clinical response: 2. Average endpoint score (CGI, high = poor) - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
HGCQ (Turkey) 2000 10 4.6 (1.1) 20 4 (1.4) 25.1 % 0.60 [ -0.32, 1.52 ]
HGDV (Morocco) 1999 12 4.3 (0.9) 27 2.9 (0.6) 41.7 % 1.40 [ 0.84, 1.96 ]
vs OLZ - Loza 1999 (HGDT) 14 4.6 (1) 27 4 (1.3) 33.2 % 0.60 [ -0.12, 1.32 ]
Total (95% CI) 36 74 100.0 % 0.93 [ 0.36, 1.51 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 3.90, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Chlorpromazine Olanzapine
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Analysis 1.3. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 3 Clinical response: 3.
Relapse - long term (over 12 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 3 Clinical response: 3. Relapse - long term (over 12 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs OLZ - An 2006 6/35 4/35 100.0 % 1.50 [ 0.46, 4.86 ]
Total (95% CI) 35 35 100.0 % 1.50 [ 0.46, 4.86 ]
Total events: 6 (Chlorpromazine), 4 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 4 Mental state: 1.
Average endpoint score (various scales, high = poor) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 4 Mental state: 1. Average endpoint score (various scales, high = poor) - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS total
vs OLZ - Chang 2003 27 27 (4) 31 22 (3) 30.9 % 5.00 [ 3.16, 6.84 ]
vs OLZ - Chen 2006 44 24.8 (6.4) 42 29.4 (11.3) 24.7 % -4.60 [ -8.51, -0.69 ]
vs OLZ - Loza 1999 (HGDT) 14 44 (11.2) 27 35.4 (16) 12.8 % 8.60 [ 0.18, 17.02 ]
vs OLZ - Wang 2002 28 27.1 (3.4) 32 21.7 (2.5) 31.6 % 5.40 [ 3.87, 6.93 ]
Subtotal (95% CI) 113 132 100.0 % 3.21 [ -0.62, 7.05 ]
Heterogeneity: Tau2 = 11.52; Chi2 = 23.38, df = 3 (P = 0.00003); I2 =87%
Test for overall effect: Z = 1.64 (P = 0.10)
2 BPRS activation subscale
vs OLZ - Chen 2006 44 5.3 (0.8) 42 4.9 (1.8) 11.1 % 0.40 [ -0.19, 0.99 ]
vs OLZ - Wang 2008 108 4.15 (0.95) 105 3.67 (0.57) 88.9 % 0.48 [ 0.27, 0.69 ]
Subtotal (95% CI) 152 147 100.0 % 0.47 [ 0.27, 0.67 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 4.67 (P < 0.00001)
3 BPRS anxiety-depression subscale
vs OLZ - Wang 2008 108 7.17 (0.76) 105 5.6 (0.79) 100.0 % 1.57 [ 1.36, 1.78 ]
Subtotal (95% CI) 108 105 100.0 % 1.57 [ 1.36, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 14.77 (P < 0.00001)
4 BPRS hostile-suspiciousness subscale
vs OLZ - Chen 2006 44 4.6 (0.9) 42 5.8 (2.4) 47.7 % -1.20 [ -1.97, -0.43 ]
vs OLZ - Wang 2008 108 5.02 (1.34) 105 4.52 (0.78) 52.3 % 0.50 [ 0.21, 0.79 ]
Subtotal (95% CI) 152 147 100.0 % -0.31 [ -1.98, 1.35 ]
Heterogeneity: Tau2 = 1.36; Chi2 = 16.24, df = 1 (P = 0.00006); I2 =94%
Test for overall effect: Z = 0.37 (P = 0.71)
5 BPRS thinking disorder subscale
vs OLZ - Chen 2006 44 5.1 (0.9) 42 6.9 (2.8) 47.3 % -1.80 [ -2.69, -0.91 ]
vs OLZ - Wang 2008 108 4.84 (0.59) 105 4.74 (0.99) 52.7 % 0.10 [ -0.12, 0.32 ]
Subtotal (95% CI) 152 147 100.0 % -0.80 [ -2.66, 1.06 ]
Heterogeneity: Tau2 = 1.70; Chi2 = 16.59, df = 1 (P = 0.00005); I2 =94%
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Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.84 (P = 0.40)
6 BPRS withdraw-retardation subscale
vs OLZ - Chen 2006 44 5.2 (0.2) 42 6.6 (1.5) 49.2 % -1.40 [ -1.86, -0.94 ]
vs OLZ - Wang 2008 108 3.74 (0.58) 105 3.35 (0.51) 50.8 % 0.39 [ 0.24, 0.54 ]
Subtotal (95% CI) 152 147 100.0 % -0.49 [ -2.25, 1.26 ]
Heterogeneity: Tau2 = 1.57; Chi2 = 53.34, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 0.55 (P = 0.58)
7 NOSIE total
vs OLZ - Wang 2008 108 268.84 (15.9) 105 287.2 (14.1) 100.0 % -18.36 [ -22.39, -14.33 ]
Subtotal (95% CI) 108 105 100.0 % -18.36 [ -22.39, -14.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.92 (P < 0.00001)
8 PANSS total
HGCQ (Turkey) 2000 10 72.7 (30.9) 20 67.5 (30.5) 5.4 % 5.20 [ -18.16, 28.56 ]
HGDV (Morocco) 1999 12 69.1 (22.5) 27 44.6 (12.8) 11.8 % 24.50 [ 10.88, 38.12 ]
vs OLZ - He 2003 40 60.2 (20.1) 40 54.8 (16.9) 19.5 % 5.40 [ -2.74, 13.54 ]
vs OLZ - Loza 1999 (HGDT) 14 110.9 (17.8) 27 97.1 (29.9) 10.8 % 13.80 [ -0.83, 28.43 ]
vs OLZ - Wu 2008 50 42.93 (7.67) 50 38.26 (9.37) 27.9 % 4.67 [ 1.31, 8.03 ]
vs OLZ - Zhao 2006 29 67.8 (10.2) 32 53.8 (11.1) 24.6 % 14.00 [ 8.65, 19.35 ]
Subtotal (95% CI) 155 196 100.0 % 10.46 [ 4.49, 16.43 ]
Heterogeneity: Tau2 = 30.32; Chi2 = 15.31, df = 5 (P = 0.01); I2 =67%
Test for overall effect: Z = 3.43 (P = 0.00060)
9 PANSS general pathology subscale
vs OLZ - Wu 2008 50 21.91 (4.23) 50 20.6 (4.11) 100.0 % 1.31 [ -0.32, 2.94 ]
Subtotal (95% CI) 50 50 100.0 % 1.31 [ -0.32, 2.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
10 PANSS negative symptom subscale
vs OLZ - He 2003 40 24.2 (9.2) 40 22.6 (8.3) 29.1 % 1.60 [ -2.24, 5.44 ]
vs OLZ - Zhao 2006 29 15.4 (5.7) 32 12.7 (3.8) 70.9 % 2.70 [ 0.24, 5.16 ]
Subtotal (95% CI) 69 72 100.0 % 2.38 [ 0.31, 4.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.024)
11 PANSS positive symptom subscale
vs OLZ - Wu 2008 50 9.01 (2.94) 50 8.32 (3.84) 80.6 % 0.69 [ -0.65, 2.03 ]
vs OLZ - Zhao 2006 29 13.8 (6.4) 32 12 (4.1) 19.4 % 1.80 [ -0.93, 4.53 ]
Subtotal (95% CI) 79 82 100.0 % 0.91 [ -0.30, 2.11 ]
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Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
12 SAPS total
vs OLZ - Chen 2006 44 22.7 (4.4) 42 24.8 (6.8) 100.0 % -2.10 [ -4.53, 0.33 ]
Subtotal (95% CI) 44 42 100.0 % -2.10 [ -4.53, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Chi2 = 171.97, df = 11 (P = 0.00), I2 =94%
-20 -10 0 10 20
Chlorpromazine Olanzapine
Analysis 1.5. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 5 Mental state: 2.
Average endpoint score (BPRS, high = poor) - medium term (7 to 12 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 5 Mental state: 2. Average endpoint score (BPRS, high = poor) - medium term (7 to 12 months)
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS total
vs OLZ - Wang 2002 28 31.5 (5.6) 32 22.9 (4.8) 100.0 % 8.60 [ 5.94, 11.26 ]
Subtotal (95% CI) 28 32 100.0 % 8.60 [ 5.94, 11.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.34 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 6 Mental state: 3.
Average endpoint score (various scales, high = poor) - skewed data.
Mental state: 3. Average endpoint score (various scales, high = poor) - skewed data
Study Intervention mean SD N
BPRS total BPRS total
HGCQ (Turkey) 2000 Chlorpromazine 24.7 18.4 10
HGCQ (Turkey) 2000 Olanzapine 20.2 17.9 20
HGDV (Morocco) 1999 Chlorpromazine 20.7 12.9 12
HGDV (Morocco) 1999 Olanzapine 6.7 6.4 27
vs OLZ - Wang 2008 Chlorpromazine 30.16 27.4 108
vs OLZ - Wang 2008 Olanzapine 27.34 7.89 105
HAMA (anxiety) HAMA (anxiety
HGDV (Morocco) 1999 Chlorpromazine 7.6 5.8 12
HGDV (Morocco) 1999 Olanzapine 3.3 1.8 27
MADRS (depression) MADRS (depres
HGDV (Morocco) 1999 Chlorpromazine 6.9 4.8 12
HGDV (Morocco) 1999 Olanzapine 3.3 2.0 27
PANSS negative symptom subscale PANSS negative
vs OLZ - Wu 2008 Chlorpromazine 11.62 3.93 50
vs OLZ - Wu 2008 Olanzapine 8.34 4.26 50
PANSS positive symptom subscale PANSS positive
vs OLZ - He 2003 Chlorpromazine 11.7 6.2 40
vs OLZ - He 2003 Olanzapine 10.2 4.9 40
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Analysis 1.7. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 7 Service involvement:
1. Re-hospitalisation.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 7 Service involvement: 1. Re-hospitalisation
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 long term (over 12 months)
vs OLZ - An 2006 6/35 4/35 100.0 % 1.50 [ 0.46, 4.86 ]
Subtotal (95% CI) 35 35 100.0 % 1.50 [ 0.46, 4.86 ]
Total events: 6 (Chlorpromazine), 4 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 8 Functioning: 1.
Executive function - average endpoint score (WCST, high = poor).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 8 Functioning: 1. Executive function - average endpoint score (WCST, high = poor)
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 6 months)
vs OLZ - An 2006 29 68.17 (20.31) 24 57.21 (16.63) 100.0 % 10.96 [ 1.01, 20.91 ]
Subtotal (95% CI) 29 24 100.0 % 10.96 [ 1.01, 20.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 9 Adverse effects: 1.
Anticholinergic - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 9 Adverse effects: 1. Anticholinergic - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 blurred vision
vs OLZ - He 2003 8/40 2/40 41.6 % 4.00 [ 0.90, 17.68 ]
vs OLZ - Wu 2008 9/50 2/50 41.7 % 4.50 [ 1.02, 19.79 ]
vs OLZ - Zhao 2006 0/29 2/32 16.7 % 0.22 [ 0.01, 4.40 ]
Subtotal (95% CI) 119 122 100.0 % 2.59 [ 0.66, 10.22 ]
Total events: 17 (Chlorpromazine), 6 (Olanzapine)
Heterogeneity: Tau2 = 0.60; Chi2 = 3.40, df = 2 (P = 0.18); I2 =41%
Test for overall effect: Z = 1.36 (P = 0.17)
2 dry mouth
vs OLZ - Chang 2003 1/27 7/31 16.8 % 0.16 [ 0.02, 1.25 ]
vs OLZ - He 2003 26/40 5/40 24.2 % 5.20 [ 2.22, 12.18 ]
vs OLZ - Wang 2008 1/119 7/118 16.5 % 0.14 [ 0.02, 1.13 ]
vs OLZ - Wu 2008 8/50 2/50 20.3 % 4.00 [ 0.89, 17.91 ]
vs OLZ - Zhao 2006 5/29 4/32 22.1 % 1.38 [ 0.41, 4.65 ]
Subtotal (95% CI) 265 271 100.0 % 1.13 [ 0.29, 4.45 ]
Total events: 41 (Chlorpromazine), 25 (Olanzapine)
Heterogeneity: Tau2 = 1.83; Chi2 = 18.59, df = 4 (P = 0.00095); I2 =78%
Test for overall effect: Z = 0.18 (P = 0.86)
3 excessive sweating
vs OLZ - He 2003 3/40 1/40 50.2 % 3.00 [ 0.33, 27.63 ]
vs OLZ - Wu 2008 3/50 1/50 49.8 % 3.00 [ 0.32, 27.87 ]
Subtotal (95% CI) 90 90 100.0 % 3.00 [ 0.62, 14.46 ]
Total events: 6 (Chlorpromazine), 2 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
4 hypersalivation
vs OLZ - Chen 2006 23/44 2/42 49.9 % 10.98 [ 2.76, 43.71 ]
vs OLZ - He 2003 22/40 2/40 50.1 % 11.00 [ 2.77, 43.71 ]
Subtotal (95% CI) 84 82 100.0 % 10.99 [ 4.14, 29.17 ]
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Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 45 (Chlorpromazine), 4 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 4.81 (P < 0.00001)
5 stuffy nose
vs OLZ - He 2003 12/40 4/40 100.0 % 3.00 [ 1.06, 8.52 ]
Subtotal (95% CI) 40 40 100.0 % 3.00 [ 1.06, 8.52 ]
Total events: 12 (Chlorpromazine), 4 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Chi2 = 8.13, df = 4 (P = 0.09), I2 =51%
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Analysis 1.10. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 10 Adverse effects: 2.
Cardiovascular - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 10 Adverse effects: 2. Cardiovascular - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 abnormal ECG
vs OLZ - He 2003 2/40 0/40 35.5 % 5.00 [ 0.25, 100.97 ]
vs OLZ - Wu 2008 3/50 1/50 64.5 % 3.00 [ 0.32, 27.87 ]
Subtotal (95% CI) 90 90 100.0 % 3.60 [ 0.60, 21.55 ]
Total events: 5 (Chlorpromazine), 1 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
2 apathism
vs OLZ - Wu 2008 10/50 2/50 100.0 % 5.00 [ 1.15, 21.67 ]
Subtotal (95% CI) 50 50 100.0 % 5.00 [ 1.15, 21.67 ]
0.001 0.01 0.1 1 10 100 1000
Chlorpromazine Olanzapine
(Continued . . . )
170Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 10 (Chlorpromazine), 2 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
3 blood pressure (drop)
vs OLZ - He 2003 3/40 0/40 48.9 % 7.00 [ 0.37, 131.28 ]
vs OLZ - Wu 2008 5/50 0/50 51.1 % 11.00 [ 0.62, 193.80 ]
Subtotal (95% CI) 90 90 100.0 % 8.82 [ 1.13, 68.52 ]
Total events: 8 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
4 orthostatic hypotension
vs OLZ - Chang 2003 6/27 0/31 20.9 % 14.86 [ 0.88, 252.11 ]
vs OLZ - Chen 2006 2/44 0/42 18.5 % 4.78 [ 0.24, 96.68 ]
vs OLZ - He 2003 3/40 0/40 19.5 % 7.00 [ 0.37, 131.28 ]
vs OLZ - Wang 2008 7/119 0/118 20.6 % 14.88 [ 0.86, 257.53 ]
vs OLZ - Wu 2008 5/50 0/50 20.4 % 11.00 [ 0.62, 193.80 ]
Subtotal (95% CI) 280 281 100.0 % 9.78 [ 2.68, 35.71 ]
Total events: 23 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.45 (P = 0.00056)
5 palpitation
vs OLZ - Wang 2008 20/119 0/118 100.0 % 40.66 [ 2.49, 664.56 ]
Subtotal (95% CI) 119 118 100.0 % 40.66 [ 2.49, 664.56 ]
Total events: 20 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0093)
6 tachycardia
vs OLZ - He 2003 4/40 2/40 21.1 % 2.00 [ 0.39, 10.31 ]
vs OLZ - Wu 2008 7/50 3/50 33.8 % 2.33 [ 0.64, 8.51 ]
vs OLZ - Zhao 2006 17/29 3/32 45.2 % 6.25 [ 2.04, 19.16 ]
Subtotal (95% CI) 119 122 100.0 % 3.53 [ 1.66, 7.48 ]
Total events: 28 (Chlorpromazine), 8 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.87, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi2 = 4.44, df = 5 (P = 0.49), I2 =0.0%
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Analysis 1.11. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 11 Adverse effects: 3.
Central nervous system - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 11 Adverse effects: 3. Central nervous system - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 dizziness
vs OLZ - He 2003 6/40 1/40 35.9 % 6.00 [ 0.76, 47.60 ]
vs OLZ - Wu 2008 6/50 2/50 64.1 % 3.00 [ 0.64, 14.16 ]
Subtotal (95% CI) 90 90 100.0 % 3.85 [ 1.11, 13.32 ]
Total events: 12 (Chlorpromazine), 3 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
2 drowsiness
vs OLZ - Chang 2003 15/27 6/31 24.4 % 2.87 [ 1.30, 6.35 ]
vs OLZ - He 2003 6/40 2/40 6.5 % 3.00 [ 0.64, 13.98 ]
vs OLZ - Wang 2008 18/119 11/118 30.9 % 1.62 [ 0.80, 3.29 ]
vs OLZ - Wu 2008 14/50 4/50 14.2 % 3.50 [ 1.24, 9.90 ]
vs OLZ - Zhao 2006 15/29 6/32 23.9 % 2.76 [ 1.24, 6.15 ]
Subtotal (95% CI) 265 271 100.0 % 2.46 [ 1.66, 3.64 ]
Total events: 68 (Chlorpromazine), 29 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.07, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 4.49 (P < 0.00001)
3 fatigue
vs OLZ - Wu 2008 6/50 3/50 68.7 % 2.00 [ 0.53, 7.56 ]
vs OLZ - Zhao 2006 0/29 2/32 31.3 % 0.22 [ 0.01, 4.40 ]
Subtotal (95% CI) 79 82 100.0 % 1.00 [ 0.13, 7.66 ]
Total events: 6 (Chlorpromazine), 5 (Olanzapine)
Heterogeneity: Tau2 = 1.11; Chi2 = 1.79, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Chi2 = 1.24, df = 2 (P = 0.54), I2 =0.0%
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Analysis 1.12. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 12 Adverse effects: 4.
Gastrointestinal - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 12 Adverse effects: 4. Gastrointestinal - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 appetite loss
vs OLZ - He 2003 28/40 4/40 67.3 % 7.00 [ 2.70, 18.13 ]
vs OLZ - Wu 2008 28/50 1/50 32.7 % 28.00 [ 3.96, 197.94 ]
Subtotal (95% CI) 90 90 100.0 % 11.01 [ 2.82, 42.94 ]
Total events: 56 (Chlorpromazine), 5 (Olanzapine)
Heterogeneity: Tau2 = 0.48; Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 3.45 (P = 0.00055)
2 constipation
vs OLZ - Chang 2003 12/27 1/31 6.3 % 13.78 [ 1.91, 99.16 ]
vs OLZ - Chen 2006 10/44 4/42 21.2 % 2.39 [ 0.81, 7.02 ]
vs OLZ - He 2003 16/40 5/40 30.3 % 3.20 [ 1.30, 7.90 ]
vs OLZ - Wang 2008 14/119 2/118 11.6 % 6.94 [ 1.61, 29.87 ]
vs OLZ - Wu 2008 18/50 4/50 24.2 % 4.50 [ 1.64, 12.36 ]
vs OLZ - Zhao 2006 12/29 1/32 6.3 % 13.24 [ 1.83, 95.63 ]
Subtotal (95% CI) 309 313 100.0 % 4.29 [ 2.61, 7.05 ]
Total events: 82 (Chlorpromazine), 17 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.83, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 5.74 (P < 0.00001)
3 diarrhoea
vs OLZ - He 2003 2/40 0/40 100.0 % 5.00 [ 0.25, 100.97 ]
Subtotal (95% CI) 40 40 100.0 % 5.00 [ 0.25, 100.97 ]
Total events: 2 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
4 dysphagia
vs OLZ - Wu 2008 1/50 0/50 100.0 % 3.00 [ 0.13, 71.92 ]
Subtotal (95% CI) 50 50 100.0 % 3.00 [ 0.13, 71.92 ]
Total events: 1 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
5 nausea/vomiting
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(. . . Continued)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs OLZ - He 2003 4/40 2/40 57.8 % 2.00 [ 0.39, 10.31 ]
vs OLZ - Wu 2008 2/50 2/50 42.2 % 1.00 [ 0.15, 6.82 ]
Subtotal (95% CI) 90 90 100.0 % 1.49 [ 0.43, 5.20 ]
Total events: 6 (Chlorpromazine), 4 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 4.63, df = 4 (P = 0.33), I2 =14%
0.002 0.1 1 10 500
Chlorpromazine Olanzapine
Analysis 1.13. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 13 Adverse effects: 5.
Haematology - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 13 Adverse effects: 5. Haematology - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 abnormal haemogram
vs OLZ - He 2003 4/40 1/40 39.6 % 4.00 [ 0.47, 34.24 ]
vs OLZ - Wu 2008 4/50 1/50 39.2 % 4.00 [ 0.46, 34.54 ]
Subtotal (95% CI) 90 90 78.8 % 4.00 [ 0.87, 18.31 ]
Total events: 8 (Chlorpromazine), 2 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.074)
2 leukopenia
vs OLZ - Chen 2006 3/44 0/42 21.2 % 6.69 [ 0.36, 125.71 ]
Subtotal (95% CI) 44 42 21.2 % 6.69 [ 0.36, 125.71 ]
Total events: 3 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
0.01 0.1 1 10 100
Favours chlorpromazine Favours olanzapine
(Continued . . . )
174Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 134 132 100.0 % 4.46 [ 1.16, 17.22 ]
Total events: 11 (Chlorpromazine), 2 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
0.01 0.1 1 10 100
Favours chlorpromazine Favours olanzapine
Analysis 1.14. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 14 Adverse effects: 6.
Hepatitic - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 14 Adverse effects: 6. Hepatitic - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 abnormal liver function
vs OLZ - Wu 2008 2/50 0/50 100.0 % 5.00 [ 0.25, 101.58 ]
Subtotal (95% CI) 50 50 100.0 % 5.00 [ 0.25, 101.58 ]
Total events: 2 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 abnormal transaminase
vs OLZ - Chen 2006 0/44 7/42 50.1 % 0.06 [ 0.00, 1.08 ]
vs OLZ - Zhao 2006 5/29 0/32 49.9 % 12.10 [ 0.70, 209.71 ]
Subtotal (95% CI) 73 74 100.0 % 0.88 [ 0.01, 150.45 ]
Total events: 5 (Chlorpromazine), 7 (Olanzapine)
Heterogeneity: Tau2 = 11.69; Chi2 = 6.56, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
0.01 0.1 1 10 100
Favours chlorpromazine Favours olanzapine
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Analysis 1.15. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 15 Adverse effects: 7a.
Metabolic - weight gain - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 15 Adverse effects: 7a. Metabolic - weight gain - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs OLZ - Chang 2003 2/27 8/31 18.6 % 0.29 [ 0.07, 1.24 ]
vs OLZ - He 2003 10/40 3/40 21.1 % 3.33 [ 0.99, 11.22 ]
vs OLZ - Wang 2008 2/119 9/118 18.1 % 0.22 [ 0.05, 1.00 ]
vs OLZ - Wu 2008 6/50 4/50 21.2 % 1.50 [ 0.45, 4.99 ]
vs OLZ - Zhao 2006 3/29 8/32 20.9 % 0.41 [ 0.12, 1.41 ]
Total (95% CI) 265 271 100.0 % 0.70 [ 0.25, 1.96 ]
Total events: 23 (Chlorpromazine), 32 (Olanzapine)
Heterogeneity: Tau2 = 0.91; Chi2 = 12.17, df = 4 (P = 0.02); I2 =67%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
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Analysis 1.16. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 16 Adverse effects: 7b.
Metabolic - weight gain - continuous measures.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 16 Adverse effects: 7b. Metabolic - weight gain - continuous measures
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 6 months)
HGCQ (Turkey) 2000 10 75.2 (13.19) 20 75.2 (11.38) 17.8 % 0.0 [ -9.58, 9.58 ]
HGDV (Morocco) 1999 12 66.58 (7.62) 27 74.48 (10.73) 46.6 % -7.90 [ -13.81, -1.99 ]
vs OLZ - Loza 1999 (HGDT) 14 69.21 (14.86) 27 73.19 (13.47) 18.9 % -3.98 [ -13.28, 5.32 ]
vs OLZ - Luo 2007 20 62.3 (16.8) 30 66.35 (18.38) 16.7 % -4.05 [ -13.92, 5.82 ]
Subtotal (95% CI) 56 104 100.0 % -5.11 [ -9.15, -1.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
2 medium term (7 to 12 months)
vs OLZ - Luo 2007 20 69.13 (24.75) 30 68.54 (17.13) 100.0 % 0.59 [ -11.87, 13.05 ]
Subtotal (95% CI) 20 30 100.0 % 0.59 [ -11.87, 13.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 0.73, df = 1 (P = 0.39), I2 =0.0%
-10 -5 0 5 10
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Analysis 1.17. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 17 Adverse effects: 7c.
Metabolic - other - continuous measures.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 17 Adverse effects: 7c. Metabolic - other - continuous measures
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 cholesterol (TC) - short term (up to 6 months)
vs OLZ - Luo 2007 20 4.22 (0.93) 30 4.62 (1.31) 100.0 % -0.40 [ -1.02, 0.22 ]
Subtotal (95% CI) 20 30 100.0 % -0.40 [ -1.02, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 high-density lipoprotein (HDL) - short term (up to 6 months)
vs OLZ - Luo 2007 20 1.03 (0.25) 30 0.98 (0.35) 100.0 % 0.05 [ -0.12, 0.22 ]
Subtotal (95% CI) 20 30 100.0 % 0.05 [ -0.12, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
3 low-density lipoprotein (LDL) - short term (up to 6 months)
vs OLZ - Luo 2007 20 2.29 (0.46) 30 2.3 (0.61) 100.0 % -0.01 [ -0.31, 0.29 ]
Subtotal (95% CI) 20 30 100.0 % -0.01 [ -0.31, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
4 low-density lipoprotein (LDL) - medium term (7 to 12 months)
vs OLZ - Luo 2007 20 2.38 (0.81) 30 2.32 (0.84) 100.0 % 0.06 [ -0.41, 0.53 ]
Subtotal (95% CI) 20 30 100.0 % 0.06 [ -0.41, 0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 1.95, df = 3 (P = 0.58), I2 =0.0%
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Analysis 1.18. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 18 Adverse effects: 7d.
Metabolic - other - average endpoint scores - skewed data.
Adverse effects: 7d. Metabolic - other - average endpoint scores - skewed data
Study Intervention mean SD N
cholesterol (TC) - medium term (7 to 12 months) cholesterol (TC)
vs OLZ - Luo 2007 Chlorpromazine 4.5 2.21 20
vs OLZ - Luo 2007 Olanzapine 4.52 2.73 30
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Adverse effects: 7d. Metabolic - other - average endpoint scores - skewed data (Continued)
high-density lipoprotein (HDL) - short term (up to 6 months) high-density lip
vs OLZ - Luo 2007 Chlorpromazine 0.89 0.33 20
vs OLZ - Luo 2007 Olanzapine 0.89 0.45 30
triglyceride (TG) - short term (up to 6 months) triglyceride (TG
vs OLZ - Luo 2007 Chlorpromazine 1.44 1.07 20
vs OLZ - Luo 2007 Olanzapine 2.13 2.07 30
triglyceride (TG) - medium term (7 to 12 months) triglyceride (TG
vs OLZ - Luo 2007 Chlorpromazine 2.26 2.04 20
vs OLZ - Luo 2007 Olanzapine 2.32 2.14 30
Analysis 1.19. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 19 Adverse effects: 8a.
Movement disorders - extrapyramidal symptoms - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 19 Adverse effects: 8a. Movement disorders - extrapyramidal symptoms - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 akathisia
vs OLZ - He 2003 8/40 4/40 44.7 % 2.00 [ 0.65, 6.11 ]
vs OLZ - Wang 2008 0/119 3/118 22.6 % 0.14 [ 0.01, 2.71 ]
vs OLZ - Wu 2008 10/50 1/50 32.7 % 10.00 [ 1.33, 75.23 ]
Subtotal (95% CI) 209 208 100.0 % 1.86 [ 0.29, 11.84 ]
Total events: 18 (Chlorpromazine), 8 (Olanzapine)
Heterogeneity: Tau2 = 1.67; Chi2 = 5.51, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 0.66 (P = 0.51)
2 any EPS symptoms
vs OLZ - Wang 2008 28/119 0/118 50.3 % 56.53 [ 3.49, 915.23 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs OLZ - Zhao 2006 9/29 0/32 49.7 % 20.90 [ 1.27, 343.87 ]
Subtotal (95% CI) 148 150 100.0 % 34.47 [ 4.79, 248.30 ]
Total events: 37 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.51 (P = 0.00044)
3 muscle stiffness
vs OLZ - He 2003 1/40 0/40 45.0 % 3.00 [ 0.13, 71.51 ]
vs OLZ - Wu 2008 5/50 0/50 55.0 % 11.00 [ 0.62, 193.80 ]
Subtotal (95% CI) 90 90 100.0 % 6.13 [ 0.73, 51.45 ]
Total events: 6 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
4 tremor
vs OLZ - He 2003 2/40 0/40 48.1 % 5.00 [ 0.25, 100.97 ]
vs OLZ - Wu 2008 4/50 0/50 51.9 % 9.00 [ 0.50, 162.89 ]
Subtotal (95% CI) 90 90 100.0 % 6.78 [ 0.84, 54.57 ]
Total events: 6 (Chlorpromazine), 0 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Chi2 = 4.49, df = 3 (P = 0.21), I2 =33%
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.20. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 20 Adverse effects: 8b.
Movement disorders - extrapyramidal symptoms - average endpoint score (ESRS, high = poor).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 20 Adverse effects: 8b. Movement disorders - extrapyramidal symptoms - average endpoint score (ESRS, high = poor)
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 6 months)
HGDV (Morocco) 1999 12 13.2 (1.3) 27 12.3 (0.5) 100.0 % 0.90 [ 0.14, 1.66 ]
vs OLZ - Loza 1999 (HGDT) 27 12 (0) 14 12 (0) Not estimable
Subtotal (95% CI) 39 41 100.0 % 0.90 [ 0.14, 1.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 21 Adverse effects: 9a.
Various other - sleep - average endpoint score (LSEQ, high = better) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 21 Adverse effects: 9a. Various other - sleep - average endpoint score (LSEQ, high = better) - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 awaking from sleep
HGCQ (Turkey) 2000 10 48.4 (22.5) 20 53.7 (20.6) 100.0 % -5.30 [ -21.91, 11.31 ]
Subtotal (95% CI) 10 20 100.0 % -5.30 [ -21.91, 11.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 getting to sleep score
HGCQ (Turkey) 2000 10 61.3 (25.4) 20 61.9 (25.4) 100.0 % -0.60 [ -19.88, 18.68 ]
Subtotal (95% CI) 10 20 100.0 % -0.60 [ -19.88, 18.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
3 quality of sleep
HGCQ (Turkey) 2000 10 52 (23.3) 20 67 (24.8) 100.0 % -15.00 [ -33.07, 3.07 ]
Subtotal (95% CI) 10 20 100.0 % -15.00 [ -33.07, 3.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 1.22, df = 2 (P = 0.54), I2 =0.0%
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Analysis 1.22. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 22 Adverse effects: 9b.
Various other - sleep - average length of sleep (hour/day).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 22 Adverse effects: 9b. Various other - sleep - average length of sleep (hour/day)
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 6 months)
vs OLZ - Luo 2007 20 12.4 (2.7) 30 8.77 (2.8) 100.0 % 3.63 [ 2.08, 5.18 ]
Subtotal (95% CI) 20 30 100.0 % 3.63 [ 2.08, 5.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.59 (P < 0.00001)
2 medium term (7 to 12 months)
vs OLZ - Luo 2007 20 13.52 (3.07) 30 9.11 (2.37) 100.0 % 4.41 [ 2.82, 6.00 ]
Subtotal (95% CI) 20 30 100.0 % 4.41 [ 2.82, 6.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.43 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
-4 -2 0 2 4
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Analysis 1.23. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 23 Adverse effects: 9c.
Various other - sleep - behaviour following waking (LSEQ) - skewed data.
Adverse effects: 9c. Various other - sleep - behaviour following waking (LSEQ) - skewed data
Study Intervention mean SD N
short term (up to 6 months) short term (up t
HGCQ (Turkey) 2000 Chlorpromazine 55.1 28.3 10
HGCQ (Turkey) 2000 Olanzapine 55.9 18.8 20
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Analysis 1.24. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 24 Adverse effects: 9b.
Various other - rash.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 24 Adverse effects: 9b. Various other - rash
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (up to 6 months)
HGCQ (Turkey) 2000 1/10 1/20 100.0 % 2.00 [ 0.14, 28.76 ]
Total (95% CI) 10 20 100.0 % 2.00 [ 0.14, 28.76 ]
Total events: 1 (Chlorpromazine), 1 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 25 Quality of life: 1a.
Average endpoint scores (various scales, high = better) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 25 Quality of life: 1a. Average endpoint scores (various scales, high = better) - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 GQOLI - living condition
vs OLZ - Zhao 2006 29 25.8 (6.3) 32 26.8 (6.5) 100.0 % -1.00 [ -4.21, 2.21 ]
Subtotal (95% CI) 29 32 100.0 % -1.00 [ -4.21, 2.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 GQOLI - physical health
vs OLZ - Zhao 2006 29 33.5 (8.7) 32 43.6 (6.2) 100.0 % -10.10 [ -13.93, -6.27 ]
Subtotal (95% CI) 29 32 100.0 % -10.10 [ -13.93, -6.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.17 (P < 0.00001)
3 GQOLI - psychological health
vs OLZ - Zhao 2006 29 30.2 (6.1) 32 52.8 (7.2) 100.0 % -22.60 [ -25.94, -19.26 ]
Subtotal (95% CI) 29 32 100.0 % -22.60 [ -25.94, -19.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.26 (P < 0.00001)
4 GQOLI - social function
vs OLZ - Zhao 2006 29 32.7 (4.5) 32 50.9 (4.7) 100.0 % -18.20 [ -20.51, -15.89 ]
Subtotal (95% CI) 29 32 100.0 % -18.20 [ -20.51, -15.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 15.44 (P < 0.00001)
Test for subgroup differences: Chi2 = 105.01, df = 3 (P = 0.00), I2 =97%
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Analysis 1.26. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 26 Quality of life: 1b.
Average endpoint score (QoL, high = better) - skewed data.
Quality of life: 1b. Average endpoint score (QoL, high = better) - skewed data
Study Intervention mean SD N
short term (up to 6 months) short term (up t
vs OLZ - Loza 1999
(HGDT)
Chlorpromazine 47.7 26.6 14
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Quality of life: 1b. Average endpoint score (QoL, high = better) - skewed data (Continued)
vs OLZ - Loza 1999
(HGDT)
Olanzapine 56.6 31.3 27
Analysis 1.27. Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 27 Leaving the study
early - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 1 CHLORPROMAZINE versus OLANZAPINE
Outcome: 27 Leaving the study early - short term (up to 6 months)
Study or subgroup Chlorpromazine Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 due to any reason
HGCQ (Turkey) 2000 1/10 5/20 26.8 % 0.40 [ 0.05, 2.98 ]
HGDV (Morocco) 1999 2/12 0/27 15.6 % 10.77 [ 0.56, 208.71 ]
vs OLZ - An 2006 16/35 8/35 57.6 % 2.00 [ 0.99, 4.06 ]
Subtotal (95% CI) 57 82 100.0 % 1.69 [ 0.45, 6.40 ]
Total events: 19 (Chlorpromazine), 13 (Olanzapine)
Heterogeneity: Tau2 = 0.67; Chi2 = 3.64, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.77 (P = 0.44)
2 due to lack of efﬁcacy
HGCQ (Turkey) 2000 0/10 3/20 36.3 % 0.27 [ 0.02, 4.82 ]
vs OLZ - Loza 1999 (HGDT) 1/14 3/27 63.7 % 0.64 [ 0.07, 5.63 ]
Subtotal (95% CI) 24 47 100.0 % 0.47 [ 0.08, 2.66 ]
Total events: 1 (Chlorpromazine), 6 (Olanzapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Chi2 = 1.31, df = 1 (P = 0.25), I2 =24%
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Analysis 2.1. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 1 Clinical response: 1.
No significant clinical response.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 1 Clinical response: 1. No signiﬁcant clinical response
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (up to 6 months)
vs RPD - Chang 1998 4/20 9/38 19.8 % 0.84 [ 0.30, 2.40 ]
vs RPD - Cui 2001 2/30 2/30 6.1 % 1.00 [ 0.15, 6.64 ]
vs RPD - He 1999 4/20 5/21 16.0 % 0.84 [ 0.26, 2.69 ]
vs RPD - Lin 2005 5/35 4/35 14.4 % 1.25 [ 0.37, 4.27 ]
vs RPD - Luo 2001 6/52 13/55 27.4 % 0.49 [ 0.20, 1.19 ]
vs RPD - Wang 2002 1/20 3/49 4.5 % 0.82 [ 0.09, 7.39 ]
vs RPD - Wu 2002 5/35 3/35 11.9 % 1.67 [ 0.43, 6.45 ]
Total (95% CI) 212 263 100.0 % 0.84 [ 0.53, 1.34 ]
Total events: 27 (Chlorpromazine), 39 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.85, df = 6 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 2 Global state: 1.
Average endpoint score (CGI-CI, high = poor) - skewed data.
Global state: 1. Average endpoint score (CGI-CI, high = poor) - skewed data
Study Intervention mean SD N
short term (up to 6 months) short term (up t
vs RPD - Ma 2004 Chlorpromazine 2.4 3.7 39
vs RPD - Ma 2004 Risperidone 1.8 6.6 39
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Analysis 2.3. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 3 Global state: 2. Need
of additional benzhexol.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 3 Global state: 2. Need of additional benzhexol
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (up to 6 months)
vs RPD - Ma 2004 24/39 12/39 68.6 % 2.00 [ 1.17, 3.41 ]
vs RPD - Wang 2002 1/20 5/39 31.4 % 0.39 [ 0.05, 3.12 ]
Total (95% CI) 59 78 100.0 % 1.20 [ 0.26, 5.53 ]
Total events: 25 (Chlorpromazine), 17 (Risperidone)
Heterogeneity: Tau2 = 0.81; Chi2 = 2.36, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
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Analysis 2.4. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 4 Mental state: 1a.
Average endpoint score (various scales, high = poor) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 4 Mental state: 1a. Average endpoint score (various scales, high = poor) - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS total
vs RPD - Cui 2001 30 24.8 (8) 30 28.07 (9.53) 24.0 % -3.27 [ -7.72, 1.18 ]
vs RPD - He 1999 20 25.2 (5.8) 19 26.3 (7.2) 24.9 % -1.10 [ -5.22, 3.02 ]
vs RPD - Ma 2004 39 23.2 (6.5) 39 23.3 (6.6) 27.9 % -0.10 [ -3.01, 2.81 ]
vs RPD - Wu 2002 35 31.29 (11.04) 35 22.78 (8.96) 23.3 % 8.51 [ 3.80, 13.22 ]
Subtotal (95% CI) 124 123 100.0 % 0.90 [ -3.49, 5.28 ]
Heterogeneity: Tau2 = 15.73; Chi2 = 14.61, df = 3 (P = 0.002); I2 =79%
Test for overall effect: Z = 0.40 (P = 0.69)
2 BPRS activation subscale
vs RPD - Cui 2001 30 3.93 (1.88) 30 4.2 (1.97) 45.5 % -0.27 [ -1.24, 0.70 ]
vs RPD - Wu 2002 35 5 (1.65) 35 4.02 (1.01) 54.5 % 0.98 [ 0.34, 1.62 ]
Subtotal (95% CI) 65 65 100.0 % 0.41 [ -0.81, 1.63 ]
Heterogeneity: Tau2 = 0.60; Chi2 = 4.41, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.66 (P = 0.51)
3 BPRS anxiety-depression subscale
vs RPD - Cui 2001 30 4.5 (0.96) 30 5.27 (1.95) 48.9 % -0.77 [ -1.55, 0.01 ]
vs RPD - Wu 2002 35 5.17 (1.68) 35 4.26 (0.73) 51.1 % 0.91 [ 0.30, 1.52 ]
Subtotal (95% CI) 65 65 100.0 % 0.09 [ -1.56, 1.73 ]
Heterogeneity: Tau2 = 1.28; Chi2 = 11.14, df = 1 (P = 0.00084); I2 =91%
Test for overall effect: Z = 0.11 (P = 0.92)
4 BPRS hostile-suspiciousness subscale
vs RPD - Cui 2001 30 4.5 (1.96) 30 4.8 (1.97) 49.3 % -0.30 [ -1.29, 0.69 ]
vs RPD - Wu 2002 35 5.98 (1.96) 35 3.94 (1.63) 50.7 % 2.04 [ 1.20, 2.88 ]
Subtotal (95% CI) 65 65 100.0 % 0.89 [ -1.41, 3.18 ]
Heterogeneity: Tau2 = 2.52; Chi2 = 12.36, df = 1 (P = 0.00044); I2 =92%
Test for overall effect: Z = 0.76 (P = 0.45)
5 NORS total
vs RPD - He 1999 20 28.9 (7.8) 19 27.1 (5.9) 100.0 % 1.80 [ -2.53, 6.13 ]
Subtotal (95% CI) 20 19 100.0 % 1.80 [ -2.53, 6.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
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(. . . Continued)
Study or subgroup Chlorpromazine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
6 PANSS total
vs RPD - Cui 2001 30 42.47 (13.79) 30 49.3 (19.15) 12.5 % -6.83 [ -15.27, 1.61 ]
vs RPD - Feng 2003 30 48.79 (9.02) 30 44.82 (8.85) 24.3 % 3.97 [ -0.55, 8.49 ]
vs RPD - Lin 2005 35 53.83 (10) 35 59.06 (18.59) 15.9 % -5.23 [ -12.22, 1.76 ]
vs RPD - Luo 2001 52 48 (14) 55 51 (19) 17.9 % -3.00 [ -9.30, 3.30 ]
vs RPD - Wu 2004 50 38.93 (7.67) 50 41.26 (9.37) 29.3 % -2.33 [ -5.69, 1.03 ]
Subtotal (95% CI) 197 200 100.0 % -1.95 [ -5.58, 1.69 ]
Heterogeneity: Tau2 = 8.80; Chi2 = 8.70, df = 4 (P = 0.07); I2 =54%
Test for overall effect: Z = 1.05 (P = 0.29)
7 PANSS positive symptom subscale
vs RPD - Feng 2003 30 15.28 (3.53) 30 14.06 (4.71) 22.7 % 1.22 [ -0.89, 3.33 ]
vs RPD - Lin 2005 35 17.83 (2.64) 35 16 (4.34) 25.9 % 1.83 [ 0.15, 3.51 ]
vs RPD - Luo 2001 52 10 (5) 55 12 (6) 22.8 % -2.00 [ -4.09, 0.09 ]
vs RPD - Wu 2004 50 8.41 (2.94) 50 9.32 (3.84) 28.6 % -0.91 [ -2.25, 0.43 ]
Subtotal (95% CI) 167 170 100.0 % 0.03 [ -1.67, 1.74 ]
Heterogeneity: Tau2 = 2.18; Chi2 = 11.12, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.04 (P = 0.97)
8 PANSS negative symptom subscale
vs RPD - Feng 2003 30 12.09 (3.25) 30 9.74 (3.67) 33.5 % 2.35 [ 0.60, 4.10 ]
vs RPD - Lin 2005 35 18.5 (5.89) 35 10.5 (2.88) 32.7 % 8.00 [ 5.83, 10.17 ]
vs RPD - Wu 2004 50 9.61 (3.93) 50 10.34 (4.26) 33.8 % -0.73 [ -2.34, 0.88 ]
Subtotal (95% CI) 115 115 100.0 % 3.16 [ -1.57, 7.89 ]
Heterogeneity: Tau2 = 16.56; Chi2 = 40.11, df = 2 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.31 (P = 0.19)
9 PANSS general pathology subscale
vs RPD - Feng 2003 30 19.69 (5.73) 30 20.92 (6.64) 17.3 % -1.23 [ -4.37, 1.91 ]
vs RPD - Luo 2001 52 24 (6) 55 25 (9) 20.5 % -1.00 [ -3.88, 1.88 ]
vs RPD - Wu 2004 50 20.91 (4.32) 50 21.6 (4.11) 62.3 % -0.69 [ -2.34, 0.96 ]
Subtotal (95% CI) 132 135 100.0 % -0.85 [ -2.15, 0.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
10 SANS total
vs RPD - He 1999 20 30.1 (10.2) 19 27.3 (12.1) 48.5 % 2.80 [ -4.24, 9.84 ]
vs RPD - Liu 2000 15 52.9 (7.1) 17 34.4 (5.8) 51.5 % 18.50 [ 13.97, 23.03 ]
Subtotal (95% CI) 35 36 100.0 % 10.89 [ -4.49, 26.27 ]
Heterogeneity: Tau2 = 114.12; Chi2 = 13.51, df = 1 (P = 0.00024); I2 =93%
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(. . . Continued)
Study or subgroup Chlorpromazine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Chi2 = 8.16, df = 9 (P = 0.52), I2 =0.0%
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Analysis 2.5. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 5 Mental state: 1b.
Average endpoint score (various scales, high = poor) - skewed data - short term (up to 6 months).
Mental state: 1b. Average endpoint score (various scales, high = poor) - skewed data - short term (up to 6 months)
Study Intervention mean SD N
BPRS thinking disorder subscale BPRS thinking
vs RPD - Wu 2002 Chlorpromazine 7.96 4.25 35
vs RPD - Wu 2002 Risperidone 5.13 1.89 35
BPRS withdraw-retardation subscale BPRS withdraw
vs RPD - Cui 2001 Chlorpromazine 5.73 2.21 30
vs RPD - Cui 2001 Risperidone 6.43 3.24 30
vs RPD - Wu 2002 Chlorpromazine 7.88 3.12 35
vs RPD - Wu 2002 Risperidone 5.02 2.87 35
PANSS general pathology subscale PANSS general p
vs RPD - Cui 2001 Chlorpromazine 21.17 6.31 30
vs RPD - Cui 2001 Risperidone 24.47 9.51 30
PANSS negative symptom subscale PANSS negative
vs RPD - Cui 2001 Chlorpromazine 9.5 3.53 30
vs RPD - Cui 2001 Risperidone 12.63 7.39 30
vs RPD - Luo 2001 Chlorpromazine 14 6 52
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Mental state: 1b. Average endpoint score (various scales, high = poor) - skewed data - short term (up to 6 months) (Continued)
vs RPD - Luo 2001 Risperidone 14 8 55
PANSS positive symptom subscale PANSS positive
vs RPD - Cui 2001 Chlorpromazine 11.67 13.6 30
vs RPD - Cui 2001 Risperidone 11.6 4.67 30
SAPS total SAPS total
vs RPD - He 1999 Chlorpromazine 12.7 5.9 20
vs RPD - He 1999 Risperidone 13.9 7.8 19
Analysis 2.6. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 6 Mental state: 2.
Average change score - decreased rate (various scales, high = poor) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 6 Mental state: 2. Average change score - decreased rate (various scales, high = poor) - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PANSS total
vs RPD - Wang 2002 20 0.66 (0.22) 37 0.77 (0.2) 100.0 % -0.11 [ -0.23, 0.01 ]
Subtotal (95% CI) 20 37 100.0 % -0.11 [ -0.23, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
2 PANSS negative subscale
vs RPD - Wang 2002 20 0.58 (0.35) 37 0.79 (0.54) 100.0 % -0.21 [ -0.44, 0.02 ]
Subtotal (95% CI) 20 37 100.0 % -0.21 [ -0.44, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
3 PANSS positive subscale
vs RPD - Wang 2002 20 0.66 (0.25) 37 0.73 (0.84) 100.0 % -0.07 [ -0.36, 0.22 ]
Subtotal (95% CI) 20 37 100.0 % -0.07 [ -0.36, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 0.72, df = 2 (P = 0.70), I2 =0.0%
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Analysis 2.7. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 7 Functioning: 1.
Average endpoint score (WCST subscales, high = good) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 7 Functioning: 1. Average endpoint score (WCST subscales, high = good) - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 WCST-IQ
vs RPD - Wang 2005 50 81.5 (18.3) 50 92.8 (17.6) 100.0 % -11.30 [ -18.34, -4.26 ]
Subtotal (95% CI) 50 50 100.0 % -11.30 [ -18.34, -4.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P = 0.0016)
2 WCST-MQ
vs RPD - Wang 2005 50 56.2 (25) 50 75.8 (22) 100.0 % -19.60 [ -28.83, -10.37 ]
Subtotal (95% CI) 50 50 100.0 % -19.60 [ -28.83, -10.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.16 (P = 0.000032)
Test for subgroup differences: Chi2 = 1.96, df = 1 (P = 0.16), I2 =49%
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Analysis 2.8. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 8 Adverse effects: 1.
Anticholinergic - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 8 Adverse effects: 1. Anticholinergic - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 blurred vision
vs OLZ - He 2003 8/40 2/40 16.0 % 4.00 [ 0.90, 17.68 ]
vs OLZ - Wu 2008 9/50 2/50 16.1 % 4.50 [ 1.02, 19.79 ]
vs RPD - Ma 2004 8/39 1/39 8.8 % 8.00 [ 1.05, 60.97 ]
vs RPD - Wang 2002 2/20 3/39 12.3 % 1.30 [ 0.24, 7.16 ]
vs RPD - Wu 2002 11/35 7/35 46.7 % 1.57 [ 0.69, 3.58 ]
Subtotal (95% CI) 184 203 100.0 % 2.44 [ 1.32, 4.50 ]
Total events: 38 (Chlorpromazine), 15 (Risperidone)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.25, df = 4 (P = 0.37); I2 =6%
Test for overall effect: Z = 2.86 (P = 0.0043)
2 dry mouth
vs OLZ - Chang 2003 1/27 7/31 8.3 % 0.16 [ 0.02, 1.25 ]
vs OLZ - He 2003 26/40 5/40 14.5 % 5.20 [ 2.22, 12.18 ]
vs OLZ - Wang 2008 1/119 7/118 8.1 % 0.14 [ 0.02, 1.13 ]
vs OLZ - Wu 2008 8/50 2/50 10.9 % 4.00 [ 0.89, 17.91 ]
vs RPD - Lin 2005 10/35 2/35 11.2 % 5.00 [ 1.18, 21.19 ]
vs RPD - Ma 2004 6/39 3/39 11.9 % 2.00 [ 0.54, 7.43 ]
vs RPD - Wang 2002 0/20 6/39 5.6 % 0.15 [ 0.01, 2.48 ]
vs RPD - Wu 2002 16/35 5/35 14.3 % 3.20 [ 1.32, 7.78 ]
vs RPD - Wu 2004 41/50 6/50 15.0 % 6.83 [ 3.19, 14.64 ]
Subtotal (95% CI) 415 437 100.0 % 2.00 [ 0.88, 4.51 ]
Total events: 109 (Chlorpromazine), 43 (Risperidone)
Heterogeneity: Tau2 = 1.00; Chi2 = 28.49, df = 8 (P = 0.00039); I2 =72%
Test for overall effect: Z = 1.66 (P = 0.096)
3 excessive sweating
vs OLZ - He 2003 3/40 1/40 50.2 % 3.00 [ 0.33, 27.63 ]
vs OLZ - Wu 2008 3/50 1/50 49.8 % 3.00 [ 0.32, 27.87 ]
Subtotal (95% CI) 90 90 100.0 % 3.00 [ 0.62, 14.46 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 6 (Chlorpromazine), 2 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
4 hypersalivation
vs OLZ - Chen 2006 23/44 2/42 35.7 % 10.98 [ 2.76, 43.71 ]
vs OLZ - He 2003 22/40 2/40 35.8 % 11.00 [ 2.77, 43.71 ]
vs RPD - Lin 2005 1/35 0/35 6.8 % 3.00 [ 0.13, 71.22 ]
vs RPD - Ma 2004 2/39 0/39 7.6 % 5.00 [ 0.25, 100.89 ]
vs RPD - Wang 2002 3/20 1/39 14.1 % 5.85 [ 0.65, 52.69 ]
Subtotal (95% CI) 178 195 100.0 % 8.67 [ 3.80, 19.80 ]
Total events: 51 (Chlorpromazine), 5 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 4 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.13 (P < 0.00001)
5 stuffy nose
vs OLZ - He 2003 12/40 4/40 100.0 % 3.00 [ 1.06, 8.52 ]
Subtotal (95% CI) 40 40 100.0 % 3.00 [ 1.06, 8.52 ]
Total events: 12 (Chlorpromazine), 4 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Chi2 = 7.66, df = 4 (P = 0.10), I2 =48%
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Analysis 2.9. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 9 Adverse effects: 2a.
Cardiovascular - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 9 Adverse effects: 2a. Cardiovascular - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 abnormal ECG
vs RPD - Cui 2001 2/35 1/35 15.4 % 2.00 [ 0.19, 21.06 ]
vs RPD - Wang 2002 2/20 1/39 15.6 % 3.90 [ 0.38, 40.45 ]
vs RPD - Wu 2004 9/50 4/50 69.1 % 2.25 [ 0.74, 6.83 ]
Subtotal (95% CI) 105 124 100.0 % 2.41 [ 0.96, 6.06 ]
Total events: 13 (Chlorpromazine), 6 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
2 apathism
vs RPD - Wu 2004 25/50 4/50 100.0 % 6.25 [ 2.35, 16.65 ]
Subtotal (95% CI) 50 50 100.0 % 6.25 [ 2.35, 16.65 ]
Total events: 25 (Chlorpromazine), 4 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 3.67 (P = 0.00025)
3 blood pressure drop
vs OLZ - He 2003 3/40 0/40 15.5 % 7.00 [ 0.37, 131.28 ]
vs OLZ - Wu 2008 5/50 0/50 16.1 % 11.00 [ 0.62, 193.80 ]
vs RPD - Wu 2002 16/35 2/35 68.4 % 8.00 [ 1.99, 32.23 ]
Subtotal (95% CI) 125 125 100.0 % 8.25 [ 2.61, 26.12 ]
Total events: 24 (Chlorpromazine), 2 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00033)
4 bradycardia
vs RPD - Wu 2004 1/50 2/50 100.0 % 0.50 [ 0.05, 5.34 ]
Subtotal (95% CI) 50 50 100.0 % 0.50 [ 0.05, 5.34 ]
Total events: 1 (Chlorpromazine), 2 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
5 orthostatic hypotension
vs OLZ - Chang 2003 6/27 0/31 10.6 % 14.86 [ 0.88, 252.11 ]
vs OLZ - Chen 2006 2/44 0/42 9.4 % 4.78 [ 0.24, 96.68 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs OLZ - Wang 2008 7/119 0/118 10.5 % 14.88 [ 0.86, 257.53 ]
vs RPD - Feng 2003 2/33 0/32 9.5 % 4.85 [ 0.24, 97.31 ]
vs RPD - Wu 2004 13/50 3/50 60.0 % 4.33 [ 1.31, 14.28 ]
Subtotal (95% CI) 273 273 100.0 % 5.74 [ 2.28, 14.44 ]
Total events: 30 (Chlorpromazine), 3 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.17, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
6 palpitation
vs OLZ - Wang 2008 20/119 0/118 100.0 % 40.66 [ 2.49, 664.56 ]
Subtotal (95% CI) 119 118 100.0 % 40.66 [ 2.49, 664.56 ]
Total events: 20 (Chlorpromazine), 0 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0093)
7 sinus tachycardia
vs RPD - Zheng 2001 3/25 1/26 100.0 % 3.12 [ 0.35, 28.03 ]
Subtotal (95% CI) 25 26 100.0 % 3.12 [ 0.35, 28.03 ]
Total events: 3 (Chlorpromazine), 1 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
8 tachycardia
vs OLZ - He 2003 4/40 2/40 8.4 % 2.00 [ 0.39, 10.31 ]
vs OLZ - Wu 2008 7/50 3/50 13.6 % 2.33 [ 0.64, 8.51 ]
vs RPD - Lin 2005 6/35 0/35 2.8 % 13.00 [ 0.76, 222.31 ]
vs RPD - Ma 2004 3/39 2/39 7.6 % 1.50 [ 0.27, 8.49 ]
vs RPD - Wang 2002 4/20 0/39 2.8 % 17.14 [ 0.97, 303.44 ]
vs RPD - Wu 2002 18/35 6/35 35.8 % 3.00 [ 1.35, 6.65 ]
vs RPD - Wu 2004 13/50 6/50 29.0 % 2.17 [ 0.89, 5.25 ]
Subtotal (95% CI) 269 288 100.0 % 2.64 [ 1.64, 4.26 ]
Total events: 55 (Chlorpromazine), 19 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.82, df = 6 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 4.00 (P = 0.000063)
Test for subgroup differences: Chi2 = 12.09, df = 7 (P = 0.10), I2 =42%
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Analysis 2.10. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 10 Adverse effects: 2b.
Cardiovascular - continuous measures - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 10 Adverse effects: 2b. Cardiovascular - continuous measures - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 cardiac rate (upright position)
vs RPD - Liu 2005 50 96.74 (14.65) 50 92.84 (13.22) 100.0 % 3.90 [ -1.57, 9.37 ]
Subtotal (95% CI) 50 50 100.0 % 3.90 [ -1.57, 9.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 cardiac rate (horizontal position)
vs RPD - Liu 2005 50 85.36 (13.19) 50 77.94 (5.37) 100.0 % 7.42 [ 3.47, 11.37 ]
Subtotal (95% CI) 50 50 100.0 % 7.42 [ 3.47, 11.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00023)
3 contractive blood pressure (upright position)
vs RPD - Liu 2005 50 12.65 (3.24) 50 13.71 (2.52) 100.0 % -1.06 [ -2.20, 0.08 ]
Subtotal (95% CI) 50 50 100.0 % -1.06 [ -2.20, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
4 contractive blood pressure (horizontal position)
vs RPD - Liu 2005 50 15.52 (1.93) 50 14.14 (2.01) 100.0 % 1.38 [ 0.61, 2.15 ]
Subtotal (95% CI) 50 50 100.0 % 1.38 [ 0.61, 2.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.50 (P = 0.00046)
5 diastolic blood pressure (upright position)
vs RPD - Liu 2005 50 8.68 (1.69) 50 9.21 (2.14) 100.0 % -0.53 [ -1.29, 0.23 ]
Subtotal (95% CI) 50 50 100.0 % -0.53 [ -1.29, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
6 diastolic blood pressure (horizontal position)
vs RPD - Liu 2005 50 10.06 (1.52) 50 9.67 (1.36) 100.0 % 0.39 [ -0.18, 0.96 ]
Subtotal (95% CI) 50 50 100.0 % 0.39 [ -0.18, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 31.88, df = 5 (P = 0.00), I2 =84%
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Analysis 2.11. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 11 Adverse effects: 3.
Central nervous system - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 11 Adverse effects: 3. Central nervous system - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 agitation
vs RPD - Feng 2003 0/33 1/32 3.6 % 0.31 [ 0.01, 7.98 ]
Subtotal (95% CI) 33 32 3.6 % 0.31 [ 0.01, 7.98 ]
Total events: 0 (Chlorpromazine), 1 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2 dizziness
vs RPD - Lin 2005 8/35 3/35 7.5 % 3.16 [ 0.76, 13.11 ]
vs RPD - Wang 2002 0/20 2/39 3.8 % 0.37 [ 0.02, 7.99 ]
vs RPD - Wu 2002 15/35 3/35 7.7 % 8.00 [ 2.05, 31.16 ]
vs RPD - Wu 2004 28/50 14/50 9.1 % 3.27 [ 1.42, 7.52 ]
Subtotal (95% CI) 140 159 28.1 % 3.57 [ 1.75, 7.30 ]
Total events: 51 (Chlorpromazine), 22 (Risperidone)
Heterogeneity: Tau2 = 0.09; Chi2 = 3.52, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 3.49 (P = 0.00048)
3 drowsiness
vs RPD - Lin 2005 7/35 2/35 6.9 % 4.13 [ 0.79, 21.48 ]
vs RPD - Ma 2004 5/39 3/39 7.3 % 1.76 [ 0.39, 7.96 ]
vs RPD - Wang 2002 5/20 4/39 7.4 % 2.92 [ 0.69, 12.40 ]
vs RPD - Wu 2004 30/50 3/50 7.9 % 23.50 [ 6.42, 85.97 ]
Subtotal (95% CI) 144 163 29.5 % 4.93 [ 1.49, 16.32 ]
Total events: 47 (Chlorpromazine), 12 (Risperidone)
Heterogeneity: Tau2 = 0.93; Chi2 = 7.97, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 2.61 (P = 0.0090)
4 fatigue
vs RPD - Wu 2004 43/50 16/50 8.7 % 13.05 [ 4.82, 35.33 ]
Subtotal (95% CI) 50 50 8.7 % 13.05 [ 4.82, 35.33 ]
Total events: 43 (Chlorpromazine), 16 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 5.06 (P < 0.00001)
5 insomnia
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(. . . Continued)
Study or subgroup Chlorpromazine Risperidone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs RPD - Feng 2003 0/33 8/32 4.1 % 0.04 [ 0.00, 0.78 ]
vs RPD - Lin 2005 1/35 3/35 5.3 % 0.31 [ 0.03, 3.17 ]
vs RPD - Ma 2004 2/39 1/39 5.0 % 2.05 [ 0.18, 23.63 ]
vs RPD - Wang 2002 0/20 6/39 4.1 % 0.13 [ 0.01, 2.35 ]
vs RPD - Wu 2002 2/35 6/35 6.8 % 0.29 [ 0.05, 1.57 ]
Subtotal (95% CI) 162 180 25.2 % 0.29 [ 0.10, 0.90 ]
Total events: 5 (Chlorpromazine), 24 (Risperidone)
Heterogeneity: Tau2 = 0.22; Chi2 = 4.59, df = 4 (P = 0.33); I2 =13%
Test for overall effect: Z = 2.15 (P = 0.032)
6 reduced activity
vs RPD - Ma 2004 2/39 1/39 5.0 % 2.05 [ 0.18, 23.63 ]
Subtotal (95% CI) 39 39 5.0 % 2.05 [ 0.18, 23.63 ]
Total events: 2 (Chlorpromazine), 1 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 568 623 100.0 % 1.96 [ 0.92, 4.22 ]
Total events: 148 (Chlorpromazine), 76 (Risperidone)
Heterogeneity: Tau2 = 1.49; Chi2 = 49.19, df = 15 (P = 0.00002); I2 =70%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Chi2 = 27.83, df = 5 (P = 0.00), I2 =82%
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Analysis 2.12. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 12 Adverse effects: 4.
Gastrointestinal - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 12 Adverse effects: 4. Gastrointestinal - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 constipation
vs OLZ - Chang 2003 12/27 1/31 3.6 % 13.78 [ 1.91, 99.16 ]
vs OLZ - Chen 2006 10/44 4/42 10.9 % 2.39 [ 0.81, 7.02 ]
vs OLZ - He 2003 16/40 5/40 14.9 % 3.20 [ 1.30, 7.90 ]
vs OLZ - Wang 2008 14/119 2/118 6.3 % 6.94 [ 1.61, 29.87 ]
vs OLZ - Wu 2008 18/50 4/50 12.3 % 4.50 [ 1.64, 12.36 ]
vs RPD - Ma 2004 2/39 2/39 3.8 % 1.00 [ 0.15, 6.75 ]
vs RPD - Wang 2002 0/20 3/39 1.7 % 0.27 [ 0.01, 5.02 ]
vs RPD - Wu 2002 10/35 3/35 9.0 % 3.33 [ 1.00, 11.09 ]
vs RPD - Wu 2004 35/50 14/50 37.7 % 2.50 [ 1.55, 4.04 ]
Subtotal (95% CI) 424 444 100.0 % 3.00 [ 2.05, 4.39 ]
Total events: 117 (Chlorpromazine), 38 (Risperidone)
Heterogeneity: Tau2 = 0.04; Chi2 = 9.01, df = 8 (P = 0.34); I2 =11%
Test for overall effect: Z = 5.68 (P < 0.00001)
2 diarrhoea
vs OLZ - He 2003 2/40 0/40 100.0 % 5.00 [ 0.25, 100.97 ]
Subtotal (95% CI) 40 40 100.0 % 5.00 [ 0.25, 100.97 ]
Total events: 2 (Chlorpromazine), 0 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
3 dysphagia
vs RPD - Wu 2004 11/50 3/50 100.0 % 3.67 [ 1.09, 12.36 ]
Subtotal (95% CI) 50 50 100.0 % 3.67 [ 1.09, 12.36 ]
Total events: 11 (Chlorpromazine), 3 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
4 loss of appetite
vs OLZ - He 2003 28/40 4/40 67.3 % 7.00 [ 2.70, 18.13 ]
vs OLZ - Wu 2008 28/50 1/50 32.7 % 28.00 [ 3.96, 197.94 ]
Subtotal (95% CI) 90 90 100.0 % 11.01 [ 2.82, 42.94 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 56 (Chlorpromazine), 5 (Risperidone)
Heterogeneity: Tau2 = 0.48; Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 3.45 (P = 0.00055)
5 nausea/vomiting
vs OLZ - He 2003 4/40 2/40 24.7 % 2.00 [ 0.39, 10.31 ]
vs OLZ - Wu 2008 2/50 2/50 18.0 % 1.00 [ 0.15, 6.82 ]
vs RPD - Wu 2002 1/35 5/35 15.1 % 0.20 [ 0.02, 1.63 ]
vs RPD - Wu 2004 4/50 5/50 42.2 % 0.80 [ 0.23, 2.81 ]
Subtotal (95% CI) 175 175 100.0 % 0.85 [ 0.37, 1.91 ]
Total events: 11 (Chlorpromazine), 14 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.95, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 12.58, df = 4 (P = 0.01), I2 =68%
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Analysis 2.13. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 13 Adverse effects: 5.
Haematology - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 13 Adverse effects: 5. Haematology - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 abnormal haemogram
vs OLZ - He 2003 4/40 1/40 39.6 % 4.00 [ 0.47, 34.24 ]
vs OLZ - Wu 2008 4/50 1/50 39.2 % 4.00 [ 0.46, 34.54 ]
Subtotal (95% CI) 90 90 78.8 % 4.00 [ 0.87, 18.31 ]
Total events: 8 (Chlorpromazine), 2 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.074)
2 leukopenia
vs OLZ - Chen 2006 3/44 0/42 21.2 % 6.69 [ 0.36, 125.71 ]
Subtotal (95% CI) 44 42 21.2 % 6.69 [ 0.36, 125.71 ]
Total events: 3 (Chlorpromazine), 0 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 134 132 100.0 % 4.46 [ 1.16, 17.22 ]
Total events: 11 (Chlorpromazine), 2 (Risperidone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 2.14. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 14 Adverse effects: 6.
Hepatitic - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 14 Adverse effects: 6. Hepatitic - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 abnormal liver function
vs RPD - Ma 2004 2/39 0/39 22.2 % 5.00 [ 0.25, 100.89 ]
Subtotal (95% CI) 39 39 22.2 % 5.00 [ 0.25, 100.89 ]
Total events: 2 (Chlorpromazine), 0 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 abnormal transaminase
vs OLZ - Chen 2006 0/44 7/42 23.5 % 0.06 [ 0.00, 1.08 ]
vs RPD - Feng 2003 5/33 0/32 23.3 % 10.68 [ 0.61, 185.53 ]
vs RPD - Ma 2004 2/39 2/39 31.0 % 1.00 [ 0.15, 6.75 ]
Subtotal (95% CI) 116 113 77.8 % 0.88 [ 0.07, 11.58 ]
Total events: 7 (Chlorpromazine), 9 (Risperidone)
Heterogeneity: Tau2 = 3.51; Chi2 = 6.30, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 155 152 100.0 % 1.30 [ 0.17, 10.09 ]
Total events: 9 (Chlorpromazine), 9 (Risperidone)
Heterogeneity: Tau2 = 2.57; Chi2 = 7.40, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
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Analysis 2.15. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 15 Adverse effects: 7.
Metabolic - weight gain.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 15 Adverse effects: 7. Metabolic - weight gain
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (up to 6 months)
vs RPD - Feng 2003 0/33 7/32 9.4 % 0.06 [ 0.00, 1.09 ]
vs RPD - Ma 2004 8/39 3/39 26.8 % 2.67 [ 0.76, 9.31 ]
vs RPD - Wang 2002 2/20 3/39 19.3 % 1.30 [ 0.24, 7.16 ]
vs RPD - Wu 2004 32/50 18/50 44.4 % 1.78 [ 1.16, 2.72 ]
Total (95% CI) 142 160 100.0 % 1.36 [ 0.52, 3.59 ]
Total events: 42 (Chlorpromazine), 31 (Risperidone)
Heterogeneity: Tau2 = 0.50; Chi2 = 6.75, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 16 Adverse effects: 8.
Movement disorders - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 16 Adverse effects: 8. Movement disorders - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 akathisia
vs RPD - Chang 1998 7/20 3/38 12.9 % 4.43 [ 1.28, 15.31 ]
vs RPD - Lin 2005 12/35 4/35 17.4 % 3.00 [ 1.07, 8.40 ]
vs RPD - Ma 2004 4/39 1/39 4.8 % 4.00 [ 0.47, 34.20 ]
vs RPD - Wang 2002 0/20 4/39 2.8 % 0.21 [ 0.01, 3.75 ]
vs RPD - Wu 2002 13/35 9/35 29.4 % 1.44 [ 0.71, 2.94 ]
vs RPD - Wu 2004 26/50 9/50 32.8 % 2.89 [ 1.51, 5.53 ]
Subtotal (95% CI) 199 236 100.0 % 2.37 [ 1.46, 3.85 ]
Total events: 62 (Chlorpromazine), 30 (Risperidone)
Heterogeneity: Tau2 = 0.08; Chi2 = 6.36, df = 5 (P = 0.27); I2 =21%
Test for overall effect: Z = 3.48 (P = 0.00051)
2 any EPS symptoms
vs RPD - Feng 2003 0/33 4/32 5.4 % 0.11 [ 0.01, 1.93 ]
vs RPD - Lin 2005 20/35 11/35 47.1 % 1.82 [ 1.03, 3.21 ]
vs RPD - Wang 2005 26/50 12/50 47.5 % 2.17 [ 1.24, 3.80 ]
Subtotal (95% CI) 118 117 100.0 % 1.70 [ 0.85, 3.40 ]
Total events: 46 (Chlorpromazine), 27 (Risperidone)
Heterogeneity: Tau2 = 0.18; Chi2 = 4.33, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 1.49 (P = 0.13)
3 dystonia
vs RPD - Chang 1998 6/20 4/38 18.3 % 2.85 [ 0.91, 8.94 ]
vs RPD - Wu 2002 11/35 10/35 43.1 % 1.10 [ 0.54, 2.25 ]
vs RPD - Wu 2004 15/50 8/50 38.6 % 1.88 [ 0.87, 4.02 ]
Subtotal (95% CI) 105 123 100.0 % 1.61 [ 0.97, 2.66 ]
Total events: 32 (Chlorpromazine), 22 (Risperidone)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.20, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 1.85 (P = 0.064)
4 muscle stiffness
vs RPD - Chang 1998 8/20 2/38 24.8 % 7.60 [ 1.78, 32.46 ]
vs RPD - Lin 2005 16/35 6/35 33.6 % 2.67 [ 1.18, 6.01 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs RPD - Ma 2004 4/39 0/39 11.6 % 9.00 [ 0.50, 161.73 ]
vs RPD - Wang 2002 1/20 8/39 18.4 % 0.24 [ 0.03, 1.82 ]
vs RPD - Wu 2002 4/35 0/35 11.6 % 9.00 [ 0.50, 161.13 ]
Subtotal (95% CI) 149 186 100.0 % 2.96 [ 0.92, 9.49 ]
Total events: 33 (Chlorpromazine), 16 (Risperidone)
Heterogeneity: Tau2 = 0.88; Chi2 = 8.82, df = 4 (P = 0.07); I2 =55%
Test for overall effect: Z = 1.82 (P = 0.069)
5 torsion movements
vs RPD - Ma 2004 4/39 0/39 100.0 % 9.00 [ 0.50, 161.73 ]
Subtotal (95% CI) 39 39 100.0 % 9.00 [ 0.50, 161.73 ]
Total events: 4 (Chlorpromazine), 0 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
6 tremor
vs RPD - Chang 1998 7/20 4/38 11.5 % 3.33 [ 1.10, 10.02 ]
vs RPD - Lin 2005 10/35 3/35 9.7 % 3.33 [ 1.00, 11.09 ]
vs RPD - Ma 2004 11/39 3/39 9.8 % 3.67 [ 1.11, 12.14 ]
vs RPD - Wang 2002 0/20 3/39 1.7 % 0.27 [ 0.01, 5.02 ]
vs RPD - Wu 2002 21/35 13/35 48.8 % 1.62 [ 0.97, 2.69 ]
vs RPD - Wu 2004 15/50 6/50 18.5 % 2.50 [ 1.06, 5.92 ]
Subtotal (95% CI) 199 236 100.0 % 2.15 [ 1.47, 3.14 ]
Total events: 64 (Chlorpromazine), 32 (Risperidone)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.19, df = 5 (P = 0.39); I2 =4%
Test for overall effect: Z = 3.94 (P = 0.000080)
Test for subgroup differences: Chi2 = 2.95, df = 5 (P = 0.71), I2 =0.0%
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Analysis 2.17. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 17 Adverse events: 9.
Average endpoint score (TESS) - skewed data.
Adverse events: 9. Average endpoint score (TESS) - skewed data
Study Intervention mean SD N
short term (up to 6 months) short term (up t
vs RPD - Cui 2001 Chlorpromazine 3.23 2.87 30
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Adverse events: 9. Average endpoint score (TESS) - skewed data (Continued)
vs RPD - Cui 2001 Risperidone 3.93 5.78 30
vs RPD - He 1999 Chlorpromazine 2.9 2.1 20
vs RPD - He 1999 Risperidone 2.3 2.4 19
vs RPD - Liu 2005 Chlorpromazine 2.58 2.93 50
vs RPD - Liu 2005 Risperidone 1.46 1.58 50
Analysis 2.18. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 18 Adverse effects: 10.
Various other - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 18 Adverse effects: 10. Various other - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 concentration (poor)
vs RPD - Wu 2004 39/50 20/50 100.0 % 1.95 [ 1.35, 2.82 ]
Subtotal (95% CI) 50 50 100.0 % 1.95 [ 1.35, 2.82 ]
Total events: 39 (Chlorpromazine), 20 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 3.54 (P = 0.00040)
2 memory deterioration
vs RPD - Wu 2004 39/50 20/50 100.0 % 1.95 [ 1.35, 2.82 ]
Subtotal (95% CI) 50 50 100.0 % 1.95 [ 1.35, 2.82 ]
Total events: 39 (Chlorpromazine), 20 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 3.54 (P = 0.00040)
3 sexual dysfunction
vs RPD - Wu 2004 28/50 11/50 100.0 % 2.55 [ 1.43, 4.53 ]
Subtotal (95% CI) 50 50 100.0 % 2.55 [ 1.43, 4.53 ]
Total events: 28 (Chlorpromazine), 11 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 3.17 (P = 0.0015)
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(. . . Continued)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
4 unspeciﬁed
vs RPD - Wang 2005 33/50 24/50 100.0 % 1.38 [ 0.97, 1.95 ]
Subtotal (95% CI) 50 50 100.0 % 1.38 [ 0.97, 1.95 ]
Total events: 33 (Chlorpromazine), 24 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Chi2 = 4.01, df = 3 (P = 0.26), I2 =25%
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Analysis 2.19. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 19 Quality of life: 1.
Average endpoint score (QOL, high = good).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 19 Quality of life: 1. Average endpoint score (QOL, high = good)
Study or subgroup Chlorpromazine Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 6 months)
vs RPD - Wu 2004 50 59.04 (16.18) 50 73.24 (15.96) 100.0 % -14.20 [ -20.50, -7.90 ]
Subtotal (95% CI) 50 50 100.0 % -14.20 [ -20.50, -7.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.42 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 20 Leaving the study
early - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 2 CHLORPROMAZINE versus RISPERIDONE
Outcome: 20 Leaving the study early - short term (up to 6 months)
Study or subgroup Chlorpromazine Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 due to adverse events
vs RPD - He 1999 0/20 2/21 100.0 % 0.21 [ 0.01, 4.11 ]
Subtotal (95% CI) 20 21 100.0 % 0.21 [ 0.01, 4.11 ]
Total events: 0 (Chlorpromazine), 2 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 1 Clinical response: 1.
No significant clinical response.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 1 Clinical response: 1. No signiﬁcant clinical response
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 short term (up to 6 months)
vs QTP - Ai 2007 6/42 5/43 1.5 % 1.23 [ 0.41, 3.72 ]
vs QTP - Cai 2006 5/100 11/109 1.7 % 0.50 [ 0.18, 1.38 ]
vs QTP - Cai 2007 6/46 6/48 1.6 % 1.04 [ 0.36, 3.00 ]
vs QTP - Chen 2001 11/107 16/114 3.5 % 0.73 [ 0.36, 1.51 ]
vs QTP - Chen 2008 3/30 2/30 0.6 % 1.50 [ 0.27, 8.34 ]
vs QTP - Deng 2004 6/45 6/45 1.6 % 1.00 [ 0.35, 2.87 ]
vs QTP - Guo 2003a 8/73 8/75 2.1 % 1.03 [ 0.41, 2.59 ]
vs QTP - Guo 2005 4/40 4/40 1.0 % 1.00 [ 0.27, 3.72 ]
vs QTP - Guo 2008 13/40 11/43 3.9 % 1.27 [ 0.65, 2.50 ]
vs QTP - He 2003 2/20 2/20 0.5 % 1.00 [ 0.16, 6.42 ]
vs QTP - Jiang 2006 20/97 27/94 7.1 % 0.72 [ 0.43, 1.19 ]
vs QTP - Jiang 2008 6/30 5/30 1.6 % 1.20 [ 0.41, 3.51 ]
vs QTP - Jin 2007 4/30 5/30 1.2 % 0.80 [ 0.24, 2.69 ]
vs QTP - Liu 2003 3/39 3/44 0.8 % 1.13 [ 0.24, 5.27 ]
vs QTP - Mei 2007 5/49 4/47 1.2 % 1.20 [ 0.34, 4.19 ]
vs QTP - NCT00882518 64/190 82/194 27.0 % 0.80 [ 0.62, 1.03 ]
vs QTP - Peuskens 1997 48/100 36/101 16.4 % 1.35 [ 0.97, 1.88 ]
vs QTP - Tian 2006 4/46 6/46 1.3 % 0.67 [ 0.20, 2.21 ]
vs QTP - Wan 2002 3/30 4/30 0.9 % 0.75 [ 0.18, 3.07 ]
vs QTP - Wan 2008 5/28 4/32 1.2 % 1.43 [ 0.42, 4.81 ]
vs QTP - Wang 2004 12/48 14/48 4.2 % 0.86 [ 0.44, 1.66 ]
vs QTP - Wang 2005 12/57 14/48 4.0 % 0.72 [ 0.37, 1.41 ]
vs QTP - Yang 2007 3/30 3/30 0.8 % 1.00 [ 0.22, 4.56 ]
vs QTP - Zhang 2002 4/57 4/60 1.0 % 1.05 [ 0.28, 4.01 ]
vs QTP - Zhang 2003 22/118 27/119 7.2 % 0.82 [ 0.50, 1.36 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
vs QTP - Zhang 2008 3/30 2/30 0.6 % 1.50 [ 0.27, 8.34 ]
vs QTP - Zhou 2004 13/41 12/42 4.2 % 1.11 [ 0.58, 2.14 ]
vs QTP - Zou 2006 4/43 5/43 1.2 % 0.80 [ 0.23, 2.78 ]
Subtotal (95% CI) 1606 1635 100.0 % 0.93 [ 0.81, 1.06 ]
Total events: 299 (Chlorpromazine), 328 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.40, df = 27 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 2 Global state: 1. Need
of additional benzodiazepines/benzhexol.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 2 Global state: 1. Need of additional benzodiazepines/benzhexol
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (up to 6 months)
vs QTP - Cheng 2003 33/45 21/44 42.8 % 1.54 [ 1.08, 2.19 ]
vs QTP - Peuskens 1997 51/100 40/101 57.2 % 1.29 [ 0.95, 1.75 ]
Subtotal (95% CI) 145 145 100.0 % 1.39 [ 1.10, 1.75 ]
Total events: 84 (Chlorpromazine), 61 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0057)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 3 Global state: 2a.
Average endpoint scores (various scales, high = poor) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 3 Global state: 2a. Average endpoint scores (various scales, high = poor) - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CGI-SI
vs QTP - Cheng 2003 45 1.8 (0.8) 44 1.4 (0.9) 54.3 % 0.40 [ 0.05, 0.75 ]
vs QTP - Wang 2004 42 3.38 (1.53) 46 3.83 (1.34) 45.7 % -0.45 [ -1.05, 0.15 ]
Subtotal (95% CI) 87 90 100.0 % 0.01 [ -0.82, 0.84 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 5.67, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.03 (P = 0.98)
2 CGI-GI
vs QTP - Cheng 2003 45 1.6 (0.8) 44 1.7 (0.5) 64.8 % -0.10 [ -0.38, 0.18 ]
vs QTP - Guo 2007 26 2.3 (1.6) 26 2.3 (1.1) 8.9 % 0.0 [ -0.75, 0.75 ]
vs QTP - Wang 2004 42 2.57 (1.08) 46 2.75 (0.99) 26.3 % -0.18 [ -0.61, 0.25 ]
Subtotal (95% CI) 113 116 100.0 % -0.11 [ -0.33, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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Analysis 3.4. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 4 Global state: 2b.
Average endpoint score (CGI-SI, high = poor) - skewed data).
Global state: 2b. Average endpoint score (CGI-SI, high = poor) - skewed data)
Study Intervention Mean SD N
short term (up to 6 months) short term (up t
vs QTP - Guo 2007 Chlorpromazine 1.5 1.7 26
vs QTP - Guo 2007 Quetiapine 1.6 1.3 26
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Analysis 3.5. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 5 Global state: 3.
Average change scores (CGI-SI, high = poor).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 5 Global state: 3. Average change scores (CGI-SI, high = poor)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 6 months)
vs QTP - NCT00882518 190 -2.1 (0.11) 194 -1.8 (0.12) 100.0 % -0.30 [ -0.32, -0.28 ]
Subtotal (95% CI) 190 194 100.0 % -0.30 [ -0.32, -0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 25.55 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 6 Mental state: 1a.
Average endpoint scores (various scales, high = poor) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 6 Mental state: 1a. Average endpoint scores (various scales, high = poor) - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS total
vs QTP - Ai 2007 42 34.3 (7.6) 43 34.3 (7.6) 10.7 % 0.0 [ -3.23, 3.23 ]
vs QTP - Chen 2001 107 25.5 (8.2) 114 25.5 (7.6) 25.7 % 0.0 [ -2.09, 2.09 ]
vs QTP - Chen 2007 30 15.5 (3.1) 32 16.1 (3.4) 42.7 % -0.60 [ -2.22, 1.02 ]
vs QTP - Jiang 2008 30 28.35 (10.11) 30 26.56 (9.48) 4.5 % 1.79 [ -3.17, 6.75 ]
vs QTP - Wan 2008 28 29.61 (11.04) 32 27.56 (10.68) 3.7 % 2.05 [ -3.46, 7.56 ]
vs QTP - Yang 2007 30 27.69 (5.18) 30 28.3 (6.5) 12.7 % -0.61 [ -3.58, 2.36 ]
Subtotal (95% CI) 267 281 100.0 % -0.18 [ -1.23, 0.88 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.61, df = 5 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
2 BPRS anxiety-depression subscale
vs QTP - Yang 2007 30 5.1 (1.59) 30 5.37 (1.92) 100.0 % -0.27 [ -1.16, 0.62 ]
Subtotal (95% CI) 30 30 100.0 % -0.27 [ -1.16, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
3 BPRS activation subscale
vs QTP - Yang 2007 30 3.69 (1.04) 30 3.47 (0.86) 100.0 % 0.22 [ -0.26, 0.70 ]
Subtotal (95% CI) 30 30 100.0 % 0.22 [ -0.26, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
4 BPRS hostile-suspiciousness subscale
vs QTP - Yang 2007 30 6.21 (1.93) 30 6.3 (2.23) 100.0 % -0.09 [ -1.15, 0.97 ]
Subtotal (95% CI) 30 30 100.0 % -0.09 [ -1.15, 0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
5 BPRS thinking disorder subscale
vs QTP - Yang 2007 30 7.72 (2.33) 30 7.87 (2.58) 100.0 % -0.15 [ -1.39, 1.09 ]
Subtotal (95% CI) 30 30 100.0 % -0.15 [ -1.39, 1.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
6 BPRS withdraw-retardation subscale
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Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
vs QTP - Yang 2007 30 5.07 (1.5) 30 5.17 (1.05) 100.0 % -0.10 [ -0.76, 0.56 ]
Subtotal (95% CI) 30 30 100.0 % -0.10 [ -0.76, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
7 PANSS total
vs QTP - An 2005 30 57.68 (11.11) 30 55.67 (11) 4.2 % 2.01 [ -3.58, 7.60 ]
vs QTP - Cai 2007 46 24.8 (8.3) 48 45.7 (13.8) 4.5 % -20.90 [ -25.48, -16.32 ]
vs QTP - Chen 2001 107 48.1 (15.2) 114 48.5 (14.8) 4.8 % -0.40 [ -4.36, 3.56 ]
vs QTP - Chen 2007 30 34.6 (10.7) 32 34.1 (10.2) 4.3 % 0.50 [ -4.71, 5.71 ]
vs QTP - Chen 2008 30 42.8 (4.8) 30 44.3 (4.1) 5.3 % -1.50 [ -3.76, 0.76 ]
vs QTP - Cheng 2003 45 48.2 (15.1) 44 48 (15.2) 3.9 % 0.20 [ -6.10, 6.50 ]
vs QTP - Guo 2003a 73 46.72 (17.12) 75 47.32 (17.212) 4.2 % -0.60 [ -6.13, 4.93 ]
vs QTP - Guo 2003b 30 48.66 (8.9) 30 45.42 (8.8) 4.6 % 3.24 [ -1.24, 7.72 ]
vs QTP - Guo 2005 40 48.1 (15.2) 40 48.6 (13.8) 3.9 % -0.50 [ -6.86, 5.86 ]
vs QTP - Guo 2007 26 43.9 (12.3) 26 44.7 (12.2) 3.8 % -0.80 [ -7.46, 5.86 ]
vs QTP - Guo 2008 40 52.6 (16.4) 43 42.3 (17) 3.6 % 10.30 [ 3.11, 17.49 ]
vs QTP - He 2003 20 50 (12.9) 20 43.1 (10.2) 3.6 % 6.90 [ -0.31, 14.11 ]
vs QTP - Ji 2004 29 34.63 (10.7) 30 34.05 (10.17) 4.3 % 0.58 [ -4.75, 5.91 ]
vs QTP - Jiang 2008 30 39.24 (10.36) 30 37.21 (11.48) 4.2 % 2.03 [ -3.50, 7.56 ]
vs QTP - Liu 2003 39 40.2 (13.9) 44 41.4 (14.4) 4.0 % -1.20 [ -7.29, 4.89 ]
vs QTP - Mei 2007 49 52.9 (18.3) 47 53.2 (23.6) 3.1 % -0.30 [ -8.77, 8.17 ]
vs QTP - Sun 2006 36 47.55 (10.63) 35 46.67 (11.4) 4.3 % 0.88 [ -4.25, 6.01 ]
vs QTP - Tian 2006 46 47.6 (17.7) 46 45.2 (19.2) 3.4 % 2.40 [ -5.15, 9.95 ]
vs QTP - Wan 2002 30 48 (14.3) 30 54.2 (14.4) 3.5 % -6.20 [ -13.46, 1.06 ]
vs QTP - Wan 2008 28 40.13 (18.24) 32 38.57 (12.56) 3.3 % 1.56 [ -6.48, 9.60 ]
vs QTP - Wang 2004 42 58.67 (20.93) 46 61.63 (23.73) 2.9 % -2.96 [ -12.29, 6.37 ]
vs QTP - Wang 2005 57 53.1 (18.5) 48 53.7 (23.8) 3.2 % -0.60 [ -8.87, 7.67 ]
vs QTP - Zhang 2006 33 49.9 (7.02) 28 47.1 (7.06) 4.9 % 2.80 [ -0.75, 6.35 ]
vs QTP - Zhou 2004 39 53.15 (9.84) 40 51.47 (10.62) 4.6 % 1.68 [ -2.83, 6.19 ]
vs QTP - Zou 2006 43 49.9 (14.7) 43 47.8 (15.4) 3.9 % 2.10 [ -4.26, 8.46 ]
Subtotal (95% CI) 1018 1031 100.0 % -0.05 [ -2.30, 2.19 ]
Heterogeneity: Tau2 = 23.45; Chi2 = 102.88, df = 24 (P<0.00001); I2 =77%
Test for overall effect: Z = 0.05 (P = 0.96)
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Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
8 PANSS positive symptoms
vs QTP - An 2005 30 11.48 (4.45) 30 10.46 (4.89) 4.3 % 1.02 [ -1.35, 3.39 ]
vs QTP - Chen 2001 107 11.4 (5.4) 114 11.2 (4.9) 13.1 % 0.20 [ -1.16, 1.56 ]
vs QTP - Chen 2007 30 7.9 (3.3) 32 7.6 (3.2) 9.3 % 0.30 [ -1.32, 1.92 ]
vs QTP - Cheng 2003 45 11.1 (4.8) 44 11 (5) 5.9 % 0.10 [ -1.94, 2.14 ]
vs QTP - Guo 2003b 30 16.01 (3.38) 30 14.03 (4.72) 5.6 % 1.98 [ -0.10, 4.06 ]
vs QTP - Guo 2005 40 11.4 (5.4) 40 11.3 (5.3) 4.4 % 0.10 [ -2.24, 2.44 ]
vs QTP - Guo 2008 40 11.2 (3.2) 43 10.8 (2.3) 16.7 % 0.40 [ -0.81, 1.61 ]
vs QTP - Hu 2003 19 14.64 (4.37) 22 14.09 (6.25) 2.3 % 0.55 [ -2.72, 3.82 ]
vs QTP - Ji 2004 29 7.85 (3.32) 30 7.56 (3.24) 8.7 % 0.29 [ -1.38, 1.96 ]
vs QTP - Li 2003 37 13.5 (4.3) 40 11.7 (4.2) 6.7 % 1.80 [ -0.10, 3.70 ]
vs QTP - Tian 2006 46 11.6 (5) 46 11.4 (5) 5.8 % 0.20 [ -1.84, 2.24 ]
vs QTP - Zhang 2002 57 9.97 (3.52) 60 11.08 (4.25) 12.2 % -1.11 [ -2.52, 0.30 ]
vs QTP - Zhang 2006 33 13.8 (4.25) 28 12.47 (4.62) 4.8 % 1.33 [ -0.91, 3.57 ]
Subtotal (95% CI) 543 559 100.0 % 0.39 [ -0.11, 0.88 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.93, df = 12 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
9 PANSS negative symptoms
vs QTP - An 2005 30 22.03 (5.68) 30 21.81 (5.6) 4.8 % 0.22 [ -2.63, 3.07 ]
vs QTP - Chen 2001 107 12.2 (4.8) 114 13 (5.6) 7.4 % -0.80 [ -2.17, 0.57 ]
vs QTP - Chen 2007 30 8.4 (3.7) 32 9.4 (3.7) 6.5 % -1.00 [ -2.84, 0.84 ]
vs QTP - Cheng 2003 45 12.6 (5.3) 44 13.7 (6.2) 5.5 % -1.10 [ -3.50, 1.30 ]
vs QTP - Guo 2003b 30 11.98 (3.24) 30 9.73 (3.67) 6.7 % 2.25 [ 0.50, 4.00 ]
vs QTP - Guo 2005 40 18.5 (4.8) 40 13.2 (5.8) 5.6 % 5.30 [ 2.97, 7.63 ]
vs QTP - Guo 2007 26 10.7 (3.5) 26 9.1 (3.7) 6.3 % 1.60 [ -0.36, 3.56 ]
vs QTP - Guo 2008 40 12.1 (4.3) 43 8.1 (2.6) 7.1 % 4.00 [ 2.46, 5.54 ]
vs QTP - Hu 2003 19 14.71 (5.22) 22 14.72 (6.72) 3.7 % -0.01 [ -3.67, 3.65 ]
vs QTP - Ji 2004 29 8.36 (3.71) 30 9.36 (3.66) 6.5 % -1.00 [ -2.88, 0.88 ]
vs QTP - Sun 2006 36 10.41 (3.24) 35 9.43 (2.55) 7.4 % 0.98 [ -0.37, 2.33 ]
vs QTP - Tian 2006 46 14.5 (6) 46 12.4 (7) 5.1 % 2.10 [ -0.56, 4.76 ]
vs QTP - Wan 2002 30 15.4 (5.9) 30 17 (5.4) 4.8 % -1.60 [ -4.46, 1.26 ]
vs QTP - Wang 2005 57 12.6 (6.3) 48 11.9 (6.1) 5.6 % 0.70 [ -1.68, 3.08 ]
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Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
vs QTP - Zhang 2006 33 13.23 (3.37) 28 11.47 (4.37) 6.3 % 1.76 [ -0.23, 3.75 ]
vs QTP - Zhou 2004 39 15.55 (5.24) 40 13.78 (5.11) 5.7 % 1.77 [ -0.51, 4.05 ]
vs QTP - Zou 2006 43 13.6 (6.8) 43 11.5 (5.9) 5.1 % 2.10 [ -0.59, 4.79 ]
Subtotal (95% CI) 680 681 100.0 % 1.05 [ 0.13, 1.98 ]
Heterogeneity: Tau2 = 2.55; Chi2 = 54.37, df = 16 (P<0.00001); I2 =71%
Test for overall effect: Z = 2.23 (P = 0.026)
10 PANSS general pathology
vs QTP - An 2005 30 23.1 (4.23) 30 23.11 (3.4) 6.0 % -0.01 [ -1.95, 1.93 ]
vs QTP - Chen 2001 107 24.4 (7) 114 24.2 (6.7) 6.0 % 0.20 [ -1.61, 2.01 ]
vs QTP - Chen 2007 30 18.4 (4.6) 32 17.1 (4.6) 5.9 % 1.30 [ -0.99, 3.59 ]
vs QTP - Cheng 2003 45 24.5 (6.8) 44 23.3 (7) 5.6 % 1.20 [ -1.67, 4.07 ]
vs QTP - Guo 2003b 30 20.91 (6.62) 30 19.7 (5.72) 5.5 % 1.21 [ -1.92, 4.34 ]
vs QTP - Guo 2005 40 24.5 (6.2) 40 25.4 (7.6) 5.5 % -0.90 [ -3.94, 2.14 ]
vs QTP - He 2003 22 30.71 (7.14) 22 30.54 (6.18) 5.1 % 0.17 [ -3.78, 4.12 ]
vs QTP - Ji 2004 29 18.42 (4.57) 30 17.13 (4.56) 5.8 % 1.29 [ -1.04, 3.62 ]
vs QTP - Mei 2007 49 27 (8.2) 47 27.4 (11.4) 5.0 % -0.40 [ -4.39, 3.59 ]
vs QTP - Sun 2006 36 24.1 (3.42) 35 23.4 (5.86) 5.9 % 0.70 [ -1.54, 2.94 ]
vs QTP - Tian 2006 46 21.5 (6) 46 21.4 (5) 5.9 % 0.10 [ -2.16, 2.36 ]
vs QTP - Wan 2002 30 23.7 (6.2) 30 25.5 (6.7) 5.4 % -1.80 [ -5.07, 1.47 ]
vs QTP - Wang 2004 42 29.14 (9.79) 46 30 (9.79) 5.0 % -0.86 [ -4.96, 3.24 ]
vs QTP - Wang 2005 57 27.2 (8.4) 48 27.6 (11.6) 5.1 % -0.40 [ -4.34, 3.54 ]
vs QTP - Zhang 2002 57 24.63 (5.17) 60 26.34 (7.76) 5.8 % -1.71 [ -4.09, 0.67 ]
vs QTP - Zhang 2006 33 23.8 (4.1) 28 22.6 (4.08) 6.0 % 1.20 [ -0.86, 3.26 ]
vs QTP - Zhou 2004 39 27.45 (6.1) 40 51.47 (10.62) 5.1 % -24.02 [ -27.83, -20.21 ]
vs QTP - Zou 2006 43 23.8 (7.8) 43 23.2 (7.6) 5.4 % 0.60 [ -2.66, 3.86 ]
Subtotal (95% CI) 765 765 100.0 % -1.11 [ -3.06, 0.84 ]
Heterogeneity: Tau2 = 15.51; Chi2 = 160.66, df = 17 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.11 (P = 0.27)
11 HAMD total
vs QTP - Li 2010 31 12.9 (4.4) 32 5.5 (4.8) 100.0 % 7.40 [ 5.13, 9.67 ]
Subtotal (95% CI) 31 32 100.0 % 7.40 [ 5.13, 9.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.38 (P < 0.00001)
Test for subgroup differences: Chi2 = 46.97, df = 10 (P = 0.00), I2 =79%
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Analysis 3.7. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 7 Mental state: 1b.
Average endpoint scores (various scales, high = poor) - medium term (6 to 12 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 7 Mental state: 1b. Average endpoint scores (various scales, high = poor) - medium term (6 to 12 months)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PANSS total
vs QTP - Li 2003 37 58.7 (9.8) 4 53.8 (0.1) 100.0 % 4.90 [ 1.74, 8.06 ]
Subtotal (95% CI) 37 4 100.0 % 4.90 [ 1.74, 8.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.04 (P = 0.0024)
2 PANSS general pathology
vs QTP - Li 2003 37 22.1 (4.1) 4 22.3 (4) 100.0 % -0.20 [ -4.34, 3.94 ]
Subtotal (95% CI) 37 4 100.0 % -0.20 [ -4.34, 3.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.92)
3 PANSS negative symptoms
vs QTP - Li 2003 37 24.6 (4) 40 21.9 (6) 100.0 % 2.70 [ 0.44, 4.96 ]
Subtotal (95% CI) 37 40 100.0 % 2.70 [ 0.44, 4.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Chi2 = 3.72, df = 2 (P = 0.16), I2 =46%
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Analysis 3.8. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 8 Mental state: 1c.
Average endpoint scores (various scales, high = poor) -skewed data.
Mental state: 1c. Average endpoint scores (various scales, high = poor) -skewed data
Study Intervention Mean SD N
PANSS total - short term (up to 6 months) PANSS total - sh
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Mental state: 1c. Average endpoint scores (various scales, high = poor) -skewed data (Continued)
vs QTP - Zhang 2002 Chlorpromazine 28.39 16.57 57
vs QTP - Zhang 2002 Quetiapine 9.27 16.36 60
PANSS positive symptoms - short term (up to 6 months) PANSS positive
vs QTP - Guo 2003a Chlorpromazine 11.4 5.8 73
vs QTP - Guo 2003a Quetiapine 11.3 5.7 75
vs QTP - Guo 2007 Chlorpromazine 9.9 5.5 26
vs QTP - Guo 2007 Quetiapine 10.9 6.4 26
vs QTP - Mei 2007 Chlorpromazine 11.9 6.2 49
vs QTP - Mei 2007 Quetiapine 14.0 8.2 47
vs QTP - Sun 2006 Chlorpromazine 9.46 4.55 36
vs QTP - Sun 2006 Quetiapine 10.37 3.29 35
vs QTP - Wan 2002 Chlorpromazine 11.5 6.1 30
vs QTP - Wan 2002 Quetiapine 11.8 4.3 30
vs QTP - Wang 2004 Chlorpromazine 11.38 4.2 42
vs QTP - Wang 2004 Quetiapine 13.0 8.16 46
vs QTP - Wang 2005 Chlorpromazine 12.09 6.39 57
vs QTP - Wang 2005 Quetiapine 14.2 8.4 48
vs QTP - Zhang 2008 Chlorpromazine 11.47 5.71 30
vs QTP - Zhang 2008 Quetiapine 10.33 6.82 30
vs QTP - Zhou 2004 Chlorpromazine 17.12 7.82 39
vs QTP - Zhou 2004 Quetiapine 16.12 8.3 40
vs QTP - Zou 2006 Chlorpromazine 10.8 6.2 43
vs QTP - Zou 2006 Quetiapine 10.09 7.2 43
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Mental state: 1c. Average endpoint scores (various scales, high = poor) -skewed data (Continued)
PANSS negative symptoms - short term (up to 6 months) PANSS negative
vs QTP - Guo 2003a Chlorpromazine 12.3 7.1 73
vs QTP - Guo 2003a Quetiapine 12.9 6.9 75
vs QTP - Mei 2007 Chlorpromazine 12.4 6.1 49
vs QTP - Mei 2007 Quetiapine 11.7 5.9 47
vs QTP - Wang 2004 Chlorpromazine 18.14 9.38 42
vs QTP - Wang 2004 Quetiapine 18.63 9.3 46
vs QTP - Zhang 2002 Chlorpromazine 15.88 4.11 57
vs QTP - Zhang 2002 Quetiapine 10.87 6.19 60
PANSS general pathology - short term (up to 6 months PANSS general p
vs QTP - Guo 2008 Chlorpromazine 20.1 10.9 40
vs QTP - Guo 2008 Quetiapine 19.2 11.4 43
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Analysis 3.9. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 9 Mental state: 1d.
Average change score (various scales, high = poor) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 9 Mental state: 1d. Average change score (various scales, high = poor) - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PANSS total
vs QTP - NCT00882518 150 -35.9 (1.35) 159 -33.4 (1.45) 99.7 % -2.50 [ -2.81, -2.19 ]
vs QTP - Zhang 2002 57 -43.23 (12.77) 60 -39.35 (17.63) 0.3 % -3.88 [ -9.44, 1.68 ]
Subtotal (95% CI) 207 219 100.0 % -2.50 [ -2.82, -2.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 15.75 (P < 0.00001)
2 PANSS positive symptoms
vs QTP - NCT00882518 194 -9.9 (0.53) 190 -11.1 (0.51) 100.0 % 1.20 [ 1.10, 1.30 ]
Subtotal (95% CI) 194 190 100.0 % 1.20 [ 1.10, 1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 22.61 (P < 0.00001)
3 PANSS negative symptoms
vs QTP - NCT00882518 194 -5.9 (0.5) 190 -6.7 (0.48) 100.0 % 0.80 [ 0.70, 0.90 ]
Subtotal (95% CI) 194 190 100.0 % 0.80 [ 0.70, 0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 16.00 (P < 0.00001)
4 PANSS general pathology
vs QTP - NCT00882518 194 -12.9 (0.74) 190 -13.9 (0.71) 100.0 % 1.00 [ 0.85, 1.15 ]
Subtotal (95% CI) 194 190 100.0 % 1.00 [ 0.85, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.51 (P < 0.00001)
Test for subgroup differences: Chi2 = 493.44, df = 3 (P = 0.00), I2 =99%
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Analysis 3.10. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 10 Mental state: 1e.
Average score decreased rate of BPRS/PANSS (%) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 10 Mental state: 1e. Average score decreased rate of BPRS/PANSS (%) - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS
vs QTP - Cai 2006 96 49.4 (13.1) 101 50.2 (15.9) 100.0 % -0.80 [ -4.86, 3.26 ]
Subtotal (95% CI) 96 101 100.0 % -0.80 [ -4.86, 3.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
2 PANSS
vs QTP - Cai 2007 46 67 (20) 48 83 (22) 14.8 % -16.00 [ -24.49, -7.51 ]
vs QTP - Chen 2001 94 66.4 (26.3) 105 65.9 (27.8) 16.2 % 0.50 [ -7.02, 8.02 ]
vs QTP - Guo 2003a 73 64.9 (25.3) 75 64.7 (26.5) 15.0 % 0.20 [ -8.15, 8.55 ]
vs QTP - Jin 2007 30 50.24 (6.93) 30 48.07 (6.11) 22.2 % 2.17 [ -1.14, 5.48 ]
vs QTP - Zhang 2003 108 59.23 (33.61) 112 54.7 (33.83) 14.3 % 4.53 [ -4.38, 13.44 ]
vs QTP - Zhang 2006 33 48.06 (13.2) 28 52.75 (13.1) 17.5 % -4.69 [ -11.31, 1.93 ]
Subtotal (95% CI) 384 398 100.0 % -1.96 [ -7.20, 3.28 ]
Heterogeneity: Tau2 = 29.41; Chi2 = 18.14, df = 5 (P = 0.003); I2 =72%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
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Analysis 3.11. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 11 Functioning: 1.
Average endpoint score (various scales, high = better) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 11 Functioning: 1. Average endpoint score (various scales, high = better) - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 WCST-IQ
vs QTP - Nai 2007 60 81.6 (18.2) 60 92.9 (17.1) 100.0 % -11.30 [ -17.62, -4.98 ]
Subtotal (95% CI) 60 60 100.0 % -11.30 [ -17.62, -4.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.50 (P = 0.00046)
2 WCST-MQ
vs QTP - Nai 2007 60 56.3 (25.1) 60 75.9 (17.7) 100.0 % -19.60 [ -27.37, -11.83 ]
Subtotal (95% CI) 60 60 100.0 % -19.60 [ -27.37, -11.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.64, df = 1 (P = 0.10), I2 =62%
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Analysis 3.12. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 12 Cognitive function:
1. Average endpoint score (various scales, high = better) - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 12 Cognitive function: 1. Average endpoint score (various scales, high = better) - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 WCST
vs QTP - Guo 2007 26 67.5 (29) 26 64.6 (27.1) 31.2 % 2.90 [ -12.36, 18.16 ]
vs QTP - Sun 2006 36 79.37 (22.17) 35 67.73 (21.95) 68.8 % 11.64 [ 1.38, 21.90 ]
Subtotal (95% CI) 62 61 100.0 % 8.92 [ 0.40, 17.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
2 WMS-RC
vs QTP - Sun 2006 35 98.81 (16.95) 36 108.15 (18.23) 100.0 % -9.34 [ -17.53, -1.15 ]
Subtotal (95% CI) 35 36 100.0 % -9.34 [ -17.53, -1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Chi2 = 9.18, df = 1 (P = 0.00), I2 =89%
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Analysis 3.13. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 13 Adverse effects: 1.
Anticholinergic - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 13 Adverse effects: 1. Anticholinergic - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 blurred vision
vs QTP - Cai 2006 15/96 6/101 16.5 % 2.63 [ 1.06, 6.50 ]
vs QTP - Chen 2001 14/107 2/114 6.4 % 7.46 [ 1.74, 32.05 ]
vs QTP - Chen 2007 7/30 2/32 6.1 % 3.73 [ 0.84, 16.57 ]
vs QTP - Cheng 2003 6/45 1/44 3.1 % 5.87 [ 0.74, 46.76 ]
vs QTP - Guo 2003a 9/73 1/75 3.2 % 9.25 [ 1.20, 71.16 ]
vs QTP - Guo 2003b 3/20 2/30 4.7 % 2.25 [ 0.41, 12.28 ]
vs QTP - Guo 2008 2/40 0/43 1.5 % 5.37 [ 0.27, 108.47 ]
vs QTP - He 2003 3/20 0/20 1.6 % 7.00 [ 0.38, 127.32 ]
vs QTP - Jiang 2006 28/97 4/94 13.3 % 6.78 [ 2.47, 18.60 ]
vs QTP - Jiang 2008 4/30 0/30 1.6 % 9.00 [ 0.51, 160.17 ]
vs QTP - Jin 2007 7/30 1/30 3.3 % 7.00 [ 0.92, 53.47 ]
vs QTP - Mei 2007 14/49 2/47 6.6 % 6.71 [ 1.61, 27.96 ]
vs QTP - Tian 2006 7/46 0/46 1.7 % 15.00 [ 0.88, 255.20 ]
vs QTP - Wan 2008 6/28 0/32 1.7 % 14.79 [ 0.87, 251.39 ]
vs QTP - Wang 2005 14/57 2/48 6.6 % 5.89 [ 1.41, 24.66 ]
vs QTP - Zhang 2006 4/33 2/28 5.1 % 1.70 [ 0.34, 8.58 ]
vs QTP - Zhou 2004 10/39 2/40 6.4 % 5.13 [ 1.20, 21.92 ]
vs QTP - Zou 2006 20/43 3/43 10.5 % 6.67 [ 2.14, 20.79 ]
Subtotal (95% CI) 883 897 100.0 % 5.00 [ 3.46, 7.22 ]
Total events: 173 (Chlorpromazine), 30 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.79, df = 17 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 8.58 (P < 0.00001)
2 dry mouth
vs QTP - Cai 2006 21/96 18/101 11.0 % 1.23 [ 0.70, 2.16 ]
vs QTP - Chen 2001 14/107 6/114 8.3 % 2.49 [ 0.99, 6.23 ]
vs QTP - Chen 2007 0/30 4/32 1.8 % 0.12 [ 0.01, 2.11 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs QTP - Cheng 2003 7/45 3/44 6.0 % 2.28 [ 0.63, 8.26 ]
vs QTP - Guo 2003a 9/73 4/75 6.8 % 2.31 [ 0.74, 7.18 ]
vs QTP - Guo 2008 3/40 1/43 2.8 % 3.23 [ 0.35, 29.75 ]
vs QTP - He 2003 4/20 4/20 6.2 % 1.00 [ 0.29, 3.45 ]
vs QTP - Ji 2004 6/30 0/30 1.9 % 13.00 [ 0.76, 220.96 ]
vs QTP - Jin 2007 9/30 2/30 5.2 % 4.50 [ 1.06, 19.11 ]
vs QTP - Liu 2003 2/39 2/44 3.5 % 1.13 [ 0.17, 7.63 ]
vs QTP - Mei 2007 8/49 1/47 3.2 % 7.67 [ 1.00, 59.01 ]
vs QTP - Tian 2006 31/46 0/46 1.9 % 63.00 [ 3.97, 999.69 ]
vs QTP - Wan 2002 7/30 5/30 7.5 % 1.40 [ 0.50, 3.92 ]
vs QTP - Wan 2008 1/28 0/32 1.5 % 3.41 [ 0.14, 80.59 ]
vs QTP - Wang 2005 17/57 3/48 6.6 % 4.77 [ 1.49, 15.31 ]
vs QTP - Zhang 2006 9/33 5/28 7.9 % 1.53 [ 0.58, 4.03 ]
vs QTP - Zhou 2004 18/39 12/40 10.9 % 1.54 [ 0.86, 2.75 ]
vs QTP - Zou 2006 25/43 3/43 6.9 % 8.33 [ 2.72, 25.55 ]
Subtotal (95% CI) 835 847 100.0 % 2.34 [ 1.54, 3.54 ]
Total events: 191 (Chlorpromazine), 73 (Quetiapine)
Heterogeneity: Tau2 = 0.33; Chi2 = 32.99, df = 17 (P = 0.01); I2 =48%
Test for overall effect: Z = 4.00 (P = 0.000064)
3 excessive sweating
vs QTP - Chen 2007 3/30 1/32 48.4 % 3.20 [ 0.35, 29.10 ]
vs QTP - He 2003 1/20 0/20 23.9 % 3.00 [ 0.13, 69.52 ]
vs QTP - Wan 2002 3/30 0/30 27.7 % 7.00 [ 0.38, 129.93 ]
Subtotal (95% CI) 80 82 100.0 % 3.91 [ 0.84, 18.19 ]
Total events: 7 (Chlorpromazine), 1 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
4 hypersalivation
vs QTP - Chen 2001 5/107 1/114 5.3 % 5.33 [ 0.63, 44.86 ]
vs QTP - Chen 2007 23/30 2/32 13.0 % 12.27 [ 3.16, 47.62 ]
vs QTP - Cheng 2003 2/45 1/44 4.3 % 1.96 [ 0.18, 20.80 ]
vs QTP - Guo 2003a 7/73 0/75 3.0 % 15.41 [ 0.90, 264.93 ]
vs QTP - He 2003 1/20 0/20 2.4 % 3.00 [ 0.13, 69.52 ]
vs QTP - Jiang 2006 22/97 7/94 37.3 % 3.05 [ 1.37, 6.79 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs QTP - Mei 2007 10/49 3/47 15.9 % 3.20 [ 0.94, 10.90 ]
vs QTP - Wan 2002 3/30 0/30 2.8 % 7.00 [ 0.38, 129.93 ]
vs QTP - Wan 2008 1/28 0/32 2.4 % 3.41 [ 0.14, 80.59 ]
vs QTP - Wang 2005 7/57 2/48 10.3 % 2.95 [ 0.64, 13.53 ]
vs QTP - Yang 2007 1/32 1/31 3.2 % 0.97 [ 0.06, 14.82 ]
Subtotal (95% CI) 568 567 100.0 % 3.85 [ 2.36, 6.28 ]
Total events: 82 (Chlorpromazine), 17 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.08, df = 10 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.39 (P < 0.00001)
5 stuffy nose
vs QTP - Chen 2001 1/107 5/114 4.2 % 0.21 [ 0.03, 1.79 ]
vs QTP - Chen 2007 0/30 3/32 2.2 % 0.15 [ 0.01, 2.83 ]
vs QTP - Cheng 2003 1/45 2/44 3.4 % 0.49 [ 0.05, 5.20 ]
vs QTP - Guo 2003a 2/73 3/75 6.1 % 0.68 [ 0.12, 3.98 ]
vs QTP - Jiang 2006 12/97 15/94 38.1 % 0.78 [ 0.38, 1.57 ]
vs QTP - Jin 2007 3/30 4/30 9.5 % 0.75 [ 0.18, 3.07 ]
vs QTP - Mei 2007 6/49 7/47 18.4 % 0.82 [ 0.30, 2.27 ]
vs QTP - Wang 2005 6/57 7/48 18.1 % 0.72 [ 0.26, 2.00 ]
Subtotal (95% CI) 488 484 100.0 % 0.69 [ 0.45, 1.06 ]
Total events: 31 (Chlorpromazine), 46 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.58, df = 7 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Chi2 = 50.82, df = 4 (P = 0.00), I2 =92%
0.001 0.01 0.1 1 10 100 1000
Chlorpromazine Quetiapine
228Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.14. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 14 Adverse effects: 2.
Cardiovascular - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 14 Adverse effects: 2. Cardiovascular - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 abnormal ECG
vs QTP - Chen 2007 6/30 0/32 3.0 % 13.84 [ 0.81, 235.53 ]
vs QTP - Cheng 2003 6/45 3/44 13.8 % 1.96 [ 0.52, 7.34 ]
vs QTP - Deng 2004 13/45 9/45 43.7 % 1.44 [ 0.69, 3.04 ]
vs QTP - Liu 2003 7/39 1/44 5.7 % 7.90 [ 1.02, 61.38 ]
vs QTP - Zhang 2003 3/118 2/119 7.7 % 1.51 [ 0.26, 8.89 ]
vs QTP - Zhang 2006 3/33 1/28 4.9 % 2.55 [ 0.28, 23.12 ]
vs QTP - Zou 2006 7/43 5/43 21.2 % 1.40 [ 0.48, 4.07 ]
Subtotal (95% CI) 353 355 100.0 % 1.82 [ 1.11, 2.98 ]
Total events: 45 (Chlorpromazine), 21 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.68, df = 6 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
2 blood pressure drop
vs QTP - Chen 2001 28/114 26/107 27.6 % 1.01 [ 0.64, 1.61 ]
vs QTP - Guo 2003b 9/30 1/30 7.2 % 9.00 [ 1.21, 66.70 ]
vs QTP - Guo 2007 1/26 0/26 3.3 % 3.00 [ 0.13, 70.42 ]
vs QTP - He 2003 1/20 0/20 3.3 % 3.00 [ 0.13, 69.52 ]
vs QTP - Tian 2006 6/46 15/46 19.9 % 0.40 [ 0.17, 0.94 ]
vs QTP - Wan 2008 3/28 1/32 6.2 % 3.43 [ 0.38, 31.12 ]
vs QTP - Zhou 2004 7/39 8/40 18.8 % 0.90 [ 0.36, 2.24 ]
vs QTP - Zou 2006 3/43 8/43 13.6 % 0.38 [ 0.11, 1.32 ]
Subtotal (95% CI) 346 344 100.0 % 0.97 [ 0.53, 1.79 ]
Total events: 58 (Chlorpromazine), 59 (Quetiapine)
Heterogeneity: Tau2 = 0.29; Chi2 = 13.18, df = 7 (P = 0.07); I2 =47%
Test for overall effect: Z = 0.09 (P = 0.93)
3 orthostatic hypotension
vs QTP - Chen 2007 2/30 0/32 7.0 % 5.32 [ 0.27, 106.54 ]
vs QTP - Guo 2007 0/26 1/26 6.3 % 0.33 [ 0.01, 7.82 ]
vs QTP - Liu 2003 8/39 0/44 7.7 % 19.13 [ 1.14, 320.92 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
vs QTP - Peuskens 1997 18/100 5/101 33.8 % 3.64 [ 1.40, 9.42 ]
vs QTP - Wan 2002 0/30 3/30 7.3 % 0.14 [ 0.01, 2.65 ]
vs QTP - Zhang 2006 4/33 1/28 12.3 % 3.39 [ 0.40, 28.64 ]
vs QTP - Zou 2006 8/43 3/43 25.5 % 2.67 [ 0.76, 9.38 ]
Subtotal (95% CI) 301 304 100.0 % 2.64 [ 1.14, 6.12 ]
Total events: 40 (Chlorpromazine), 13 (Quetiapine)
Heterogeneity: Tau2 = 0.31; Chi2 = 8.02, df = 6 (P = 0.24); I2 =25%
Test for overall effect: Z = 2.26 (P = 0.024)
4 tachycardia
vs QTP - Cai 2006 39/96 17/101 19.0 % 2.41 [ 1.47, 3.97 ]
vs QTP - Cai 2007 6/46 4/48 4.0 % 1.57 [ 0.47, 5.19 ]
vs QTP - Chen 2001 18/107 12/114 11.3 % 1.60 [ 0.81, 3.16 ]
vs QTP - Chen 2007 3/30 2/32 2.0 % 1.60 [ 0.29, 8.92 ]
vs QTP - Cheng 2003 8/45 5/44 5.3 % 1.56 [ 0.55, 4.41 ]
vs QTP - Guo 2003a 9/73 8/75 7.0 % 1.16 [ 0.47, 2.83 ]
vs QTP - Guo 2008 2/40 3/43 2.0 % 0.72 [ 0.13, 4.07 ]
vs QTP - He 2003 1/20 2/20 1.1 % 0.50 [ 0.05, 5.08 ]
vs QTP - Ji 2004 4/30 2/30 2.3 % 2.00 [ 0.40, 10.11 ]
vs QTP - Jiang 2008 7/30 3/30 3.7 % 2.33 [ 0.67, 8.18 ]
vs QTP - Liu 2003 12/39 4/44 5.2 % 3.38 [ 1.19, 9.64 ]
vs QTP - Tian 2006 18/46 2/46 3.0 % 9.00 [ 2.21, 36.59 ]
vs QTP - Wan 2008 5/28 6/32 5.0 % 0.95 [ 0.33, 2.78 ]
vs QTP - Zhang 2003 6/118 7/119 5.1 % 0.86 [ 0.30, 2.50 ]
vs QTP - Zhang 2006 10/33 5/28 6.3 % 1.70 [ 0.66, 4.38 ]
vs QTP - Zhou 2004 16/39 8/40 10.2 % 2.05 [ 0.99, 4.24 ]
vs QTP - Zou 2006 8/43 9/43 7.6 % 0.89 [ 0.38, 2.09 ]
Subtotal (95% CI) 863 889 100.0 % 1.70 [ 1.33, 2.18 ]
Total events: 172 (Chlorpromazine), 99 (Quetiapine)
Heterogeneity: Tau2 = 0.02; Chi2 = 17.24, df = 16 (P = 0.37); I2 =7%
Test for overall effect: Z = 4.22 (P = 0.000025)
Test for subgroup differences: Chi2 = 4.31, df = 3 (P = 0.23), I2 =30%
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Analysis 3.15. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 15 Adverse effects: 3.
Central nervous system - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 15 Adverse effects: 3. Central nervous system - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 dizziness
vs QTP - Cai 2006 20/96 15/101 20.7 % 1.40 [ 0.76, 2.58 ]
vs QTP - Chen 2001 8/107 1/114 5.2 % 8.52 [ 1.08, 67.01 ]
vs QTP - Chen 2007 5/30 1/32 5.1 % 5.33 [ 0.66, 43.05 ]
vs QTP - Cheng 2003 5/45 1/44 5.0 % 4.89 [ 0.59, 40.18 ]
vs QTP - Guo 2003a 5/73 0/75 2.9 % 11.30 [ 0.64, 200.71 ]
vs QTP - Guo 2007 4/26 3/26 9.4 % 1.33 [ 0.33, 5.38 ]
vs QTP - Guo 2008 1/40 2/43 4.1 % 0.54 [ 0.05, 5.70 ]
vs QTP - Tian 2006 5/46 11/46 14.3 % 0.45 [ 0.17, 1.20 ]
vs QTP - Wan 2002 0/30 4/30 2.9 % 0.11 [ 0.01, 1.98 ]
vs QTP - Wan 2008 1/28 0/32 2.5 % 3.41 [ 0.14, 80.59 ]
vs QTP - Yang 2007 4/32 3/31 9.2 % 1.29 [ 0.31, 5.31 ]
vs QTP - Zhou 2004 12/39 10/40 18.7 % 1.23 [ 0.60, 2.51 ]
Subtotal (95% CI) 592 614 100.0 % 1.40 [ 0.83, 2.35 ]
Total events: 70 (Chlorpromazine), 51 (Quetiapine)
Heterogeneity: Tau2 = 0.24; Chi2 = 16.88, df = 11 (P = 0.11); I2 =35%
Test for overall effect: Z = 1.26 (P = 0.21)
2 drowsiness
vs QTP - Ai 2007 15/42 6/43 8.7 % 2.56 [ 1.10, 5.96 ]
vs QTP - Cai 2006 32/96 6/101 8.8 % 5.61 [ 2.46, 12.82 ]
vs QTP - Chen 2001 14/107 8/114 8.8 % 1.86 [ 0.81, 4.27 ]
vs QTP - Chen 2007 0/30 2/32 1.7 % 0.21 [ 0.01, 4.26 ]
vs QTP - Cheng 2003 6/45 3/44 5.7 % 1.96 [ 0.52, 7.34 ]
vs QTP - Guo 2003a 10/73 4/75 6.8 % 2.57 [ 0.84, 7.82 ]
vs QTP - Guo 2003b 19/30 4/30 7.9 % 4.75 [ 1.83, 12.31 ]
vs QTP - Guo 2007 4/26 3/26 5.3 % 1.33 [ 0.33, 5.38 ]
vs QTP - Guo 2008 6/40 2/43 4.7 % 3.23 [ 0.69, 15.06 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
vs QTP - Ji 2004 7/30 0/30 1.9 % 15.00 [ 0.89, 251.42 ]
vs QTP - Jiang 2008 7/30 2/30 4.9 % 3.50 [ 0.79, 15.49 ]
vs QTP - Peuskens 1997 16/100 14/101 10.1 % 1.15 [ 0.60, 2.24 ]
vs QTP - Tian 2006 0/46 12/46 1.9 % 0.04 [ 0.00, 0.66 ]
vs QTP - Wan 2002 5/30 5/30 6.7 % 1.00 [ 0.32, 3.10 ]
vs QTP - Wan 2008 5/28 4/32 6.3 % 1.43 [ 0.42, 4.81 ]
vs QTP - Zhang 2006 6/33 1/28 3.1 % 5.09 [ 0.65, 39.79 ]
vs QTP - Zou 2006 20/43 3/43 6.7 % 6.67 [ 2.14, 20.79 ]
Subtotal (95% CI) 829 848 100.0 % 2.28 [ 1.51, 3.45 ]
Total events: 172 (Chlorpromazine), 79 (Quetiapine)
Heterogeneity: Tau2 = 0.33; Chi2 = 31.15, df = 16 (P = 0.01); I2 =49%
Test for overall effect: Z = 3.92 (P = 0.000090)
3 headache
vs QTP - He 2003 1/20 2/20 43.3 % 0.50 [ 0.05, 5.08 ]
vs QTP - Tian 2006 0/46 2/46 28.2 % 0.20 [ 0.01, 4.05 ]
vs QTP - Wan 2002 2/30 0/30 28.5 % 5.00 [ 0.25, 99.95 ]
Subtotal (95% CI) 96 96 100.0 % 0.74 [ 0.13, 4.18 ]
Total events: 3 (Chlorpromazine), 4 (Quetiapine)
Heterogeneity: Tau2 = 0.40; Chi2 = 2.40, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.34 (P = 0.74)
4 insomnia
vs QTP - Chen 2001 6/107 3/114 14.5 % 2.13 [ 0.55, 8.31 ]
vs QTP - Cheng 2003 2/45 1/44 4.8 % 1.96 [ 0.18, 20.80 ]
vs QTP - Guo 2003a 3/73 2/75 8.6 % 1.54 [ 0.27, 8.96 ]
vs QTP - He 2003 5/20 4/20 19.9 % 1.25 [ 0.39, 3.99 ]
vs QTP - Ji 2004 0/30 5/30 3.3 % 0.09 [ 0.01, 1.57 ]
vs QTP - Liu 2003 0/39 4/44 3.2 % 0.13 [ 0.01, 2.25 ]
vs QTP - Zhang 2006 2/33 3/28 9.1 % 0.57 [ 0.10, 3.15 ]
vs QTP - Zhou 2004 3/39 4/40 13.1 % 0.77 [ 0.18, 3.22 ]
vs QTP - Zou 2006 5/43 7/43 23.5 % 0.71 [ 0.25, 2.08 ]
Subtotal (95% CI) 429 438 100.0 % 0.92 [ 0.55, 1.54 ]
Total events: 26 (Chlorpromazine), 33 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.40, df = 8 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
5 reduced activity
vs QTP - Chen 2001 9/107 0/114 11.0 % 20.23 [ 1.19, 343.40 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
vs QTP - Cheng 2003 4/45 0/44 10.5 % 8.80 [ 0.49, 158.85 ]
vs QTP - Guo 2003a 6/73 1/75 20.1 % 6.16 [ 0.76, 49.95 ]
vs QTP - Guo 2003b 2/30 1/30 16.0 % 2.00 [ 0.19, 20.90 ]
vs QTP - Wan 2008 2/28 0/32 9.8 % 5.69 [ 0.28, 113.72 ]
vs QTP - Yang 2007 3/32 0/31 10.3 % 6.79 [ 0.36, 126.24 ]
vs QTP - Zhang 2006 10/33 0/28 11.3 % 17.91 [ 1.10, 292.63 ]
vs QTP - Zou 2006 9/43 0/43 11.1 % 19.00 [ 1.14, 316.52 ]
Subtotal (95% CI) 391 397 100.0 % 7.80 [ 3.05, 19.92 ]
Total events: 45 (Chlorpromazine), 2 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.56, df = 7 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 4.29 (P = 0.000018)
6 sedation
vs QTP - He 2003 0/20 1/20 100.0 % 0.33 [ 0.01, 7.72 ]
Subtotal (95% CI) 20 20 100.0 % 0.33 [ 0.01, 7.72 ]
Total events: 0 (Chlorpromazine), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 20.04, df = 5 (P = 0.00), I2 =75%
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Analysis 3.16. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 16 Adverse effects: 4.
Gastrointestinal - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 16 Adverse effects: 4. Gastrointestinal - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 constipation
vs QTP - Cai 2006 20/96 12/101 11.6 % 1.75 [ 0.91, 3.39 ]
vs QTP - Chen 2001 11/107 4/114 4.1 % 2.93 [ 0.96, 8.92 ]
vs QTP - Chen 2007 10/30 4/32 4.6 % 2.67 [ 0.94, 7.60 ]
vs QTP - Cheng 2003 5/45 2/44 2.0 % 2.44 [ 0.50, 11.94 ]
vs QTP - Guo 2003a 8/73 2/75 2.2 % 4.11 [ 0.90, 18.71 ]
vs QTP - Guo 2003b 8/30 2/30 2.4 % 4.00 [ 0.92, 17.30 ]
vs QTP - Guo 2007 1/26 0/26 0.5 % 3.00 [ 0.13, 70.42 ]
vs QTP - Guo 2008 5/40 2/43 2.0 % 2.69 [ 0.55, 13.08 ]
vs QTP - He 2003 4/20 3/20 2.7 % 1.33 [ 0.34, 5.21 ]
vs QTP - Jiang 2006 47/97 13/94 17.0 % 3.50 [ 2.03, 6.04 ]
vs QTP - Jiang 2008 0/30 2/30 0.6 % 0.20 [ 0.01, 4.00 ]
vs QTP - Jin 2007 11/30 4/30 4.8 % 2.75 [ 0.99, 7.68 ]
vs QTP - Liu 2003 4/39 2/44 1.9 % 2.26 [ 0.44, 11.65 ]
vs QTP - Mei 2007 22/49 7/47 9.0 % 3.01 [ 1.42, 6.39 ]
vs QTP - Tian 2006 23/46 0/46 0.7 % 47.00 [ 2.94, 751.41 ]
vs QTP - Wan 2002 11/30 4/30 4.8 % 2.75 [ 0.99, 7.68 ]
vs QTP - Wan 2008 3/28 3/32 2.2 % 1.14 [ 0.25, 5.21 ]
vs QTP - Wang 2005 21/57 7/48 8.6 % 2.53 [ 1.18, 5.43 ]
vs QTP - Yang 2007 9/32 3/31 3.5 % 2.91 [ 0.87, 9.74 ]
vs QTP - Zhang 2006 7/33 2/28 2.3 % 2.97 [ 0.67, 13.16 ]
vs QTP - Zhou 2004 11/39 8/40 8.0 % 1.41 [ 0.64, 3.13 ]
vs QTP - Zou 2006 13/43 4/43 4.7 % 3.25 [ 1.15, 9.18 ]
Subtotal (95% CI) 1020 1028 100.0 % 2.55 [ 2.04, 3.20 ]
Total events: 254 (Chlorpromazine), 90 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 15.01, df = 21 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 8.18 (P < 0.00001)
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(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
2 diarrhoea
vs QTP - Chen 2007 2/30 0/32 100.0 % 5.32 [ 0.27, 106.54 ]
Subtotal (95% CI) 30 32 100.0 % 5.32 [ 0.27, 106.54 ]
Total events: 2 (Chlorpromazine), 0 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
3 loss of appetite
vs QTP - Chen 2001 4/107 1/114 17.0 % 4.26 [ 0.48, 37.53 ]
vs QTP - Chen 2007 24/30 3/32 32.8 % 8.53 [ 2.86, 25.43 ]
vs QTP - Cheng 2003 3/45 2/44 22.1 % 1.47 [ 0.26, 8.36 ]
vs QTP - Guo 2003b 1/30 1/30 12.5 % 1.00 [ 0.07, 15.26 ]
vs QTP - He 2003 1/20 2/20 15.6 % 0.50 [ 0.05, 5.08 ]
Subtotal (95% CI) 232 240 100.0 % 2.52 [ 0.82, 7.72 ]
Total events: 33 (Chlorpromazine), 9 (Quetiapine)
Heterogeneity: Tau2 = 0.68; Chi2 = 7.06, df = 4 (P = 0.13); I2 =43%
Test for overall effect: Z = 1.62 (P = 0.10)
4 nausea/vomiting
vs QTP - Chen 2001 2/107 2/114 15.1 % 1.07 [ 0.15, 7.43 ]
vs QTP - Chen 2007 3/30 2/32 19.3 % 1.60 [ 0.29, 8.92 ]
vs QTP - Cheng 2003 1/45 1/44 7.6 % 0.98 [ 0.06, 15.15 ]
vs QTP - Guo 2003a 1/73 1/75 7.5 % 1.03 [ 0.07, 16.12 ]
vs QTP - Guo 2003b 0/30 1/30 5.7 % 0.33 [ 0.01, 7.87 ]
vs QTP - He 2003 1/20 2/20 10.6 % 0.50 [ 0.05, 5.08 ]
vs QTP - Wan 2002 2/30 2/30 15.9 % 1.00 [ 0.15, 6.64 ]
vs QTP - Wan 2008 1/28 0/32 5.7 % 3.41 [ 0.14, 80.59 ]
vs QTP - Zhou 2004 4/39 1/40 12.4 % 4.10 [ 0.48, 35.10 ]
Subtotal (95% CI) 402 417 100.0 % 1.23 [ 0.58, 2.63 ]
Total events: 15 (Chlorpromazine), 12 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.04, df = 8 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 3.55, df = 3 (P = 0.31), I2 =15%
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Analysis 3.17. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 17 Adverse effects: 5a.
Endocrine - various - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 17 Adverse effects: 5a. Endocrine - various - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 gynaecomastia, galactorrhoea
vs QTP - Guo 2008 2/40 0/43 100.0 % 5.37 [ 0.27, 108.47 ]
Subtotal (95% CI) 40 43 100.0 % 5.37 [ 0.27, 108.47 ]
Total events: 2 (Chlorpromazine), 0 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 hyperprolactinemia
vs QTP - Jiang 2006 38/97 7/94 93.3 % 5.26 [ 2.47, 11.19 ]
vs QTP - Zou 2006 8/43 0/43 6.7 % 17.00 [ 1.01, 285.60 ]
Subtotal (95% CI) 140 137 100.0 % 5.69 [ 2.74, 11.79 ]
Total events: 46 (Chlorpromazine), 7 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.67 (P < 0.00001)
3 menstrual irregularities
vs QTP - Guo 2007 2/26 0/26 100.0 % 5.00 [ 0.25, 99.34 ]
Subtotal (95% CI) 26 26 100.0 % 5.00 [ 0.25, 99.34 ]
Total events: 2 (Chlorpromazine), 0 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 0.01, df = 2 (P = 1.00), I2 =0.0%
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Analysis 3.18. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 18 Adverse effects: 5b.
Endocrine - average endpoint - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 18 Adverse effects: 5b. Endocrine - average endpoint - short term (up to 6 months)
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 prolactin level (ng/mL)
vs QTP - Kong 2003 15 31.83 (12.98) 15 7.21 (3.88) 100.0 % 24.62 [ 17.76, 31.48 ]
Total (95% CI) 15 15 100.0 % 24.62 [ 17.76, 31.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.04 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.19. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 19 Adverse effects: 5c.
Endocrine - skewed data - short term (up to 6 months).
Adverse effects: 5c. Endocrine - skewed data - short term (up to 6 months)
Study Intervention Mean SD N
average prolactin level (ng/mL) average prolacti
vs QTP - Jiang 2006 Chlorpromazine 680.2 688.0 97
vs QTP - Jiang 2006 Quetiapine 123.2 132.1 94
vs QTP - Wang 2005 Chlorpromazine 697.21 80.26 57
vs QTP - Wang 2005 Quetiapine 112.85 92.37 48
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Analysis 3.20. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 20 Adverse effects: 6a.
Haematology - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 20 Adverse effects: 6a. Haematology - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 elevated ALT
vs QTP - Cai 2007 2/46 2/48 8.9 % 1.04 [ 0.15, 7.10 ]
vs QTP - Chen 2007 0/30 3/32 3.8 % 0.15 [ 0.01, 2.83 ]
vs QTP - Deng 2004 2/45 0/45 3.6 % 5.00 [ 0.25, 101.31 ]
vs QTP - Guo 2003b 2/30 2/30 9.1 % 1.00 [ 0.15, 6.64 ]
vs QTP - Guo 2008 2/40 0/46 3.6 % 5.73 [ 0.28, 115.97 ]
vs QTP - Wan 2002 0/30 1/30 3.3 % 0.33 [ 0.01, 7.87 ]
vs QTP - Zhang 2003 16/118 9/119 54.1 % 1.79 [ 0.83, 3.90 ]
vs QTP - Zou 2006 6/43 2/43 13.7 % 3.00 [ 0.64, 14.04 ]
Subtotal (95% CI) 382 393 100.0 % 1.62 [ 0.92, 2.87 ]
Total events: 30 (Chlorpromazine), 19 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.85, df = 7 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
2 decreased white blood cell count
vs QTP - Deng 2004 6/45 5/45 60.8 % 1.20 [ 0.39, 3.65 ]
vs QTP - He 2003 1/20 0/20 7.6 % 3.00 [ 0.13, 69.52 ]
vs QTP - Wan 2002 0/30 1/30 7.5 % 0.33 [ 0.01, 7.87 ]
vs QTP - Zhang 2003 2/118 3/119 24.0 % 0.67 [ 0.11, 3.95 ]
Subtotal (95% CI) 213 214 100.0 % 1.02 [ 0.43, 2.42 ]
Total events: 9 (Chlorpromazine), 9 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
3 increased white blood cell count
vs QTP - Zhou 2004 4/39 2/40 100.0 % 2.05 [ 0.40, 10.56 ]
Subtotal (95% CI) 39 40 100.0 % 2.05 [ 0.40, 10.56 ]
Total events: 4 (Chlorpromazine), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Chi2 = 0.96, df = 2 (P = 0.62), I2 =0.0%
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Analysis 3.21. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 21 Adverse effects: 6b.
Haematology - average endpoint - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 21 Adverse effects: 6b. Haematology - average endpoint - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 blood glucose
vs QTP - Guo 2006 65 4.9 (0.8) 65 4.8 (0.8) 100.0 % 0.10 [ -0.18, 0.38 ]
Subtotal (95% CI) 65 65 100.0 % 0.10 [ -0.18, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 blood TG
vs QTP - Guo 2006 65 1.4 (0.8) 65 1.4 (0.8) 100.0 % 0.0 [ -0.28, 0.28 ]
Subtotal (95% CI) 65 65 100.0 % 0.0 [ -0.28, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 blood TC
vs QTP - Guo 2006 65 4.6 (0.9) 65 4.4 (0.9) 100.0 % 0.20 [ -0.11, 0.51 ]
Subtotal (95% CI) 65 65 100.0 % 0.20 [ -0.11, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Chi2 = 0.90, df = 2 (P = 0.64), I2 =0.0%
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Analysis 3.22. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 22 Adverse effects: 7.
Hepatitic - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 22 Adverse effects: 7. Hepatitic - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 abnormal liver function
vs QTP - Cai 2006 21/96 11/101 46.9 % 2.01 [ 1.02, 3.94 ]
vs QTP - Guo 2007 2/26 2/26 6.0 % 1.00 [ 0.15, 6.57 ]
vs QTP - Ji 2004 2/30 0/30 2.4 % 5.00 [ 0.25, 99.95 ]
vs QTP - Jiang 2006 16/97 7/94 30.1 % 2.22 [ 0.95, 5.14 ]
vs QTP - Zhang 2006 9/33 3/28 14.7 % 2.55 [ 0.76, 8.50 ]
Subtotal (95% CI) 282 279 100.0 % 2.10 [ 1.32, 3.33 ]
Total events: 50 (Chlorpromazine), 23 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.05, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 3.15 (P = 0.0016)
Test for subgroup differences: Not applicable
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Analysis 3.23. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 23 Adverse effects: 8.
Movement disorders - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 23 Adverse effects: 8. Movement disorders - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 agitation
vs QTP - He 2003 1/20 4/20 21.2 % 0.25 [ 0.03, 2.05 ]
vs QTP - Ji 2004 2/30 1/30 17.0 % 2.00 [ 0.19, 20.90 ]
vs QTP - Tian 2006 0/46 2/46 10.3 % 0.20 [ 0.01, 4.05 ]
vs QTP - Wan 2002 2/30 6/30 40.6 % 0.33 [ 0.07, 1.52 ]
vs QTP - Zhang 2006 0/33 3/28 11.0 % 0.12 [ 0.01, 2.26 ]
Subtotal (95% CI) 159 154 100.0 % 0.36 [ 0.14, 0.95 ]
Total events: 5 (Chlorpromazine), 16 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.85, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
2 akathisia
vs QTP - Chen 2001 17/107 3/114 10.2 % 6.04 [ 1.82, 20.02 ]
vs QTP - Chen 2007 7/30 0/32 1.8 % 15.97 [ 0.95, 268.00 ]
vs QTP - Cheng 2003 10/45 2/44 6.8 % 4.89 [ 1.14, 21.06 ]
vs QTP - Guo 2003a 9/73 1/75 3.5 % 9.25 [ 1.20, 71.16 ]
vs QTP - Guo 2003b 7/30 1/30 3.5 % 7.00 [ 0.92, 53.47 ]
vs QTP - Guo 2008 3/40 0/43 1.7 % 7.51 [ 0.40, 141.04 ]
vs QTP - Ji 2004 4/30 2/30 5.6 % 2.00 [ 0.40, 10.11 ]
vs QTP - Jiang 2006 10/97 5/94 13.6 % 1.94 [ 0.69, 5.46 ]
vs QTP - Jin 2007 7/30 1/30 3.5 % 7.00 [ 0.92, 53.47 ]
vs QTP - Mei 2007 4/49 2/47 5.4 % 1.92 [ 0.37, 9.98 ]
vs QTP - Peuskens 1997 6/101 4/100 9.6 % 1.49 [ 0.43, 5.10 ]
vs QTP - Tian 2006 16/46 1/46 3.7 % 16.00 [ 2.21, 115.71 ]
vs QTP - Wang 2005 3/57 1/48 2.9 % 2.53 [ 0.27, 23.50 ]
vs QTP - Yang 2007 6/32 0/31 1.8 % 12.61 [ 0.74, 214.70 ]
vs QTP - Zhang 2006 9/33 1/28 3.6 % 7.64 [ 1.03, 56.63 ]
vs QTP - Zhou 2004 10/39 5/40 15.2 % 2.05 [ 0.77, 5.46 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
vs QTP - Zou 2006 18/43 2/43 7.5 % 9.00 [ 2.22, 36.44 ]
Subtotal (95% CI) 882 875 100.0 % 3.73 [ 2.55, 5.47 ]
Total events: 146 (Chlorpromazine), 31 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.71, df = 16 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 6.76 (P < 0.00001)
3 any EPS symptoms
vs QTP - Cai 2006 43/96 8/101 55.0 % 5.65 [ 2.81, 11.40 ]
vs QTP - Guo 2007 3/26 0/26 3.2 % 7.00 [ 0.38, 129.11 ]
vs QTP - He 2003 16/20 0/20 3.6 % 33.00 [ 2.11, 515.02 ]
vs QTP - Jiang 2008 12/30 0/30 3.5 % 25.00 [ 1.55, 403.99 ]
vs QTP - Liu 2003 20/39 3/44 21.0 % 7.52 [ 2.42, 23.39 ]
vs QTP - Tian 2006 28/46 0/46 3.5 % 57.00 [ 3.58, 906.58 ]
vs QTP - Wan 2002 11/30 1/30 6.9 % 11.00 [ 1.51, 79.96 ]
vs QTP - Wan 2008 8/28 0/32 3.4 % 19.34 [ 1.17, 320.74 ]
Subtotal (95% CI) 315 329 100.0 % 8.03 [ 4.78, 13.51 ]
Total events: 141 (Chlorpromazine), 12 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.04, df = 7 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 7.86 (P < 0.00001)
4 dystonia
vs QTP - Peuskens 1997 0/101 1/100 100.0 % 0.33 [ 0.01, 8.01 ]
Subtotal (95% CI) 101 100 100.0 % 0.33 [ 0.01, 8.01 ]
Total events: 0 (Chlorpromazine), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
5 myotonia
vs QTP - Chen 2001 14/107 7/114 18.0 % 2.13 [ 0.89, 5.08 ]
vs QTP - Chen 2007 1/30 0/32 1.4 % 3.19 [ 0.14, 75.49 ]
vs QTP - Cheng 2003 5/45 2/44 5.4 % 2.44 [ 0.50, 11.94 ]
vs QTP - Guo 2003a 9/73 4/75 10.6 % 2.31 [ 0.74, 7.18 ]
vs QTP - Guo 2003b 5/30 0/30 1.7 % 11.00 [ 0.64, 190.53 ]
vs QTP - Guo 2008 5/40 0/43 1.7 % 11.80 [ 0.67, 206.88 ]
vs QTP - Jiang 2006 52/97 6/94 21.4 % 8.40 [ 3.79, 18.62 ]
vs QTP - Jin 2007 12/30 2/30 6.8 % 6.00 [ 1.47, 24.55 ]
vs QTP - Mei 2007 27/49 3/47 10.7 % 8.63 [ 2.81, 26.56 ]
vs QTP - Wang 2005 27/57 3/48 10.6 % 7.58 [ 2.45, 23.45 ]
vs QTP - Yang 2007 3/32 1/31 2.8 % 2.91 [ 0.32, 26.46 ]
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(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
vs QTP - Zhou 2004 9/39 3/40 9.0 % 3.08 [ 0.90, 10.53 ]
Subtotal (95% CI) 629 628 100.0 % 4.59 [ 3.18, 6.64 ]
Total events: 169 (Chlorpromazine), 31 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.74, df = 11 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 8.11 (P < 0.00001)
6 need additional medication for EPS symptoms
vs QTP - Peuskens 1997 15/101 10/101 100.0 % 1.50 [ 0.71, 3.18 ]
Subtotal (95% CI) 101 101 100.0 % 1.50 [ 0.71, 3.18 ]
Total events: 15 (Chlorpromazine), 10 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
7 torsion movement
vs QTP - Chen 2001 5/107 0/114 6.7 % 11.71 [ 0.66, 209.31 ]
vs QTP - Cheng 2003 2/45 0/44 6.1 % 4.89 [ 0.24, 99.08 ]
vs QTP - Guo 2003a 14/73 0/75 7.1 % 29.78 [ 1.81, 490.26 ]
vs QTP - Jiang 2006 12/97 3/94 36.4 % 3.88 [ 1.13, 13.30 ]
vs QTP - Jin 2007 7/30 0/30 7.0 % 15.00 [ 0.89, 251.42 ]
vs QTP - Mei 2007 5/49 1/47 12.4 % 4.80 [ 0.58, 39.53 ]
vs QTP - Tian 2006 1/46 0/46 5.5 % 3.00 [ 0.13, 71.78 ]
vs QTP - Wang 2005 4/57 1/48 11.9 % 3.37 [ 0.39, 29.13 ]
vs QTP - Zhang 2006 7/33 0/28 7.0 % 12.79 [ 0.76, 214.54 ]
Subtotal (95% CI) 537 526 100.0 % 5.81 [ 2.76, 12.23 ]
Total events: 57 (Chlorpromazine), 5 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.14, df = 8 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 4.64 (P < 0.00001)
8 tremor
vs QTP - Chen 2001 24/107 9/114 20.4 % 2.84 [ 1.38, 5.83 ]
vs QTP - Chen 2007 2/30 0/32 2.0 % 5.32 [ 0.27, 106.54 ]
vs QTP - Cheng 2003 11/45 2/44 7.4 % 5.38 [ 1.26, 22.88 ]
vs QTP - Guo 2003a 13/73 5/75 13.7 % 2.67 [ 1.00, 7.12 ]
vs QTP - Guo 2003b 4/30 0/30 2.1 % 9.00 [ 0.51, 160.17 ]
vs QTP - Guo 2008 0/43 6/40 2.2 % 0.07 [ 0.00, 1.23 ]
vs QTP - Jiang 2006 11/97 7/94 15.3 % 1.52 [ 0.62, 3.76 ]
vs QTP - Jin 2007 7/30 1/30 4.1 % 7.00 [ 0.92, 53.47 ]
vs QTP - Mei 2007 7/49 4/47 10.6 % 1.68 [ 0.53, 5.36 ]
vs QTP - Wang 2005 7/57 2/48 6.8 % 2.95 [ 0.64, 13.53 ]
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Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
vs QTP - Yang 2007 8/32 1/31 4.1 % 7.75 [ 1.03, 58.38 ]
vs QTP - Zhou 2004 5/39 1/40 3.8 % 5.13 [ 0.63, 41.93 ]
vs QTP - Zou 2006 15/43 2/43 7.7 % 7.50 [ 1.82, 30.83 ]
Subtotal (95% CI) 675 668 100.0 % 2.90 [ 1.89, 4.45 ]
Total events: 114 (Chlorpromazine), 40 (Quetiapine)
Heterogeneity: Tau2 = 0.10; Chi2 = 14.41, df = 12 (P = 0.28); I2 =17%
Test for overall effect: Z = 4.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 42.50, df = 7 (P = 0.00), I2 =84%
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Analysis 3.24. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 24 Adverse effects: 9a.
Metabolic - weight gain.
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 24 Adverse effects: 9a. Metabolic - weight gain
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 weight gain
vs QTP - Chen 2001 27/107 19/114 19.7 % 1.51 [ 0.90, 2.56 ]
vs QTP - Chen 2007 9/30 8/32 12.4 % 1.20 [ 0.53, 2.70 ]
vs QTP - Cheng 2003 10/45 6/44 10.4 % 1.63 [ 0.65, 4.10 ]
vs QTP - Guo 2003a 12/73 9/75 12.5 % 1.37 [ 0.61, 3.05 ]
vs QTP - Guo 2003b 9/30 1/30 2.9 % 9.00 [ 1.21, 66.70 ]
vs QTP - Guo 2007 1/26 0/26 1.2 % 3.00 [ 0.13, 70.42 ]
vs QTP - Guo 2008 3/40 4/43 5.3 % 0.81 [ 0.19, 3.38 ]
vs QTP - He 2003 5/20 3/20 6.3 % 1.67 [ 0.46, 6.06 ]
vs QTP - Ji 2004 2/30 2/30 3.2 % 1.00 [ 0.15, 6.64 ]
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Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
vs QTP - Jiang 2008 5/30 0/30 1.5 % 11.00 [ 0.64, 190.53 ]
vs QTP - Liu 2003 6/39 0/44 1.5 % 14.63 [ 0.85, 251.51 ]
vs QTP - Tian 2006 0/46 8/46 1.5 % 0.06 [ 0.00, 0.99 ]
vs QTP - Wan 2002 5/30 4/30 6.9 % 1.25 [ 0.37, 4.21 ]
vs QTP - Yang 2007 2/32 1/31 2.2 % 1.94 [ 0.18, 20.30 ]
vs QTP - Zou 2006 21/43 6/43 12.5 % 3.50 [ 1.57, 7.81 ]
Total (95% CI) 621 638 100.0 % 1.67 [ 1.17, 2.39 ]
Total events: 117 (Chlorpromazine), 71 (Quetiapine)
Heterogeneity: Tau2 = 0.10; Chi2 = 17.94, df = 14 (P = 0.21); I2 =22%
Test for overall effect: Z = 2.81 (P = 0.0049)
Test for subgroup differences: Not applicable
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Analysis 3.25. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 25 Adverse effects: 9b.
Metabolic - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 25 Adverse effects: 9b. Metabolic - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 average BMI
vs QTP - Wang 2005 57 22.4 (3.1) 48 21.9 (3) 100.0 % 0.50 [ -0.67, 1.67 ]
Subtotal (95% CI) 57 48 100.0 % 0.50 [ -0.67, 1.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 average weight (KG)
vs QTP - Guo 2006 65 59.7 (10.5) 65 60.7 (10.9) 100.0 % -1.00 [ -4.68, 2.68 ]
Subtotal (95% CI) 65 65 100.0 % -1.00 [ -4.68, 2.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Chi2 = 0.58, df = 1 (P = 0.45), I2 =0.0%
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Analysis 3.26. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 26 Adverse effects: 10.
Various other - short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 26 Adverse effects: 10. Various other - short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 unspeciﬁed adverse effects
vs QTP - Cai 2006 61/96 28/101 27.0 % 2.29 [ 1.62, 3.25 ]
vs QTP - Ji 2004 22/33 18/33 25.4 % 1.22 [ 0.82, 1.81 ]
vs QTP - Peuskens 1997 44/100 34/101 26.9 % 1.31 [ 0.92, 1.86 ]
vs QTP - Wang 2004 32/48 12/48 20.7 % 2.67 [ 1.57, 4.53 ]
Total (95% CI) 277 283 100.0 % 1.73 [ 1.19, 2.52 ]
Total events: 159 (Chlorpromazine), 92 (Quetiapine)
Heterogeneity: Tau2 = 0.10; Chi2 = 10.62, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.88 (P = 0.0040)
Test for subgroup differences: Not applicable
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Analysis 3.27. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 27 Adverse effects: 11.
Average endpoint score (TESS, high = poor) - skewed data.
Adverse effects: 11. Average endpoint score (TESS, high = poor) - skewed data
Study Intervention Mean SD N
short term (up to 6 months) short term (up t
vs QTP - Cai 2007 Chlorpromazine 3.0 2.2 46
vs QTP - Cai 2007 Quetiapine 2.4 2.3 48
vs QTP - Guo 2005 Chlorpromazine 4.2 3.0 40
vs QTP - Guo 2005 Quetiapine 2.0 2.4 40
vs QTP - Guo 2008 Chlorpromazine 2.8 2.2 40
vs QTP - Guo 2008 Quetiapine 1.9 1.6 43
vs QTP - Hu 2003 Chlorpromazine 5.33 3.94 22
247Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Adverse effects: 11. Average endpoint score (TESS, high = poor) - skewed data (Continued)
vs QTP - Hu 2003 Quetiapine 6.92 4.35 19
vs QTP - Li 2003 Chlorpromazine 4.8 3.1 37
vs QTP - Li 2003 Quetiapine 2.9 2.8 40
vs QTP - Zhang 2002 Chlorpromazine 6.94 4.35 57
vs QTP - Zhang 2002 Quetiapine 6.07 5.04 60
vs QTP - Zhang 2008 Chlorpromazine 9.35 6.23 30
vs QTP - Zhang 2008 Quetiapine 6.63 5.2 30
medium term (7 to 12 months) medium term (7
vs QTP - Li 2003 Chlorpromazine 4.2 3.0 37
vs QTP - Li 2003 Quetiapine 2.1 2.3 40
Analysis 3.28. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 28 Quality of life: 1.
General - average endpoint score (GQOL1 - 74, high = better).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 28 Quality of life: 1. General - average endpoint score (GQOL1 - 74, high = better)
Study or subgroup Chlorpromazine Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 6 months)
vs QTP - Ji 2004 29 60.49 (9.62) 30 66.98 (9.23) 100.0 % -6.49 [ -11.30, -1.68 ]
Subtotal (95% CI) 29 30 100.0 % -6.49 [ -11.30, -1.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
Test for subgroup differences: Not applicable
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Analysis 3.29. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 29 Leaving the study
early: 1a. Short term (up to 6 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 29 Leaving the study early: 1a. Short term (up to 6 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 due to adverse effect
vs QTP - Chen 2001 7/107 2/114 4.3 % 3.73 [ 0.79, 17.55 ]
vs QTP - Cheng 2003 2/45 0/44 1.2 % 4.89 [ 0.24, 99.08 ]
vs QTP - Guo 2008 2/43 0/43 1.2 % 5.00 [ 0.25, 101.18 ]
vs QTP - Ji 2004 4/33 3/33 5.2 % 1.33 [ 0.32, 5.50 ]
vs QTP - Jiang 2006 17/97 16/94 27.0 % 1.03 [ 0.55, 1.92 ]
vs QTP - NCT00882518 18/192 9/196 17.4 % 2.04 [ 0.94, 4.43 ]
vs QTP - Peuskens 1997 9/100 4/101 8.0 % 2.27 [ 0.72, 7.14 ]
vs QTP - Wang 2004 4/48 2/48 3.8 % 2.00 [ 0.38, 10.41 ]
vs QTP - Wang 2005 12/57 11/48 20.0 % 0.92 [ 0.45, 1.89 ]
vs QTP - Zhang 2003 10/118 7/119 12.0 % 1.44 [ 0.57, 3.66 ]
Subtotal (95% CI) 840 840 100.0 % 1.43 [ 1.04, 1.98 ]
Total events: 85 (Chlorpromazine), 54 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.90, df = 9 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
2 due to inefﬁcacy
vs QTP - Chen 2001 3/107 2/114 17.4 % 1.60 [ 0.27, 9.38 ]
vs QTP - Guo 2008 1/43 0/43 5.4 % 3.00 [ 0.13, 71.65 ]
vs QTP - NCT00882518 12/196 9/192 77.2 % 1.31 [ 0.56, 3.03 ]
Subtotal (95% CI) 346 349 100.0 % 1.42 [ 0.68, 2.96 ]
Total events: 16 (Chlorpromazine), 11 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
3 due to any other reason
vs QTP - Cao 2005 8/25 7/25 12.6 % 1.14 [ 0.49, 2.67 ]
vs QTP - Cheng 2003 0/45 3/44 1.1 % 0.14 [ 0.01, 2.63 ]
vs QTP - Guo 2003b 6/36 5/35 7.6 % 1.17 [ 0.39, 3.48 ]
vs QTP - Li 2010 1/32 0/32 0.9 % 3.00 [ 0.13, 71.00 ]
vs QTP - NCT00882518 16/192 17/196 21.3 % 0.96 [ 0.50, 1.85 ]
0.005 0.1 1 10 200
Chlorpromazine Quetiapine
(Continued . . . )
249Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
vs QTP - Peng 2006 2/20 2/20 2.6 % 1.00 [ 0.16, 6.42 ]
vs QTP - Peuskens 1997 27/100 27/101 43.6 % 1.01 [ 0.64, 1.59 ]
vs QTP - Wang 2004 2/48 0/48 1.0 % 5.00 [ 0.25, 101.48 ]
vs QTP - Yang 2007 2/30 1/31 1.6 % 2.07 [ 0.20, 21.61 ]
vs QTP - Zhou 2003 2/20 2/20 2.6 % 1.00 [ 0.16, 6.42 ]
vs QTP - Zhou 2004 2/41 2/42 2.5 % 1.02 [ 0.15, 6.93 ]
vs QTP - Zou 2006 2/20 2/20 2.6 % 1.00 [ 0.16, 6.42 ]
Subtotal (95% CI) 609 614 100.0 % 1.04 [ 0.77, 1.41 ]
Total events: 70 (Chlorpromazine), 68 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.77, df = 11 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.78)
4 due to loss to follow-up
vs QTP - Cai 2006 4/100 8/109 59.0 % 0.55 [ 0.17, 1.75 ]
vs QTP - Jiang 2006 3/97 5/94 41.0 % 0.58 [ 0.14, 2.36 ]
Subtotal (95% CI) 197 203 100.0 % 0.56 [ 0.23, 1.37 ]
Total events: 7 (Chlorpromazine), 13 (Quetiapine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Chi2 = 4.91, df = 3 (P = 0.18), I2 =39%
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Analysis 3.30. Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 30 Leaving the study
early: 1b. Medium term (7 to 12 months).
Review: Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Comparison: 3 CHLORPROMAZINE versus QUETIAPINE
Outcome: 30 Leaving the study early: 1b. Medium term (7 to 12 months)
Study or subgroup Chlorpromazine Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
vs QTP - Li 2003 14/51 12/52 100.0 % 1.19 [ 0.61, 2.32 ]
Total (95% CI) 51 52 100.0 % 1.19 [ 0.61, 2.32 ]
Total events: 14 (Chlorpromazine), 12 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Related Cochrane Reviews
Comparison Reference
Chlorpromazine versus placebo Adams 2014
Chlorpromazine versus haloperidol Leucht 2008
Chlorpromazine doses Liu 2009
Chlorpromazine cessation Almerie 2007
Chlorpromazine for acute aggression Ahmed 2010
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A P P E N D I C E S
Appendix 1. Previous searches
1.1 Search in 2013 (Protocol Step)
1.1.1 Electronic searches
1.1.1.1 Cochrane Schizophrenia Group Trials Register
The Trials Search Co-ordinator will search the Cochrane Schizophrenia Group’s Trials Register using the phrase:
[((*chlorpromazine* AND (*amisulprid* or *aripiprazol* or *clozapin* or *olanzapin* or *quetiapin* or *risperidon* or *sertindol*
or *ziprasidon* or *zotepin*or *sulpiride* or *remoxipride* or *paliperidone* or *perospirone*)) in title, abstract or index terms of
REFERENCE or interventions of STUDY)]
The Cochrane SchizophreniaGroup’s Trials Register is compiled by systematic searches of major databases, handsearches and conference
proceedings (see Group Module). Incoming trials are assigned to existing or new review titles.
1.1.2 Searching other resources
1.1.2.1 Reference searching
We will inspect references of all included studies for further relevant studies published in any language.
1.1.2.2 Personal contact
We will contact the ﬁrst author of each included study for information regarding unpublished trials.
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We adhered to theCochrane protocol for data extraction and datamanagement. However, due to the large number of results we obtained
from the literature searches, we have presented comparisons with chlorpromazine with the speciﬁc name of the comparator drug instead
of the planned, generic ’chlorpromazine versus atypical antipsychotics’. We have only included data for three drug comparisons and
will include all other comparator atypical antipsychotics in future updates of this Cochrane review. We clariﬁed and amended the
anticholinergic outcomes to include hypersalivation and leaving the study data.
The adverse effects outcomes have been arranged into new categories that are now used by the Cochrane Schizophrenia Group.
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